Drugs;Gene;Alleles;Genotype;Outcome_category;Effect_direction;Effect_category;Entity;Entity_name;Affected_Pop;Therapeutic_Outcome
SITAGLIPTIN;DPP4;TT;rs2909451;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;DPP4;TT;rs2909451;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;KCNQ1;GG;rs163184;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;KCNQ1;GG;rs163184;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN;DPP4;GG;rs4664443;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;DPP4;GG;rs4664443;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;CYP2C9;TT;rs1799853;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;CYP2C9;TT;rs1799853;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AG;rs3765467;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;GLP1R;AG;rs3765467;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
FLUOXETINE;CYP2C19;;INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2C19;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXENATIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULAGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULAGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLP-1 RECEPTOR AGONISTS;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLP-1 RECEPTOR AGONISTS;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;TCF7L2;CT + TT;rs7903146;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXENATIDE;TCF7L2;CT + TT;rs7903146;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;HISTORY OF GASTRIC BYPASS SURGERY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2XN;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LURBINECTEDIN;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LURBINECTEDIN;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ALBIGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLP-1 RECEPTOR AGONISTS;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN;CAUTION_DRUG_ACCUMULATION
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN;CAUTION_DRUG_ACCUMULATION
RALOXIFENE-4′-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN;CAUTION_DRUG_ACCUMULATION
RALOXIFENE-4′-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOPOROSIS;WOMEN;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;PON1;GG;rs705379;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
DABIGATRAN;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;SCN1A;T;rs10167228;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*5;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*5;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;;;ACTIVITY;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;;CAUTION_DRUG_ACCUMULATION
TELMISARTAN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TELMISARTAN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*28/*28;UGT1A1*1;OTHER;INCREASED;;DISEASE;NEOPLASMS;PEOPLE;
BILIRUBIN;UGT1A1;*28/*28;UGT1A1*28;OTHER;INCREASED;;DISEASE;NEOPLASMS;PEOPLE;
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;ANGINA PECTORIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;INCREASED;METABOLISM;OTHER;ANGINA PECTORIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;;;
OLANZAPINE;GSTM3;TCCTC/TCCTC;rs36120609;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTM3;TCCTC/TCCTC;rs36120609;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"TYPE 2""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"""OTHER:OBESITY""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLONIDINE;ADRA2C;GGGGAGCTTTCCCAGAGACCC/del + del/del;rs11269124;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:DYSLIPIDAEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:DYSLIPIDAEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLONIC NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLONIC NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;SLCO1B1;TT;rs4149032;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MODAFINIL;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;OTHER;METHAMPHETAMINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;;AA;rs1495741;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALSARTAN;AGT;GG;rs699;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MELOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;;DEFICIENCY;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
REMIFENTANIL;ADRA2A;CG + GG;rs1800544;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
REMIFENTANIL;ADRA2A;CG + GG;rs1800544;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;DOSAGE;INCREASED;DOSE;OTHER;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;DOSAGE;INCREASED;DOSE;OTHER;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
POSACONAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*6;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*6;CYP3A5*6;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*7;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*7;CYP3A5*7;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;ORGAN TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;ORGAN TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *2/*2;CYP2A6*1;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*1/*2 + *2/*2;CYP2A6*2;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*28;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*36;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*46/*46;CYP2A6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*46/*46;CYP2A6*46;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;SLC39A10;C;rs149319538;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*1;CYP2A6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;CYP2A6;*1/*1;CYP2A6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;CYP2A6;*1/*1;CYP2A6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;CYP2A6;*1/*1;CYP2A6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;CYP2A6;*1/*1;CYP2A6*12;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*1/*2;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*1/*2;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:STROKE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIVAROXABAN;ABCB1;CC;rs4148738;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2B6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;TYMS;GG;rs2853542;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
METHOTREXATE;ATIC;TT;rs4673993;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*3;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*4;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*5;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*6;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*9;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*10;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;OTHER;OTHER:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*60 + *6/*28;UGT1A1*60;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DIHYDROPYRIDINE DERIVATIVES;NUMA1;AA + AG;rs10898815;OTHER;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;NR3C1;GG;rs10482634;EFFICACY;INCREASED;RESISTANCE;OTHER;NEPHROTIC SYNDROME;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*10;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;TT;rs6759892;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*46/*46;CYP2A6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*46/*46;CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;SYT1;AA + AG;rs2251214;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*11;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SEPTIN3;AG;rs11914200;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SREBF2;AC;rs133290;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*11;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
N-DESMETHYLTAMOXIFEN;TCF20;GG;rs5751251;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs2267439;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PIROXICAM;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PIROXICAM;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs9607850;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;AG;rs8140869;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SOFOSBUVIR;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VARENICLINE;CYP2A6;;HIGH ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;;AA;rs446112;OTHER;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;DIABETES MELLITUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OPIOIDS;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
LUMACAFTOR;CFTR;del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;EGFR;GG;rs28929495;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
3-AMINOISOBUTYRATE;DPYD;TT;rs3918290;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;DOSAGE;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE;CAUTION_DOSE_ADJUST
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;EFFICACY;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEXILETINE;CYP2D6;*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;OTHER;MYOTONIC DYSTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEXILETINE;CYP2D6;*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:NONDYSTROPHIC MYOTONIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
3-AMINOISOBUTYRATE;UPB1;AA;rs143493067;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
3-AMINOISOBUTYRATE;AGXT2;TT;rs114286107;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*13;CYP2C9*1;PD;DECREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MELOXICAM;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*13;CYP2C9*13;PD;DECREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MELOXICAM;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;TT;rs3918290;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
2-AMINOHEPTANOATE;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
2-AMINOOCTANOIC ACID;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
2-HYDROXYLAURATE;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
CYSTEINE-S-SULFATE;NPC2;TT;rs140130028;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
L-ORNITHINE;NPC2;TT;rs140130028;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
5;UPB1;AA;rs143493067;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
6-DIHYDROTHYMINE;UPB1;AA;rs143493067;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;G;rs2273697;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A5;TT;rs776746;TOXICITY;DECREASED;CONCENTRATIONS;OTHER;VENOUS THROMBOEMBOLISM;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;CYP1A2*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;CYP1A2*30;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;CYP2C9*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;CYP2C9*9;METABOLISM/PK;INCREASED;METABOLISM;OTHER;SCHISTOSOMIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;AA + AG;rs1065852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TIC DISORDERS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TIC DISORDERS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;DECREASED;CLEARANCE;OTHER;TIC DISORDERS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*17/*17;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*17/*17;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3A;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3C;EFFICACY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;UGT1A4;TT;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;GG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;DIABETES MELLITUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"TYPE 2""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"""OTHER:FATTY LIVER DISEASE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;"""OTHER:BODY WEIGHT CHANGES""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
LUMACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
SERTRALINE;DRD3;AG;rs167770;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;DRD3;AG;rs11721264;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ILOPERIDONE;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ILOPERIDONE METABOLITE P88;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
EFAVIRENZ;CYP2B6;*1/*4;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*4;CYP2B6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
VALPROIC ACID;CACNA1H;T;rs3751664;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PENICILLIN G;IFNG;CC;rs1861494;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SYPHILIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PENICILLIN G;IFNG;TT;rs2430561;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SYPHILIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*1;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*1XN;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*2;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*2XN;DOSAGE;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;MEN;
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;MEN;
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AVATROMBOPAG;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AVATROMBOPAG;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*1;DOSAGE;;DOSE;;;;
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*2;DOSAGE;;DOSE;;;;
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*3;DOSAGE;;DOSE;;;;
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*5;DOSAGE;;DOSE;;;;
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
AVATROMBOPAG;ABCB1;AA + AG;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ACUTE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;NFIB;CT;rs28379954;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SLC6A2;GG;rs998424;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
LITHIUM;;T;rs7405404;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;"GASTROINTESTINAL NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;"GASTROINTESTINAL NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
VARENICLINE;HYKK;CT + TT;rs7164594;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*5;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;GG;rs8109525;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*2;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*3;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*4;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*5;DOSAGE;INCREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEPHROTIC SYNDROME;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEPHROTIC SYNDROME;CHILDREN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MESALAZINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MESALAZINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;NAT1;*10;NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ORGAN TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ORGAN TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;ORGAN TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;ORGAN TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1XN;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;*3;CYP4F2*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;*3;CYP4F2*3;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CETUXIMAB;VEGFA;del/del;rs144854329;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;TROUGH CONCENTRATION;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*6;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*6;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
LETROZOLE;;C;rs7937;;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
PROPOFOL;CYP2C9;*1/*1 + *1/*2;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2C9;*1/*1 + *1/*2;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NOROXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DISULFIRAM;SLC6A3;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;rs28363170;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERINDOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CROHN DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CROHN DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CROHN DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MALARIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MALARIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MALARIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
ARTEMETHER;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARTEMETHER;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;rs36118214;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;CYP2B6*30;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;CYP2B6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;DOSAGE;INCREASED;METABOLISM;;;HEALTHY;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
QUINAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1A;EFFICACY;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1A;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;UGT1A4;*3a;UGT1A4*3A;EFFICACY;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;UGT1A4;*3a;UGT1A4*3A;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;;DOSE;;;;
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;;DOSE;;;;
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1A;EFFICACY;DECREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1A;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*2;EFFICACY;DECREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*3A;EFFICACY;DECREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*3A;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CURCUMIN;CFTR;AA + AG;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
IVACAFTOR;CFTR;AA + AG;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE;CYP2A6;*1/*12;CYP2A6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
3-HYDROXYCOTININE;CYP2A6;*1/*12;CYP2A6*12;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*18;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*21;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*49;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*52;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*9;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*10;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*17;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*29;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*45;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*45;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*46;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*46;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;HLA-G;del/del;rs371194629;EFFICACY;INCREASED;RESPONSE;EFFICACY;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*3;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*4;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*5;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*6;TOXICITY;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*6;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*2;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*3;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHIGLITAZAR;PPARA;CC + CT;rs1800234;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHIGLITAZAR;PPARA;CC + CT;rs1800234;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*1b;UGT1A4*1A;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;*1b;UGT1A4*1B;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;;INTERMEDIATE ACTIVITY;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
SULFASALAZINE;NAT2;;SLOW ACETYLATOR;OTHER;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C/C;rs2242480;OTHER;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;GRK5;T;rs4752292;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON BETA-1A;HLA-B;*15:01;HLA-B*15:01;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RUBELLA VACCINES;HLA-B;*35:03;HLA-B*35:03;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;GG;rs671531;EFFICACY;DECREASED;RESPONSE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*18;CYP3A4*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*18;CYP3A4*18;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;*18/*18;CYP3A4*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;*18/*18;CYP3A4*18;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;*18/*18;CYP3A4*1;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;*18/*18;CYP3A4*18;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RUBELLA VACCINES;HLA-C;*15:02;HLA-C*15:02;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*02:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*03:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*04:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*05:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*06:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*07:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*08:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*12:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*14:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*15:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*16:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*17:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*02:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*03:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*04:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*05:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*06:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*07:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*08:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*12:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*14:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*15:02;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*16:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*17:01;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DQA1;*01:04;HLA-DQA1*01:04;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEASLES VACCINES;HLA-DRB1;*01:01;HLA-DRB1*01:01;EFFICACY;;RESPONSE;;;CHILDREN;
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;MEN;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;MEN;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEPATITIS VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLUENZA VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DRB1;*08:01;HLA-DRB1*08:01;EFFICACY;;RESPONSE;;;CHILDREN;
INFLUENZA VACCINES;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;CYP2C8;*4;CYP2C8*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;CYP2C8;*4;CYP2C8*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;CYP2C8;*3;CYP2C8*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;CYP2C8*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;CYP2C8*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;GGH;AA + AG;rs11545078;TOXICITY;INCREASED;DISCONTINUATION;SIDE EFFECT;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*1/*3;CYP2C8*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;CYP2C8;*1/*3;CYP2C8*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C8;*3;CYP2C8*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*5;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*7;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*9/*9;CYP2B6*1;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*9/*9;CYP2B6*9;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*15;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*11;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*11;EFFICACY;INCREASED;RESPONSE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*2;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*5;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;*14;SLCO1B1*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;*31;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*31;SLCO1B1*31;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*31;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*20;SLCO1B1*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*20;SLCO1B1*20;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*20;SLCO1B1*37;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CONJUGATED ESTROGENS;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*23;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*23;SLCO1B1*23;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*23;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C18;GG;rs1998591;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESISTANCE;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*37;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
3;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
3;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CEREBRAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOMYOPATHY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;OTHER;DILATED;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYBUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*1XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*4XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SULT1C4;G;rs1402467;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;SULT1C4;G;rs1402467;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;DOSAGE;DECREASED;DOSE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17;CYP2D6*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*17/*17;CYP2C19*1;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2C19;*17/*17;CYP2C19*17;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;*17/*17;CYP2C19*1;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;*17/*17;CYP2C19*17;OTHER;INCREASED;DISCONTINUATION;OTHER;BIPOLAR DISORDER;PEOPLE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*2;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*3;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*5;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*6;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*6;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*7;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
BREXPIPRAZOLE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;EFFICACY;INCREASED;RESPONSE;OTHER;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;RESPONSE;OTHER;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;DECREASED;DISCONTINUATION;SIDE EFFECT;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP3A4;*22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP3A4;*22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*29;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LIRAGLUTIDE;GLP1R;TT;rs10305420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;TT;rs10305420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LUNG TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LUNG TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLICLAZIDE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*4/*4;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*4;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP3A4;;LOW ACTIVITY;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;OTHER;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
N-DESMETHYLCLOZAPINE;CYP1A2;;LOW ACTIVITY;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;ALDH2;;DEFICIENCY;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*46 + *46/*46;CYP2A6*1;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*46 + *46/*46;CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*20;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*23;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*24;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*25;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*26;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*27;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15/*15 + *15/*37;SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15/*15 + *15/*37;SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;rs11150606;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PITAVASTATIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*1;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*2;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*4;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*9;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*14;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*38;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*38;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*46;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OXALIPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;;LOW ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;;LOW ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:ANXIETY DISORDERS;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*8;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*7;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*9;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*18;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*4;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*7;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;DOSAGE;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE;CAUTION_DOSE_ADJUST
HYDRALAZINE;NAT2;;RAPID ACETYLATOR;EFFICACY;INCREASED;DOSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*13;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*13;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;A;rs11045854;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;;CAUTION_DRUG_ACCUMULATION
SOMATROPIN RECOMBINANT;COL1A1;AA;rs1800012;DOSAGE;DECREASED;DOSE;OTHER;GROWTH HORMONE DEFICIENCY;PEOPLE;CAUTION_DOSE_ADJUST
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*17;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*20;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*23;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*35;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*46;CYP2A6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*46;CYP2A6*46;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*20;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*23;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*24;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*25;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*26;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*27;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*46;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VITAMIN B-COMPLEX;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INCL. COMBINATIONS;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SLCO1B1;GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VITAMIN B-COMPLEX;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INCL. COMBINATIONS;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;SLC6A2;A;rs12708954;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;SIDE EFFECT;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;SIDE EFFECT;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIZATRIPTAN;DRD2;AA + AG;rs6275;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;G;rs61162043;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SULFONAMIDES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;FOXA3;T;rs16980091;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;rs34671512;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYSTEAMINE;CFTR;CTT/del + del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROPROPOXYPHENE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROPROPOXYPHENE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FELODIPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FELODIPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SICKLE CELL;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*1;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*1;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*2;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*2;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*17;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*17;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;MEN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;MEN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*1;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*1;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*2;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*2;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*17;DOSAGE;;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*17;DOSAGE;;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAXANES;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAXANES;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SALVIANOLIC ACID B;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPHENYTOIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN;
VALPROIC ACID;UGT1A6;*1a;UGT1A6*2A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN;
VALPROIC ACID;UGT1A6;*1a;UGT1A6*3A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN;
VALPROIC ACID;UGT1A6;*1a;UGT1A6*4A;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN;
VALPROIC ACID;UGT1A6;*1a;UGT1A6*8;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;CHILDREN;
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;MYASTHENIA GRAVIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;MYASTHENIA GRAVIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;*1a;UGT1A6*2A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;*1a;UGT1A6*3A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;*1a;UGT1A6*4A;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;*1a;UGT1A6*8;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8/*8;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8/*8;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*18;CYP3A4*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*18;CYP3A4*18;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;DOSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;DOSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;INFANTS;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;;NORMAL METABOLIZER AND ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LOW BACK PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:OSTEOARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
RASAGILINE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;NR1I2;del/del;rs3842689;EFFICACY;INCREASED;RESISTANCE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*4;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1;METABOLISM/PK;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*2;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*2;METABOLISM/PK;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;del/del;rs72552763;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC22A1;GAT/del + del/del;rs72552763;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;GSTT1;null/null;GSTT1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;GSTT1;null/null;GSTT1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;GSTT1;null/null;GSTT1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;GSTT1;null/null;GSTT1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;HSD3B1;AA + AC;rs1047303;EFFICACY;INCREASED;RESISTANCE;OTHER;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;;CONCENTRATIONS;;;;
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;;CONCENTRATIONS;;;;
MORPHINE;SLC22A1;del/del;rs72552763;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*5;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28 + *1/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*28/*28 + *1/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*14;SLCO1B1*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*14;SLCO1B1*14;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*14;SLCO1B1*37;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*6 + *1/*6;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6/*6 + *1/*6;UGT1A1*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;RXRA;A;rs1805343;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*3;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*9;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*10;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*17;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*41;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;;METABOLISM;;;CHILDREN;
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;;METABOLISM;;;CHILDREN;
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;;METABOLISM;;;CHILDREN;
BUPROPION;CYP2B6;*4;CYP2B6*4;OTHER;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*4;CYP2B6*4;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLATIRAMER ACETATE;CCR5;del;rs333;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*13;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*16;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*60;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*8;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
GLIPIZIDE;TCF7L2;T;rs7903146;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CAROTID ARTERY DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CAROTID ARTERY DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;SLC14A2;T;rs12456693;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAVOSONSTAT;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10 + *5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;DOSAGE;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*4XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6 + *28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6 + *28;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6 + *28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TELMISARTAN;UGT1A3;*3;UGT1A3*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TELMISARTAN;UGT1A3;*3;UGT1A3*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
HALOPERIDOL;CYP2D6;*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*8;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MEASLES VACCINES;HLA-B;*51:01;HLA-B*51:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUCINDOLOL;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;DOSAGE;DECREASED;DOSE;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
MEASLES VACCINES;HLA-B;*07:02;HLA-B*07:02;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEASLES VACCINES;HLA-B;*13:01;HLA-B*13:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-B;*08:01;HLA-B*08:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCB11;G;rs7579275;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
INFLUENZA VACCINES;HLA-DQB1;*03:03;HLA-DQB1*03:03;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DQA1;*02:01;HLA-DQA1*02:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DRB1;*03:01;HLA-DRB1*03:01;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*20;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*20;CYP3A4*20;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:GASTROINTESTINAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:RECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CISPLATIN;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCB11;G;rs2287622;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEMSIROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GRANISETRON;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GRANISETRON;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*40;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*40;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*40;CYP2D6*40;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*40;CYP2D6*40;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*17;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*17;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;OTHER;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;OTHER;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*6;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*6;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*6;CYP2D6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*6;CYP2D6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*5;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*5;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*5;CYP2D6*5;EFFICACY;DECREASED;RESPONSE;DISEASE;ANEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*5;CYP2D6*5;EFFICACY;DECREASED;RESPONSE;DISEASE;SICKLE CELL;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;CYP1A1;*2A;CYP1A1*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;CYP1A1;*2A;CYP1A1*2A;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
HMG-COA_REDUCTASE_INHIBITORS;UGT1A1;*28;UGT1A1*28;TOXICITY;DECREASED;DISCONTINUATION;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROCURONIUM;SLCO1A2;CC;rs7967354;DOSAGE;DECREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCC2;A;rs8187692;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*3;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*4;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*10;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLC10A1;T;rs56903885;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN K1;CYP4F2;*1/*3 + *3/*3;CYP4F2*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VITAMIN K1;CYP4F2;*1/*3 + *3/*3;CYP4F2*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TORASEMIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MORPHINE;SLC22A1;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VARENICLINE;CYP2A6;;NORMAL METABOLIZER;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL;METABOLISM/PK;INCREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*1A;METABOLISM/PK;INCREASED;METABOLISM;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*2;METABOLISM/PK;INCREASED;METABOLISM;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*3;METABOLISM/PK;INCREASED;METABOLISM;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:ANXIETY DISORDERS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:ANXIETY DISORDERS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;NR1I2;T;rs12721616;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DIMETHYL FUMARATE;GSTP1;GG;rs1695;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C9;*3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;C;rs11045874;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;*3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;OTHER;INCREASED;DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;OTHER;INCREASED;DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;OTHER;INCREASED;DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
O-DESMETHYLTRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LOW BACK PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:OSTEOARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*5;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*10;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;;METABOLISM;;;HEALTHY;
CLOPIDOGREL;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;;METABOLISM;;;HEALTHY;
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*9;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*10;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*35;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*35XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;OTHER;INCREASED;RESISTANCE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;OTHER;INCREASED;RESISTANCE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;TYMP;AA + AG;rs11479;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
FLUOROURACIL;TYMP;AA + AG;rs11479;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;*2 + *3;CYP2C19*2;DOSAGE;;DOSE;DISEASE;EPILEPSY;CHILDREN;
PHENYTOIN;CYP2C19;*2 + *3;CYP2C19*3;DOSAGE;;DOSE;DISEASE;EPILEPSY;CHILDREN;
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*3;CYP2C9*3;DOSAGE;;DOSE;DISEASE;EPILEPSY;CHILDREN;
ANTIPSYCHOTICS;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC ACID;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYCHLOROQUINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TROPISETRON;CYP2D6;*1/*1xN;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TROPISETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;ACE;del/del;rs1799752;EFFICACY;;RESPONSE;OTHER;NON-HYPERCHOLESTEROLAEMIC PATIENTS SCHEDULED FOR ANGIOPLASTY;PEOPLE;
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*3;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*4;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*6;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*9;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*9;CYP2B6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
FLUOROURACIL;DPYD;CT;rs3918290;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;A;rs12305884;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
METOPROLOL;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
FLUOROURACIL;DPYD;AT;rs67376798;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;CG;rs75017182;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
FLUOROURACIL;DPYD;CG;rs75017182;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
SIROLIMUS;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEMSIROLIMUS;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*2XN;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;A;rs11045873;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;;G;rs4646458;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*2;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*3;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*5;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*10;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ROCURONIUM;IAPP, SLCO1A2;CC;rs11045995;DOSAGE;DECREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
MEASLES VACCINES;HLA-B;*44:02;HLA-B*44:02;EFFICACY;;RESPONSE;;;CHILDREN;
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;del/del;rs5030655;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;;RESPONSE;;;;
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*1;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*2;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*3;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*1;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*2;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*3;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*5;TOXICITY;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ESTRONE SULFATE;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;INCREASED;;OTHER;BREAST NEOPLASMS;WOMEN;
ESTRONE SULFATE;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;INCREASED;;OTHER;BREAST NEOPLASMS;WOMEN;
HMG-COA_REDUCTASE_INHIBITORS;CXCL5;CC;rs352046;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*36;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;TCF20;C;rs5758651;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTRORPHAN;TCF20;C;rs5758651;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*9;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;;DOSE;;;;
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;;DOSE;;;;
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*8;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CSMD1;CT + TT;rs2954625;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
ESTRONE;SLCO1B1;*5/*5;SLCO1B1*1;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE;SLCO1B1;*5/*5;SLCO1B1*5;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NT5C2;AA + AG;rs72846714;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*2/*2;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*2/*2;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
IRINOTECAN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*8 + *8/*8;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*8 + *8/*8;CYP2C9*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*29;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*35;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C18;GG;rs11188059;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP2D6;*14;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP2D6;*14;CYP2D6*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*7;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*7;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*7;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;;HIGH ACTIVITY;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*29;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP2D6;*29;CYP2D6*29;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*10X2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*9;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*35;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVONORGESTREL;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;;T;rs9828223;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;IP6K2;AG;rs61740999;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTRORPHAN;IP6K2;AG;rs61740999;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEBRISOQUINE;CYP2D6;*29/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*29/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;WOMEN;CAUTION_DRUG_ACCUMULATION
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;WOMEN;CAUTION_DRUG_ACCUMULATION
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;WOMEN;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVONORGESTREL;CYP2B6;CT;rs4803419;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*5/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*5/*17;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*5/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*29/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*29/*29;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*29/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
OMEPRAZOLE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*1;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*2;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*3A;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*3C;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A4;*22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A4;*22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;C;rs3842;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;;METABOLISM;DISEASE;EPILEPSY;PEOPLE;
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;SERPINE1;G;rs2227631;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;SERPINE1;G;rs2227631;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
ATENOLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*17;CYP2C19*1;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*17;CYP2C19*17;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*2;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*3;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;CNNM2;CC + CT;rs58700372;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OXYCODONE;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;TTAAAGTTA/del;rs11280056;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*2;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*4;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*9;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*10;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;C;rs17216177;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CILOSTAZOL;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CILOSTAZOL;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RASAGILINE;SLC22A1;CT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A7;*1A/*1A;CYP3A7*1A;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A7;*1A/*1A;CYP3A7*1C;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
COTININE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
KETAMINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
KETAMINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
KETAMINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
KETAMINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;T;rs7899457;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCC2;A;rs8187706;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLURBIPROFEN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLURBIPROFEN;CYP2C9;*1/*1;CYP2C9*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;SLC6A3;del;rs28363170;OTHER;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;DRD2;A;rs1800497;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
VARDENAFIL;CYP3A5;TT;rs776746;OTHER;INCREASED;CLEARANCE;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
VARDENAFIL;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SIPOGLITAZAR;UGT2B15;*2;UGT2B15*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIPOGLITAZAR;UGT2B15;*2;UGT2B15*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ETHANOL;SLC6A3;del;rs28363170;TOXICITY;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;INCREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1A;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*2A;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:ATRIAL FLUTTER;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:ATRIAL FLUTTER;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT1A6;*2a/*2a + *1a/*2a;UGT1A6*1A;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;UGT1A6;*2a/*2a + *1a/*2a;UGT1A6*2A;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT2B15;*2;UGT2B15*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;*2;UGT2B15*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRK1;TT;rs3802281;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;OTHER;ULCERATIVE COLITIS;CHILDREN;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;OTHER;OTHER:CROHN DISEASE;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIANSERIN;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIANSERIN;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRTAZAPINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRTAZAPINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;AUTOIMMUNE DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;AUTOIMMUNE DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;SIN3A;GG;rs7166737;EFFICACY;DECREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799964;EFFICACY;INCREASED;RESPONSE;DISEASE;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799964;EFFICACY;INCREASED;RESPONSE;DISEASE;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*6;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*6;CYP3A5*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RALTITREXED;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*7;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*7;CYP3A5*7;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*3;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;CYP2D6;;NORMAL METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;;CAUTION_DRUG_ACCUMULATION
RASAGILINE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;;NORMAL METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ELDERLY ADULT;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_SIDE_EFFECT
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*5;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LYMPHOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;B-CELL;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LYMPHOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;B-CELL;CHILDREN;CAUTION_DRUG_ACCUMULATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASAGILINE;ABCC2;AA;rs2273697;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;HTR2A;CC;rs2770296;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;POOR METABOLIZER;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
DONEPEZIL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ALZHEIMER DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;ABCB1;A;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DIPYRONE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DIPYRONE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ULCERATIVE COLITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;GSTM1;;GSTM1 NULL;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:CROHN DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DOSE_ADJUST
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;DOSAGE;DECREASED;DOSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DOSE_ADJUST
COTININE;CYP2B6;*1/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CYP2B6;*1/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2B6;*1/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2B6;*1/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;DBH;CC;rs2873804;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;GSTM1;non-null;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;GSTM1;non-null;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;GSTM1;non-null;GSTM1 NON-NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;GSTM1;non-null;GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;DISEASE;HODGKIN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LISINOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;SLC18A2;CC;rs363225;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*4;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALTEGRAVIR;UGT1A9;*3a;UGT1A9*3A;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C18;TT;rs2860840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;OTHER;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYAMITRIPTYLINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYAMITRIPTYLINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACETYLCYSTEINE;EPHX1;;POOR METABOLIZER;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SLC18A2;GG;rs363226;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4XN;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*29;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;;DEFICIENCY;METABOLISM/PK;;CLEARANCE;DISEASE;HEAD AND NECK NEOPLASMS;PEOPLE;
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*4XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*29;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
BUPROPION;FKBP5;TT;rs17614642;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*1;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*2;EFFICACY;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON BETA-1A;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;ESOPHAGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;ESOPHAGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;ESOPHAGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;rs35599367;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;CYP2C19;*2;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;ERYTHEMA NODOSUM;PEOPLE;CAUTION_DOSE_ADJUST
THALIDOMIDE;CYP2C19;*2;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:LEPROSY;PEOPLE;CAUTION_DOSE_ADJUST
THALIDOMIDE;CYP2C19;*2;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;ERYTHEMA NODOSUM;PEOPLE;CAUTION_DOSE_ADJUST
THALIDOMIDE;CYP2C19;*2;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:LEPROSY;PEOPLE;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANGINA PECTORIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*1;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;;LOW ACTIVITY;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;SLCO1B1;*5 + *15;SLCO1B1*5;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;SLCO1B1;*5 + *15;SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;CC;rs7668258;DOSAGE;INCREASED;CLEARANCE;;;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B7;CC;rs7668258;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;UGT2B7;*2;UGT2B7;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;DOSAGE;INCREASED;DOSE;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AG;rs1045642;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AG;rs1045642;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*6;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*3;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*13;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE;CAUTION_DRUG_ACCUMULATION
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROXYBUPROPION;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYBUPROPION;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*22;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*22;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*1;CYP2C19*1;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*1;CYP2C19*2;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*1;CYP2C19*3;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*6;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;A;rs60369023;OTHER;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;A;rs60369023;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
APIXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EDOXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;A;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;A;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;CC;rs1360780;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;A;rs1128503;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;A;rs1128503;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GNB3;CC + CT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;A;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;A;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;OPRK1;CC;rs963549;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
IMATINIB;ABCG2;T;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;T;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;DECREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;PPARA;G;rs4823613;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;T;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;BDNF;CT;rs6265;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;ADRB1;G;rs1801253;EFFICACY;DECREASED;RESPONSE;DISEASE;TACHYCARDIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLECAINIDE;ADRB1;G;rs1801253;EFFICACY;DECREASED;RESPONSE;DISEASE;TACHYCARDIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;NEUROMYELITIS OPTICA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*18;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*18;CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;CC;rs13273672;EFFICACY;DECREASED;CLINICAL BENEFIT;DISEASE;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHORIONIC GONADOTROPIN;FSHR;CC;rs6166;DOSAGE;INCREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
BEPRIDIL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;CARDIAC RHYTHM DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;GG;rs35599367;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
NICARDIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIMODIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1A;DOSAGE;DECREASED;DOSE;DISEASE;ADRENAL HYPERPLASIA;CHILDREN;CAUTION_DOSE_ADJUST
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1A;DOSAGE;DECREASED;DOSE;DISEASE;CONGENITAL;CHILDREN;CAUTION_DOSE_ADJUST
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1C;DOSAGE;DECREASED;DOSE;DISEASE;ADRENAL HYPERPLASIA;CHILDREN;CAUTION_DOSE_ADJUST
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1C;DOSAGE;DECREASED;DOSE;DISEASE;CONGENITAL;CHILDREN;CAUTION_DOSE_ADJUST
DAUNORUBICIN;G6PD;A-202A_376G;G6PD A- 202A_376G;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*7;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;OTHER;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;HNF1B;AA + AG;rs11868513;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLATIRAMER ACETATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;ANGINA PECTORIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAFFEINE;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*2;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*3;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
"""INTERFERON ALFA-2A";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2B";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERONS""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""PEGINTERFERON ALFA-2A""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""PEGINTERFERON ALFA-2B""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANOSINE DIPHOSPHATE;TPMT;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE MONOPHOSPHATE;TPMT;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE TRIPHOSPHATE;TPMT;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2A6;*4;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2A6;*4;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*7;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*7;CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;*3/*3;CYP4F2*1;DOSAGE;INCREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;*3/*3;CYP4F2*3;DOSAGE;INCREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;CYP2C8*1;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;CYP2C8*3;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*4;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*9;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
TOCILIZUMAB;IL6R;CT + TT;rs4845625;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;T;rs17216198;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAPYRIDINE;NAT2;*7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2B";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERONS""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""PEGINTERFERON ALFA-2A""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""PEGINTERFERON ALFA-2B""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""RIBAVIRIN""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HUMAN LIVER MICROSOMES;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HUMAN LIVER MICROSOMES;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*2;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*3/*3;CYP2D6*3;EFFICACY;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*2;CYP2C9*1;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*2;CYP2C9*2;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*2;CYP2C9*3;EFFICACY;DECREASED;RESPONSE;DISEASE;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;MYOCARDIAL ISCHEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLMESARTAN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OLMESARTAN;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*2;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*37;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*4;CYP3A4*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CYP3A4;*1/*4;CYP3A4*4;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*13;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*13;CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*1;EFFICACY;DECREASED;RESPONSE;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;;;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
NATEGLINIDE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NATEGLINIDE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCC2;T;rs3740066;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*4;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*5;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*6;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*3;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*3;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;RESPONSE;EFFICACY;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;RESPONSE;EFFICACY;EFFICACY:MAJOR DEPRESSIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
METFORMIN;;CG;rs6719578;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*10;CYP2D6*1;EFFICACY;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10;CYP2D6*10;EFFICACY;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BENZBROMARONE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BENZBROMARONE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LABETALOL;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LABETALOL;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*22;CYP2B6*1;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*22;CYP2B6*22;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;DOSAGE;DECREASED;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;DOSAGE;DECREASED;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*2;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*17;DOSAGE;DECREASED;DOSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*17;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:LUNG TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;PANIC DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;OTHER;HYPERTENSION;MEN;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;TOXICITY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;TOXICITY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;TOXICITY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CA/CA;rs70950385;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ASPIRIN;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;G;rs28399504;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LAMIVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
NEVIRAPINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
STAVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*60;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*60;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
BOCEPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
TICAGRELOR;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;RESISTANCE;DISEASE;DISEASE:STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;DISEASE;DISEASE:STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*11;CYP2B6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*11;CYP2B6*11;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;POR;CT + TT;rs41301394;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;DRD2;AA + AG;rs6275;;INCREASED;DOSE;OTHER;TREATMENT FOR HEROIN ADDICTION;PEOPLE;
CARBOPLATIN;GSTP1;G;rs1695;TOXICITY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;GSTP1;G;rs1695;TOXICITY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*18;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;MIR335;AA + AG;rs3807348;EFFICACY;INCREASED;RESPONSE;OTHER;MESOTHELIOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;;LOW ACTIVITY;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*1;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*3;DOSAGE;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;DECREASED;TROUGH CONCENTRATION;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
NIMODIPINE;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;INCREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIMODIPINE;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;INCREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*9;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP2D6;*9;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIMVASTATIN;F3;CT;rs3917643;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL ISCHEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETYLCHOLINE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NITROPRUSSIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
MEPERIDINE;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
MIDAZOLAM;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
MEPERIDINE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
MIDAZOLAM;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;UGT1A1;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
MEPERIDINE;UGT1A1;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
MIDAZOLAM;UGT1A1;;POOR METABOLIZER;METABOLISM/PK;DECREASED;DOSE;OTHER;SEDATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*1;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*3;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*4;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*9;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*10;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*41;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;C;rs2242480;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;C;rs2242480;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FULVESTRANT;CYP2C9;;CYP2C9 POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FULVESTRANT;CYP2C9;;CYP2C9 POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;CYP2C9;;CYP2C9 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP2C9;;CYP2C9 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ABATACEPT;HLA-DRB1;*04:05;HLA-DRB1*04:05;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;;RAPID METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
APATINIB;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;CYP2C19 RAPID METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
DULOXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
AMOXICILLIN;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLARITHROMYCIN;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLARITHROMYCIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;A;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;OTHER;OBESITY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;OTHER;OBESITY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs1065852;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;AUTISM SPECTRUM DISORDER;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*22;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;PPARD;G;rs6922548;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;PPARD;G;rs6922548;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;RECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*6;UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;RECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;INCREASED;TIME RESPONSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:CONSTIPATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:CONSTIPATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*65;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;PPARD;G;rs7769719;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;PPARD;G;rs7769719;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;NEDD4;G;rs2288344;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;DDHD1;G;rs17126068;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE 5;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
6-ORTHOQUINONE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DESVENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;rs9923231;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;;T;rs7903366;EFFICACY;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PALIPERIDONE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;PK;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*16;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;;A;rs7081864;EFFICACY;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFINPYRAZONE;UGT1A9;T;rs72551330;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AA;rs1051792;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SPONDYLARTHROPATHIES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*4;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*9;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
3;CYP2C19;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
LITHIUM;GSK3B;GG;rs6438552;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
LITHIUM;NR1D1, THRA;TT;rs2071427;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAPYRIDINE;NAT2;*5/*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*4;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*5;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6J;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7G;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*39;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED;DISCONTINUATION;EFFICACY;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6/*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENZYME INHIBITORS;CYP19A1;CC;rs700518;OTHER;;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;
TACROLIMUS;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;FCER2;G;rs28364072;DOSAGE;INCREASED;DOSE;DISEASE;ASTHMA;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OLMESARTAN;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;;G;rs12154537;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*4/*4;NAT2*4;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*6;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*6;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*7;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*7;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*14;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*14;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*16;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*16;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*19;DOSAGE;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*19;METABOLISM/PK;INCREASED;DOSE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;G;rs11045585;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*7;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;A;rs7311358;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;G;rs4149118;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*6J;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*7G;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TUBERCULOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*7;NAT2*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;VDR;C;rs1544410;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;GG;rs1154831;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SPONDYLARTHROPATHIES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIAZEPAM;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;DEPRESSION;CHILDREN;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:ANXIETY DISORDERS;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;MAJOR DEPRESSIVE DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EFFICACY:OBSESSIVE-COMPULSIVE DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*6;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*7;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*14;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*16;EFFICACY;INCREASED;RESPONSE;OTHER;RESISTANT HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*6;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*14;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*1xN/*41;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*41;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*41;CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs7294;METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;SUBSTANCE-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MARAVIROC;CYP3A5;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1/*2xN;CYP2D6*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*2xN/*41;CYP2D6*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*2xN/*41;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*2xN/*41;CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*10;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*10;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*10;CYP2D6*10;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PERPHENAZINE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MARAVIROC;CYP3A5;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;DOSAGE;INCREASED;TIME RESPONSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;INCREASED;TIME RESPONSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2D6;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCODONE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;EFFICACY;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;DOSE;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DOSE_ADJUST
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*36;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TACHYCARDIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*1;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*2;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;DOSAGE;DECREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*2;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*8;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*17;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*36;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1;DOSAGE;INCREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2;DOSAGE;INCREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*2XN;DOSAGE;INCREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;AA + AC;rs890293;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PERPHENAZINE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*2;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*3;DOSAGE;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;DOSE;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
VORTIOXETINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
VORTIOXETINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
FENTANYL;;;METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;ULTRARAPID METABOLIZER PHENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*2;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*3;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*1;CYP2C9*8;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*14;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;G;rs2075572;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTON PUMP INHIBITORS;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;;POOR METABOLIZErs;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;T;rs548646;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;T;rs2237892;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;T;rs2237892;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;G/del + del/del;rs1799732;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LINAGLIPTIN;TCF7L2;CC + CT;rs7903146;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;TCF7L2;CC + CT;rs7903146;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;;POOR METABOLIZER PHENOTYPE;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;;POOR METABOLIZER PHENOTYPE;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;T;rs681243;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYBUPROPION;CYP2B6;;CYP2B6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLARITHROMYCIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR METABOLIZErs;EFFICACY;DECREASED;RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;COMT;AG + GG;rs4680;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;;INTERMEDIATE METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROMORPHONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROMORPHONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;A;rs1461773;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*5;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*9;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;T;rs3778148;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLARITHROMYCIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLARITHROMYCIN;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;;NORMAL METABOLIZER GENOTYPE;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;VDR;T;rs4516035;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;CYP2D6*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;CYP2D6*4;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;CYP2D6*6;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;RESPONSE;OTHER;PHANTOM LIMB SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYMORPHONE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;POOR METABOLIZER PHENOTYPE;EFFICACY;INCREASED;RESPONSE;OTHER;PHANTOM LIMB SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYCODONE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;LOW BACK PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;;POOR METABOLIZErs;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;;CAUTION_DRUG_ACCUMULATION
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
ATENOLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;;POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;C;rs2237895;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;C;rs2237895;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;;NORMAL METABOLIZErs;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SOLANIDINE;CYP2D6;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;OTHER;DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLECAINIDE;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;;CONCENTRATIONS;DISEASE;TACHYCARDIA;PEOPLE;
FLECAINIDE;CYP2D6;;NORMAL METABOLIZER GENOTYPE;METABOLISM/PK;;CONCENTRATIONS;DISEASE;SUPRAVENTRICULAR;PEOPLE;
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*2XN;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIDOPIDINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2 + *3;CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;TOXICITY;INCREASED;METABOLISM;;;;CAUTION_SIDE_EFFECT
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*4/*4;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;FOXP3;G;rs3761548;OTHER;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;TACHYCARDIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C2;TT;rs11598702;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;TT;rs1048977;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*2;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*4;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*5;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*6;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*9;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*17;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*41;METABOLISM/PK;INCREASED;EXPOSURE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;GG + GT;rs7202877;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;GG + GT;rs7202877;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2C9;;POOR METABOLIZErs;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;TOXICITY;INCREASED;METABOLISM;;;;CAUTION_SIDE_EFFECT
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;ULTRARAPID METABOLIZER PHENOTYPE;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs2239179;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs1540339;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2C9;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;DOSAGE;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;DISEASE:INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CARISOPRODOL;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CARISOPRODOL;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
GEMIGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMIGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SAXAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SAXAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VILDAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VILDAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*1;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*6;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
GLICLAZIDE;CYP2C9;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NORQUETIAPINE;CYP2D6;;CYP2D6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TROPISETRON;CYP2D6;*1/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
INDOMETHACIN;CYP2C9;G;rs2153628;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;;POOR METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;SLC6A4;TT;rs25531;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NIMODIPINE;CACNA1C;CC;rs2239128;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
NIMODIPINE;CACNA1C;CG;rs2239050;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;;POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MARAVIROC;CYP3A5;;POOR METABOLIZErs;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;GABRQ;AA + AT;rs3810651;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;;NORMAL METABOLIZErs;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
HYDROMORPHONE;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;;ULTRARAPID METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
2-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IBOGAINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;*2 + *22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;*2 + *22;CYP3A4*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;*2 + *22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*2;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE;CYP2D6;;POOR METABOLIZER;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LISDEXAMFETAMINE;CYP2D6;;POOR METABOLIZER;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;CC;rs502434;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;GRIA3;CC;rs502434;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*41;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*41;CYP2A6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*39;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*39;CYP2A6*39;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:INFLAMMATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE;;DOSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;;DOSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*1;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*87;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*95;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*97;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
1-HYDROXYMIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
1-HYDROXYMIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;TT;rs3761554;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;GRIA3;TT;rs3761554;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;;NAT2 INTERMEDIATE ACETYLATOR;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*18;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*18;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;FALCIPARUM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;OTHER:BORDERLINE PERSONALITY DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCC2;TT;rs3740066;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
LEVONORGESTREL;CYP2B6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;TT;rs3761555;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;GRIA3;TT;rs3761555;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NKX2-6;AG + GG;rs310279;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;;CC + CT;rs16935279;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;;CC + CT;rs16935279;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
FOLLITROPIN BETA;FSHR;CC + CT;rs6166;DOSAGE;INCREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
UROFOLLITROPIN;FSHR;CC + CT;rs6166;DOSAGE;INCREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;OTHER:ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;OTHER;OTHER:PANIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;ULTRARAPID METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*1;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*2;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*4;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*8;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*11;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;UBE2I;CG;rs9597;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UBE2I;CG;rs9597;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;FRAS1;AA + AG;rs4386623;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;FAM201A;AG + GG;rs1890109;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;SCN1A;T;rs3812718;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROESOPHAGEAL CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;A;rs6277;EFFICACY;INCREASED;RESPONSE;;;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
DABIGATRAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
EDOXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*6;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;A;rs648007;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA7;CC;rs2337980;EFFICACY;INCREASED;RESPONSE;;;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;DRD2;GG;rs1799732;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;;CONCENTRATIONS;;;;
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;;CONCENTRATIONS;;;;
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;EPHX1;A;rs1131873;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC2A2;C;rs8192675;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;CONNECTIVE TISSUE DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs28371685;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DULOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:DEPRESSIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;del;rs9332131;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
HYDROXYUREA;BCL11A;A;rs4671393;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BETA BLOCKING AGENTS;KL;A/del + del/del;rs36217263;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;ACE;TT;rs8075924;EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B7;A;rs7438284;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT2B7;A;rs7438284;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B7;T;rs7439366;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT2B7;T;rs7439366;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
HYDROXYCHLOROQUINE;CYP3A4;CC;rs3735451;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYCHLOROQUINE;CYP3A4;CC;rs3735451;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;CT;rs11030918;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;HNF4A;C;rs3212207;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;INTERMEDIATE METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCC2;A;rs8187710;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;A;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CHRONIC KIDNEY FAILURE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;CHRONIC KIDNEY FAILURE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;PPARD;T;rs3734254;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;PPARD;T;rs3734254;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;OR10P1;G;rs17117817;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;OR10P1;G;rs17117817;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1X2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBOPLATIN;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FAMOTIDINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:01;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:04;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:05;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:10;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*10:01;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;;AG + GG;rs17180299;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*2;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*3;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*9;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATENOLOL;SNX9;A;rs2364349;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;SNX9;A;rs2364349;PD;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;;GT + TT;rs11265572;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEMSIROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A5;*3/*3;CYP3A5*1;;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;
PERAMPANEL;CYP3A5;*3/*3;CYP3A5*3;;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
URACIL;DPYD;c.295_298delTCAT (*7);DPYD C.295_298DELTCAT (*7);METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.295_298delTCAT (*7);DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.2846A>T;DPYD C.2846A>T;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.2846A>T;DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1679T>G (*13);DPYD C.1679T>G (*13);METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1679T>G (*13);DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1905+1G>A (*2A);DPYD C.1905+1G>A (*2A);METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1905+1G>A (*2A);DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1XN;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*2XN;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;CC;rs3842;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;INFANTS;CAUTION_DRUG_ACCUMULATION
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*03:01;HLA-A*03:01;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*03:01;HLA-A*03:01;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*23:17;HLA-A*23:17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*23:17;HLA-A*23:17;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;*57:03;HLA-B*57:03;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;*57:03;HLA-B*57:03;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*7;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*35;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;CYP2C19;;POOR METABOLIZER;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;*6 + *18;CYP2B6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6 + *18;CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6 + *18;CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*3b;UGT1A4*3B;EFFICACY;DECREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;PPARD;C;rs2016520;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;PPARD;C;rs2016520;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*4;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;CHST3;A;rs1871450;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;A;rs1871450;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;*6;CYP2B6*1;TOXICITY;DECREASED;RESPONSE;OTHER;BRAIN INJURY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;*6;CYP2B6*6;TOXICITY;DECREASED;RESPONSE;OTHER;BRAIN INJURY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TILDRAKIZUMAB;PDE4D;CT/CT;rs10556657;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
DIHYDROCODEINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
HYDROMORPHONE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OXYCODONE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
PIRITRAMIDE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TILIDINE;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TRAMADOL;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;PPARD;C;rs1883322;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;PPARD;C;rs1883322;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2C9;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;*2a;UGT1A6*1A;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;*2a;UGT1A6*2A;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28;UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:METASTATIC NEOPLASM;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CHST3;A;rs12418;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;A;rs12418;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*1;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*28;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*60;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*1;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*28;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*60;DOSAGE;DECREASED;DOSE;OTHER;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MIRABEGRON;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PEPTIC ULCER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:ESOPHAGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PEPTIC ULCER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:ESOPHAGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PEPTIC ULCER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:GASTROESOPHAGEAL REFLUX;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;OTHER;OTHER:ESOPHAGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*8;TPMT*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*8;TPMT*8;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*1;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*8;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1X2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;CAESARIAN SECTION;WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;WOMEN;CAUTION_DOSE_ADJUST
DULOXETINE;DRD3;GG;rs963468;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*17;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*17;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
DEHYDROARIPIPRAZOLE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PIMOZIDE;CYP3A4;*22;CYP3A4*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PIMOZIDE;CYP3A4;*22;CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;CHST3;C;rs4148943;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;C;rs4148943;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;CHST3;C;rs4148945;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;C;rs4148945;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCB11;G;rs4148776;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1B3;AA + AG;rs7311358;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLCO1B3;AA + AG;rs7311358;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLCO1B3;GG + GT;rs4149117;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLCO1B3;GG + GT;rs4149117;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHISTOSOMIASIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1X2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1X2;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FESOTERODINE;CYP2D6;;ULTRARAPID METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE LYMPHOBLASTIC LEUKEMIA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LYMPHOMA""";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"""OTHER:LEUKEMIA";CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;"ACUTE""";CHILDREN;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;CHST13;C;rs1054097;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACOSAMIDE;CYP2C19;;NORMAL METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSIGLITAZONE;CYP2C8;C;rs10509681;DOSAGE;INCREASED;METABOLISM;;;HEALTHY;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;C;rs10509681;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LACOSAMIDE;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;CYP3A4;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SURGERY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SURGERY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SURGERY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;;NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2D6;;NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;;CYP2B6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3A;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ITIH3;AA;rs2535629;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;;POOR METABOLIZER;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CYP2A6;;LOW ACTIVITY;METABOLISM/PK;INCREASED;METABOLISM;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CYP2A6;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*12;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*20;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*23;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*24;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*25;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*26;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*27;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;ADORA1;CC;rs10920573;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;APNEA OF PREMATURITY;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
NORQUETIAPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NORQUETIAPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
AMLODIPINE;CACNA1D;GG;rs312481;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;ZHX2;C;rs17289471;EFFICACY;INCREASED;RESPONSE;OTHER;HEPATITIS B VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BERBERINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;WOMEN;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
CLOPIDOGREL;CYP2C19;T;rs12248560;OTHER;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
RANIBIZUMAB;VEGFA;CC + CT;rs833069;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs4646449;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ONDANSETRON;CYP2D6;;POOR METABOLIZER;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;PEOPLE;CAUTION_DOSE_ADJUST
IMATINIB;ABCA3;GG + GT;rs150929;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCA3;GG + GT;rs150929;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CBARP, STK11;TT;rs2301759;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CBARP, STK11;TT;rs2301759;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A3;T;rs3127602;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A3;T;rs3127602;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;PRKAA1;A;rs11749180;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAA1;A;rs11749180;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC29A4;A;rs10234709;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC29A4;A;rs10234709;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAG2;T;rs4725434;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;PRKAG2;T;rs4725434;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;rs2120274;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;rs2120274;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;STK11;C;rs2301759;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;STK11;C;rs2301759;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;C;rs4621031;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC47A2;C;rs4621031;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALECTINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;TCF7L2;T;rs7903146;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRK1;CC;rs3802279;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*29;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*45;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*29;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*45;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;IMMUNOGLOBULIN A VASCULITIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;IMMUNOGLOBULIN A VASCULITIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;AG + GG;rs35717427;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;CG + GG;rs6690230;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;IL6R;AA + AG;rs11265621;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;;AA;rs10108210;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;CLEC2D;GG;rs1560011;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;KCNMB1;AA + AG;rs703505;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;CCL11;AA;rs17809012;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;CCL11;AA;rs17809012;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;IL16;TT;rs4778889;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL16;TT;rs4778889;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;SLC16A1;GG;rs7169;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;AC + CC;rs3742106;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;FKBP5;CT + TT;rs1360780;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PATENT DUCTUS ARTERIOSUS;INFANTS;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PREMATURE BIRTH;INFANTS;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*5B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PATENT DUCTUS ARTERIOSUS;INFANTS;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*5B;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PREMATURE BIRTH;INFANTS;CAUTION_DRUG_ACCUMULATION
FENTANYL;ABCC1;(A)14;rs58572178;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PAIN;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCC1;(A)14;rs58572178;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;OTHER:PREMATURE BIRTH;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2 + *17;CYP2C19*2;DOSAGE;;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;
VORICONAZOLE;CYP2C19;*2 + *17;CYP2C19*17;DOSAGE;;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;
ROSUVASTATIN;ABCG2;;ABCG2 POOR METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;NAT2;;NAT2 SLOW ACETYLATOR;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;TPMT;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;T;rs20572;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
SUNITINIB;KDR;AG;rs34231037;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;CC;rs3800373;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLIMEPIRIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLIMEPIRIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLIPIZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLIPIZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
RAMIPRIL;SLCO1B1;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
RAMIPRIL;ABCG2;;ABCG2 POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DULOXETINE;DRD3;CC + CT;rs324026;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;OTHER;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;TT;rs1751034;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
DULOXETINE;DRD3;CT;rs324023;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EZETIMIBE;ABCG8;;DEFICIENCY;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EZETIMIBE;ABCG5;;DEFICIENCY;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;DRD3;AG;rs167770;EFFICACY;DECREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;*10 + *41;CYP2D6*10;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PROSTATIC HYPERPLASIA;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;*10 + *41;CYP2D6*41;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PROSTATIC HYPERPLASIA;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;HBG2;AA + AG;rs7482144;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;HBG2;AA;rs7482144;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;SCN1A;AA + AT;rs121917953;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ENG;G;rs1800956;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;PKD1L2;A;rs16954698;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*1;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*2;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*3;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*4;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
PREGABALIN;NAT2;;SLOW ACETYLATOR;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;FKBP5;TT;rs1360780;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITAVASTATIN;CYP2C9;;CYP2C9 POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED;RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;FKBP5;AA;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;NORMAL METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2D6;C;rs202102799;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;C;rs202102799;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;G;rs28371726;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;G;rs28371726;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DRD4;C;rs762502;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;DRD4;C;rs762502;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD4;del;rs2133251840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;DRD4;del;rs2133251840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLCLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLCLOZAPINE;CYP1A2;;ULTRARAPID METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;SORCS1;GG;rs1416406;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXENATIDE;SORCS1;GG;rs1416406;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VILDAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VILDAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SAXAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SAXAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VILDAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VILDAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;NR1I2;CC;rs2461817;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;RESPIRATORY FAILURE REQUIRING ASSISTED VENTILATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
R-EDDP;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
S-EDDP;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:CROHN DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:AUTOIMMUNE HEPATITIS;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;OTHER;OTHER:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;CC;rs2282143;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A2;CC;rs316019;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHACHOLINE;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TEMSIROLIMUS;NR1I2;TT;rs3814055;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TEMSIROLIMUS;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;;C;rs4646457;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A5;G;rs15524;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A4;A;rs12333983;DOSAGE;;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;RHEUMATIC HEART DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ATENOLOL;;A;rs294610;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;;A;rs294610;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;CT;rs56038477;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
FLUOROURACIL;DPYD;CT;rs56038477;DOSAGE;;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7975;OTHER;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7975;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;C;rs1046428;OTHER;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;C;rs1046428;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7972;OTHER;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7972;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;AG + GG;rs17376848;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;;AA + AG;rs11065987;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;CT;rs12720461;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;T;rs553202;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;A;rs524731;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;HINT1;CT + TT;rs3852209;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG;rs1799971;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG;rs1799971;EFFICACY;DECREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;CT;rs3892097;EFFICACY;INCREASED;CONCENTRATIONS;EFFICACY;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;CT;rs3892097;EFFICACY;INCREASED;CONCENTRATIONS;EFFICACY;EFFICACY:MAJOR DEPRESSIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;DBH;CT + TT;rs1611115;EFFICACY;INCREASED;RESPONSE;DISEASE;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;CYP1A2;AA;rs2069514;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;OR2B11;A;rs35305980;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE;
SULFONAMIDES;KCNJ11;CT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;KCNJ11;CT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFONAMIDES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIRACIL HYDROCHLORIDE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIFLURIDINE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;UGT1A10, UGT1A8, UGT1A9;del;rs3832043;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE;
AXITINIB;UGT1A7;G;rs17868323;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE;
RISPERIDONE;HTR2C;A;rs3813928;EFFICACY;DECREASED;RESPONSE;DISEASE;AUTISM;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTRR;CT + TT;rs1532268;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HTR2A;CT + TT;rs6311;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;ABCB1;A;rs1045642;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE;
BUTORPHANOL;COMT;GG;rs6269;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;ABCG2;T;rs2231142;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE;
AXITINIB;ABCB1;T;rs2032582;METABOLISM/PK;;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA;PEOPLE;
VORICONAZOLE;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;EGFR;GT + TT;rs121434568;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUTORPHANOL;COMT;CC;rs4633;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;DISEASE:METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC + TT;rs1051266;EFFICACY;DECREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_METABOLITE(SN-38);UGT1A9;TT;rs3832043;DOSAGE;INCREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;rs2279345;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;CRHR1;T;rs1876828;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);SLCO1B1;CC + CT;rs4149056;DOSAGE;INCREASED;DOSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DOSE_ADJUST
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;AA + AG;rs4986893;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;GRIN2B;CC;rs2284411;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;BURNS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICARDIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIMODIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;AG;rs1367117;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;
IRBESARTAN;APOB;AG;rs1367117;METABOLISM/PK;;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;
IRBESARTAN;APOB;GG;rs1367117;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;
ATORVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;PRCP;GG + GT;rs2229437;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;UGT2B7;GG;rs28365062;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
CLOPIDOGREL;CYP2C19;A;rs4244285;OTHER;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;G;rs1045642;EFFICACY;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
CLOPIDOGREL;ABCB1;G;rs1045642;OTHER;;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;
MIDAZOLAM;VDR;CT + TT;rs11568820;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLDOPA;ARG2;G;rs3742879;EFFICACY;INCREASED;RESPONSE;OTHER;PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLDOPA;ARG2;G;rs3742879;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:PRE-ECLAMPSIA;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;CYP2C8;C;rs10509681;DOSAGE;INCREASED;METABOLISM;;;HEALTHY;CAUTION_DOSE_ADJUST
REPAGLINIDE;CYP2C8;C;rs10509681;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;CYP2C8;T;rs11572080;DOSAGE;INCREASED;METABOLISM;;;HEALTHY;CAUTION_DOSE_ADJUST
REPAGLINIDE;CYP2C8;T;rs11572080;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;TT;rs12248560;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;TT;rs12248560;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;TT;rs12248560;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;TT;rs11188072;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;TT;rs11188072;DOSAGE;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;TT;rs11188072;METABOLISM/PK;INCREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;TT;rs3211371;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
GEMCITABINE;CMPK1;CC;rs1044457;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;CG + GG;rs1800035;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CG + GG;rs1800035;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUDESONIDE;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE / SALMETEROL;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FORMOTEROL;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
OMALIZUMAB;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs775887911;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs775887911;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs201376588;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs201376588;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;GG;rs35687416;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DCTD;CC;rs12507552;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;;T;rs139945292;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;TENT4A;GG;rs274713;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;CT + TT;rs1544105;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDC5L;CT + TT;rs992160;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;AA;rs2853539;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;
ROSUVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;
SIMVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;
BUDESONIDE;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE / SALMETEROL;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FORMOTEROL;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
OMALIZUMAB;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SH2D5;GT + TT;rs10916852;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CETP;A;rs708272;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;ITPA;AC;rs1127354;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;SLCO1B1;TT;rs4149056;METABOLISM/PK;;EXPOSURE;;;HEALTHY;
BUPRENORPHINE;CYP3A4;TT;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;ISCHEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;CYP3A4;TT;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERINDOPRIL;AGTR1;AA;rs5186;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NITRENDIPINE;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE;OPRM1;AG + GG;rs1799971;PD;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HNF4A;AA;rs2071197;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;ABCG2;CC + CT;rs3114020;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;TSPYL1;AG + GG;rs3828743;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;CC;rs7543016;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
GEMCITABINE;ESR2;TT;rs944050;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;TT;rs1799978;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;T;rs1799978;OTHER;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOSE;SLCO1B1;TT;rs4149056;METABOLISM/PK;;CONCENTRATIONS;;;HEALTHY;
WARFARIN;;A;rs12777823;DOSAGE;;DOSE;;;;
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CONJUGATED ESTROGENS;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED;RESPONSE;DISEASE;MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
DIAZEPAM;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ALCOHOL ABUSE;MEN;CAUTION_DRUG_ACCUMULATION
ALPRAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:ANXIETY DISORDERS;MEN;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;IGF2R;AG;rs8191725;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;SLC24A4;AG;rs77441273;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;AG;rs35599367;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ALPRAZOLAM;CYP3A4;AG;rs35599367;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:ANXIETY DISORDERS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OVARIAN NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASM OF ESOPHAGUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ULINASTATIN;MMP2;T;rs243865;EFFICACY;DECREASED;RESPONSE;OTHER;PANCREATITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;G;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ULINASTATIN;MMP9;T;rs3918242;EFFICACY;INCREASED;RESPONSE;OTHER;PANCREATITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;NR1I2;CT + TT;rs2276707;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;NR1I2;AA;rs10934498;TOXICITY;DECREASED;EXPOSURE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;NR1I2;AA;rs10934498;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;IL10;CC;rs1800896;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD3;C;rs324026;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;TLR3;CT;rs3775291;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TAMOXIFEN;ABCC2;CT;rs717620;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;CT;rs77149876;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
SALBUTAMOL;PAPPA2;CT;rs77977790;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORBUPRENORPHINE;OPRD1;GG;rs569356;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SALMETEROL;ADRB2;G;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;AG;rs116551936;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;NCOA3;CT;rs115501901;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;AG;rs74973995;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;CT;rs73294475;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP3A4;C;rs2740574;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
SALBUTAMOL;ADCY9;AG;rs144315541;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERPHENAZINE;MCPH1;A;rs17570753;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
PERPHENAZINE;CDH13;G;rs2116971;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
PERPHENAZINE;SKOR2;G;rs9952628;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC47A2;AA;rs12943590;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;KCNMA1;G;rs35793;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
PERPHENAZINE;MAML3;A;rs11100483;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
VALPROIC ACID;UGT2B7;CC + CT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHACHOLINE;RUNX1;AA;rs11702779;OTHER;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;LRP1B;G;rs874295;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
BEVACIZUMAB;HTRA1;AA;rs11200638;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;PSMD14;A;rs9713;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
RISPERIDONE;AGAP1;C;rs1869295;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
BEVACIZUMAB;ARMS2;TT;rs10490924;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;APEH;CC;rs3816877;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NPAS3;G;rs1315115;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
RISPERIDONE;TMEFF2;G;rs3738883;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
METFORMIN;PCK1;CT + TT;rs4810083;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;PCK1;CT + TT;rs4810083;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIPRASIDONE;CDH4;A;rs4925300;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
ZIPRASIDONE;LYN;G;rs1546519;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
BEVACIZUMAB;CFH;GG;rs800292;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ZIPRASIDONE;NALCN;C;rs9585618;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
ZIPRASIDONE;CNTN4;A;rs17194378;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
IMATINIB;SLCO1A2;CT + TT;rs4148978;TOXICITY;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_SIDE_EFFECT
IMATINIB;SLCO1A2;CT + TT;rs4148978;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_SIDE_EFFECT
IMATINIB;SLCO1B3;GG;rs4149117;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CALU;AA;rs2290228;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;;T;rs12610827;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOB;AA;rs676210;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHACHOLINE;RUNX1;AG + GG;rs11702779;OTHER;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SERPINE1;G;rs1799889;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;SERPINE1;G;rs1799889;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTR;G;rs1805087;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-HODGKIN LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTR;G;rs1805087;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;DISEASE;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CSMD1;A;rs17070785;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
OLANZAPINE;PLAGL1;C;rs2247408;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
SIROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;PLAGL1;A;rs3819811;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
SIROLIMUS;CYP3A5;CC;rs4646453;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;PTPRN2;C;rs221253;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
IMATINIB;SLC22A1;AA + AG;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;AA + AG;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PERPHENAZINE;PRKCE;C;rs2278773;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
PERPHENAZINE;;C;rs11774231;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;DOT1L;CT + TT;rs2269879;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ADM;CC;rs11042725;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TILDRAKIZUMAB;ATG5;CT;rs9373839;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TILDRAKIZUMAB;IL17RC;CC;rs708567;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;BDNF;TT;rs7124442;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;OXT;T;rs2740204;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DIAZEPAM;CYP3A4;GG;rs35599367;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;C;rs408626;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NOS1AP;T;rs10494366;DOSAGE;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;CAUTION_DOSE_ADJUST
REPAGLINIDE;NOS1AP;T;rs10494366;DOSAGE;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;CAUTION_DOSE_ADJUST
REPAGLINIDE;NOS1AP;T;rs10494366;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;NOS1AP;T;rs10494366;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;BDNF;TT;rs7103411;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMIVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITONAVIR;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ZIDOVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;BDNF;CT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TILDRAKIZUMAB;TNFAIP3;GG;rs610604;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ERICH3;CC;rs11580409;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT;rs12248560;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENTACAPONE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELMISARTAN;SLCO1B3;C;rs60140950;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2D6;GG;rs16947;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;rs121909011;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ULK3;GG;rs2290573;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ULK3;GG;rs2290573;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD1;GT;rs265976;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS;STAT3;GG;rs4796793;EFFICACY;INCREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;SLCO2B1;AA + AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;DOSAGE;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;DOSAGE;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;DOSAGE;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RISPERIDONE;HRH3;TT;rs3787430;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AC + CC;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RISPERIDONE;HRH3;TT;rs3787429;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;TAAR6;AA + AG;rs4305746;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IL6;G;rs1800795;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFASALAZINE;ABCG2;TT;rs2231142;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IL6;G;rs1800796;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IL6;G;rs1800797;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;AA + AG;rs2199936;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ILOPERIDONE;CNTF, ZFP91-CNTF;GG;rs1800169;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DISULFIRAM;OPRD1;CC;rs678849;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROPOIETIN;STIM1;AG + GG;rs1561876;EFFICACY;INCREASED;RESISTANCE;OTHER;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROPOIETIN;STIM1;AG + GG;rs1561876;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LATANOPROST;PTGFR;CC;rs3753380;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ABCC4;T;rs17268282;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;CC;rs622342;EFFICACY;;RESPONSE;OTHER;GENETIC VARIATION AT RS2289669;PEOPLE;
MORPHINE;COMT;T;rs737866;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;T;rs737866;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;G;rs2075507;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;G;rs2075507;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;CYP1A1;AA;rs2606345;EFFICACY;DECREASED;RESPONSE;DISEASE;EPILEPSY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs5746849;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;rs5746849;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT, TXNRD2;C;rs7287550;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT, TXNRD2;C;rs7287550;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs6269;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;rs6269;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs740603;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;rs740603;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;ABCC3;T;rs4793665;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;POR;T;rs1057868;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCC2;CC;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;SORCS2;A;rs73208473;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;CC;rs9304742;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;UGT2B7;AA;rs28365063;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;NR1I2;T;rs3814055;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;CC + CT;rs2916205;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;GNB3;CT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;CLUSTER HEADACHE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;G;rs1135840;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABINOIDS;TRPV1;CC;rs8065080;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABINOIDS;UGT2B7;AA;rs7438135;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;AA;rs11126740;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;GT;rs2231142;OTHER;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;GT;rs2231142;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;KCNJ11;T;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;KCNJ11;T;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;TCF7L2;TT;rs290487;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;TCF7L2;TT;rs290487;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;A;rs4680;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;rs4680;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;TT;rs1051740;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;COMT;C;rs4818;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;C;rs4818;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROPOIETIN;ORAI1;GG + GT;rs12320939;EFFICACY;INCREASED;RESISTANCE;OTHER;KIDNEY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROPOIETIN;ORAI1;GG + GT;rs12320939;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs2239393;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;rs2239393;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
MORPHINE;ARVCF, COMT;T;rs165728;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;ARVCF, COMT;T;rs165728;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AG;rs4148740;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;TT;rs4148739;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;ARVCF, COMT;T;rs174699;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;ARVCF, COMT;T;rs174699;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;del;rs1799732;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;CETP;AA;rs1532624;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;CT + TT;rs6908425;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SIK3;AA;rs533556;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;CT + TT;rs12191877;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITODRINE;KCNMB2;TT;rs7624046;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCC2;AA + AG;rs4148386;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCC2;CT + TT;rs3740066;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;MEN;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITODRINE;KCNMB2;CC;rs9839376;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;G;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;G;rs7643645;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;METTL21A;CC;rs2952768;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;METTL21A;CC;rs2952768;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;T;rs4688040;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABINOIDS;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;C;rs2461817;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;ABCB1;AA + AG;rs1045642;DOSAGE;;DOSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
ATAZANAVIR;SLCO1B1;TT;rs4149056;DOSAGE;;DOSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;NR1I2;TT;rs2472677;DOSAGE;;DOSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
WARFARIN;VKORC1;AC;rs61742245;DOSAGE;INCREASED;DOSE;OTHER;WARFARIN MAINTENANCE TREATMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DOCETAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINORELBINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINORELBINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINORELBINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VINORELBINE;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;SLC26A9;A;rs11240594;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;SLC26A9;A;rs11240594;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOLANIDINE;NFIB;CC + CT;rs28379954;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ZIPRASIDONE;EHF;A;rs286913;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ZIPRASIDONE;EHF;A;rs286913;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;SLC6A3;A;rs2975226;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;SLC6A3;A;rs2975226;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;IL1A;C;rs11677416;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;IL1A;C;rs11677416;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;POR;TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;C;rs1051740;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AA;rs10929302;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;PTPRD;CC;rs17584499;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;PTPRD;CC;rs17584499;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE;CAUTION_SIDE_EFFECT
ACAMPROSATE;GRIN2B;A;rs2058878;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ATP1A2;T;rs6688363;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;;T;rs8050896;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TNFRSF11A;A;rs2980976;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;PPA2;G;rs2636697;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;;A;rs1232027;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;;A;rs1232027;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
HYDROMORPHONE;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
OXYCODONE;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
TRAMADOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;WOMEN;CAUTION_DOSE_ADJUST
RISPERIDONE;PPA2;A;rs2636719;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;DOSAGE;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;CAUTION_DOSE_ADJUST
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;DOSAGE;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;CAUTION_DOSE_ADJUST
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASAGILINE;COMT;AA;rs4680;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;DOSAGE;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;CAUTION_DOSE_ADJUST
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;DOSAGE;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;CAUTION_DOSE_ADJUST
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DISULFIRAM;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"PSORIATIC""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:CROHN DISEASE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:PSORIASIS""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:SPONDYLITIS";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;"ANKYLOSING""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;AT;rs4646244;TOXICITY;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;AT;rs4646244;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;BEST3;AA + AG;rs61747221;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"PSORIATIC""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:CROHN DISEASE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:PSORIASIS""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:SPONDYLITIS";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;"ANKYLOSING""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;GG;rs6759892;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TNF;GG;rs1800629;DOSAGE;INCREASED;DOSE;OTHER;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
OPIOIDS;TNF;GG;rs1800629;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;CHILDREN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CT;rs3812718;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
PACLITAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TJP1;T;rs813676;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;A;rs1800797;DOSAGE;DECREASED;DOSE;OTHER;NEOPLASMS;CHILDREN;CAUTION_DOSE_ADJUST
OPIOIDS;IL6;A;rs1800797;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PAIN;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;DOSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADGRL3;CC + CT;rs734644;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE;CA10;CC + CT;rs967676;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;CA10;CC + CT;rs967676;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;CT;rs1051740;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;CT;rs1051740;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;CC;rs1051740;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;CC;rs1051740;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
GEMCITABINE;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE;;AA + AG;rs1786929;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;;AA + AG;rs1786929;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;ADGRL3;AG + GG;rs1355368;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADGRL3;CC + CG;rs6813183;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;;C;rs7395555;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;CFH;TT;rs1061170;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;SPOPL;C;rs10170310;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;PDE4D;T;rs17382202;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;;DOSE;;;;
QUETIAPINE;PDE4D;G;rs17742120;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;PDE4D;A;rs2164660;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
PERINDOPRIL;AGTR1;CC + CT;rs5182;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TJP1;T;rs711355;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TJP1;A;rs785423;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR ALAFENAMIDE;ABCB1;CT;rs3842;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;SLC6A4;T;rs25531;EFFICACY;;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;
RALOXIFENE;UGT1A8;CC;rs1042597;EFFICACY;INCREASED;RESPONSE;DISEASE;MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;UGT1A8;CC;rs1042597;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;STAT6;CC + CT;rs1059513;EFFICACY;INCREASED;RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;WBP2NL;A;rs5758550;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;CD40LG;T;rs1126535;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;ESR1;CC;rs11543791;EFFICACY;DECREASED;RESPONSE;DISEASE;MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;ESR1;CC;rs11543791;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PERINDOPRIL;AGTR1;AA + AT;rs275651;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;MYO1H;C;rs7959663;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;FCGR2A;G;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;EPHX2;T;rs59724122;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;FBXW12;CT;rs17080138;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN E-3174;FBXW12;CT;rs17080138;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LITHIUM;GRAMD1B;A;rs61123830;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LITHIUM;;A;rs66486766;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;A;rs324899;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;T;rs1611259;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;A;rs6942227;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;DOSAGE;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CATECHOLAMINES;ADRB1;CC;rs1801253;DOSAGE;DECREASED;DOSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;APOE;CC;rs429358;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;APOE;CC;rs429358;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
LOSARTAN;ZNF703;CT;rs79707182;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN E-3174;ZNF703;CT;rs79707182;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PERINDOPRIL;BDKRB1;AA + AG;rs12050217;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;SLC17A4;A;rs11754288;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN E-3174;SLC17A4;A;rs11754288;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs17708472;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;C;rs680244;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;G;rs16969968;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs680244;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;OTHER;GOUT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;FAM177A1;T;rs79403677;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;;A;rs2487032;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;G;rs11591741;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LITHIUM;ADCY1;A;rs1521470;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
REPAGLINIDE;KCNQ1;CT + TT;rs2237892;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;KCNQ1;CT + TT;rs2237892;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;A;rs7588746;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;FAM178B;A;rs6728642;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;EFFICACY;INCREASED;RESPONSE;OTHER;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZILEUTON;PRORP;AA;rs12436663;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;GT;rs10509680;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN E-3174;CYP2C9;GT;rs10509680;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LITHIUM;ZNF804A;T;rs62200793;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;A;rs1611255;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;A;rs209474;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;KCNQ1;AC + CC;rs2237895;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;KCNQ1;AC + CC;rs2237895;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;A;rs3919583;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLATIRAMER ACETATE;TGFB1;A;rs1800469;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCC2;CT + TT;rs3740066;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLUCOCORTICOIDS;GLCCI1;G;rs37973;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;CYP3A4;AG + GG;rs2246709;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENELIGLIPTIN;FMO3;AG + GG;rs2266780;METABOLISM/PK;DECREASED;CLEARANCE;;;MEN;CAUTION_DRUG_ACCUMULATION
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;A;rs16969968;OTHER;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;COMT;C;rs4818;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;GPR83;GG;rs3758785;EFFICACY;DECREASED;RESPONSE;EFFICACY;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;COMT;T;rs5993883;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TENELIGLIPTIN;FMO3;CT + TT;rs909530;METABOLISM/PK;DECREASED;CLEARANCE;;;MEN;CAUTION_DRUG_ACCUMULATION
MENOTROPINS;FSHR;CT;rs6166;;DECREASED;DOSE;;;WOMEN;
QUETIAPINE;COMT;A;rs6269;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;GPR83;GG;rs3758785;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;rs1800795;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TENELIGLIPTIN;FMO3;AG + GG;rs2266782;METABOLISM/PK;DECREASED;CLEARANCE;;;MEN;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;ABCB1;CT;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;OVARIAN NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;HSD3B1;CC + CT;rs7553527;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;TTC6;CC + CT;rs177852;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENELIGLIPTIN;CYP3A4;CT + TT;rs2242480;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;IFNAR1;G;rs1012335;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
5-HYDROXYOMEPRAZOLE;;A;rs12777823;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;;A;rs12777823;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;RESPONSE;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;ADRB2;AA;rs1042713;PD;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;NR1I3;GG;rs3003596;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;GG + GT;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;GG + GT;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA + AC;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;CC + CT;rs13120400;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;CC + CT;rs13120400;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CT + TT;rs10841753;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;AC + CC;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;AC + CC;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACIDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NITRENDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMEFANTRINE;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;WOMEN;CAUTION_DRUG_ACCUMULATION
LUMEFANTRINE;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;HTR1A;TT;rs10042486;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;MEN;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOMIPRAMINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLORPROMAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIFLUOPERAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FELODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;GSK3B;GG;rs334558;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;GSK3B;GG;rs334558;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SRPRB;CT;rs17376019;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETHANOL;ALDH2;AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LUMEFANTRINE;CYP3A5;T;rs10264272;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;WOMEN;CAUTION_DRUG_ACCUMULATION
LUMEFANTRINE;CYP3A5;T;rs10264272;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HYPERLIPIDEMIAS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETHANOL;PGM1;CC;rs4643;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACETALDEHYDE;ADH1A;CT;rs1229976;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LUMEFANTRINE;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MALARIA;WOMEN;CAUTION_DRUG_ACCUMULATION
LUMEFANTRINE;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
ACETALDEHYDE;ALDH2;AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETALDEHYDE;PGM1;CC;rs4643;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
VERAPAMIL;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACETALDEHYDE;ADH1B;CT;rs1229984;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FELODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A5;T;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;CAUTION_DOSE_ADJUST
N-DESMETHYLCLOZAPINE;UGT2B10;GT;rs61750900;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMEFANTRINE;CYP3A4;T;rs2740574;EFFICACY;DECREASED;RESPONSE;DISEASE;MALARIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMEFANTRINE;CYP3A4;T;rs2740574;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:PREGNANCY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;N6AMT1;G;rs2254638;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;TT;rs6759892;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;ASTN2;CT + TT;rs7858836;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;ASTN2;CT + TT;rs7858836;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
BENAZEPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIDAPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ASTN2;CC + CT;rs958804;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;ASTN2;CC + CT;rs958804;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;AA;rs1105879;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;AA;rs2070959;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VERAPAMIL;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETIDRONIC ACID;COL1A1;AA + AC;rs1800012;EFFICACY;DECREASED;RESPONSE;DISEASE;METABOLIC BONE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR1A;CG + GG;rs6295;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;MEN;CAUTION_DRUG_ACCUMULATION
DULOXETINE;;G;rs4858478;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;AT;rs67376798;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;GG;rs6759892;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;T;rs13093500;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC ACID;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYCHLOROQUINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;T;rs4334661;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC ACID;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYCHLOROQUINE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs7625956;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs4646453;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;SULT1A1;TT;rs1042028;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;G;rs7616119;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TERBUTALINE;ADRB2;CT;rs1800888;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;T;rs2933304;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;NRXN1;T;rs4971678;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;G;rs12630569;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
BEVACIZUMAB;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROPOIETIN;HFE;A;rs1800562;DOSAGE;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE;CAUTION_DOSE_ADJUST
ERYTHROPOIETIN;HFE;A;rs1800562;METABOLISM/PK;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE;CAUTION_DOSE_ADJUST
DULOXETINE;;C;rs6700741;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROPOIETIN;HFE;G;rs1799945;DOSAGE;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE;CAUTION_DOSE_ADJUST
ERYTHROPOIETIN;HFE;G;rs1799945;METABOLISM/PK;DECREASED;DOSE;OTHER;HEMODIALYSIS TREATMENT;PEOPLE;CAUTION_DOSE_ADJUST
DULOXETINE;TEX10;C;rs6479008;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;TEX10;A;rs7035619;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;TEX10;T;rs10989064;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ATP10A;G;rs12595802;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;TEX10;G;rs7472;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs56229625;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;G;rs61692318;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs62319299;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;TEX10;G;rs10124893;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;INVS;G;rs10123866;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABEMACICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DOSE_ADJUST
ABEMACICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALBOCICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DOSE_ADJUST
PALBOCICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBOCICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN;CAUTION_DOSE_ADJUST
RIBOCICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED;DOSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;C;rs10007051;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;C;rs9879065;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;C;rs55881666;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;;CC + CT;rs2097432;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;CYP2C9;CC + CT;rs4918758;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;;A;rs11933890;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;C;rs9310658;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;A;rs7653345;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ABAT;GG;rs1731017;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;T;rs9310657;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;G;rs9824595;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;C;rs9873889;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;G;rs9819548;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE;CDA;CC;rs532545;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;GG;rs1799983;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs56165452;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;CRP;AG + GG;rs1130864;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A43;AA;rs472660;DOSAGE;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP3A43;AA;rs472660;EFFICACY;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A43;AA;rs472660;TOXICITY;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;CYP3A43;AA;rs472660;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;EOMES;T;rs2371108;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANGINA PECTORIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETOPOSIDE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;ATG5;CC + CT;rs9373839;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;MIEF2;G;rs56355515;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;MIEF2;G;rs12603700;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;ATG5;CT + TT;rs510432;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DULOXETINE;MIEF2;G;rs3889402;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;AOX1;G;rs55754655;EFFICACY;DECREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;AOX1;AG + GG;rs55754655;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;AA;rs1799998;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs58042962;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C;rs2740574;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DULOXETINE;;T;rs10771997;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;LPL;GG;rs320;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;FCN2;T;rs3124955;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOA1;CG;rs2727786;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;FCN2;A;rs3128624;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs7306991;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;CLEC16A;A;rs6498169;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DULOXETINE;;C;rs10771999;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs10771998;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;SKIC3;G;rs12657120;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHOSUXIMIDE;CACNA1H;T;rs61734410;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;SKIC3;G;rs4639250;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs4437856;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHOSUXIMIDE;CACNA1I;T;rs3747178;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;TREML4;A;rs9369266;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;MOCOS;AA + AC;rs594445;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DULOXETINE;TREML4;G;rs13204353;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCB1;A;rs2032582;EFFICACY;DECREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CALM1;T;rs12885713;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;C;rs2419128;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs12502866;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;T;rs12094644;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;AA + AC;rs2072671;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;CACNA1H;A;rs2753326;EFFICACY;INCREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;GG;rs4728709;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ADRA2A;GG;rs1800545;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ADRA2A;GG;rs1800545;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;;G;rs2874116;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;CC;rs1801701;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;CC;rs1801701;EFFICACY;INCREASED;RESPONSE;DISEASE;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;CC;rs4148738;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;T;rs183701923;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;rs140278421;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs4803419;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CHLORPROMAZINE;DRD2;GG;rs1799732;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;TT;rs7079;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;GASTROESOPHAGEAL REFLUX;INFANTS;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AA;rs1799971;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AA;rs1799971;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NELFINAVIR;CYP2C19;AA;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;C;rs771237265;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOLBUTAMIDE;CYP2C9;T;rs762081829;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;A;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A1;A;rs628031;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;A;rs145119820;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;C;rs761895497;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;F7;AA + AG;rs510317;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPHENYTOIN;CYP2C19;T;rs61311738;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFONAMIDES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
UREA DERIVATIVES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
UREA DERIVATIVES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;AGT;G;rs4762;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;AGT;A;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BENAZEPRIL;AGT;T;rs7079;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOA5;CG + GG;rs3135506;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AG;rs35303484;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM;;CT;rs585719;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;CYP2E1;A;rs6413432;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs4803419;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GATA4;TT;rs2645400;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;GATA4;TT;rs4841588;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;GG;rs7662029;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;UGT2B7;CC;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;CC;rs7439366;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;AA;rs2838958;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SILDENAFIL;VEGFA;AA;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
SILDENAFIL;VEGFA;AA + AC;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE2;GG;rs2106809;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;UGT2B7;GG;rs7662029;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ECULIZUMAB;CR1;AG + GG;rs2274567;EFFICACY;DECREASED;RESPONSE;DISEASE;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRABEGRON;UGT1A4;GT;rs2011425;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLIC ACID;UGT1A1;AG;rs4148323;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;UGT1A3;AA;rs2008584;METABOLISM/PK;DECREASED;HALF-LIFE TIME;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;SLC6A2;CC;rs12708954;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOZAPINE;DRD1;G;rs686;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;AA;rs7438135;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;SLC19A1;TT;rs1051266;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD3;TT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;G;rs12199316;DOSAGE;INCREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
TICAGRELOR;CYP3A4;CC;rs56324128;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;SLCO1B1;C;rs113681054;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;SLCO1B1;T;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SLC29A1;A;rs760370;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;SLC29A1;A;rs760370;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;CES1;CT;rs71647871;DOSAGE;DECREASED;DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;CES1;CT;rs71647871;METABOLISM/PK;DECREASED;DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DOSE_ADJUST
TICAGRELOR;UGT2B7;TT;rs61361928;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;HTR1A;GG;rs6295;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;MEN;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A43;G;rs62471956;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;CC;rs1042028;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL2;AA;rs2069762;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;IL2;AA;rs2069762;DOSAGE;INCREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;BDNF;CC;rs6265;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;BDNF;CC;rs6265;DOSAGE;INCREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP3A4;AG;rs4646437;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;IL6;CC;rs1800795;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;IL6;CC;rs1800795;DOSAGE;INCREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
ATENOLOL;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC4;AA + AG;rs1059751;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HEPATITIS B;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;AA + AG;rs1059751;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A1;T;rs2472297;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;IL1B;AA + AG;rs1143634;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;IL1B;AA + AG;rs1143634;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;SCARB1;CT + TT;rs4238001;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;SLC22A6;TT;rs4149170;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEPATITIS B;PEOPLE;CAUTION_DRUG_ACCUMULATION
TENOFOVIR;SLC22A6;TT;rs4149170;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CHRONIC;PEOPLE;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRD1;CC;rs678849;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRD1;CC;rs678849;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
IRBESARTAN;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTROPHY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;OTHER;LEFT VENTRICULAR;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;rs75039782;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;APOA5;CC + CG;rs3135506;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INSULIN RECOMBINANT;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZINC ACETATE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD1;CT + TT;rs5326;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC ACID;ATIC;CC;rs2372536;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;rs2372536;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;ADAM33;AA;rs2853209;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;AA;rs2853209;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LITHIUM;GADL1;T;rs17026688;EFFICACY;INCREASED;RESPONSE;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FOLIC ACID;ITPA;CC;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;C;rs12714145;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ADA;C;rs244076;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ADORA2A;T;rs5751876;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC ACID;AMPD1;A;rs17602729;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;A;rs17602729;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RITUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;EGFR;CC;rs2293347;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;TGFBR3;TT;rs12082710;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;rs2231142;DOSAGE;INCREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIFAMPIN;AADAC;GG;rs1803155;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;SLCO2B1;AA + AG;rs1077858;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CETUXIMAB;AREG;AA;rs9996584;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;AREG;AA;rs9996584;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;AREG;GG;rs1353295;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;AREG;GG;rs1353295;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"BURKITT LYMPHOMA""";PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:LYMPHOMA";PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"T-CELL""";PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";PEOPLE;CAUTION_DRUG_ACCUMULATION
RIFAMPIN;ABCB1;CC;rs3842;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"BURKITT LYMPHOMA""";PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:LYMPHOMA";PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"T-CELL""";PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;DRD1;CC + CT;rs4867798;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD3;TT;rs6280;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD4;AA;rs11246226;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;CC;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE SULFATE;SLCO1B1;C;rs10841753;EFFICACY;DECREASED;CONCENTRATIONS;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOBUTAMINE;GNAS;CC + CT;rs62205366;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE SULFATE;SLCO1B1;C;rs10841753;METABOLISM/PK;DECREASED;;OTHER;BREAST NEOPLASMS;WOMEN;
WARFARIN;GGCX;TT;rs12714145;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CETUXIMAB;AREG;GG;rs13104811;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;AREG;GG;rs13104811;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CRHR1;AA + AG;rs28364032;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;rs4148324;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;POR;T;rs1057868;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIRACIL HYDROCHLORIDE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIFLURIDINE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;A;rs2018417;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1B;A;rs2018417;METABOLISM/PK;;METABOLISM;;;;
ETHANOL;ADH1B;C;rs17033;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1B;C;rs17033;METABOLISM/PK;;METABOLISM;;;;
ETHANOL;ADH1B;G;rs1229985;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1B;G;rs1229985;METABOLISM/PK;;METABOLISM;;;;
PHENPROCOUMON;PPARA;A;rs4253728;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1A;A;rs931635;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1A;A;rs931635;METABOLISM/PK;;METABOLISM;;;;
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;KCNJ6;TT;rs2070995;;INCREASED;DOSE;DISEASE;SUBSTANCE-RELATED DISORDERS;PEOPLE;
ETHANOL;ADH1C;A;rs283416;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1C;A;rs283416;METABOLISM/PK;;METABOLISM;;;;
ROSIGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1C;A;rs283411;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1C;A;rs283411;METABOLISM/PK;;METABOLISM;;;;
ETHANOL;ADH1C;C;rs1662060;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1C;C;rs1662060;METABOLISM/PK;;METABOLISM;;;;
TACROLIMUS;SUMO4;AA;rs237025;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;TT;rs17878544;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA + AG;rs7200749;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;ABCG2;G;rs2231142;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs7200749;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM;NEDD4L;A;rs520210;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
HMG-COA_REDUCTASE_INHIBITORS;TOMM40;G;rs2075650;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;rs55894764;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs28898617;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
METHYLPHENIDATE;PEBP4;T;rs17685420;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
VERAPAMIL;ITGAL;C;rs2230433;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MIGRAINE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PAZOPANIB;KDR;AG;rs34231037;EFFICACY;INCREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH7;C;rs1154461;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH7;C;rs1154461;METABOLISM/PK;;METABOLISM;;;;
HEPATITIS VACCINES;IL4R;C;rs1805015;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;rs1229967;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1A;C;rs1229967;METABOLISM/PK;;METABOLISM;;;;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;rs2276332;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1A;C;rs2276332;METABOLISM/PK;;METABOLISM;;;;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;CC;rs5051;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIDAPRIL;AGT;CC;rs5051;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;rs1229976;TOXICITY;;METABOLISM;;;;
ETHANOL;ADH1A;C;rs1229976;METABOLISM/PK;;METABOLISM;;;;
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHOLANGITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;A;rs4244285;METABOLISM/PK;;EXPOSURE;;;;
HEPATITIS VACCINES;IL13;T;rs1295686;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN;CES1;AA + AG;rs8192935;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;VDR;TT;rs11574077;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADGRL3;AA;rs1868790;EFFICACY;DECREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SNAP25;GG + GT;rs3746544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A3;CC + CT;rs2550948;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
INTERFERONS;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;AA + AG;rs34059508;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;A;rs10514475;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;A;rs6108160;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;LRP1;TT;rs1800139;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;LRP1;CC;rs1800154;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;T;rs56113850;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS;IFNL3;GG;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;AA + AG;rs2359612;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XRCC1;G;rs1799782;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC22A1;TT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;LGR5;CC + CT;rs17109924;EFFICACY;INCREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;AA;rs34059508;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;A;rs1902023;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;AA;rs34130495;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ADENOTONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;AA;rs1902023;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED;DOSE;OTHER;NEOPLASMS;WOMEN;CAUTION_DOSE_ADJUST
FLUOROURACIL;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED;DOSE;OTHER;NEOPLASMS;WOMEN;CAUTION_DOSE_ADJUST
PITAVASTATIN;SLCO1B1;A;rs4363657;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN LACTONE;SLCO1B1;A;rs4363657;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCG2;AG + GG;rs1481012;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOMATROPIN RECOMBINANT;CDK4;CC;rs2069502;EFFICACY;DECREASED;RESPONSE;DISEASE;TURNER SYNDROME;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;FMO5;A;rs7541245;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;DECREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;USP24;CC + CT;rs17111584;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A;RORA;TT;rs4774388;EFFICACY;INCREASED;RESPONSE;OTHER;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIMAZOLAM;CES1;CT + TT;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NICOTINE;;T;rs113288603;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;APOE;CC + CT;rs71352238;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADRA2A;GG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;;A;rs12461964;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;LPA;AG + GG;rs10455872;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs887829;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;BDNF;CC;rs6265;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG + GT;rs3745274;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
ATORVASTATIN;CYP3A7;G;rs45446698;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs2279345;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SOMATROPIN RECOMBINANT;CDK4;TT;rs2270777;EFFICACY;INCREASED;RESPONSE;DISEASE;GROWTH HORMONE DEFICIENCY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;T;rs75039782;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METFORMIN;PRPF31;C;rs254271;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRPF31;C;rs254271;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GABAPENTIN;SLC7A5;AG;rs4240803;DOSAGE;INCREASED;DOSE;OTHER;NEUROPATHIC PAIN;PEOPLE;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
METFORMIN;NBEA;C;rs57081354;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;NBEA;C;rs57081354;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUMATRIPTAN;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FENOTEROL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FENOTEROL;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SUMATRIPTAN;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED;RESPONSE;OTHER;LUPUS NEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DRUGS USED IN DIABETES;IRS1;CT + TT;rs1801278;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS USED IN DIABETES;IRS1;CT + TT;rs1801278;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUMATRIPTAN;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;A;rs1801394;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;NEDD4L;A;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EMTRICITABINE;ABCC2;TT;rs2273897;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EMTRICITABINE;ABCC2;TT;rs2273897;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OTHER:PREGNANCY;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOGUANIL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
CYCLOGUANIL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GABAPENTIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED;RESPONSE;OTHER;NEUROPATHIC PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREGABALIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED;RESPONSE;OTHER;NEUROPATHIC PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA;rs4680;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;AA;rs4680;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;AA;rs4680;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;AA;rs4680;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CPA6;T;rs2162145;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CPA6;T;rs2162145;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;DUSP1;G;rs881152;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;A;rs34059508;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;SLCO1B3;GG + GT;rs4149117;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;IL11;CT + TT;rs1126757;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CES1;CT + TT;rs2307240;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;SLC2A2;CC;rs1499821;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ABIRATERONE;YBX1;AC + CC;rs10493112;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NFATC4;CC + CT;rs1955915;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
GRAZOPREVIR;SLCO1B1;C;rs4149056;PD;INCREASED;EXPOSURE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;CYP2D6;CC;rs1080985;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GRAZOPREVIR;SLCO1B1;A;rs11045819;PD;INCREASED;EXPOSURE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs9923231;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;rs9923231;METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;BDNF, BDNF-AS;C;rs7127507;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ENALAPRIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;BDNF, BDNF-AS;G;rs11030118;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AG + GG;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;BDNF, BDNF-AS;C;rs1967554;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BISOPROLOL;CYP2D6;G;rs1080985;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;BDNF;G;rs2030324;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BISOPROLOL;CYP2D6;CT + TT;rs3892097;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTA1;AA;rs3957357;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;BDKRB2;TT;rs1799722;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;BDNF;C;rs988748;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;PAIN;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;C;rs55918055;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHADONE;BDNF;G;rs11030119;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TRAMADOL;SLC22A1;T;rs12208357;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T;rs2242480;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T;rs2242480;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;CYP3A5;TT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;A;rs34130495;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;AA;rs4149570;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;AA;rs4149570;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;AA + AG;rs5030728;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;CT + TT;rs8065082;EFFICACY;INCREASED;RESPONSE;OTHER;GLUCOSE INTOLERANCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;TT;rs4696480;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;AA + AT;rs2430561;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;AA + AT;rs2430561;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;TT;rs352139;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;TT;rs352139;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1L1;AA;rs4072879;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CC + CT;rs3804099;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CT + TT;rs1816702;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;OPRM1;G;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;ENPP2;AA;rs2249015;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;ENPP2;AA;rs2249015;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
DONEPEZIL;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GALANTAMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVASTIGMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;APOE;CT;rs429358;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;CC + CT;rs10499563;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;CC + CT;rs10499563;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;AA + AG;rs2275913;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;AA + AG;rs2275913;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LATANOPROST;ABCC4;AC;rs11568658;EFFICACY;DECREASED;RESPONSE;DISEASE;OPEN-ANGLE GLAUCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;CC + CT;rs1554973;EFFICACY;DECREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BOTULINUM TOXIN TYPE A;CALCA;G;rs3781719;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;AA + AG;rs2569190;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BOTULINUM TOXIN TYPE A;TRPV1;A;rs222749;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ENPP2;AA;rs7832704;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;ENPP2;AA;rs7832704;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AA + AG;rs4848306;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AA + AG;rs4848306;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;CC + CT;rs4251961;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;CG + GG;rs6927172;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;CG + GG;rs6927172;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;APOE;CC;rs429358;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;FOLR3;CT + TT;rs61734430;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMETREXED;FOLR3;CT + TT;rs61734430;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MESOTHELIOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;GRK4;CT;rs1801058;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG;rs7997012;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ELBASVIR / GRAZOPREVIR;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;GRK4;GT + TT;rs2960306;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCC2;CT + TT;rs3740066;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCC2;CT + TT;rs3740066;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METOPROLOL;GRK4;CC;rs1024323;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GAD1;G;rs3762556;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;GAD1;TT;rs769404;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
ROCURONIUM;SLCO1A2;T/del + TT;rs3834939;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP1A2;AA + AC;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;GG;rs1058164;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;AA;rs28371699;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP4F2;AA;rs2074900;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;UGT1A4;C;rs2011404;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;UGT1A4;C;rs2011404;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;DECREASED;DOSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
URIC ACID;VEGFC;C;rs1002976;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
LETERMOVIR;SLCO1B1;TT;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;T;rs34946978;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;T;rs34946978;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CAPN10;G;rs3792269;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LETERMOVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
LETERMOVIR;UGT1A1;AA + AG;rs4148323;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A;FHIT;C;rs760316;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;FHIT;C;rs760316;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLYBURIDE;FMO2;T;rs7512785;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;AG + GG;rs1801394;EFFICACY;INCREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;ADRB2;GG;rs1042713;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;DECREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC16A7;T;rs12231740;EFFICACY;DECREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ARID5B;CC;rs4948496;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;APOE;CT + TT;rs7412;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GAD1;G;rs3762555;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;GAD1;G;rs3749034;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;NAT2;AG + GG;rs1495741;EFFICACY;DECREASED;CLINICAL BENEFIT;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON BETA-1A;;T;rs4278350;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;;T;rs4278350;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CC;rs28371702;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VILDAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VILDAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IGURATIMOD;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A;GAPVD1;G;rs2291858;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;GAPVD1;G;rs2291858;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRD1;GG;rs204047;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;AA;rs797397;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRD1;GG;rs204047;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;ZNF804A;AA;rs1344706;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC1;CC + CT;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
INTERFERON BETA-1A;GAPVD1;T;rs10819043;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;GAPVD1;T;rs10819043;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A;;A;rs3133084;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;;A;rs3133084;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
GLYBURIDE;CYP51A1;G;rs7793861;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A;;G;rs1448673;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;;G;rs1448673;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;FMO2;T;rs7515157;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
AMISULPRIDE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
URIC ACID;BRINP3;T;rs950569;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;UGT2B15;G;rs4148269;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A;GAPVD1;C;rs10760397;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;GAPVD1;C;rs10760397;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
URIC ACID;PADI4;G;rs2477134;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A;ZNF697;A;rs10494227;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;ZNF697;A;rs10494227;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCC5;TT;rs1533682;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC3;AA + AG;rs861539;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;MAPK1;A;rs1803545;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCC5;A;rs3749442;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;GG;rs1135840;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;SPINK5;T;rs2303070;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;BDKRB2;A;rs5224;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;MAPK1;G;rs3729910;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;ABCB1;CT + TT;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETHANOL;KLB;A;rs11940694;TOXICITY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ESR1;T;rs2077647;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:AUTOIMMUNE DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;BDNF;C;rs6265;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUNISOLIDE;TBXT;TT;rs2305089;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GRANISETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;NAUSEA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GRANISETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALONOSETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;NAUSEA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALONOSETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;rs1800795;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;T;rs1061622;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;rs1800795;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RASAGILINE;DRD2;CC;rs1076560;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RASAGILINE;DRD2;CC;rs2283265;EFFICACY;INCREASED;RESPONSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CTLA4;AG + GG;rs4553808;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;BDNF-AS;T;rs10501087;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;IL3;AA;rs181781;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;CC;rs6755571;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TELAPREVIR;CYP24A1;C;rs2585428;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CTLA4;AA;rs4553808;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VARENICLINE;CHRNA4;GG;rs1044396;EFFICACY;DECREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;T;rs4646425;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;G;rs2069526;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;C;rs4646427;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;RESISTANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;A;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLARTHROPATHIES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;ORMDL3;AA + AG;rs2872507;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATAZANAVIR / RITONAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;ABCG2;CT + TT;rs13120400;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR / RITONAVIR;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs10509680;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GOLIMUMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;NR3C1;GG;rs41423247;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
FLUVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TALINOLOL;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;TT;rs7439366;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC + CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
RITODRINE;PDE4B;AA;rs598961;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PREMATURE BIRTH;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;G;rs4986910;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;G;rs4986910;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;XPA;CC;rs1800975;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
DEHYDROARIPIPRAZOLE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;IL10;AA;rs1800871;METABOLISM/PK;DECREASED;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIHYPERTENSIVES;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLDOPA;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NIFEDIPINE;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;RHEUMATIC HEART DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:HEART VALVE DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:CORONARY ARTERY DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
DACLATASVIR;VDR;TT;rs11568820;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;AG + GG;rs4680;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLDOPA;MMP9;CT + TT;rs3918242;EFFICACY;DECREASED;RESPONSE;DISEASE;GESTATIONAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DACLATASVIR;CYP24A1;CT + TT;rs2248359;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;
OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM CHANNEL BLOCKERS;NUMA1;GG;rs10898815;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;
OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;
CALCIUM CHANNEL BLOCKERS;TANC2;GG;rs2429427;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIBUTRAMINE;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;OTHER;OBESITY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCC2;AG;rs2273697;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;
OXCARBAZEPINE;ABCC2;AG;rs2273697;EFFICACY;;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;
BUSULFAN;GSTA1;T;rs3957356;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
S-EDDP;CYP2B6;CT;rs8192709;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTA1;A;rs3957357;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;UGT1A9;T;rs12052787;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIMVASTATIN;UGT1A9;A;rs2003569;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC4;TT;rs1799801;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMIPRAMINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MAPROTILINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
MAPROTILINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIPRAMOL;CYP2D6;TT;rs3892097;DOSAGE;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
OPIPRAMOL;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;DOSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ERCC3;AG + GG;rs3738948;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEGAFUR;CYP2A6;AA + AG;rs8192720;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLORPROMAZINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TERBUTALINE;ADRB2;GG;rs1042714;METABOLISM/PK;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HRH4;TT;rs4483927;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GRK4;T;rs2960306;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GRK4;T;rs1024323;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM CHANNEL BLOCKERS;PICALM;GG;rs588076;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DELEOBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FALDAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
PROPOFOL;GABRA2;CC;rs11503014;OTHER;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;HNF4A;T;rs3212198;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
CODEINE;CYP1B1;C;rs1056836;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP1B1;C;rs1056836;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NR1I3;TT;rs2501873;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
VERAPAMIL;PCDHB8;G;rs3733694;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;POR;TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VERAPAMIL;PCDHB6;A;rs17844444;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;AGTR1;AC;rs5186;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;BDKRB2;CT;rs1799722;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LOSARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;OPRM1;AG;rs9479757;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;T;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;MEN;CAUTION_DRUG_ACCUMULATION
SEROTONIN;MAOB;T;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;MEN;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;CT;rs4148738;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;TT;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;WOMEN;CAUTION_DRUG_ACCUMULATION
SEROTONIN;MAOB;TT;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER;WOMEN;CAUTION_DRUG_ACCUMULATION
APIXABAN;POR;T;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;UGT1A9;CC;rs2741049;EFFICACY;INCREASED;RESPONSE;DISEASE;SEIZURES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP1B1;A;rs1056837;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP1B1;A;rs1056837;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;CYP11B2;GG;rs1799998;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-HYDROXYCOTININE;;CC + CT;rs4105144;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-HYDROXYCOTININE;EGLN2;AA + AG;rs3733829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP1A1;AC + CC;rs2606345;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PITRAKINRA;IL4R;GG;rs1029489;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
RADIOTHERAPY;CACNA2D3;AG + GG;rs11130424;EFFICACY;INCREASED;RESISTANCE;OTHER;NASOPHARYNGEAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;MAP3K5;CC;rs9483947;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;CLNK;G;rs13144136;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;MAP3K5;CC;rs9376230;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LENALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;MAOA;AA;rs979605;METABOLISM/PK;DECREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ALDH2;AG;rs671;OTHER;INCREASED;EXPOSURE;;;MEN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;NEDD4L;CC + CG;rs292449;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;GG;rs8832;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
PITRAKINRA;IL4R;AA;rs3024530;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;AA;rs1110470;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;AA;rs2239347;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
BENAZEPRIL;MTR;AG + GG;rs1805087;EFFICACY;DECREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PITRAKINRA;IL4R;AA;rs1805010;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;GG;rs9934438;TOXICITY;INCREASED;DOSE;;;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;GG;rs9934438;TOXICITY;INCREASED;DOSE;;;;CAUTION_SIDE_EFFECT
SULINDAC;FMO3;AA;rs2266782;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLATE MOFETIL;SLCO1B3;A;rs7311358;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SULINDAC;FMO3;GG;rs2266780;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;METABOLISM;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;C;rs8105790;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;C;rs8105790;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3;C;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;C;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEMANTINE;NR1I2;CT + TT;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DEMENTIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;G;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;G;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;A;rs7248668;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;A;rs7248668;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;ANKS1B;CC;rs7968606;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;C;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;C;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;C;rs4803219;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;C;rs4803219;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
ESCITALOPRAM;;A;rs2069521;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SCARB1;CC;rs4238001;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MYOCARDIAL ISCHEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;ABCC2;GG;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;SV2C;TT;rs11960832;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;TBX21;CG;rs2240017;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC1;GG;rs2238476;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AG + GG;rs6314;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMIDONE;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMIDONE;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMIDONE;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMIDONE;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMIDONE;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
DULOXETINE;ANO2;C;rs61908411;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs61908409;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;rs61908410;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;rs78615940;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs78482393;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs61908405;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs61908406;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;A;rs2781659;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs61908404;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;rs61908408;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;rs61908407;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs17786412;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DULOXETINE;ANO2;A;rs17786400;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;C;rs9282564;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs61908403;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;rs61908402;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ANO2;C;rs17724452;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;PVT1;A;rs2114358;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs7316769;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs17724494;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CT;rs56165452;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;A;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;rs17786394;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs17724464;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;UGT2B7;CT;rs7439366;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEMETREXED;CCND1;A;rs9344;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CCND1;A;rs9344;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LIRAGLUTIDE;GLP1R;CT + TT;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;OBESITY;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LIRAGLUTIDE;GLP1R;CT + TT;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:POLYCYSTIC OVARY SYNDROME;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;CACNA1H;A;rs2753325;EFFICACY;INCREASED;CLINICAL BENEFIT;EFFICACY;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC + CT;rs2297595;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ASPIRIN;GP1BA;CT + TT;rs6065;EFFICACY;INCREASED;RESPONSE;;;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;rs1801160;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;GG;rs1801265;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;ABCC2;CC;rs717620;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;;G;rs11648166;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
LACOSAMIDE;ABCC2;A;rs2273697;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
LACOSAMIDE;ABCC2;T;rs717620;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;;T;rs28845026;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
TRAZODONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ARID5B;A;rs10994982;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENOFIBRATE;PPARA;GG;rs4253778;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC22A11;AT + TT;rs11231809;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;rs246240;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs3846662;EFFICACY;DECREASED;RESPONSE;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;rs3784864;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;AG + GG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;CC + CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;C;rs7254579;METABOLISM/PK;;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS;PEOPLE;
HMG-COA_REDUCTASE_INHIBITORS;;A;rs445925;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
HMG-COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;IL6;CC + CG;rs1800795;EFFICACY;INCREASED;RESPONSE;OTHER;PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;NRP1;T;rs2070296;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CETP;GG;rs708272;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CETP;GG;rs708272;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;CC;rs13120400;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DBH;GG;rs77905;DOSAGE;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
NICOTINE;MAOA;TT;rs1137070;DOSAGE;INCREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
OMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;HELICOBACTER INFECTIONS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;AA;rs7975232;METABOLISM/PK;;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN;
FLUVOXAMINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;G;rs2228570;METABOLISM/PK;;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;CHILDREN;
ANTIPSYCHOTICS;GRM3;AA;rs6465084;TOXICITY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;AA;rs2289669;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DIABETES MELLITUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;AA;rs2289669;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TYPE 2;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;G;rs2307424;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;AG;rs2307424;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIHYPERTENSIVES;ATP2B1;CT + TT;rs12817819;EFFICACY;INCREASED;RESISTANCE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIHYPERTENSIVES;ATP2B1;CT + TT;rs12817819;EFFICACY;INCREASED;RESISTANCE;DISEASE;DISEASE:HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;EPHX1;CT;rs1051741;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;PRSS53, VKORC1;CT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMLODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FELODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;SLCO1B1;CC;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;SLCO1B1;CC;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM CHANNEL BLOCKERS;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;A;rs2900478;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM CHANNEL BLOCKERS;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;CELSR2;C;rs646776;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT2B7;GG;rs12233719;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;T;rs28399454;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CALCIUM CHANNEL BLOCKERS;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;AG;rs2279343;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT2B7;CT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;APOC1, APOE;T;rs429358;DOSAGE;DECREASED;DOSE;OTHER;HAPLOTYPE EPSILON2;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT2B7;TT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;APOC1, APOE;T;rs7412;DOSAGE;DECREASED;DOSE;OTHER;HAPLOTYPE EPSILON2;PEOPLE;CAUTION_DOSE_ADJUST
INFLIXIMAB;;CC + CT;rs2097432;EFFICACY;INCREASED;DISCONTINUATION;EFFICACY;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHOTODYNAMIC THERAPY;CFH;TT;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT2B7;TT;rs7439366;METABOLISM/PK;;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;
RISPERIDONE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;CC + TT;rs9361233;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CC;rs8192709;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;;T;rs73277969;EFFICACY;INCREASED;DISCONTINUATION;EFFICACY;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;T;rs12248560;;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;
CLOPIDOGREL;CYP2C19;T;rs12248560;;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
ASPIRIN;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRASUGREL;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ASPIRIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;TT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;rs397508453;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
LOVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
LOVASTATIN;PPARA;AG + GG;rs4823613;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP1A2;CC;rs762551;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
SEROTONIN;ERICH3;T;rs696692;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
TACROLIMUS;ABCB1;AG + GG;rs1045642;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;EFFICACY;INCREASED;RESPONSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SEROTONIN;TSPAN5;G;rs11947402;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;G;rs3761847;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;CTNNB1;AA;rs4533622;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:CARDIOMYOPATHIES;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PERIPHERAL VASCULAR DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
CYCLOPHOSPHAMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL17A;A;rs2275913;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;IL17A;A;rs2275913;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;IL17A;A;rs2275913;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL17A;A;rs2275913;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CYP1A1;CC + CT;rs1048943;EFFICACY;INCREASED;RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A7;TT;rs10211;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs9923231;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;INCREASED;RESPONSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;OPRM1;AA;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;NEUROPATHIC PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;AA;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;NEUROPATHIC PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;UGT2B10;CC;rs2942857;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;;GG;rs6961071;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;GG;rs6961071;EFFICACY;INCREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEC100;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB2;GG;rs1042714;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;GG;rs13093031;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;GG;rs13093031;EFFICACY;INCREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTERIOSCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;UGT2B10;CC;rs2942857;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;ABCB1;A;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;A;rs11615;EFFICACY;DECREASED;RESPONSE;OTHER;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;PRSS53, VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENOBARBITAL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;FMO3;CC;rs1800822;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
FENOFIBRATE;CRP;TT;rs1417938;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;DYSLIPIDAEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A3;G;rs2076828;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;CC + TT;rs9361235;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;GG;rs10517;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENOFIBRATE;CRP;AG + GG;rs3091244;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;MMP3;A/del + AA;rs35068180;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;UGT1A4;G;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;CRP;GG + GT;rs3091244;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C18;T;rs1126545;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DESLORATADINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED;RESPONSE;DISEASE;URTICARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIZOLASTINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED;RESPONSE;DISEASE;URTICARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;TT;rs17161788;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;;CC;rs2952768;EFFICACY;DECREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;;CC;rs2952768;EFFICACY;DECREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;PCSK9;T;rs11591147;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;AG;rs28371759;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;AG;rs28371759;EFFICACY;INCREASED;RESPONSE;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;COLONIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR / TEZACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT2B7;T;rs12233719;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUPROPION;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT2B7;G;rs28365063;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;FMO3;CC;rs909530;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AA + AT;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;NR1I2;CT + TT;rs3814055;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LUMACAFTOR;CFTR;AA;rs121909047;EFFICACY;;RESPONSE;;;;
METHADONE;CDH2;AA;rs8094439;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERTUSSIS VACCINES;TLR4;AA;rs4986790;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CDH2;CC;rs17446819;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SORAFENIB;ABCG2;CT;rs2231137;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
NICOTINE;CYP2A6;CT + TT;rs376817657;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SORAFENIB;ABCG2;GT;rs2231142;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
IMATINIB;SLC22A1;CC;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BILIRUBIN;UGT1A1;TT;rs887829;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;A;rs186364861;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
IMIQUIMOD;TLR7;A;rs179008;EFFICACY;INCREASED;RESPONSE;DISEASE;BASAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
METHOTREXATE;GGH;CC + CT;rs11545077;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;OTHER;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;LIVER CIRRHOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
CLOZAPINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;METABOLISM;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;TAOK3;AG + GG;rs1277441;DOSAGE;INCREASED;DOSE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;AG + GG;rs1277441;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
OPIOIDS;TAOK3;TT;rs795484;DOSAGE;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;TT;rs795484;DOSAGE;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;CT + TT;rs795484;DOSAGE;INCREASED;DOSE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;CT + TT;rs795484;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;AC + CC;rs3742106;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VITAMIN B12 AND FOLIC ACID;MTHFR;A;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERHOMOCYSTEINEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN B12 AND FOLIC ACID;MTHFR;A;rs1801133;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;EXPOSURE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CAPTOPRIL;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;MYELOID;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;ACUTE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SILIBININ;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
MERCAPTOPURINE;TPMT;CC;rs1142345;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;C;rs1910167;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ALCOHOL ABUSE;MEN;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;MEN;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;PSORS1C1;C;rs2233945;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;ABCC4;AA;rs2274407;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;TPH2;AA + AT;rs4290270;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;NR3C2;TT;rs5522;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;T;rs4086116;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;STAT4;T;rs7574865;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;AC + CC;rs11545076;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AG;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;GOUT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
TEZACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;ABCA1;CT;rs2230806;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;HTR2A;AA + AG;rs6313;DOSAGE;INCREASED;DOSE;OTHER;DEPRESSION;CHILDREN;CAUTION_DOSE_ADJUST
SERTRALINE;HTR2A;AA + AG;rs6313;DOSAGE;INCREASED;DOSE;OTHER;OTHER:ANXIETY DISORDERS;CHILDREN;CAUTION_DOSE_ADJUST
FENOFIBRATE;ABCA1;CC;rs2230808;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;NUP107;C;rs79419059;EFFICACY;INCREASED;RESISTANCE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;ABCA1;TT;rs2230806;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;ANXIETY DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;NQO1;AA;rs1800566;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
KETOPROFEN;CYP2C9;CC;rs1799853;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOPROFEN;CYP2C9;CC;rs1799853;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TANK;CC;rs1267067;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;VEGFA;T;rs25648;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;GG;rs1801253;DOSAGE;INCREASED;DOSE;DISEASE;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;GG;rs4646450;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNF;GG;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;VASP;AG + GG;rs10995;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNFAIP3;T;rs2230926;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;AA + AG;rs2838958;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;
METHOTREXATE;SLC19A1;AG + GG;rs3788200;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
LITHIUM;NR1D1, THRA;T;rs2314339;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;APOE;C;rs429358;DOSAGE;DECREASED;DOSE;DISEASE;VENOUS THROMBOEMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATAZANAVIR;SORCS2;A;rs73208473;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BEVACIZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CNR1;CT + TT;rs806368;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;TPH2;GG;rs1386493;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
BUMETANIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FUROSEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TORASEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;rs35303484;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;CT;rs16974799;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;OPRL1;CT;rs2229205;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
ROSUVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADRENERGICS;;T;rs34548976;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
INHALANTS;;T;rs34548976;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TOPIRAMATE;GRIK1;AA + AC;rs2832407;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ALCOHOL-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TORASEMIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;GRIK1;AA + AC;rs2832407;EFFICACY;DECREASED;RESPONSE;DISEASE;ALCOHOL-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC1;AA;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;ERCC1;AA;rs11615;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TORASEMIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;ABCB1;AA;rs1922242;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;CT + TT;rs2237897;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;CT + TT;rs2237897;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F11;G;rs1060467;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBOPLATIN;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED;RESPONSE;;;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED;RESPONSE;;;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEBRISOQUINE;CYP2D6;C;rs1080985;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;AC;rs28399433;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CETP;GG;rs4783961;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;CC + CT;rs9282564;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTRR;AG + GG;rs1801394;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TENOFOVIR;IFNL3, IFNL4;C;rs12979860;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A1;A;rs622342;EFFICACY;INCREASED;RESPONSE;EFFICACY;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOCORTICOIDS;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;BCL11A;T;rs1427407;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;A;rs2860905;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;;MEN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED;DOSE;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TIOTROPIUM;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMEFANTRINE;ABCC2;AA;rs8187710;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MALARIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;MEN;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TORASEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUMETANIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FUROSEMIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TORASEMIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;rs7439366;EFFICACY;DECREASED;RESPONSE;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;rs7439366;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUMETANIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FUROSEMIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TORASEMIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;AC + CC;rs1105879;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR2A;AA + AG;rs6314;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;ACE;CG + GG;rs4341;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LPL;GG;rs328;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;CETP;AG;rs708272;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;UGT2B7;CC;rs10028494;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;UGT2B7;CC;rs10028494;EFFICACY;DECREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNA3;A;rs1051730;METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUVASTATIN;LIPC;CC + CT;rs1800588;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A1;T;rs2472297;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;CES1;CG;rs114119971;DOSAGE;DECREASED;DOSE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;CAUTION_DOSE_ADJUST
SIMVASTATIN;LIPC;CT;rs1800588;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
ATORVASTATIN;SLCO1B1;AC + CC;rs4149036;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERTUSSIS VACCINES;TLR4;GG;rs2770150;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + TT;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;NEPHROTIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;SLCO1B1;GT + TT;rs2291073;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;NEPHROTIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CATECHOLAMINES;SLC22A3;T;rs8187725;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CATECHOLAMINES;SLC22A3;T;rs8187725;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A3;T;rs8187725;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A3;T;rs8187725;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
LOVASTATIN;LDLR;TT;rs688;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;CYP3A4;AG;rs4986910;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ADH1C;C;rs698;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ADH1B;A;rs2066702;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;LDLR;CC;rs5925;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG;rs6313;EFFICACY;DECREASED;TIME RESPONSE;OTHER;DEPRESSION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR2A;GG;rs6313;EFFICACY;DECREASED;TIME RESPONSE;OTHER;OTHER:ANXIETY DISORDERS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
NALTREXONE;ALDH2;G;rs671;EFFICACY;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CYP2B6;AG + GG;rs8109525;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA;rs2046934;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;C;rs3814637;DOSAGE;;DOSE;;;;
TACROLIMUS;ABCB1;AA;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs4917639;DOSAGE;;DOSE;;;;
WARFARIN;VKORC1;A;rs2359612;DOSAGE;;DOSE;;;;
TACROLIMUS;CYP3A7;CG + GG;rs2257401;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;GG;rs3732759;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIBIOTICS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HELICOBACTER INFECTIONS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CARFILZOMIB;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;DRD3;TT;rs6280;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARFILZOMIB;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARFILZOMIB;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;DISEASE;MULTIPLE MYELOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;LIVER CANCER;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
SORAFENIB;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:LIVER CANCER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID;ABCC2;T;rs717620;METABOLISM/PK;;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;
FENTANYL;ATF2;A;rs7583431;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ATF2;A;rs7583431;EFFICACY;INCREASED;RESPONSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;T;rs717620;METABOLISM/PK;;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;NR1I2;CT + TT;rs3814055;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
AFLIBERCEPT;ANO2;TT;rs2110166;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;ANO2;TT;rs2110166;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NR1I2;CT + TT;rs3814055;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;SLC6A2;CC;rs2242446;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BOCEPREVIR;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GALANTAMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;FCGR2A;A;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ENOSF1;CC;rs2612091;EFFICACY;INCREASED;RESPONSE;OTHER;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACLATASVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
ADALIMUMAB;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;T;rs78015114;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;;
PHENOBARBITAL;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;;
PHENYTOIN;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;;
VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;;
QUETIAPINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LITHIUM;;T;rs79663003;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;CYP3A4, TMEM130;C;rs1203844;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;CYP3A4;A;rs35599367;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;MYLIP;AA;rs9370867;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;T;rs75222709;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;G;rs74795342;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;PDE4D;T;rs295943;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SCAP;TT;rs12487736;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA + AG;rs2069514;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CYP1A2;AA + AG;rs2069514;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
APREMILAST;CDKN2B, CDKN2B-AS1;G;rs1063192;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LIPC;CT + TT;rs1800588;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
LOSARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
(R)-METHADONE;NR1I3;GG;rs2307424;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2A;GG;rs6314;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
(R)-METHADONE;NR1I3;GG;rs3003596;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;CFH;CT;rs1061170;DOSAGE;INCREASED;DOSE;DISEASE;MACULAR DEGENERATION;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;CC;rs678849;EFFICACY;INCREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
BEVACIZUMAB;ARMS2;GT + TT;rs10490924;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;ABCB1;CC;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
BUDESONIDE;;AG + GG;rs2392165;EFFICACY;INCREASED;RESPONSE;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIORIDAZINE;CYP2D6;CC + CG;rs1080985;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;CYP1A2;CC + CT;rs2470890;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP1A2;AC + CC;rs762551;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCC2;AG;rs2273697;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;DRD2;AA + AC;rs1076560;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP1A1;AC + CC;rs2606345;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;UGT1A1;TT;rs887829;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLC10A1;A;rs2296651;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;GG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DACLATASVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;;T;rs6973474;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;;T;rs13169373;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;DISEASE;ALCOHOLIC PSYCHOSIS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:ALCOHOL-RELATED DISORDERS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;WOMEN;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A1;GG;rs628031;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A1;GG;rs628031;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNA5;A;rs16969968;DOSAGE;INCREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
BUPRENORPHINE;;G;rs62368105;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;;T;rs11782370;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;;T;rs7205113;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;IL10;CC;rs1800896;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;ADAMTSL2;A;rs756770;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
(R)-METHADONE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TGFB1;CG;rs1800471;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;AG + GG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;T;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
XK469;AOX1;G;rs10931910;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;WOMEN;CAUTION_DRUG_ACCUMULATION
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;HEART FAILURE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CT;rs4986907;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;AG + GG;rs2189784;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
PHENPROCOUMON;EPHX1;CC;rs1051740;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;EPHX1;CC;rs1051740;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ASPIRIN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INDOMETHACIN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOROLAC;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAPROXEN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;PROC;CC;rs1799808;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;PROC;CC;rs1799808;METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
ATORVASTATIN;TNF;AA + AG;rs1800629;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A5;CG + GG;rs2631367;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A5;CG + GG;rs2631372;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SP1;G;rs784888;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TNF;CT + TT;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;rs7412;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP3A4;AA;rs28371759;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP1A2;GG;rs2069514;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
IMATINIB;ABCC4;AG;rs9561765;EFFICACY;INCREASED;RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
ATORVASTATIN;DRD3;TT;rs6280;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;SLC15A2;TT;rs1143671;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;MTHFR;AA + AG;rs1801133;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;DECREASED;STEADY-STATE CONCENTRATION;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;EPHX1;CC;rs2260863;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
RITONAVIR;NR1I2;CC + CT;rs1523130;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
L-TRYPTOPHAN;SLC22A2;CC;rs316019;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
RITONAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RITONAVIR;ABCB1;AC + CC;rs2032582;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
ERENUMAB;RAMP1;A;rs13386048;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERENUMAB;RAMP1;A;rs13386048;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;CYP1A2;AA + AG;rs2472304;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;BDNF;CC;rs6265;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;NR1I2;AA + AG;rs6785049;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
ERENUMAB;RAMP1;G;rs6431564;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB;RAMP1;G;rs6431564;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;SLC22A12;CC + CT;rs1529909;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;SLC22A12;CC + CT;rs1529909;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERURICEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;G;rs12465864;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERENUMAB;RAMP1;G;rs12465864;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;SLC22A12;CT + TT;rs3825016;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;SLC22A12;CT + TT;rs3825016;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERURICEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;rs1799971;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;IL10;CC;rs1800896;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;CT;rs9282564;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2A";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2B";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;AA;rs2279343;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2A";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2B";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;PSMA4;A;rs57064725;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;GG;rs16853826;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;TT;rs35592;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CHRNA5;A;rs16969968;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2B";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2B";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""RIBAVIRIN""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""RIBAVIRIN""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;;G;rs77107237;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DTNBP1;CT + TT;rs742105;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CHRNB4;A;rs10851907;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;SLCO1B3;AA;rs7311358;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;SLC15A2;AA;rs1143672;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
"""INTERFERON ALFA-2A";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2B";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;SLCO1B3;GG;rs4149117;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CHRNA3;A;rs7170068;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUNITINIB;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC;rs2108622;EFFICACY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2B";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUPENTHIXOL;NFKB1;CT + TT;rs230504;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;SLCO2B1;AG;rs12422149;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;SLCO2B1;AG;rs12422149;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;CYP24A1;CT + TT;rs927650;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP24A1;CT + TT;rs2585428;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUPENTHIXOL;NFKB1;AG;rs3774959;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;TPH2;C;rs10879346;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE POLYGLUTAMATE;IMPDH1;GG;rs4731448;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE POLYGLUTAMATE;CEP72;TT;rs924607;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL10;TT;rs1800896;DOSAGE;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
MIRTAZAPINE;TPH2;C;rs1487278;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;TPH2;C;rs1487278;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
BILIRUBIN;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP24A1;CT + TT;rs2248359;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUPENTHIXOL;NFKB1;AT;rs230493;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE POLYGLUTAMATE;SLCO1B3;AA + AG;rs7311358;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
NICOTINE;FMO3;AA;rs2266780;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;VEGFA;A;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE POLYGLUTAMATE;FSTL5;AA + AC;rs3749598;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE POLYGLUTAMATE;ATG16L1;AG + GG;rs2241880;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC;rs3918290;EFFICACY;INCREASED;RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;OTHER;DECREASED;METABOLISM;DISEASE;ASTHMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ASTHMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;G;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;VEGFA;T;rs833061;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;PTTG1;CC + CT;rs2431697;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;CMPK1;CC;rs4492666;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;CC;rs4492666;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;HLA-B;TT;rs13437088;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;GBP6;AG + GG;rs928655;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELIPROLOL;ABCB1;G;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELIPROLOL;SLCO1A2;G;rs11568563;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TEMOZOLOMIDE;ABCB1;AA + AG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;GLIOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;SLC26A9;CC + CT;rs7512462;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DCK;AG + GG;rs66878317;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;CC;rs3814057;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;ADRA2A;CC + CG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;GG;rs4244809;EFFICACY;DECREASED;RESISTANCE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;FMO3;AA;rs2266780;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;FGF2;CC + CT;rs1449683;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;POR;GG;rs10954732;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;INS-IGF2;GG;rs3842761;EFFICACY;DECREASED;RESISTANCE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;HTR1A;CC + CG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SCN2A;AA + AG;rs17183814;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;NR1I2;AA;rs2461817;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;GG;rs3732359;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC2;TT;rs3740066;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;RRM1;TT;rs720106;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;TT;rs720106;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;AA;rs7643645;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;RRM1;AA;rs232043;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AA;rs232043;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;CMPK1;CC;rs11211524;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;CC;rs11211524;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;RRM1;TT;rs2284449;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;TT;rs2284449;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;GGCX;G;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;NR1I2;G;rs6785049;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;TGFB1;AG;rs1800470;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;TGFB1;CG;rs1800471;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CYP3A4;A;rs35599367;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;ADIPOQ;GT;rs2241766;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
NALOXONE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIFARNIB;ABCB1;AA;rs1128503;OTHER;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TIPIFARNIB;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;ZNF816;CC;rs9304742;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRG1;G;rs13250975;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1A2;CC + CT;rs4149009;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;;A;rs2513265;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;ADCY2;C;rs1544938;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRG1;A;rs17716295;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA5;GG;rs16969968;OTHER;DECREASED;DOSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;DAO;TT;rs55944529;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CCL2;G;rs4795893;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CCL2;T;rs4586;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;DAO;TT;rs55944529;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;WOMEN;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:MALARIA;WOMEN;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;DRD1;TT;rs5326;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;CYP2D6;GG;rs1065852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;CYP2D6;CG;rs1135840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs7196161;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;GLP1R;A;rs6923761;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;GLP1R;A;rs6923761;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OTHER:GASTROINTESTINAL STROMAL TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;CC;rs1135840;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GRK5;A;rs3740563;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;G;rs2069705;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;MLLT3;AA;rs6475448;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GRK5;A;rs10787959;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;;C;rs1908557;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;GRK5;A;rs11198893;EFFICACY;DECREASED;RESPONSE;OTHER;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;CYP27B1;AG + GG;rs4646536;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;ST13;G;rs138335;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;VDR;TT;rs1544410;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;GG + GT;rs3745274;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
DOCETAXEL;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RAMIPRIL;ADRB2;AA + AG;rs2053044;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"BREAST NEOPLASMS""";WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";WOMEN;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";WOMEN;CAUTION_DOSE_ADJUST
METHADONE;NGF;AA;rs2239622;DOSAGE;DECREASED;DOSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DOSE_ADJUST
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;INCREASED;EXPOSURE;OTHER;URINARY BLADDER NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;AA + AG;rs2279343;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
GEMCITABINE;NT5C3A;AA;rs3750117;OTHER;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C3A;AA;rs3750117;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C2;TT;rs11598702;OTHER;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;NT5C2;TT;rs11598702;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;PGAP6;T;rs199670311;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;PGAP6;T;rs199670311;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT1A4;GT;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ADCY9;CC;rs2230739;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;PI4KA;AG + GG;rs165854;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GRM3;AA + AT;rs1468412;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUDESONIDE;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE / SALMETEROL;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;SLC1A3;AA + AG;rs1529461;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GRM3;CC;rs2299214;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;GRM3;AG + GG;rs6465084;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;CC;rs1048977;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ST13;G;rs138337;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;SLC1A4;AA;rs10211524;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;GRM3;CC + CT;rs2299214;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;COMT;AA;rs4680;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
SUFENTANIL;COMT;AA;rs4680;EFFICACY;DECREASED;DOSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUINDIONE;VKORC1;TT;rs9923231;METABOLISM/PK;;DOSE;;;CHILDREN;
APREMILAST;LEPR, LEPROT;AA + AG;rs1045895;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINAPRIL;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KCNJ6;CC;rs6517442;DOSAGE;INCREASED;DOSE;OTHER;LOW BACK PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;T/del;rs35694136;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;DISEASE:PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;NEOPLASMS;PEOPLE;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;NEOPLASMS;PEOPLE;CAUTION_SIDE_EFFECT
TEGAFUR;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;NEOPLASMS;PEOPLE;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2C9;AC;rs1057910;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOPROFEN;CYP2C9;AC;rs1057910;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY ARTERY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNFRSF1B;GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNFRSF1B;GT;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIFENTANIL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;PDE4B;T;rs12745871;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SCARB1;AA;rs5888;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;TSPAN16;C;rs322144;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;FCAR;AA + AG;rs11666735;EFFICACY;INCREASED;RESPONSE;DISEASE;MYOCARDIAL INFARCTION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;APOA1;G;rs964184;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;SCN1A;CT;rs10188577;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;DOCK6;G;rs12979813;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPTOMYCIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NALTREXONE;DBH;CT + TT;rs1611115;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLC28A2;CC;rs11854484;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;ABCG2;GG;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SLC28A2;CC;rs1060896;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;G;rs2305795;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;GG;rs1139130;EFFICACY;INCREASED;RESISTANCE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
APREMILAST;ILF3;T;rs76966440;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;PRSS53, VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;NOS3;TT;rs1799983;EFFICACY;INCREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;NOS3;TT;rs1799983;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;GREM2;T;rs1934341;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;NAT1;AG + GG;rs13253389;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;GREM2;G;rs77567654;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;CC;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ALLOPURINOL;ABCG2;C;rs45499402;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EXENATIDE;GLP1R;T;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;GLP1R;T;rs10305420;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOPIRAMATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT2B7;TT;rs7668258;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BENAZEPRIL;AGT;GG;rs4762;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;MEN;
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT2B7;GG;rs28365063;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
3;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC4;GG;rs7317112;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;AGTR1;GG;rs2640543;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;WOMEN;
ALENDRONATE;MVK;GG;rs10161126;EFFICACY;INCREASED;RESPONSE;DISEASE;BONE DISEASES;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;A;rs1127354;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;SPTA1;G;rs2106089;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;MEN;
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;AT + TT;rs1934969;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;C;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;C;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SALBUTAMOL;COL2A1;GT + TT;rs3809324;PD;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1C;CC;rs2238087;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""HYDROCHLOROTHIAZIDE""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""THIAZIDES";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"PLAIN""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1B;CC;rs2229949;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CORTICOSTEROIDS;GLCCI1;GG;rs37973;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHINITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;GC;AA;rs7041;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;CES1;T;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
INTERFERON BETA-1A;CD58;CC;rs12044852;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON BETA-1B;CD58;CC;rs12044852;EFFICACY;DECREASED;RESPONSE;DISEASE;MULTIPLE SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;OTHER;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;OTHER;"PSORIATIC""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;OTHER;"""OTHER:PSORIASIS""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;OTHER;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;OTHER;"PSORIATIC""";PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;OTHER;"""OTHER:PSORIASIS""";PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNB2;TT;rs12245847;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
DEFERASIROX;UGT1A1;CC;rs887829;EFFICACY;DECREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNG3;TT;rs1859204;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
DEFERASIROX;UGT1A3;TT;rs1983023;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP27B1;GG;rs10877012;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;rs4646437;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A4;A;rs4646437;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
ADALIMUMAB;ATG16L1;CT + TT;rs10210302;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;CC;rs982003;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
DEFERASIROX;VDR;GG;rs731236;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;TT;rs1544410;EFFICACY;INCREASED;RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
CAPECITABINE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;rs4646450;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A5;A;rs4646450;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
"""DIURETICS""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""HYDROCHLOROTHIAZIDE""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""THIAZIDES";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CG;rs28371686;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNB2;TT;rs10741058;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED;DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_SIDE_EFFECT
"""DIURETICS""";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""HYDROCHLOROTHIAZIDE""";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"""THIAZIDES";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
"PLAIN""";;A;rs238;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA2D3;AA;rs4505744;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""HYDROCHLOROTHIAZIDE""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""THIAZIDES";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C9;AC;rs1057910;EFFICACY;DECREASED;TIME RESPONSE;OTHER;PATENT DUCTUS ARTERIOSUS;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1E;TT;rs12060765;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;TAAR6;GG;rs7772821;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;VEGFA;CT + TT;rs3025039;PD;DECREASED;RESPONSE;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;TT;rs795484;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;CHILDREN;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;TT;rs795484;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;TT;rs795484;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TAOK3;TT;rs795484;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;NR3C1;G;rs6196;EFFICACY;DECREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AA;rs4148323;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;;G;rs4842198;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;HTR2A;CC;rs6311;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;NR3C1;A;rs258751;EFFICACY;DECREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEDIPASVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A9;del/del;rs3832043;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;G;rs28371686;OTHER;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;G;rs28371686;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;CT + TT;rs2231137;DOSAGE;DECREASED;DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;A;rs10052957;EFFICACY;DECREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP1A2;CC;rs762551;DOSAGE;DECREASED;DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS;PEOPLE;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;A;rs7900194;OTHER;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;OTHER;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LURASIDONE;HTR1A;CG + GG;rs6295;EFFICACY;DECREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;T;rs28371685;OTHER;INCREASED;METABOLISM;PK;NO DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;T;rs28371685;METABOLISM/PK;INCREASED;METABOLISM;PK;NO DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;del;rs9332131;OTHER;DECREASED;METABOLISM;PK;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;del;rs9332131;METABOLISM/PK;DECREASED;METABOLISM;PK;NO DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;RXRA;A;rs3132291;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNFRSF1B;G;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;TT;rs12208357;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;UGT2B7;TT;rs7439366;DOSAGE;DECREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;CC;rs4237348;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB4;AA + AC;rs3768652;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;;TROUGH CONCENTRATION;DISEASE;DISEASE:TRANSPLANTATION;PEOPLE;
ANTIPSYCHOTICS;CACNA2D3;CC;rs7427395;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;TT;rs1277733;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;CES1;A;rs4513095;EFFICACY;DECREASED;RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;SCN9A;AA + AG;rs6746030;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
SALBUTAMOL;PRKG1;A;rs7081864;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;AG + GG;rs11030104;EFFICACY;INCREASED;RESISTANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPOFOL;HTR2A;AA;rs6313;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;BDNF-AS;CC + CT;rs10501087;EFFICACY;INCREASED;RESISTANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;GABRA1;GG;rs2279020;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
OPIOIDS;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISOLONE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;RESISTANCE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AG;rs4680;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
"""METFORMIN""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALIPERIDONE;NFIB;CT;rs28379954;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NFIB;CT;rs28379954;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;OTHER;TONSILLECTOMY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;OTHER;TONSILLECTOMY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TAOK3;GG;rs1277441;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;CHILDREN;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;GG;rs1277441;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;GG;rs1277441;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TAOK3;GG;rs1277441;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISOLONE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;OTHER;ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;OTHER;"SICKLE CELL""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;OTHER;"""OTHER:BETA-THALASSEMIA AND RELATED DISEASES""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
OXYCODONE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CT + TT;rs2242480;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs11045821;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs11045821;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;A;rs11045821;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BILIRUBIN;UGT1A;AG + GG;rs11563250;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A3;CT + TT;rs1983023;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;CT + TT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;CC + CT;rs55918055;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2A6;T;rs4803381;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;T;rs4803381;EFFICACY;INCREASED;RESPONSE;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SRR;CC + CT;rs391300;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SRR;CC + CT;rs391300;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A2;AG + GG;rs5569;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROMYCIN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;T;rs4803381;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ABCB1;G;rs7787082;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA + AC;rs762551;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;;AA + AC;rs12346562;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;;AA + AC;rs12346562;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;;AA + AG;rs1104514;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;AA + AG;rs34130495;METABOLISM/PK;DECREASED;CLEARANCE;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATENOLOL;;GG + GT;rs10739150;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;A;rs10248420;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;UGT1A3;CC;rs3806596;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRANDOLAPRIL;PTPRD;T;rs4742610;EFFICACY;;RESISTANCE;DISEASE;HYPERTENSION;PEOPLE;
VERAPAMIL;PTPRD;T;rs4742610;EFFICACY;;RESISTANCE;DISEASE;HYPERTENSION;PEOPLE;
DEFERASIROX;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
"""METFORMIN""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VDR;GG;rs11168292;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
4-HYDROXYTAMOXIFEN;SULT1A2;AA;rs1136703;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;SULT1A2;AA;rs1136703;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VDR;GG;rs4760658;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VDR;TT;rs11168293;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CERTOLIZUMAB PEGOL;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;SLIT1;AA;rs2784917;METABOLISM/PK;DECREASED;INHIBITION;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;C;rs4149056;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;A;rs2306283;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs2306283;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;A;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-HYDROXYTAMOXIFEN;SULT1A2;TT;rs1059491;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;SULT1A2;TT;rs1059491;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs4149081;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs4149081;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;A;rs4149081;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CERTOLIZUMAB PEGOL;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;C;rs11045879;EFFICACY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;C;rs11045879;TOXICITY;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;C;rs11045879;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PHENYLEPHRINE;ADRB2;AA;rs1042713;DOSAGE;INCREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;CSMD1;G;rs6990851;EFFICACY;INCREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;;C;rs6806020;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;C;rs6806020;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs7294;EFFICACY;INCREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;;A;rs1931704;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;A;rs1931704;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACAMPROSATE;CHDH, IL17RB;A;rs6801605;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED;DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;GG;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
COUMARIN;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IL21R;C;rs3093390;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IL21R;C;rs3093390;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;;A;rs7512595;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;A;rs7512595;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;CARD16;C;rs1792774;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;CARD16;C;rs1792774;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;CC;rs3814637;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA + AC;rs1057910;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;ABCC2;TT;rs3740066;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;;G;rs7750468;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;G;rs7750468;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCC3;C;rs11079921;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PAIN;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCC3;C;rs11079921;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;OTHER:PREMATURE BIRTH;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;CARD16;A;rs1503391;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;CARD16;A;rs1503391;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;CASP1;T;rs557905;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;CASP1;T;rs557905;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;;A;rs2066911;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;A;rs2066911;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;CFAP44;G;rs13064411;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;CASP1;A;rs568910;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;CASP1;A;rs568910;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNB2;AG;rs2072658;OTHER;INCREASED;RESPONSE;OTHER;DAILY SMOKING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs8330;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;C;rs2229959;OTHER;INCREASED;RESPONSE;OTHER;DAILY SMOKING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;TUT7;C;rs17461620;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;TUT7;C;rs17461620;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLCYSTEINE;TOLLIP;TT;rs3750920;EFFICACY;INCREASED;RESPONSE;DISEASE;PULMONARY FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;ABCB1;A;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;UGT2B7;C;rs7439366;EFFICACY;DECREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED;RESISTANCE;DISEASE;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs10929303;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;ABCG2;GT + TT;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;GOUT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
AMANTADINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
AMANTADINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTICHOLINERGICS;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
ANTICHOLINERGICS;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
LEVODOPA;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELEGILINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;CAUTION_DOSE_ADJUST
SELEGILINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;DOSE;DISEASE;PARKINSON DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;MYELOID;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ACUTE;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE-3-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
MORPHINE-3-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
MORPHINE-6-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;SCOLIOSIS;CHILDREN;CAUTION_DRUG_ACCUMULATION
MORPHINE-6-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:TONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE-3-GLUCURONIDE;ABCC3;TT;rs4148412;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;TONSILLECTOMY;CHILDREN;CAUTION_DRUG_ACCUMULATION
GLUCOSE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;CONCENTRATIONS;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIATIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
SERTRALINE;GNB3;GG;rs5441;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;TT;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;TT;rs2242480;EFFICACY;INCREASED;RESPONSE;OTHER;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;A;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;OTHER;"LUNG NEOPLASMS""";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
HDL CHOLESTEROL;CRTC2;AA;rs8450;TOXICITY;DECREASED;CONCENTRATIONS;DISEASE;TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
O-DESMETHYLTRAMADOL;SLC22A1;GG;rs34130495;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;ABCC2;TT;rs717620;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;DEATH;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;AA + AG;rs12782374;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;AA + AG;rs12782374;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;ABCC3;T;rs8077268;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;PAIN;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCC3;T;rs8077268;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;OTHER:PREMATURE BIRTH;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;COMT;G;rs4680;EFFICACY;INCREASED;CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs1799853;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;DECREASED;EXPOSURE;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;METABOLISM;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;UGT2B7;G;rs7662029;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;TH;GG;rs2070762;EFFICACY;DECREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;CC + CG;rs5744247;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A4;CC + CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CETUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HTR2C;CC;rs518147;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE;CYP2C8;C;rs7910936;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROXYCHLOROQUINE;CYP2C8;C;rs7910936;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;EPHX1;CG;rs3738046;METABOLISM/PK;;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;CT;rs1799853;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C19;AG;rs4244285;OTHER;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C19;AG;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR2C;C;rs6318;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;AG + GG;rs2234922;METABOLISM/PK;;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;
CARBAMAZEPINE;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
SULFONAMIDES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFONAMIDES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
UREA DERIVATIVES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
UREA DERIVATIVES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;ADORA1;CC;rs16851030;EFFICACY;INCREASED;RESPONSE;OTHER;APNEA OF PREMATURITY;INFANTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;CC + CT;rs4329505;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2C;CC;rs1023574;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;TT;rs9698290;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""HYDROCHLOROTHIAZIDE""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""THIAZIDES";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;RGS17;A;rs672170;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED;CLEARANCE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;SLCO1B3;GT + TT;rs4149117;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;NBEA;T;rs9315310;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CRH;C;rs4737771;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FHIT;C;rs49411;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;PARP11;G;rs2532560;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;;T;rs2831440;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SILDENAFIL;GNB3;TT;rs5443;EFFICACY;INCREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;MTRF1L;G;rs766127;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;POR;CT + TT;rs1057868;EFFICACY;DECREASED;RESPONSE;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;HSD11B1;AA;rs846908;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;CC;rs4845625;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SALVIANOLIC ACID B;NOS3;GG;rs1799983;EFFICACY;INCREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;COMT;AA + AG;rs165599;EFFICACY;INCREASED;RESPONSE;OTHER;SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;COMT;AA;rs737865;EFFICACY;DECREASED;RESPONSE;OTHER;SMOKERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;CRHR2;G;rs2267715;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE;CYP2C8;T;rs10882521;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYCHLOROQUINE;CYP2C8;T;rs10882521;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;HFE;CC + CT;rs2071303;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;LPIN1;G;rs10192566;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;LPIN1;G;rs10192566;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;HSD11B1;AA;rs4844880;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;HSD11B1;AA;rs846910;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;GATA4;AG + GG;rs3735814;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
"""BETA BLOCKING AGENTS";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"SELECTIVE""";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CTNNA3;C;rs10997242;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALDOSTERONE ANTAGONISTS;NEDD4L;G;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMILORIDE;NEDD4L;G;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;A;rs255100;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;HTR2A;GG;rs6313;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CACNA1A;A;rs2112460;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;G;rs2284220;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;ORM1;AG + GG;rs17650;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;;T;rs521093;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;CC;rs7439366;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;UGT2B7;CC;rs7439366;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;RAPGEF5;C;rs16873129;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;ABCB1;AA;rs1128503;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;PON2;G;rs2299267;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;GALNT18;GG;rs7937567;EFFICACY;INCREASED;RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;;CC;rs3759467;EFFICACY;DECREASED;RESPONSE;DISEASE;VASCULITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;HDAC1;CC;rs1741981;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HODGKIN DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:RHABDOMYOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:MEDULLOBLASTOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:GLIOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
MORPHINE;TLR2;CC + CT;rs3804100;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;TLR2;CC + CT;rs3804100;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;TLR2;CC + CT;rs3804100;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;TLR2;CC + CT;rs3804100;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;OTHER;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;CHST3;T;rs4148947;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;T;rs4148947;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL1B;A;rs1143634;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;IL1B;A;rs1143634;DOSAGE;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;IL1B;A;rs1143634;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;IL1B;A;rs1143634;EFFICACY;DECREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
CISPLATIN;MLLT3;AA + AC;rs10964552;EFFICACY;DECREASED;RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;IL1B;A;rs1143634;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;IL1B;A;rs1143634;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;IL1B;A;rs1143634;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL1B;A;rs1143634;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CHST3;A;rs4148950;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;A;rs4148950;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;MTTP;TT;rs1800591;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NITROGLYCERIN;ALDH2;AA + AG;rs671;EFFICACY;DECREASED;RESPONSE;DISEASE;CONGENITAL HEART DEFECTS;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;GALNT18;CC;rs4910008;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;RARS1;TT;rs244898;EFFICACY;INCREASED;RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ABCB1;AG + GG;rs2235048;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;OTHER;HEART TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
NITROGLYCERIN;ALDH2;AA + AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;CONGENITAL HEART DEFECTS;CHILDREN;CAUTION_DRUG_ACCUMULATION
NITROGLYCERIN;ALDH2;AA + AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PULMONARY HYPERTENSION;CHILDREN;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AT;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TOCILIZUMAB;CD69;A;rs11052877;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;CC + CT;rs12248560;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL-RELATED DISORDERS;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:HODGKIN DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:RHABDOMYOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:MEDULLOBLASTOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OTHER:GLIOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATENOLOL;;A;rs7184292;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;XIRP2;C;rs7606603;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A7;TT;rs10211;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A7;CC;rs2257401;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;CC;rs12343867;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NILOTINIB;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;;C;rs16872401;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;GG;rs3212217;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;ADRB1;G;rs1801252;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;CC + CT;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;CYP1A1;CT + TT;rs1048943;EFFICACY;INCREASED;RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NILOTINIB;CYP1A1;CT + TT;rs1048943;EFFICACY;INCREASED;RESPONSE;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;CG + GG;rs10754558;EFFICACY;INCREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;;GG;rs7184292;DOSAGE;DECREASED;DOSE;OTHER;HYPERTENSION;PEOPLE;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;GT + TT;rs1946518;EFFICACY;INCREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;AKT1;CT;rs3803300;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;AKT1;TT;rs2494732;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP2B6;GG + TT;rs3745274;EFFICACY;INCREASED;RESISTANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP2B6;GG + TT;rs3745274;EFFICACY;INCREASED;RESISTANCE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;AA + AG;rs4986893;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C19;CT + TT;rs3814637;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CANNABIDIOL;AOC1;CT + TT;rs12539;EFFICACY;INCREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT + TT;rs3211371;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;CC;rs17250932;EFFICACY;DECREASED;RESPONSE;DISEASE;ULCERATIVE COLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:HODGKIN DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:RHABDOMYOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:MEDULLOBLASTOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;OTHER:GLIOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CHST3;C;rs730720;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;CHST3;C;rs730720;EFFICACY;INCREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;CC;rs8126756;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABIDIOL;SLC15A1;TT;rs1339067;EFFICACY;DECREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;;T;rs12772169;DOSAGE;;DOSE;;;;
ROSIGLITAZONE;SLCO1B1;C;rs4149056;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;CG + GG;rs3212217;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;CC;rs1741981;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;COMT;G;rs165599;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GRM3;G;rs724226;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;AG;rs5744174;EFFICACY;DECREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;KCNJ6;CC;rs6517442;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;KCNJ6;TT;rs6517442;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIFENTANIL;KCNJ6;TT;rs6517442;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ENALAPRIL;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LITHIUM;CACNG2;TT;rs2284018;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;;T;rs1437153;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
DOCETAXEL;ORM2;AA;rs2250242;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
ETANERCEPT;CARD8;TT;rs2043211;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;CARD8;TT;rs2043211;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED;RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;NLRP3;TT;rs4612666;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;NLRP3;TT;rs4612666;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ANASTROZOLE;DLG2;T;rs2449598;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;NEPHROTIC SYNDROME;CHILDREN;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;NEPHROTIC SYNDROME;CHILDREN;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;HLA-DPA1;GG;rs3077;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS B;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;HLA-DPA1;GG;rs3077;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;BCHE;CC;rs1803274;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABIDIOL;ABCC5;AA + AG;rs3749442;EFFICACY;DECREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;CC + CT;rs3181842;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AA + AG;rs707265;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;CT + TT;rs7246465;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;NFKBIA;TT;rs696;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
SUFENTANIL;NFKBIA;TT;rs696;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs1042389;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
PAROXETINE;BDNF;TT;rs6265;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
REMIFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;GG;rs4680;EFFICACY;DECREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;PAIN;INFANTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;DOSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ADALIMUMAB;TLR2;T;rs3804099;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TLR2;T;rs3804099;EFFICACY;DECREASED;RESPONSE;OTHER;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON ALFA-N1;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
INTERFERON ALFA-N1;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;HSCT;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;OTHER;KIDNEY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;GT;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;GT;rs2231142;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CHRM1;CC;rs2075748;DOSAGE;DECREASED;DOSE;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON ALFA-N1;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON ALFA-N1;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERENUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FREMANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FREMANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GALCANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GALCANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;DISEASE;ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;DISEASE;"SICKLE CELL""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:BETA-THALASSEMIA AND RELATED DISEASES""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;CSMD1;T;rs6981827;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;DISEASE;ANEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;DISEASE;"SICKLE CELL""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;DISEASE;"""DISEASE:BETA-THALASSEMIA AND RELATED DISEASES""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
EPIRUBICIN;NQO1;AA;rs1800566;EFFICACY;DECREASED;RESPONSE;OTHER;BREAST CANCER CELL LINES;;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RESPONSE;OTHER;BREAST CANCER CELL LINES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;MDM4;AA;rs1563828;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;MDM4;AA;rs1563828;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;C;rs2072671;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs75982813;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNJ11;TT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNJ11;TT;rs5219;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;BREAST NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;GG;rs6277;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;AREG;AA + AC;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;AREG;AA + AC;rs11942466;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED;RESPONSE;DISEASE;RECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;VEGFA;CG;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;VEGFA;CG;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT2B15;AA;rs1902023;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED;DOSE;OTHER;"CORONARY ARTERY DISEASE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED;DOSE;OTHER;"""EFFICACY:PAIN";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;TRPV1;AA + AG;rs224534;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR3A;G;rs1150226;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GRM7;CC;rs2069062;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR3A;A;rs2276302;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOSE;COMT;AA + AG;rs4680;TOXICITY;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR3A;C;rs1062613;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DISCONTINUATION;DISEASE;KIDNEY DISORDER;PEOPLE;CAUTION_SIDE_EFFECT
RISPERIDONE;GRID2;GG;rs1875705;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ABCB1;CC;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;NR1I2;CC;rs2276707;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;VEGFA;AC;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;VEGFA;AC;rs699947;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;PRSS53, VKORC1;A;rs17886199;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
4-HYDROXYATORVASTATIN;SLCO2B1;AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;ABCB1;AA + AT;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AA;rs4148323;DOSAGE;DECREASED;METABOLISM;DISEASE;NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;GABRA1;AA + AG;rs10068980;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CHRM1;GG;rs1942499;DOSAGE;DECREASED;DOSE;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SCAP;C;rs12487736;EFFICACY;INCREASED;RESPONSE;DISEASE;METABOLIC SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;CT;rs4803219;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;CT;rs4803219;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;DISEASE;CYSTIC FIBROSIS;CHILDREN;
ROCURONIUM;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;UGT1A9;AA + AT;rs6714486;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ROCURONIUM;SLCO1B1;AA;rs2306283;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A5, ZSCAN25;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;AA + AG;rs7438135;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;INFANTS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;GT;rs8099917;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;;GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;;CG + GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;;CG + GG;rs10853728;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;MAINTENANCE DOSAGE BY 1.5 MG/WEEK;;CAUTION_DOSE_ADJUST
ATENOLOL;EDN1;GT;rs5370;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;EDN1;GT;rs5370;EFFICACY;INCREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR2A;CC;rs6311;EFFICACY;INCREASED;RESPONSE;OTHER;OBSESSIVE-COMPULSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;T;rs4086116;DOSAGE;DECREASED;DOSE;OTHER;MAINTENANCE DOSAGE BY 2.2 MG/WEEK;;CAUTION_DOSE_ADJUST
ATORVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;NR1I2;CT;rs2472677;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN;CYP3A5;CC + CT;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIACIN;HCAR2;CT + TT;rs2454727;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERLIPIDEMIAS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFTRIAXONE;ABCG2;TT;rs13120400;METABOLISM/PK;;CONCENTRATIONS;DISEASE;CENTRAL NERVOUS SYSTEM INFECTIOUS DISORDER;PEOPLE;
RIBAVIRIN;ITPA;CC;rs1127354;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;RESPONSE;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CREATINE;MOBP;AA + AG;rs616147;EFFICACY;INCREASED;RESPONSE;OTHER;AMYOTROPHIC LATERAL SCLEROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;EXO1;AA + AG;rs1047840;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED;RESPONSE;DISEASE;TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;OTHER;MAINTENANCE DOSAGE BY 4.8 MG/WEEK;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;DOSAGE;INCREASED;DOSE;DISEASE;MYELODYSPLASTIC SYNDROMES;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;DOSE;DISEASE;MYELODYSPLASTIC SYNDROMES;PEOPLE;CAUTION_DOSE_ADJUST
APIXABAN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;SLC6A2;TT;rs2242446;OTHER;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;TT;rs2242446;OTHER;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
3;SLC6A2;GG;rs1861647;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;GG;rs1861647;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3;SLC6A2;AA;rs36029;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;AA;rs36029;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;AGT;CT + TT;rs5051;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOCORTICOIDS;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DISULFIRAM;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED;RESPONSE;OTHER;COCAINE DEPENDENCE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CERTOLIZUMAB PEGOL;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
FELODIPINE;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;CLEARANCE;;;WOMEN;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;CT;rs1799853;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
NITRIC OXIDE;NAMPT;TT;rs1319501;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;PRE-ECLAMPSIA;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;GALNT18;CC + CT;rs4910008;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;AA;rs529520;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;;C;rs12459249;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;GGCX;AA + AG;rs2592551;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ARSENIC COMPOUNDS;AS3MT;C;rs11191439;TOXICITY;INCREASED;METABOLISM;;;HEALTHY;CAUTION_SIDE_EFFECT
ARSENIC COMPOUNDS;AS3MT;C;rs11191439;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DESVENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6;CC;rs2069840;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;MTHFR;G;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;MTHFR;G;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";WOMEN;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:CAESARIAN SECTION""";WOMEN;CAUTION_DOSE_ADJUST
PEMETREXED;CAMKK2;GT;rs1653586;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;SRD5A2;CC;rs523349;EFFICACY;INCREASED;RESPONSE;OTHER;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;
LONAFARNIB;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;
PACLITAXEL;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;DISEASE;OVARIAN NEOPLASMS;WOMEN;
METHOTREXATE;ABCG2;GG;rs12505410;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;BMP5;A;rs41271330;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;CES1;CT;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCG2;GT + TT;rs13137622;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;CYP3A4;CT + TT;rs2740574;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;GG + GT;rs1946518;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL10;TT;rs1800896;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
EFAVIRENZ;CYP2B6;G;rs35303484;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
VALPROIC ACID;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AG + GG;rs1801133;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;DECREASED;DOSE;DISEASE;LEUKOPENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;PTGS2;CC;rs689466;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;NFIB;CT;rs28379954;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;AA + AG;rs594709;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AA + AG;rs594709;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;TDP1;GG;rs2401863;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;AA;rs1934969;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;GG;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;GG;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;CC + CG;rs5744247;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;CYP2D6;GG;rs16947;DOSAGE;INCREASED;DOSE;OTHER;SURGERY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;CYP3A4;T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;rs4148324;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OSTEOSARCOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;C;rs3842;METABOLISM/PK;;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;WBP2NL;AG + GG;rs5758550;TOXICITY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE;CAUTION_SIDE_EFFECT
MEMANTINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CC;rs699664;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIVASTIGMINE;BCHE;CT;rs1803274;EFFICACY;INCREASED;RESPONSE;DISEASE;LEWY BODY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
APIXABAN;ABCG2;G;rs2231142;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;GG;rs1061622;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;CC;rs3397;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
LATANOPROST;PTGFR;CC;rs3766355;EFFICACY;INCREASED;RESPONSE;DISEASE;GLAUCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LATANOPROST;PTGFR;CC;rs3766355;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:OCULAR HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;AA;rs1061631;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;C;rs3397;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHADONE;NECTIN4;AA;rs11265549;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOID ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OTHER GENERAL ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VOLATILE ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOID ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OTHER GENERAL ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VOLATILE ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;NECTIN4;AA;rs11265549;DOSAGE;DECREASED;DOSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;DOSAGE;DECREASED;DOSE;OTHER;SURGERY;PEOPLE;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;GG;rs1800544;DOSAGE;DECREASED;DOSE;OTHER;SURGERY;PEOPLE;CAUTION_DOSE_ADJUST
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
IMATINIB;CYP2B6;GG + GT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP2B6;GG + GT;rs3745274;EFFICACY;INCREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;GG;rs7079;EFFICACY;;RESPONSE;DISEASE;HYPERTENSION;WOMEN;
WARFARIN;CYP2C9;GG;rs9332098;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CANNABIDIOL;;CC;rs6729738;EFFICACY;INCREASED;RESPONSE;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AG + GG;rs1801133;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;TT;rs9332092;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;TXNDC11;G;rs3784921;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP1A2;A;rs762551;METABOLISM/PK;INCREASED;DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;TT;rs1799853;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;TOXICITY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE;CAUTION_SIDE_EFFECT
TOPOTECAN;ABCG2;AA + AG;rs4148157;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BRAIN NEOPLASMS;CHILDREN;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A4;G;rs2246709;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;KMT2E;GG;rs117986340;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;ACHE;TT;rs2571598;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;NCAM1;TT;rs2303377;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;TT;rs4261893;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A4;C;rs3735451;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;;CC;rs141294036;TOXICITY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE;CAUTION_SIDE_EFFECT
AMPHETAMINE;CDH13;AG + GG;rs3784943;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY STENOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;KCNMB1;CC + CT;rs11739136;EFFICACY;INCREASED;RESPONSE;OTHER;SURGERY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;CC + CT;rs7668282;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;ANEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
MORPHINE;UGT2B7;CC + CT;rs7668282;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;SICKLE CELL;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A7P1, CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;PREGNANCY;WOMEN;CAUTION_DRUG_ACCUMULATION
DABIGATRAN;CES1;GG;rs8192935;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;DOSE;;;WOMEN;CAUTION_DOSE_ADJUST
METHOTREXATE;CLCN6, MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;C1orf167, CLCN6, MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTR;AA;rs1805087;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AA;rs10485057;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;DECREASED;DOSE;OTHER;OTHER:NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
METHOTREXATE;BIRC5;CG;rs9904341;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;GG;rs9934438;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;;A;rs17834628;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;rs1051730;DOSAGE;DECREASED;DOSE;OTHER;TOBACCO USE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
ABIRATERONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISOLONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED;RESPONSE;DISEASE;PROSTATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;RICTOR;GG;rs6878291;EFFICACY;DECREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DRD2;T;rs2514218;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;KDR;AA + AG;rs2071559;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG;rs1799971;OTHER;INCREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;GSTA1;CT;rs3957356;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CT + TT;rs12995526;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR3A;T;rs1062613;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CT + TT;rs7563206;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;KCNK3;C;rs1275988;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;OTHER;PAIN;CHILDREN;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;CHILDREN;CAUTION_DOSE_ADJUST
ADALIMUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED;RESPONSE;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMMUNOGLOBULINS;CASP3, PRIMPOL;CT + TT;rs113420705;EFFICACY;DECREASED;RESPONSE;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;COMT;AA;rs4680;DOSAGE;INCREASED;DOSE;OTHER;PAIN;CHILDREN;CAUTION_DOSE_ADJUST
SUFENTANIL;COMT;AA;rs4680;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED;CONCENTRATIONS;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
IMMUNOGLOBULINS;COQ8B, ITPKC;CC + CG;rs28493229;EFFICACY;DECREASED;RESPONSE;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
INFLIXIMAB;IL17F;CT;rs763780;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;CSK;C;rs1378942;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;;G;rs35661809;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD3;CT + TT;rs6280;EFFICACY;INCREASED;RESISTANCE;OTHER;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD3;CT + TT;rs6280;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;PDE3A;C;rs12579720;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANDESARTAN;SULT1C3;T;rs6722745;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;STN1;A;rs4387287;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;;TT;rs10783050;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;IL1B;GG;rs1143623;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAPENTINE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGAPTANIB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;INCREASED;DOSE;OTHER;LEFT VENTRICULAR DYSFUNCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;METASTATIC NEOPLASM;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;BIPOLAR DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:DEPRESSION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;DECREASED;RESPONSE;OTHER;LEFT VENTRICULAR DYSFUNCTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;OTHER;AUTOIMMUNE DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3, CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR3A;G;rs2276302;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AT + TT;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AT + TT;rs2032582;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TELMISARTAN;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs8192719;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LITHIUM;;CC;rs2769605;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;;CC;rs2769605;EFFICACY;DECREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GNAS;CC;rs7121;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GNAS;CC;rs7121;EFFICACY;INCREASED;RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATENOLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
LITHIUM;DRD2;GG;rs1800497;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;GG;rs1800497;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;;T;rs247616;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CERTOLIZUMAB PEGOL;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;PRKAG2;A;rs10224002;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AGOMELATINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MELATONIN RECEPTOR AGONISTS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CERTOLIZUMAB PEGOL;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;PLCE1;A;rs932764;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;;T;rs1446468;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;RRP1B;T;rs9306160;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;TBX2;C;rs8068318;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMISULPRIDE;DRD2;C;rs1079597;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;NFKBIA;CC;rs2145623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;ADO;C;rs10995311;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XBP1;CC;rs2269577;EFFICACY;INCREASED;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANDESARTAN;DOT1L, PLEKHJ1;A;rs740406;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;ADAM33;CC;rs2787094;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;NUCB2;C;rs757081;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;;AG + GG;rs1975974;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXENATIDE;KCNQ1;G;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;KCNQ1;G;rs163184;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;DISEASE:TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
USTEKINUMAB;AGBL4;CC + CT;rs191190;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;SLC39A14;C;rs17060812;EFFICACY;INCREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;CHUK;CC + CG;rs11591741;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;HTR2A;CT + TT;rs6311;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;C5orf56;G;rs12521868;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CANDESARTAN;SH2B3;T;rs3184504;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
2-HYDROXYATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
2-HYDROXYATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
4-HYDROXYATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
4-HYDROXYATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
PAROXETINE;COMT;A;rs4680;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TP53;GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;TP53;GG;rs1042522;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;CYP3A4;CC;rs2242480;DOSAGE;INCREASED;DOSE;OTHER;PAIN;WOMEN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;CC;rs2242480;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;WOMEN;CAUTION_DOSE_ADJUST
TRIGLYCERIDES;CYP19A1;A;rs749292;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;A;rs749292;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs1062033;OTHER;INCREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;CAUTION_DRUG_ACCUMULATION
HDL CHOLESTEROL;CYP19A1;G;rs1062033;OTHER;INCREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;OTHER;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;PPM1A;AA;rs2273623;EFFICACY;DECREASED;RESPONSE;DISEASE;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMILORIDE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SPIRONOLACTONE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;CC;rs3806596;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;AA + AG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SPIRONOLACTONE;CYP4A11;CC;rs3890011;EFFICACY;DECREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;AADAC;AA;rs1803155;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;TUBERCULOSIS;PEOPLE;CAUTION_DRUG_ACCUMULATION
APATINIB;CYP2C9;GG;rs1934968;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
APATINIB METABOLITE M1-1;CYP2C9;GG;rs1934968;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;AT + TT;rs11075995;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPRENAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACAMPROSATE;;G;rs77583603;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;CYP3A5;CC + CT;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
NALTREXONE;;A;rs12749274;EFFICACY;DECREASED;RESPONSE;OTHER;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RITONAVIR;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;APOE;CC;rs429358;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEHYDROARIPIPRAZOLE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;OTHER:TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
PREDNISOLONE;GATA3;AA;rs3824662;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;GSTM3;TT;rs7483;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AG;rs1051792;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;CC;rs1799724;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;GG;rs1051792;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;AA + TT;rs130058;EFFICACY;INCREASED;RESPONSE;DISEASE;MENTAL DISORDERS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;APOE;TT;rs7412;EFFICACY;INCREASED;CLINICAL BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;rs361525;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC6A4;CC;rs1042173;DOSAGE;DECREASED;DOSE;OTHER;LUNG NEOPLASMS;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;SLC6A4;CC;rs1042173;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FLUOXETINE;TPH2;TT;rs4570625;EFFICACY;INCREASED;RESPONSE;DISEASE;MENTAL DISORDERS;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A-AS1;CT + TT;rs17004921;EFFICACY;INCREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;AA;rs2032582;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ALDH1A2;T;rs261316;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;ALDH1A2;T;rs261316;EFFICACY;DECREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;REV3L;AG + GG;rs462779;EFFICACY;DECREASED;RESPONSE;DISEASE;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;REV1;CT + TT;rs3087403;EFFICACY;INCREASED;RESPONSE;DISEASE;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;SCN1A;CC + CT;rs2298771;EFFICACY;INCREASED;RESISTANCE;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
AZITHROMYCIN;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
AZITHROMYCIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
FENTANYL;OPRM1;AA;rs9384179;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AA;rs9384179;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AA;rs9384179;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AA;rs9384179;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
FENTANYL;KCNJ6;TT;rs2835859;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;KCNJ6;TT;rs2835859;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;KCNJ6;TT;rs2835859;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;KCNJ6;TT;rs2835859;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABIRATERONE;HSD3B1;AC;rs1047303;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;;CC;rs2952768;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;;CC;rs2952768;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;;CC;rs2952768;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;CC;rs2952768;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;AA;rs11959113;DOSAGE;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;;AA;rs11959113;DOSAGE;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;;AA;rs11959113;EFFICACY;INCREASED;DOSE;SIDE EFFECT;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;AA;rs11959113;EFFICACY;INCREASED;DOSE;SIDE EFFECT;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;EFFICACY;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;TOXICITY;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;METABOLISM/PK;DECREASED;RESPONSE;DISEASE;LUPUS NEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;SOD2;GG;rs4880;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;UGT1A3;T;rs7604115;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;ABCC9;T;rs704212;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA;rs77010898;EFFICACY;INCREASED;RESPONSE;DISEASE;CYSTIC FIBROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;AKR1C3;GG;rs1937840;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;AKR1C3;GG;rs1937840;EFFICACY;INCREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GRIK4;TT;rs1954787;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;OTHER;AN INTERNATIONAL NORMALIZED RATIO (INR) OF 2.0-3.0;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BUPRENORPHINE;OPRM1;CC + CG;rs2075572;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;C;rs2651899;EFFICACY;INCREASED;RESPONSE;OTHER;MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;C;rs2651899;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;NR1I2;AA + AG;rs6785049;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
RIVAROXABAN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;ABCB1;A;rs1128503;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;COMT;CC + CT;rs933271;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AG;rs2070959;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AG;rs2070959;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
ATAZANAVIR;ABCB1;AC + CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;GT + TT;rs1801131;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;GRIN2B;AC;rs1019385;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;GRIN2B;AC;rs1019385;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;GRIN2B;CC;rs1019385;DOSAGE;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;GRIN2B;CC;rs1019385;METABOLISM/PK;DECREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;CT + TT;rs1051266;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHOSUXIMIDE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVETIRACETAM;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOPINAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;AC;rs1105879;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;AC;rs1105879;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;OTHER:KIDNEY NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH CONCENTRATION;OTHER;OTHER:NEUROENDOCRINE TUMORS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
AMISULPRIDE;SNAP25;CT;rs8636;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCA1;A;rs2487032;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;N6AMT1;G;rs2254638;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TENOFOVIR;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;WOMEN;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;A;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;NRXN1;AA;rs12467557;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRXN1;TT;rs10490162;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CES1;GG;rs8192935;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERTOLIZUMAB PEGOL;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GOLIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;BEHCET SYNDROME;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;OTHER;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs2070959;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs2070959;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CISPLATIN;DPYD;CT;rs3918290;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs3918290;EFFICACY;DECREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs6759892;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs6759892;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GT;rs6759892;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GT;rs6759892;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT1A6;CC;rs1105879;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;CC;rs1105879;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
10-MONOHYDROXY OXCARBAZEPINE;INSR;C;rs2396185;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR1A;GG;rs6295;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
RISPERIDONE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CACNA1E;CC + CT;rs3845446;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CACNA1E;CC + CT;rs3845446;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;LAMB3;G;rs2076222;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;LAMB3;G;rs2076222;DOSAGE;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;LAMB3;G;rs2076222;EFFICACY;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;LAMB3;G;rs2076222;EFFICACY;INCREASED;DOSE;DISEASE;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;VEGFA;TT;rs833061;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;VEGFA;GG;rs1570360;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MECP2;A;rs1734791;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;MECP2;A;rs1734791;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;MECP2;A;rs1734791;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;MECP2;A;rs1734787;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;MECP2;A;rs1734787;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;MECP2;A;rs1734787;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;MECP2;A;rs17435;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;MECP2;A;rs17435;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;MECP2;A;rs17435;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
VORICONAZOLE;CYP3A4;CT;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CISPLATIN;;T;rs5906072;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;;T;rs5906072;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;;T;rs5906072;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
PROCHLORPERAZINE;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;DECREASED;RESPONSE;OTHER;NAUSEA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PROCHLORPERAZINE;DRD2;CT + TT;rs1079597;EFFICACY;DECREASED;RESPONSE;OTHER;NAUSEA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;ATM;AC;rs11212617;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;ATM;AC;rs11212617;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRK1;A;rs1051660;DOSAGE;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
MORPHINE;OPRK1;A;rs1051660;EFFICACY;DECREASED;DOSE;DISEASE;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
ATORVASTATIN;HMGCR;CT + TT;rs17671591;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED;RESPONSE;OTHER;DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
TENOFOVIR ALAFENAMIDE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
DABIGATRAN;CES1;GG;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;INCREASED;DOSE;;;HEALTHY;CAUTION_DOSE_ADJUST
CISPLATIN;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
TACROLIMUS;CYP3A4;TT;rs2740574;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
APATINIB;CYP2C9;TT;rs34532201;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
APATINIB METABOLITE M1-1;CYP2C9;TT;rs34532201;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;;C;rs5934731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;;C;rs5934731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;;C;rs5934731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;;C;rs715171;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;;C;rs715171;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;;C;rs715171;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;;C;rs4932551;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;;C;rs4932551;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;;C;rs4932551;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;;T;rs7170769;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;;T;rs7170769;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;;T;rs7170769;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;;C;rs6458232;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;;C;rs6458232;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;;C;rs6458232;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
CISPLATIN;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
FLUOROURACIL;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
MITOXANTRONE;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;
ALLOPURINOL;AOX1;G;rs3731722;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE;
FEBUXOSTAT;AOX1;G;rs3731722;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE;
PAZOPANIB;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED;RESPONSE;DISEASE;AUTOIMMUNE DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED;RESPONSE;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;AOX1;T;rs11678615;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE;
FEBUXOSTAT;AOX1;T;rs11678615;DOSAGE;;DOSE;DISEASE;GOUT;PEOPLE;
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DIAZEPAM;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs34650714;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs34650714;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
ALLOPURINOL;XDH;G;rs1884725;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
FEBUXOSTAT;XDH;G;rs1884725;DOSAGE;DECREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
ALLOPURINOL;AOX1;T;rs75995567;DOSAGE;INCREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
FEBUXOSTAT;AOX1;T;rs75995567;DOSAGE;INCREASED;DOSE;DISEASE;GOUT;PEOPLE;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;AC;rs622342;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC;rs622342;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC3;TT;rs4148416;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;CG;rs17004785;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;BCHE;T;rs1803274;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;GDNF;CT + TT;rs2973049;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;GDNF;AA + AG;rs2216711;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;AA;rs4819554;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;SLC6A2;T;rs3785143;EFFICACY;DECREASED;RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;BDNF;CC + CT;rs6265;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CETP;G;rs5882;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;GT;rs28371703;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;C;rs1135840;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;INCREASED;RESPONSE;DISEASE;ALCOHOL ABUSE;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;A;rs1065852;METABOLISM/PK;INCREASED;HALF-LIFE TIME;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;STEADY-STATE CONCENTRATION;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;GG;rs9606186;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;C6;CC + TT;rs10052999;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;C6;CC + CT;rs9200;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;RGS4;C;rs2661319;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;SLC22A1;AA + AG;rs628031;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ANKK1;A;rs1800497;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;OTHER;TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;OTHER;OSTEOSARCOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;C;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
PHENYTOIN;SCN1A;T;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;T;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs28371738;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;ABCB1;G;rs1045642;OTHER;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;ABCB1;G;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;ABCB1;T;rs4148738;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;AT + TT;rs1934969;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY HYPERTENSION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;APOC1;G;rs4420638;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;APOC1;G;rs4420638;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY HYPERTENSION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
PHOTODYNAMIC THERAPY;F13A1;AA + AC;rs5985;EFFICACY;DECREASED;RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PULMONARY HYPERTENSION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:VENOUS THROMBOSIS;PEOPLE;CAUTION_DOSE_ADJUST
CITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;NPC1L1;G;rs2072183;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;NPC1L1;G;rs2072183;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SORT1;T;rs629301;EFFICACY;DECREASED;RESPONSE;DISEASE;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SORT1;T;rs629301;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;UGT1A9;del;rs3832043;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;ACY3;T;rs2514036;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
IMATINIB;BCL2L11;T;rs724710;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;BCL2L11;T;rs724710;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
ITOPRIDE;FMO3;AA;rs2266782;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METOPROLOL;SEPTIN3;G;rs56234624;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ITOPRIDE;FMO3;GG;rs2266780;METABOLISM/PK;DECREASED;METABOLISM;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;LYMPHOCYTIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;DISEASE;B-CELL;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;ABCC2;CT;rs3740066;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AA;rs9937;EFFICACY;DECREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AC;rs183484;EFFICACY;DECREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AC;rs183484;TOXICITY;DECREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AA;rs4148323;DOSAGE;INCREASED;CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DOSE_ADJUST
COTININE GLUCURONIDE;UGT1A9;CT;rs12471326;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;GT;rs145014075;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CC + CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;NAUSEA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GRANISETRON;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;HEART FAILURE;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CC + CT;rs3812718;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;DISEASE;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
ETANERCEPT;CD84;AG;rs6427528;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOPINAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;MEN;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;SCN1A;TT;rs2298771;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRM1;AA;rs10485058;EFFICACY;INCREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;GABRA1;AA + AG;rs2290732;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;IL12B;CT;rs3213094;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;DISEASE;PANCREATIC NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;DISEASE;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CETUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED;RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HNF4A;CC;rs1884613;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;ALDH5A1;CT + TT;rs2760118;EFFICACY;DECREASED;RESPONSE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;CHAT;A;rs1880676;DOSAGE;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
OLANZAPINE;CHAT;A;rs1880676;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;ABCC2;CG;rs113646094;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
RAMIPRIL;ACE;CC + TT;rs4359;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RAMIPRIL;ACE;AA + GG;rs4344;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;;DOSE;;;;
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GLOMERULONEPHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MEMBRANOUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;KLRK1;GG;rs1049174;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;KLRK1;GG;rs1049174;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CRHR2;CC + CG;rs2270007;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;NR1I2;AA + AG;rs3732357;METABOLISM/PK;DECREASED;EXPOSURE;OTHER;TUBERCULOSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;OSTEOSARCOMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;;CT;rs6848893;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ATP7B;G;rs9535826;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;NR3C1;CC;rs6198;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:DEPRESSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ATP7B;A;rs9535828;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;NR3C1;AA;rs33388;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CCL2;AA + AG;rs4795893;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CCL2;CC + CT;rs4586;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;TT;rs1544105;EFFICACY;INCREASED;RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;FPGS;TT;rs1544105;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
DEXAMETHASONE;NR3C1;TT;rs33389;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ADRB2;A;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;A;rs1042713;EFFICACY;DECREASED;RESPONSE;DISEASE;ASTHMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CCL2;GG;rs2857657;EFFICACY;INCREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT1A4;TT;rs2011425;EFFICACY;INCREASED;RESPONSE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;A;rs1127354;METABOLISM/PK;;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;
LAMOTRIGINE;UGT1A4;TT;rs2011425;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;CC;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNB3;G;rs4950;EFFICACY;INCREASED;RESPONSE;OTHER;SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB3;G;rs4950;OTHER;INCREASED;RESPONSE;OTHER;SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;HMGB1;CC;rs1412125;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB3;G;rs13280604;EFFICACY;INCREASED;RESPONSE;OTHER;SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB3;G;rs13280604;OTHER;INCREASED;RESPONSE;OTHER;SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs749671;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXAMETHASONE;CYP3A4;AG;rs35599367;EFFICACY;INCREASED;TIME RESPONSE;OTHER;COVID-19;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ABCB1;T;rs3842;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HMGB1;GG;rs2249825;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;G;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;NASOPHARYNGEAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;ACE;AT + TT;rs4291;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED;RESPONSE;OTHER;MACULAR DEGENERATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;TIRAP;CT + TT;rs8177374;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
USTEKINUMAB;TLR5;AG + GG;rs5744174;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;CG + GG;rs11465996;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;BRD3;AA;rs467387;PD;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AT + TT;rs4696480;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;ABCB1;A;rs1045642;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC + CT;rs429358;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;GG;rs2276706;METABOLISM/PK;DECREASED;METABOLISM;;;MEN;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;T;rs510769;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;C;rs9606186;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;CC;rs3814058;METABOLISM/PK;DECREASED;METABOLISM;;;MEN;CAUTION_DRUG_ACCUMULATION
ATEZOLIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;rs12209447;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;C;rs2020917;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;rs3798676;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
RISPERIDONE;COMT;C;rs933271;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;rs553202;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs1074287;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRD1;AA + AC;rs529520;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;A;rs1799971;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;T;rs6912029;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PREDNISONE;EDNRA;CC + CT;rs5333;EFFICACY;INCREASED;RESISTANCE;DISEASE;NEPHROTIC SYNDROME;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;CC;rs3814058;METABOLISM/PK;INCREASED;METABOLISM;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;TLR4;CC;rs1927907;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
PAZOPANIB;NR1I2;T;rs3814055;EFFICACY;DECREASED;RESPONSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
ADALIMUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CALU;G;rs1043550;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL18;GG + GT;rs1946518;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;GG;rs2276706;METABOLISM/PK;INCREASED;METABOLISM;;;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;DISEASE;STOMACH NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;T;rs563649;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs2075572;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;G;rs7748401;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs495491;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs10457090;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs3778152;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;T;rs589046;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;NR1I2;T;rs3814055;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;OSTEOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC3;C;rs4793665;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;OSTEOSARCOMA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;NR1I2;G;rs7643038;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;OSTEOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;C;rs9282564;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;CHILDREN;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCG2;T;rs2231142;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;OSTEOSARCOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
GLUCOCORTICOIDS;;AA;rs17446593;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN GLUCURONIDE;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;NTRK2;CC;rs10465180;EFFICACY;DECREASED;RESPONSE;DISEASE;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;G;rs9332238;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED;RESISTANCE;OTHER;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;WOMEN;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;CG;rs1800544;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC1;GG;rs28364006;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LOSARTAN;AGTR1;CC;rs5186;EFFICACY;DECREASED;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;KDR;T;rs2305948;EFFICACY;DECREASED;RESPONSE;DISEASE;CORONARY DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;DOSAGE;INCREASED;DOSE;OTHER;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
METFORMIN;ARFGEF3;AC;rs143276236;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;ARFGEF3;AC;rs143276236;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERBB2;G;rs1136201;TOXICITY;;RESPONSE;;;;
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAB2;A;rs7541245;EFFICACY;DECREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAB2;A;rs7541245;EFFICACY;DECREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;rs1057868;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAMIPEXOLE;DRD3;T;rs6280;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs7196161;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
BENZODIAZEPINE DERIVATIVES;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRTAZAPINE;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PREGNANCY;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;A;rs41303343;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;GG;rs628031;EFFICACY;INCREASED;RESPONSE;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;GG;rs628031;EFFICACY;INCREASED;RESPONSE;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs10264272;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;T;rs10264272;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;rs2884737;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLIC ACID;ABCC2;CC;rs717620;METABOLISM/PK;INCREASED;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;PRSS53, VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED;METABOLISM;OTHER;HEAVY COFFEE CONSUMPTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;METABOLISM;OTHER;HEAVY COFFEE CONSUMPTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;PEAR1;GT + TT;rs4661012;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED;RESPONSE;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;PEAR1;TT;rs12566888;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;PEAR1;AA;rs12041331;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;PEAR1;AA;rs12041331;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;PRSS53, VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;AA + AG;rs2069885;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;AA + AG;rs2069885;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;DISEASE;NEUROMYELITIS OPTICA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISOLONE;CD40;CC;rs1883832;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;METABOLISM;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;OTHER;LIVER TRANSPLANTATION;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB;CALCRL;G;rs6710852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;MIGRAINE WITH AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB;CALCRL;G;rs6710852;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:MIGRAINE WITHOUT AURA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + TT;rs2032582;DOSAGE;DECREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA + TT;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;LIVER TRANSPLANTATION;CHILDREN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HALOTHANE;RYR1;T;rs118192161;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs8050894;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
2-HYDROXYATORVASTATIN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;AA + AG;rs2069812;EFFICACY;INCREASED;RESPONSE;OTHER;SPONDYLITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;AA + AG;rs2069812;EFFICACY;INCREASED;RESPONSE;OTHER;ANKYLOSING;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;BST1;A;rs28404156;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE;BST1;A;rs28404156;EFFICACY;INCREASED;RESPONSE;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
BISPHOSPHONATES;FDPS;T;rs2297480;EFFICACY;INCREASED;RESPONSE;DISEASE;OSTEOPOROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CETP;A;rs5882;EFFICACY;INCREASED;RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;TT;rs405509;EFFICACY;INCREASED;RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GG;rs17731538;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SPONDYLARTHROPATHIES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;UMOD;GT + TT;rs12917707;EFFICACY;INCREASED;RESPONSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MODAFINIL;ABCB1;AC + CT;rs2032582;EFFICACY;INCREASED;RESPONSE;DISEASE;NARCOLEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MODAFINIL;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RESPONSE;DISEASE;NARCOLEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;MYC;CT;rs4645962;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;MYC;CT + TT;rs4645943;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;rs2234922;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
MODAFINIL;ABCB1;AG;rs1128503;EFFICACY;INCREASED;RESPONSE;DISEASE;NARCOLEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SPONDYLARTHROPATHIES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISPHOSPHONATES;FDPS;A;rs11264359;EFFICACY;INCREASED;RESPONSE;DISEASE;OSTEOPOROSIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;MYC;CC;rs4645974;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;CROHN DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;DISEASE:SPONDYLARTHROPATHIES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;DHODH;CC;rs3213422;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;G;rs1799732;EFFICACY;INCREASED;RESISTANCE;OTHER;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;G;rs1799732;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HTR2A;AG;rs7997012;EFFICACY;INCREASED;RESISTANCE;OTHER;MOOD DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;HTR2A;AG;rs7997012;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;TT;rs3745274;DOSAGE;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;HTR2A;AG + GG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;CC;rs1051740;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;rs3745274;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;GG;rs2234922;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;DISEASE;BCR-ABL1 POSITIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;CC + CT;rs3778150;;DECREASED;RESPONSE;;;;
CARBAMAZEPINE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;COMT;AG;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;AG;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCC2;CT;rs717620;TOXICITY;DECREASED;DOSE;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;AA;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;AA;rs737865;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CT + TT;rs678849;EFFICACY;INCREASED;RESPONSE;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;MEN;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESISTANCE;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TNIK;CC;rs7627954;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;CG;rs4818;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;CG;rs4818;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
SUNITINIB;ABCB1;AA + AT;rs2032582;DOSAGE;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;CAUTION_DOSE_ADJUST
SUNITINIB;ABCB1;AA + AT;rs2032582;TOXICITY;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;PEOPLE;CAUTION_DOSE_ADJUST
ADALIMUMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;CAUTION_DOSE_ADJUST
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;DOSE;DISEASE;RENAL CELL CARCINOMA;PEOPLE;CAUTION_SIDE_EFFECT
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;AG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS;MEN;CAUTION_DRUG_ACCUMULATION
METHADONE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;AA;rs2279343;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
DOLUTEGRAVIR;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;GG;rs3745274;DOSAGE;INCREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
PREDNISOLONE;TLR4;T;rs4986791;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A4;CG;rs4986908;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
TELBIVUDINE;TK2;CC + CT;rs3826160;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;HEPATITIS B;PEOPLE;CAUTION_DRUG_ACCUMULATION
TELBIVUDINE;TK2;CC + CT;rs3826160;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;CHRONIC;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;EPHX1;TT;rs1877724;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;CC + CT;rs3778150;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;CLEARANCE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFOTAXIME;SLC22A8;AT;rs11568482;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GALANTAMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;OTHER;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs2279345;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
PERAMPANEL;CYP3A4;CT + TT;rs2242480;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GALANTAMINE;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVASTIGMINE;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;CHILDREN;CAUTION_DOSE_ADJUST
PREDNISOLONE;TLR4;G;rs4986790;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;THROMBOCYTOPENIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;CC;rs2032582;DOSAGE;DECREASED;DOSE;OTHER;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN_METABOLITE(SN-38);ABCB1;AC + CC;rs12720066;METABOLISM/PK;DECREASED;EXPOSURE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GABRB1;T;rs4627835;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GABRB1;T;rs4627835;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GABRB1;A;rs16860087;DOSAGE;INCREASED;DOSE;DISEASE;SCHIZOAFFECTIVE DISORDER;PEOPLE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GABRB1;A;rs16860087;DOSAGE;INCREASED;DOSE;DISEASE;DISEASE:SCHIZOPHRENIA;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;PEOPLE;CAUTION_DOSE_ADJUST
IRINOTECAN_METABOLITE(SN-38);ABCC1;CT + TT;rs35621;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;OTHER;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
LITHIUM;ASIC2;CC;rs11869731;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);ABCC1;AT + TT;rs6498588;METABOLISM/PK;INCREASED;EXPOSURE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;HLA-G;GG;rs9380142;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;HLA-G;GG;rs9380142;EFFICACY;DECREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;MAPK1;AG;rs8136867;EFFICACY;INCREASED;RESPONSE;DISEASE;MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE;HLA-G;CT;rs17179108;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;HLA-G;CT;rs17179108;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs9923231;EFFICACY;INCREASED;DOSE;DISEASE;HEART DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GALANTAMINE;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;COMT;GG;rs4680;EFFICACY;DECREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN;PPARA;AA + AG;rs4253728;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;OR52E2;TT;rs16909440;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;OR52J3;GG;rs2499984;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CREB1;GG;rs889895;EFFICACY;INCREASED;RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;CC;rs16973410;EFFICACY;INCREASED;RESPONSE;DISEASE;BIPOLAR DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;C;rs1142345;EFFICACY;;EXPOSURE;DISEASE;LEUKEMIA;CHILDREN;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GALANTAMINE;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;DISEASE;ALZHEIMER DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT2B7;G;rs28365062;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;CT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOLESTEROL;APOE;TT;rs429358;TOXICITY;INCREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_SIDE_EFFECT
METHADONE;DRD2;AA;rs6275;DOSAGE;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;DRD2;AA;rs6275;METABOLISM/PK;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA + AG;rs12943590;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;AA + AG;rs12943590;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DILTIAZEM;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;DRD2;CC;rs1799978;DOSAGE;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METHADONE;DRD2;CC;rs1799978;METABOLISM/PK;DECREASED;DOSE;DISEASE;HEROIN DEPENDENCE;PEOPLE;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A2;AA + AC;rs316019;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A2;AA + AC;rs316019;EFFICACY;INCREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AA + AC;rs2032582;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROMYCIN;ABCC2;TT;rs717620;OTHER;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROMYCIN;ABCC2;TT;rs717620;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED;RESPONSE;OTHER;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
DUTASTERIDE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED;RESPONSE;OTHER;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;PACSIN2;CT + TT;rs2413739;EFFICACY;DECREASED;RESPONSE;OTHER;IRRITABLE BOWEL SYNDROME;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO2B1;AA + AG;rs12422149;EFFICACY;DECREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED;RESPONSE;DISEASE;ERECTILE DYSFUNCTION;MEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;CHILDREN;CAUTION_DRUG_ACCUMULATION
ABIRATERONE;SRD5A2;CC;rs523349;METABOLISM/PK;INCREASED;METABOLISM;OTHER;PROSTATIC NEOPLASMS;MEN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
TRIGLYCERIDES;CYP19A1;A;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;A;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs3759811;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs3759811;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs1008805;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs1008805;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
TRIGLYCERIDES;CYP19A1;C;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;AC + CC;rs1051296;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs10046;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;PAIN;PEOPLE;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;OTHER;POSTOPERATIVE;PEOPLE;CAUTION_DOSE_ADJUST
HDL CHOLESTEROL;CYP19A1;T;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;T;rs2289105;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;ESR1;TT;rs2234693;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;GT;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
LEFLUNOMIDE;ESR1;AA;rs9340799;EFFICACY;INCREASED;RESPONSE;DISEASE;RHEUMATOID ARTHRITIS;WOMEN;LIKELIHOOD_THERAPEUTIC_SUCCESS
2-HYDROXYATORVASTATIN;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYATORVASTATIN;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN LACTONE;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;C9orf72;CC + CT;rs774359;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;GG;rs3758149;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;A;rs4646;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;A;rs4646;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL13;AA + AC;rs848;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs700518;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs700518;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIGLYCERIDES;CYP19A1;C;rs4775936;OTHER;DECREASED;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs4775936;OTHER;DECREASED;CONCENTRATIONS;DISEASE;DISEASE:MENOPAUSE;WOMEN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;STAT4;GT + TT;rs7574865;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;SLC22A4;CT;rs1050152;EFFICACY;INCREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;GG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;STX1B;AA + AG;rs72800847;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP1A1;CC;rs3826041;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;OTHER;TOBACCO USE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;DNMT3A;TT;rs2304429;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;NQO1;AA;rs10517;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
RALOXIFENE;ESR1;TT;rs2234693;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;ESR1;TT;rs2234693;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;DRD1;AG + GG;rs966775;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;DRD1;AG + GG;rs966775;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;POSTOPERATIVE;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE / SALMETEROL;CHRM2;A;rs8191992;EFFICACY;;RESPONSE;DISEASE;ASTHMA;PEOPLE;
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;NON-HODGKIN LYMPHOMA;CHILDREN;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;PSYCHOTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOAFFECTIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;OTHER;OTHER:SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:LYMPHOMA;PEOPLE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MYELODYSPLASTIC SYNDROMES;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;CC;rs887829;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;DISEASE;HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ITPA;AA + AC;rs1127354;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;METABOLISM/PK;DECREASED;METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
BEVACIZUMAB;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;G;rs1800795;EFFICACY;DECREASED;RESPONSE;DISEASE;PSORIASIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;;GG + GT;rs6983267;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;CYP2C9;G;rs77760615;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A2;TT;rs316009;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"PAIN""";PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;"PAIN""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;"""OTHER:PAIN";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;OTHER;"POSTOPERATIVE""";PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;SLCO1B1;T;rs58310495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA;CHILDREN;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;MALAT1;AG + GG;rs619586;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HOTAIR;CC + CG;rs7958904;EFFICACY;DECREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;H19;AA + AG;rs2839698;EFFICACY;INCREASED;RESPONSE;DISEASE;LUNG NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED;DOSE;DISEASE;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;C;rs1051740;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUTICASONE / SALMETEROL;CHRM2;A;rs6962027;EFFICACY;;RESPONSE;DISEASE;ASTHMA;PEOPLE;
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
BETA BLOCKING AGENTS;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOMYOPATHY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;OTHER;DILATED;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
BETA BLOCKING AGENTS;ADRB2;A;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;CARDIOMYOPATHY;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;ADRB2;A;rs1042713;EFFICACY;INCREASED;RESPONSE;OTHER;DILATED;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE / SALMETEROL;CHRM2;A;rs6962027;EFFICACY;;RESPONSE;DISEASE;ASTHMA;PEOPLE;
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;rs2234922;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
FLUTICASONE PROPIONATE;CRHR1;T;rs1876831;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TNIK;AA;rs2088885;EFFICACY;INCREASED;RESPONSE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CRHR1;T;rs1876828;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CSMD1;AC + CC;rs2617102;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE;CRHR1;C;rs1876829;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CRHR1;G;rs739645;EFFICACY;INCREASED;RESPONSE;DISEASE;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;;DOSE;;;;
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE;PEOPLE;CAUTION_DRUG_ACCUMULATION
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;PK;CYP2A6 NORMAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;PK;BUT NOT REDUCED;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;PK;METABOLIZERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;METABOLISM;DISEASE;EPILEPSY;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MYELODYSPLASTIC SYNDROMES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:LYMPHOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OTHER:MYELODYSPLASTIC SYNDROMES;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;OTHER;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;OTHER;OTHER:HEART VALVE REPLACEMENT;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;OTHER;OTHER:PULMONARY EMBOLISM;PEOPLE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
REMIFENTANIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC + CT;rs1801159;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS;PEOPLE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;DISEASE;ATRIAL FIBRILLATION;PEOPLE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CES1;CT + TT;rs71647871;METABOLISM/PK;INCREASED;EXPOSURE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;CT + TT;rs71647871;EFFICACY;INCREASED;RESPONSE;;;HEALTHY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;DOSE;DISEASE;EPILEPSY;PEOPLE;CAUTION_DOSE_ADJUST
NALTREXONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OPIOID-RELATED DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;STROKE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;TT;rs1044457;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;CC;rs55713253;DOSAGE;INCREASED;DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;CHILDREN;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;BREAST NEOPLASMS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEOXY-THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES;CHILDREN;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;PACSIN2;CC + CT;rs2413739;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES;CHILDREN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*1;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*1;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*2;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*2;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*4;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*4;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*5;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*5;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*9;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*9;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*17;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*17;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*29;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*29;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*34;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*34;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*39;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*39;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*41;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*41;EFFICACY;INCREASED;CONCENTRATIONS;OTHER;VIVAX;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CLEARANCE;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;HEALTHY;CAUTION_DRUG_ACCUMULATION
DULAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEMAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEMAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;SCHIZOPHRENIA;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;OTHER;EPILEPSY;CHILDREN;CAUTION_DRUG_ACCUMULATION
ARTEMETHER;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMEFANTRINE;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;MALARIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
4-ENE VALPROIC ACID;CPT1A;GG;rs2228502;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;EPILEPSY;PEOPLE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CC + CT;rs4673991;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;GT + TT;rs2057638;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;CG + GG;rs6017375;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;AA;rs371927;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;RHEUMATOID ARTHRITIS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*1;CYP2C9*1;;INCREASED;CLINICAL BENEFIT;;;;
LOSARTAN;CYP2C9;*1/*1;CYP2C9*2;;INCREASED;CLINICAL BENEFIT;;;;
LOSARTAN;CYP2C9;*1/*1;CYP2C9*3;;INCREASED;CLINICAL BENEFIT;;;;
CODEINE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;PAIN;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;;CYP2D6 NORMAL METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;HYPERTENSION;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL BENEFIT;OTHER;OTHER:DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;ADRB2;AA;rs1042717;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;ADRB2;GG;rs1042714;EFFICACY;DECREASED;CLINICAL BENEFIT;OTHER;ASTHMA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
PERPHENAZINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;OTHER;MENTAL DISORDERS;PEOPLE;CAUTION_DRUG_ACCUMULATION
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;CC;rs7754840;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;GG;rs7756992;EFFICACY;INCREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;DIABETES MELLITUS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;DISEASE;TYPE 2;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER;PEOPLE;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;SCHIZOPHRENIA;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:MENTAL DISORDERS;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:NEUROTIC DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;OTHER;OTHER:PERSONALITY DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;DOSAGE;INCREASED;DOSE;OTHER;LIVER TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;OTHER;KIDNEY TRANSPLANTATION;PEOPLE;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC22A3;AG + GG;rs2292334;DOSAGE;INCREASED;DOSE;OTHER;DEPRESSION;PEOPLE;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*1/*1;CYP2B6*1;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*1/*1;CYP2B6*6;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANITIDINE;SLC22A1;del;rs72552763;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*32;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*32;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*31;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*31;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*30;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*30;CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*29;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*29;CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*54;CYP2C9*54;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*44;CYP2C9*44;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*42;CYP2C9*42;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*40;CYP2C9*40;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*52;CYP2C9*52;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*43;CYP2C9*43;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*45;CYP2C9*45;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*46;CYP2C9*46;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*39;CYP2C9*39;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*36;CYP2C9*36;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*55;CYP2C9*55;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*38;CYP2C9*38;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*48;CYP2C9*48;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*53;CYP2C9*53;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*47;CYP2C9*47;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*50;CYP2C9*50;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*37;CYP2C9*37;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*60;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*60;CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*60;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*60;CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*60;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*60;CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
;CYP2B6;*1/*1;CYP2B6*1;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2B6;*1/*1;CYP2B6*6;EFFICACY;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
;CYP2E1;*7B;CYP2E1*7A;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2E1;*7B;CYP2E1*7B;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ACE;del;rs1799752;;INCREASED;ENZYME ACTIVITY;ACE;;;
FLUOXETINE;CYP2C19;*32;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*32;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*31;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*31;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*29;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*29;CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;C;rs200707504;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A9;A;rs35350960;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*26;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*26;CYP2D6*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE;SLCO2B1;T;rs1621378;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;T;rs1621378;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE;SLCO2B1;C;rs1009122956;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;C;rs1009122956;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE;SLCO2B1;T;rs199654337;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;T;rs199654337;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;TRANSPORT;SLCO2B1;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2B6;CA/CA;rs70950385;OTHER;DECREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;AGTR1;A;rs12721226;OTHER;DECREASED;AFFINITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
;NAMPT;CC + CT;rs3801266;OTHER;INCREASED;STEADY-STATE LEVEL;NAMPT;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
;CYP2E1;*7A;CYP2E1*7;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2E1;*7A;CYP2E1*7A;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP2E1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;T;rs150152656;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;rs150152656;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
RALOXIFENE;UGT1A8;*2/*2;UGT1A8*1A;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;UGT1A8;*2/*2;UGT1A8*2;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*35;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*39;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*53;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*22;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*26;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*48;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs72552267;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;C;rs118203756;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;T;rs118192177;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*169;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*169;CYP2D6*169;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;G;rs76187628;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2D6;*169;CYP2D6*1;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2D6;*169;CYP2D6*169;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2D6;G;rs76187628;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RANITIDINE;SLC22A1;A;rs34130495;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
RANITIDINE;SLC22A1;T;rs12208357;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;METABOLISM/PK;INCREASED;EXPRESSION;TYMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC2;CG;rs113646094;OTHER;INCREASED;EXPRESSION;ABCC2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_METABOLITE(SN-38);UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;NR1I2;G;rs1464603;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;NR1I2;G;rs1464602;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;del/del;rs3215400;;INCREASED;EXPRESSION;CDA;;;
PHENYTOIN;CYP2C9;del;rs71486745;;DECREASED;EXPRESSION;CYP2C9;;;
DEXTROMETHORPHAN;CYP2D6;*2;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*2;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;CYP3A4;*8;CYP3A4*8;;DECREASED;STEADY-STATE LEVEL;CYP3A4;;;
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP3A4;*12;CYP3A4*12;;DECREASED;ENZYME ACTIVITY;CYP3A4;;;
;CYP3A4;*11;CYP3A4*11;;DECREASED;STEADY-STATE LEVEL;CYP3A4;;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;C;rs11692021;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*46;CYP2A6*46;;INCREASED;EXPRESSION;CYP2A6;;;
IRINOTECAN_METABOLITE(SN-38);UGT1A9;G;rs34993780;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*7 + *19;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*7 + *19;CYP2A6*7;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*7 + *19;CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*7 + *19;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*7 + *19;CYP2A6*7;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*7 + *19;CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*7;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*4;CYP2A6*1;;DECREASED;EXPRESSION;CYP2A6;;;
;CYP2A6;*4;CYP2A6*4;;DECREASED;EXPRESSION;CYP2A6;;;
COUMARIN;CYP2A6;*4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*4/*9;CYP2A6*4;;DECREASED;EXPRESSION;CYP2A6;;;
;CYP2A6;*4/*9;CYP2A6*9;;DECREASED;EXPRESSION;CYP2A6;;;
COUMARIN;CYP2A6;*18;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*18;CYP2A6*18;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*18;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*18;CYP2A6*18;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A9;G;rs72551344;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
NIMESULIDE;PTGS2;G;rs5273;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;PTGS2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NIMESULIDE;PTGS2;C;rs5272;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;PTGS2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2A6;*46;CYP2A6*46;;INCREASED;EXPRESSION;CYP2A6;;;
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*4;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*7;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*9;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*46;CYP2A6*46;;INCREASED;TRANSCRIPTION;CYP2A6;;;
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*6;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*30;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*10;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*20;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*20;CYP3A4*20;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
;ERCC2;TT;rs1799793;;INCREASED;EXPRESSION;ERCC2;;;
;ERCC2;GG;rs13181;;INCREASED;EXPRESSION;ERCC2;;;
VORICONAZOLE;CYP2C19;*23;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*23;CYP2C19*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*33;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*33;CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;GGH;A;rs11545078;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;ERCC1;GG;rs11615;;INCREASED;EXPRESSION;ERCC1;;;
;CDA;C/del + del/del;rs3215400;OTHER;INCREASED;EXPRESSION;CDA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;del;rs121918596;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;CFTR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;CFTR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;CFTR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*31;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*31;CYP2C9*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*19;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*19;CYP2C9*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*27;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*27;CYP2C9*27;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*54;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*54;CYP2C9*54;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*53;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*53;CYP2C9*53;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*56;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*56;CYP2C9*56;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*55;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*55;CYP2C9*55;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EBASTINE;CYP2J2;(CTC)1;rs757528200;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*30;CYP2B6*1;OTHER;DECREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*30;CYP2B6*30;OTHER;DECREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*6;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CYTARABINE;CDA;AA + AG;rs60369023;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CDA;;;CAUTION_DRUG_ACCUMULATION
CISPLATIN;ERCC2;GG;rs13181;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AG;rs1695;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATRASENTAN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*5;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*9;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*9;SLCO1B1*9;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*9;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*14;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*14;SLCO1B1*14;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*14;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15;SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
;CD38;T;rs1130169;;DECREASED;EXPRESSION;CD38;;;
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
;DPYD;CG;rs75017182;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;;DECREASED;ENZYME ACTIVITY;TPMT;;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;;DECREASED;ENZYME ACTIVITY;TPMT;;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;;DECREASED;ENZYME ACTIVITY;TPMT;;;
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;;DECREASED;ENZYME ACTIVITY;TPMT;;;
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*14;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*14;CYP2C19*14;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*15;OTHER;DECREASED;ENZYME ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*21;OTHER;DECREASED;ENZYME ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*22;OTHER;DECREASED;ENZYME ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;SLCO1B1;*37;SLCO1B1*1;OTHER;INCREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*37;SLCO1B1*37;OTHER;INCREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*20;SLCO1B1*1;OTHER;INCREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*20;SLCO1B1*20;OTHER;INCREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*14;SLCO1B1*1;OTHER;INCREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*14;SLCO1B1*14;OTHER;INCREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANINE;TPMT;*16;TPMT*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*16;TPMT*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
;CYP2C19;*19;CYP2C19*1;OTHER;DECREASED;EXPRESSION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C19;*19;CYP2C19*19;OTHER;DECREASED;EXPRESSION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*19;CYP2C19*19;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRANYLCYPROMINE;CYP2C19;*15;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRANYLCYPROMINE;CYP2C19;*15;CYP2C19*15;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRANYLCYPROMINE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRANYLCYPROMINE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*2;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*5;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*6;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*8;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*11;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*12;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*13;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*8;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUCONAZOLE;CYP2C19;*11;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;*11;CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*11;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*11;CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2C19;*11;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2C19;*11;CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TROGLITAZONE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TROGLITAZONE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRANYLCYPROMINE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRANYLCYPROMINE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TROGLITAZONE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TROGLITAZONE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*2;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*3A;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*3B;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*3C;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*5;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*6;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*7;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*9;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*12;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*14;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*17;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*18;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*19;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*20;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*21;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*22;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*23;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*30;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*1;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*2;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*3A;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*5;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*12;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*14;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*18;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*22;METABOLISM/PK;DECREASED;EXPRESSION;TPMT;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*1;TPMT*1;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*1;TPMT*3A;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*1;TPMT*3C;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*28;CYP2C19*28;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*23;CYP2C19*23;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*23;CYP2C19*23;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*28;CYP2C19*28;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*13;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*14;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*15;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*18;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*23;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*25;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
;ABCB1;AC + CC;rs2032582;METABOLISM/PK;INCREASED;ACTIVITY;ABCB1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;AG + GG;rs1128503;METABOLISM/PK;INCREASED;ACTIVITY;ABCB1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;CYP2D6*53;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*4;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*7;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*8;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*12;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*14;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*16;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*17;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*18;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*19;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*20;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*23;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;METABOLISM;POOR METABOLIZER;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*134;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*153;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;EXPRESSION;IFNAR1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*134;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*153;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2;CYP2D6*1;OTHER;DECREASED;ACTIVITY;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*2;CYP2D6*2;OTHER;DECREASED;ACTIVITY;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*49;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*55;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*54;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*54;CYP2D6*54;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2C19;*16;CYP2C19*1;OTHER;DECREASED;FORMATION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C19;*16;CYP2C19*16;OTHER;DECREASED;FORMATION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*18;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*47;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*49;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*50;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*51;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*54;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*55;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*114;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*47;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*47;CYP2D6*47;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*18;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*18;CYP2D6*18;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*3A + *3C + *24;TPMT*1;OTHER;DECREASED;EXPRESSION;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*3A + *3C + *24;TPMT*3A;OTHER;DECREASED;EXPRESSION;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*3A + *3C + *24;TPMT*3C;OTHER;DECREASED;EXPRESSION;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*3A + *3C + *24;TPMT*24;OTHER;DECREASED;EXPRESSION;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*50;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*50;CYP2D6*50;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*36;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*36;CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*51;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*51;CYP2D6*51;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*2;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*3;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*11;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*29;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
CERIVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
CERIVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
CERIVASTATIN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
CERIVASTATIN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*2;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*9;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*10;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*18;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*23;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*5;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*6;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*7;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*9;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*17;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*18;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*19;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*26;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*5;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*6;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*7;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*9;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*17;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*18;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*19;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*26;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*14;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*14;CYP2D6*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*53;CYP2D6*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*53;CYP2D6*53;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs9999111;OTHER;DECREASED;EXPRESSION;ABCG2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP;CYP2B6;*4;CYP2B6*1;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
R-EDDP;CYP2B6;*4;CYP2B6*4;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
S-EDDP;CYP2B6;*4;CYP2B6*1;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
S-EDDP;CYP2B6;*4;CYP2B6*4;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*2;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*9;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*29;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*29;CYP2D6*29;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*29;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*29;CYP2D6*29;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1A;METABOLISM/PK;INCREASED;ACTIVITY;UGT1A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*2A;METABOLISM/PK;INCREASED;ACTIVITY;UGT1A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*18;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*23;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*2;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*9;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*14;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*16;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*19;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*23;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*24;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*28;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*32;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*28;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*16;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*16;CYP2C19*16;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*8;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*8;CYP2C19*8;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*9;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*9;CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*13;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*13;CYP2C19*13;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*2;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3A;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*9;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*21;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*32;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*33;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*34;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*2;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3A;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*9;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*21;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*32;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*33;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*34;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*4;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*9;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*9;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*9;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*2;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*89;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*93;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*89;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*93;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*17;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*24;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*14;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2D6;*92 + *96;CYP2D6*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2D6;*92 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2D6;*92 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*18;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*18;CYP2C19*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*6;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*6;CYP2C19*6;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*3;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*4;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*5;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*10;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;UGT1A4;*3a;UGT1A4*1A;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;UGT1A4;*3a;UGT1A4*3A;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;G;rs1361528097;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;ACTIVITY;ABCB1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
COPTISINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
COPTISINE;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
COPTISINE;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;INHIBITION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;T;rs1431015009;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
;SLCO1B1;*15;SLCO1B1*1;OTHER;DECREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;SLCO1B1;*15;SLCO1B1*15;OTHER;DECREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;A;rs1230912765;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2B6;*27;CYP2B6*1;;DECREASED;EXPRESSION;CYP2B6;;;
;CYP2B6;*27;CYP2B6*27;;DECREASED;EXPRESSION;CYP2B6;;;
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;G;rs1466428833;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;T;rs1058171;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
CORR-4A;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;G;rs148247410;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;AKR1C3;T;rs62621365;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;AKR1C4;A;rs11253043;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;rs1393133490;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*24;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*24;CYP2C19*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*24;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*24;CYP2C19*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;DPYD;AC;rs55886062;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ABCC10;TT;rs2125739;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*9;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*9;CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4;CYP2A6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4;CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*75;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*75;CYP2D6*75;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*4;CYP1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*4;CYP1A1*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*2C;CYP1A1*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*2C;CYP1A1*2C;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*11;CYP1A2*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*11;CYP1A2*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*3A + *3C;TPMT*1;OTHER;DECREASED;ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*3A + *3C;TPMT*3A;OTHER;DECREASED;ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*3A + *3C;TPMT*3C;OTHER;DECREASED;ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*17 + *35;CYP2A6*1;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*17 + *35;CYP2A6*17;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*17 + *35;CYP2A6*35;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;TOXICITY;INCREASED;CONCENTRATIONS;DEFICIENCY;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;METABOLISM/PK;INCREASED;CONCENTRATIONS;DEFICIENCY;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;TOXICITY;INCREASED;CONCENTRATIONS;DEFICIENCY;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;METABOLISM/PK;INCREASED;CONCENTRATIONS;DEFICIENCY;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;A;rs140278421;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*92 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*92 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*29;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*30;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*31;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*33;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*29;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*30;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*31;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*33;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*32;CYP2C19*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*32;CYP2C19*32;METABOLISM/PK;DECREASED;ACTIVITY;CYP2C19;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*92 + *96;CYP2D6*92;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*92 + *96;CYP2D6*96;METABOLISM/PK;DECREASED;ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CISPLATIN;TPMT;*3A;TPMT*1;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;TPMT*3A;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;TPMT*1;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;TPMT*3A;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;TPMT*1;OTHER;INCREASED;EXPRESSION;TLR4;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;*3A;TPMT*3A;OTHER;INCREASED;EXPRESSION;TLR4;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*1;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*5;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*10;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*14;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*18;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*21;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*41;EFFICACY;INCREASED;EXPRESSION;MKI67;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADEFOVIR DIPIVOXIL;SLC22A6;T;rs11568634;OTHER;DECREASED;UPTAKE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*89;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*87;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*88;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*90;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*91;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*93;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*94;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;CYP3A5;*3/*3;CYP3A5*1;OTHER;DECREASED;EXPRESSION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*3/*3;CYP3A5*3;OTHER;DECREASED;EXPRESSION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*3/*3;CYP3A5*1;OTHER;DECREASED;EXPRESSION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*3/*3;CYP3A5*3;OTHER;DECREASED;EXPRESSION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs138142612;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SCAP;TT;rs12487736;OTHER;DECREASED;TRANSCRIPTION;SCAP;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NAMPT;CC + CT;rs1319501;OTHER;DECREASED;STEADY-STATE LEVEL;NAMPT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED;EXPRESSION;FKBP5;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE 5-N-GLUCURONIDE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;*28;UGT1A1*1;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A1;*28;UGT1A1*28;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;*28/*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;UGT1A1;*28/*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*28;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*37;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*62;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*62;CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*62;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*62;CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*62;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*62;CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*1;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*47;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*47;CYP2C9*47;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*49;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*49;CYP2C9*49;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*43;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*43;CYP2C9*43;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*45;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*45;CYP2C9*45;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*39;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*39;CYP2C9*39;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*42;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*42;CYP2C9*42;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*41;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*41;CYP2C9*41;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*37;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*37;CYP2C9*37;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*36;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*36;CYP2C9*36;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*33;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*33;CYP2C9*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*13;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*13;CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*16;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*16;CYP2C9*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*14;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*14;CYP2C9*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*8;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*8;CYP2C9*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*50;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*50;CYP2C9*50;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*52;CYP2C9*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*52;CYP2C9*52;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*51;CYP2C9*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*51;CYP2C9*51;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;;ACTIVITY;CFTR;;;
;CYP2C9;AT + TT;rs7089580;OTHER;INCREASED;EXPRESSION;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DICLOFENAC;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*72;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*72;CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*72;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*72;CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*72;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*72;CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*75;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*75;CYP2C9*75;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*74;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*74;CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*74;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*74;CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*74;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*74;CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*73;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*73;CYP2C9*73;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*73;CYP2C9*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*73;CYP2C9*73;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*6;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*21;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*30;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;MIR27A;C;rs895819;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;CYP2D6;G;rs1058164;OTHER;DECREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*1;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*30;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*31;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*32;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*33;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*1;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*4;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*5;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*18;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*23;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*28;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*29;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*31;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*32;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*33;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*34;OTHER;DECREASED;CLEARANCE;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*1;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*3;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*35;OTHER;DECREASED;CATALYTIC ACTIVITY;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*36;CYP2D6*1;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*36;CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*1;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*9;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*11;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*1;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*9;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*11;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*1;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*11;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*20;CYP3A4*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*20;CYP3A4*20;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*1;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*4;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*5;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*7;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*8;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*9;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*10;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*12;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*13;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*14;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*16;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*17;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*18;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*23;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*24;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*28;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*31;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*33;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*34;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*29;CYP3A4*1;METABOLISM/PK;INCREASED;ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BLONANSERIN;CYP3A4;*29;CYP3A4*29;METABOLISM/PK;INCREASED;ACTIVITY;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*39;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*40;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*41;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*42;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*43;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*44;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*46;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE;NAT2;*4/*4;NAT2*4;OTHER;INCREASED;ACTIVITY;NAT2 RAPID ACETYLATOR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*4/*4;NAT2*5;OTHER;INCREASED;ACTIVITY;NAT2 RAPID ACETYLATOR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*4/*4;NAT2*6;OTHER;INCREASED;ACTIVITY;NAT2 RAPID ACETYLATOR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOLITHROMYCIN;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SOLITHROMYCIN;NAT2;*4;NAT2*5;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SOLITHROMYCIN;NAT2;*4;NAT2*6;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SOLITHROMYCIN;NAT2;*4;NAT2*7;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SOLITHROMYCIN;NAT2;*4;NAT2*14;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*4;OTHER;INCREASED;ACTIVITY;NAT2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*5;OTHER;INCREASED;ACTIVITY;NAT2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*6;OTHER;INCREASED;ACTIVITY;NAT2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*7;OTHER;INCREASED;ACTIVITY;NAT2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ALDH1A2;AA + AG;rs12915901;OTHER;DECREASED;EXPRESSION;ALDH1A2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;BCL2L11;CC;rs724710;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;BCL2L11;AA;rs2241843;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
THIOXANTHINE;XDH;T;rs45442092;METABOLISM/PK;DECREASED;CLEARANCE;XDH;;;CAUTION_DRUG_ACCUMULATION
THIOXANTHINE;XDH;T;rs2295474;METABOLISM/PK;DECREASED;CLEARANCE;XDH;;;CAUTION_DRUG_ACCUMULATION
;HLA-G;C;rs1063320;OTHER;INCREASED;EXPRESSION;HLA-G;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;HLA-G;GG;rs1063320;OTHER;INCREASED;EXPRESSION;HLA-G;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*46;CYP2B6*46;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*47;CYP2B6*47;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*47;CYP2B6*47;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*46;CYP2B6*46;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;HDAC2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;HDAC2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;FKBP5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;FKBP5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;GLCCI1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;GLCCI1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;PD;DECREASED;EXPRESSION;NR3C1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;PD;DECREASED;EXPRESSION;NR3C1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*2;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*87;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*92;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*93;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CDA;GG;rs602950;OTHER;INCREASED;EXPRESSION;CDA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TPH2;T;rs4290270;OTHER;INCREASED;EXPRESSION;TPH2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;TT;rs532545;OTHER;INCREASED;EXPRESSION;CDA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOTHANE;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOTHANE;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIHYDROERGOTAMINE;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;HTR1B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYSERGIDE;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;HTR1B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;HTR1B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETANSERIN;HTR1B;C;rs130060;PD;DECREASED;AFFINITY;HTR1B;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;TT;rs1048977;OTHER;INCREASED;EXPRESSION;CDA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TPH2;AA;rs7305115;OTHER;INCREASED;EXPRESSION;TPH2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;CC;rs2072671;OTHER;INCREASED;EXPRESSION;CDA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;DECREASED;EXPRESSION;CYP2D6;;;CAUTION_DRUG_ACCUMULATION
;DPYD;A;rs547099198;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs568132506;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs760663364;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs780025995;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;T;rs114096998;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;G;rs748639205;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;AA;rs2784917;OTHER;INCREASED;EXPRESSION;WNT5B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;GG;rs6539870;OTHER;INCREASED;EXPRESSION;IL1B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;PROTEIN STABILITY;CFTR;;;
IVACAFTOR;CFTR;A;rs121909047;EFFICACY;;ACTIVITY;CFTR;;;
NICOTINE;CYP2A6;CC + CT;rs56113850;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;TT;rs7259706;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;AA + AG;rs28399453;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;CC + CG;rs8192733;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*19;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*23;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*24;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*28;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*29;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*12;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LURASIDONE;CYP3A4;*12;CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*28;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*18;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs9999111;OTHER;DECREASED;EXPRESSION;ABCG2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCG2;C;rs2725263;OTHER;INCREASED;EXPRESSION;ABCG2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;A;rs149713212;OTHER;DECREASED;EXPRESSION;ABCG2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs74503330;OTHER;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;G;rs12508471;OTHER;DECREASED;EXPRESSION;ABCG2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCA12;A;rs2888327;;INCREASED;EXPRESSION;ABCA12;;;
;ABCA12;C;rs10182702;;INCREASED;EXPRESSION;ABCA12;;;
DAUNORUBICINOL;AKR1A1;C;rs6690497;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICINOL;AKR1A1;C;rs6690497;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCA8;T;rs11656365;;DECREASED;EXPRESSION;ABCA8;;;
;;G;rs2000068;;INCREASED;EXPRESSION;ABCA1;;;
;PITPNM2;C;rs12425009;;DECREASED;EXPRESSION;ABCB9;;;
DOXORUBICINOL;AKR1A1;G;rs2229540;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;PSMB8, TAP1, TAP2;T;rs2071543;;INCREASED;EXPRESSION;TAP2;;;
;PSMB8, TAP2;A;rs9357155;;INCREASED;EXPRESSION;TAP2;;;
;ABCB9;T;rs4148866;;INCREASED;EXPRESSION;ABCB9;;;
DAUNORUBICINOL;AKR1A1;G;rs2229540;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCA1;G;rs2515629;;INCREASED;EXPRESSION;ABCA1;;;
;ABCA1;G;rs4149297;;INCREASED;EXPRESSION;ABCA1;;;
;;T;rs2487030;;INCREASED;EXPRESSION;ABCA1;;;
;ABCA1;C;rs2472507;;INCREASED;EXPRESSION;ABCA1;;;
;F3;T;rs841698;;INCREASED;EXPRESSION;ABCD3;;;
;ABCD2;C;rs4284427;;DECREASED;EXPRESSION;ABCD2;;;
;REDIC1;T;rs10783969;;INCREASED;EXPRESSION;ABCD2;;;
;;G;rs4285917;;DECREASED;EXPRESSION;ABCD2;;;
;ABCC10;A;rs2487663;;DECREASED;EXPRESSION;ABCC10;;;
;ABCC4;T;rs4773866;;INCREASED;EXPRESSION;ABCC4;;;
;ABCC10;A;rs2185631;;DECREASED;EXPRESSION;ABCC10;;;
;;G;rs12195350;;DECREASED;EXPRESSION;ABCC10;;;
;ABCD1, BCAP31;C;rs17091297;;INCREASED;EXPRESSION;ABCD1;;;
;ABCC10;G;rs9394952;;DECREASED;EXPRESSION;ABCC10;;;
;PLXNB3;A;rs4898439;;INCREASED;EXPRESSION;ABCD1;;;
;;C;rs4898437;;INCREASED;EXPRESSION;ABCD1;;;
;TMPRSS11E;T;rs2168047;;INCREASED;EXPRESSION;UGT2B4;;;
;;CC;rs6822259;;INCREASED;EXPRESSION;UGT2B17;;;
NICOTINE;CYP2A6;AG + GG;rs57837628;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT2B4;T;rs4557343;;INCREASED;EXPRESSION;UGT2B15;;;
NICOTINE;CYP2A6;GG;rs7260629;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;CC + CT;rs4803381;METABOLISM/PK;INCREASED;ACTIVITY;CYP2A6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;GG;rs1799971;EFFICACY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;RARG;A;rs2229774;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;IL18;GG + GT;rs1946518;OTHER;INCREASED;EXPRESSION;IL18;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;IL18;CC + CG;rs5744247;OTHER;INCREASED;EXPRESSION;IL18;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*1;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*11;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*5;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*15;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*3;CYP1A2*1;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*3;CYP1A2*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;T;rs71647871;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;C;rs151291296;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;T;rs2307240;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CES1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIMAZOLAM;CES1;G;rs143718310;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CES1;;;CAUTION_DRUG_ACCUMULATION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;A;rs35516286;PD;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR / TEZACAFTOR;CFTR;A;rs35516286;PD;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;DPP4;CC;rs759717;PD;INCREASED;ACTIVITY;DPP4;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;DPP4;TT;rs2909451;PD;INCREASED;ACTIVITY;DPP4;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;rs113993958;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;G;rs397508288;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs397508537;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs78769542;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;C;rs1800111;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs121909020;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;T;rs397508442;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs74551128;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs186045772;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs397508256;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;T;rs368505753;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;T;rs202179988;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs121909019;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs121908753;EFFICACY;;ACTIVITY;CFTR;;;
DAUNORUBICIN;AKR1C4;G;rs17134592;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C4;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;rs77834169;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;G;rs121908752;EFFICACY;;ACTIVITY;CFTR;;;
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CT;rs186089140;PD;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;AKR7A2;T;rs1043657;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR7A2;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR7A2;T;rs1043657;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR7A2;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;T;rs141033578;EFFICACY;;ACTIVITY;CFTR;;;
DAUNORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;rs121909011;EFFICACY;;ACTIVITY;CFTR;;;
DAUNORUBICIN;AKR1C3;T;rs35575889;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;T;rs35575889;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;rs77409459;EFFICACY;;ACTIVITY;CFTR;;;
DAUNORUBICIN;AKR1C3;A;rs4987102;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;AKR1C3;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;C;rs397508510;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs397508139;EFFICACY;;ACTIVITY;CFTR;;;
;DPYD;C;rs2297595;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs67376798;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;rs397508435;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs121908751;EFFICACY;;ACTIVITY;CFTR;;;
;EPO;AA;rs1617640;OTHER;INCREASED;EXPRESSION;EPO;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;G;rs397508328;EFFICACY;;ACTIVITY;CFTR;;;
DOXORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;A;rs28943579;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;T;rs62621365;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;CYP4F2;A;rs2189784;OTHER;INCREASED;EXPRESSION;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F11;A;rs1060467;OTHER;INCREASED;EXPRESSION;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F2;T;rs2108622;OTHER;INCREASED;EXPRESSION;CYP4F11;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F2;T;rs2108622;OTHER;INCREASED;EXPRESSION;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F2;A;rs2189784;OTHER;DECREASED;EXPRESSION;CYP4F12;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;T;rs11971167;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;C;rs75541969;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;G;rs34911792;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;G;rs150212784;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs397508759;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;T;rs115545701;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;C;rs397508513;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;T;rs1800100;EFFICACY;;ACTIVITY;CFTR;;;
ADALIMUMAB;TNF;AG;rs1800629;METABOLISM/PK;DECREASED;STEADY-STATE LEVEL;TNF;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;TNF;AA + AG;rs1800629;METABOLISM/PK;INCREASED;ACTIVITY;TNF;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;VKORC1;C;rs56314408;OTHER;INCREASED;TRANSCRIPTION;VKORC1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;NFATC2;T;rs6021191;OTHER;INCREASED;EXPRESSION;NFATC2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLC22A3;G;rs2076828;OTHER;DECREASED;EXPRESSION;SLC22A3;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP4F2;CT;rs2108622;OTHER;INCREASED;CONCENTRATIONS;CYP4F2;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;POR;AG + GG;rs2868177;METABOLISM/PK;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;OTHER;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
;WBP2NL;AG + GG;rs5758550;OTHER;INCREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2D6;AA + AG;rs16947;OTHER;DECREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;A;rs12782374;;DECREASED;EXPRESSION;CYP2C9;;;
;RALGAPA2;GG;rs3827963;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DISP1;TT;rs61840266;OTHER;INCREASED;TRANSCRIPTION;ABCC1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SPAG16;CC;rs35945601;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DISP1;GG;rs17535305;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TXLNB;CC;rs9495425;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ZNF890P;AA;rs62442010;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;NAF1;AA;rs17571991;OTHER;INCREASED;TRANSCRIPTION;ABCC1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ECHDC1;AA;rs6569487;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ZBED5;GG;rs10840501;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DHRS4L1;GG;rs10147475;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;KCNQ3;AA;rs7818112;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;AMPH;CC;rs12701634;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;STXBP4;AA;rs9303363;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ADCYAP1;AA;rs304400;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CHD2;TT;rs28458425;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;RGMA;GG;rs7165938;OTHER;INCREASED;TRANSCRIPTION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;UGT1A1;AG;rs4148323;METABOLISM/PK;DECREASED;FORMATION;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;AG;rs4148323;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
;CYP2C19;A;rs7902257;OTHER;DECREASED;EXPRESSION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOCISTEINE;PAH;G;rs75193786;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs143154602;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs186169810;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs190577302;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs183105782;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs183385770;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs146356975;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs137999090;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs59086055;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs145773863;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs138616379;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs72549304;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs111858276;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs200687447;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;rs72549307;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs1801266;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs115232898;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs72549308;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs143986398;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs60139309;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs114096998;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;rs2297595;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;C;rs1105879;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;DECREASED;FORMATION;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_METABOLITE(SN-38);UGT1A1;GG + GT;rs4124874;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
CALCIUM;RYR1;AG;rs118192167;OTHER;INCREASED;STEADY-STATE LEVEL;;;;CAUTION_DRUG_ACCUMULATION
;XRCC4;T;rs2075685;OTHER;INCREASED;EXPRESSION;XRCC4;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;FORMATION;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
;XRCC4;G;rs10040363;OTHER;INCREASED;EXPRESSION;ERCC1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;IL12RB2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ERCC1;A;rs2298881;OTHER;DECREASED;EXPRESSION;ERCC1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;IL1R2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;IL17A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;T;rs247616;OTHER;DECREASED;EXPRESSION;CETP;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED;EXPRESSION;TCL1A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED;EXPRESSION;IL17RA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;IL12RB2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED;EXPRESSION;IL17RA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;IL1R2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;IL17A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;IL1R2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;IL17A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;IL12RB2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLC22A3;AA;rs555754;;INCREASED;EXPRESSION;SLC22A3;;;
ESTRADIOL;;G;rs2369049;OTHER;INCREASED;EXPRESSION;IL17RA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PROM1;CC;rs2286455;;DECREASED;EXPRESSION;PROM1;;;
ESTRADIOL;;G;rs2369049;OTHER;INCREASED;EXPRESSION;TCL1A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;IL12RB2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;IL1R2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;G;rs11849538;OTHER;INCREASED;EXPRESSION;IL17RA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;IL17A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;G;rs11849538;OTHER;INCREASED;EXPRESSION;TCL1A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED;EXPRESSION;TCL1A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;RARG;A;rs2229774;OTHER;DECREASED;PROTEIN STABILITY;RARG;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_METABOLITE(SN-38);UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NRP2;C;rs10932125;;INCREASED;EXPRESSION;CYP1B1;;;
;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;FORMATION;UGT1A9;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;AG;rs118192167;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIMAZOLAM;CES1;T;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;T;rs118192161;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;CT;rs71647871;EFFICACY;DECREASED;CATALYTIC ACTIVITY;CES1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;G;rs3758581;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2C19;G;rs3758581;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;C;rs17878459;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2C19;C;rs181297724;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
KETOCONAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
L-PHENYLALANINE;PAH;T;rs62516101;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
CARBOCISTEINE;PAH;T;rs62516101;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;OPRM1;G;rs1799971;EFFICACY;DECREASED;ACTIVITY;OPRM1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;rs72547601;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs61757362;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs67376798;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs141044036;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs188052243;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
CARBOCISTEINE;PAH;C;rs5030860;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs112766203;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs55674432;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;C;rs5030860;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs1801268;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTM1;C;rs3754446;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOCISTEINE;PAH;A;rs76394784;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;A;rs76394784;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;A;rs142693902;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;A;rs35199625;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SOD2;G;rs4880;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT2B10;GT + TT;rs61750900;METABOLISM/PK;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
;NOS3;GT + TT;rs1799983;;DECREASED;EXPRESSION;NOS3;;;
;IL7;AA + AG;rs16906115;OTHER;INCREASED;EXPRESSION;IL7;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOCISTEINE;PAH;T;rs5030849;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;T;rs5030849;METABOLISM/PK;DECREASED;ACTIVITY;PAH;;;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;UGT2B7;A;rs7438135;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;CC;rs776746;OTHER;DECREASED;EXPRESSION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;A;rs4294451;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;DPYD;T;rs4294451;OTHER;INCREASED;EXPRESSION;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;CYP3A4;C;rs12721627;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;PACSIN2;CT + TT;rs2413739;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs138142612;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;UGT1A4;CC;rs8330;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A4;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs72552267;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;rs118203756;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;CYP19A1;;;
EXEMESTANE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;CYP19A1;;;
LETROZOLE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;CYP19A1;;;
FLUOXETINE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;CYP19A1;;;
EXEMESTANE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;CYP19A1;;;
LETROZOLE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;CYP19A1;;;
FLUOXETINE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs559628884;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;G;rs3758581;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;CG;rs11568319;METABOLISM/PK;DECREASED;FORMATION;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A9;TT;rs2741049;METABOLISM/PK;INCREASED;FORMATION;UGT1A1;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;DCTD;C;rs35932500;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;DCTD;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A9;CT + TT;rs2741049;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A9;CT + TT;rs2741049;METABOLISM/PK;INCREASED;FORMATION;UGT1A9;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs147255955;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs145328984;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs370803989;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_METABOLITE(SN-38);UGT1A9;AA;rs3806598;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;C;rs2072671;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CDA;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ABCC4;TT;rs3765534;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;TT;rs3765534;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;C;rs75017182;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;DPYD;G;rs1801265;METABOLISM/PK;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;C;rs2297595;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;NT5E;A;rs9450278;;DECREASED;EXPRESSION;NT5E;;;
;ARNT;GG;rs2134688;METABOLISM/PK;DECREASED;CONCENTRATIONS;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;;CC;rs478437;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;E2F7;CC;rs310786;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;CC;rs478437;OTHER;INCREASED;EXPRESSION;USP7;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PPARA;AA;rs4253728;METABOLISM/PK;DECREASED;CONCENTRATIONS;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs9332094;OTHER;DECREASED;TRANSCRIPTION;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs4918758;OTHER;DECREASED;TRANSCRIPTION;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A1;A;rs28967009;OTHER;INCREASED;EXPRESSION;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP3A4;TT;rs2242480;METABOLISM/PK;DECREASED;ACTIVITY;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
;CYP2B6;TT;rs3745274;OTHER;DECREASED;EXPRESSION;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;METABOLISM/PK;DECREASED;EXPRESSION;YEATS4;;;CAUTION_DRUG_ACCUMULATION
;YEATS4;CC;rs7297610;METABOLISM/PK;INCREASED;EXPRESSION;YEATS4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NQO1;A;rs1800566;;DECREASED;EXPRESSION;NQO1;;;
;NQO1;AA;rs1800566;;DECREASED;ENZYME ACTIVITY;NQO1;;;
;DPYD;T;rs1212037891;OTHER;INCREASED;EXPRESSION;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;A;rs143879757;OTHER;INCREASED;EXPRESSION;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;A;rs72549306;OTHER;INCREASED;EXPRESSION;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;G;rs748620513;OTHER;INCREASED;EXPRESSION;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;C;rs1335150891;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs188052243;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs72549306;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;DPYD;T;rs1801160;OTHER;INCREASED;EXPRESSION;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
;ABCC11;AA + AG;rs17822471;OTHER;DECREASED;EXPRESSION;ABCC11;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;CT;rs118192172;OTHER;;SENSITIVITY;;;;
HALOTHANE;RYR1;CT;rs118192172;OTHER;;SENSITIVITY;;;;
CAFFEINE;RYR1;GT;rs193922772;OTHER;;SENSITIVITY;;;;
HALOTHANE;RYR1;GT;rs193922772;OTHER;;SENSITIVITY;;;;
CAFFEINE;RYR1;CT;rs118192175;OTHER;;SENSITIVITY;;;;
HALOTHANE;RYR1;CT;rs118192175;OTHER;;SENSITIVITY;;;;
CAFFEINE;RYR1;AG;rs118192176;OTHER;;SENSITIVITY;;;;
HALOTHANE;RYR1;AG;rs118192176;OTHER;;SENSITIVITY;;;;
CAFFEINE;RYR1;CT;rs28933397;OTHER;;SENSITIVITY;;;;
HALOTHANE;RYR1;CT;rs28933397;OTHER;;SENSITIVITY;;;;
;VDR;T;rs11568820;OTHER;INCREASED;STEADY-STATE LEVEL;CYP3A4;;;CAUTION_DRUG_ACCUMULATION
;DPYD;T;rs1801158;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;T;rs1801160;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;G;rs1801265;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;G;rs748620513;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs148994843;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs59086055;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs56005131;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs143879757;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;del;rs1184321568;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
CEFOTAXIME;SLC22A8;A;rs11568482;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
;NCOA1;T;rs1804645;;INCREASED;HALF-LIFE;NCOA1;;;
TAMOXIFEN;NCOA1;T;rs1804645;;DECREASED;ACTIVITY;NCOA1;;;
;A2M;T;rs669;METABOLISM/PK;INCREASED;STEADY-STATE LEVEL;A2M;;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;;C;rs4386686;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;F12;G;rs1801020;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;F12;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs4386686;TOXICITY;INCREASED;EXPRESSION;MIRLET7I;;;CAUTION_SIDE_EFFECT
;;C;rs4386686;OTHER;INCREASED;EXPRESSION;MIRLET7I;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;C;rs4386686;TOXICITY;DECREASED;EXPRESSION;TRAF1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;C;rs4386686;OTHER;DECREASED;EXPRESSION;TRAF1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;CT;rs1801158;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC9;T;rs704212;OTHER;INCREASED;EXPRESSION;ABCC9;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;C;rs4149056;OTHER;DECREASED;EXPRESSION;SLCO1B1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs77010898;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;UGT1A3;T;rs7604115;OTHER;INCREASED;EXPRESSION;UGT1A3;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;CYP3A5;A;rs55817950;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP3A5;;;CAUTION_DRUG_ACCUMULATION
;IMPDH2;A;rs121434586;OTHER;DECREASED;ENZYME ACTIVITY;IMPDH2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ORMDL3;AG + GG;rs2872507;METABOLISM/PK;INCREASED;EXPRESSION;ORMDL3;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC2;T;rs717620;;INCREASED;TRANSCRIPTION;ABCC2;;;
CAFFEINE;RYR1;T;rs193922753;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CYP3A5;C;rs72552791;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP3A5;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;A;rs118192176;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;rs193922809;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;rs118192122;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;rs193922816;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;G;rs118192167;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE;SLC17A3;A;rs34376145;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;A;rs34902660;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;A;rs11966370;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;T;rs56027330;METABOLISM/PK;DECREASED;TRANSPORT;SLC17A3;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;T;rs2307243;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;C;rs202121317;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;A;rs202001817;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CYTARABINE;NT5C2;G;rs1163075;EFFICACY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NT5C2;G;rs1163075;METABOLISM/PK;INCREASED;TRANSCRIPTION;NT5C2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;NT5C2;GG;rs11191612;EFFICACY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NT5C2;GG;rs11191612;METABOLISM/PK;INCREASED;TRANSCRIPTION;NT5C2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMISULPRIDE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;ABCB1;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A;CC;rs10929303;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A;;;CAUTION_DRUG_ACCUMULATION
CHLOROCRESOL;RYR1;T;rs193922803;OTHER;INCREASED;ACTIVITY;RYR1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARACHIDONIC ACID;CYP4F2;G;rs753169154;PD;DECREASED;CATALYTIC ACTIVITY;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ARACHIDONIC ACID;CYP4F2;T;rs2108622;PD;DECREASED;CATALYTIC ACTIVITY;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ARACHIDONIC ACID;CYP4F2;A;rs114396708;PD;DECREASED;CATALYTIC ACTIVITY;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;CT;rs193922747;OTHER;;SENSITIVITY;;;;
HALOTHANE;RYR1;CT;rs193922747;OTHER;;SENSITIVITY;;;;
ACETAMINOPHEN;UGT1A;CC;rs1042640;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A;;;CAUTION_DRUG_ACCUMULATION
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A;CC;rs8330;METABOLISM/PK;DECREASED;ACTIVITY;UGT1A;;;CAUTION_DRUG_ACCUMULATION
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;T;rs118192178;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;T;rs118192178;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1A2;T;rs4148981;;DECREASED;EXPRESSION;SLCO1A2;;;
ALDOSTERONE;SCNN1B;A;rs34241435;OTHER;INCREASED;TRANSCRIPTION;SCNN1B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INSULIN RECOMBINANT;SCNN1B;A;rs34241435;OTHER;INCREASED;TRANSCRIPTION;SCNN1B;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;BCL2L11;T;rs724710;OTHER;DECREASED;EXPRESSION;BCL2L11;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;IL11;CT + TT;rs1126757;OTHER;DECREASED;EXPRESSION;IL11;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;UMPS;C;rs1801019;METABOLISM/PK;INCREASED;EXPRESSION;UMPS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROMOMYCIN;MT-RNR1;G;rs267606617;PD;DECREASED;ACTIVITY;MT-RNR1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;UGT1A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;G;rs118192178;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;G;rs118192178;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;ACTIVITY;CFTR;;;
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP1A2;AA + AC;rs762551;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP1A2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;EGFR;TT;rs712829;;INCREASED;EXPRESSION;EGFR;;;
DEXTROMETHORPHAN;;GG;rs729559;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;GG;rs729559;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;TT;rs4073010;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;SEPTIN3, WBP2NL;G;rs1062753;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;PHETA2, SMDT1;G;rs1807493;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;;TT;rs4073010;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;G;rs1062753;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TERFENADINE;CYP2J2;A;rs199717190;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs200858900;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;ABCC4;;;CAUTION_DRUG_ACCUMULATION
;ABCC4;C;rs11568684;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs11568681;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs142211148;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;A;rs11568644;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;ABCC4;;;CAUTION_DRUG_ACCUMULATION
;TBXAS1;AA;rs6962291;OTHER;DECREASED;EXPRESSION;TBXAS1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EBASTINE;CYP2J2;A;rs201379188;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TERFENADINE;CYP2J2;A;rs201379188;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;G;rs193922878;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TBXAS1;AA;rs6962291;OTHER;DECREASED;STEADY-STATE LEVEL;TBX2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;PHETA2, SMDT1;G;rs1807493;METABOLISM/PK;INCREASED;EXPRESSION;CYP2D6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC4;A;rs11568658;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;ABCC4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CCND1;AA + AG;rs9344;OTHER;INCREASED;TRANSCRIPTION;CCND1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EBASTINE;CYP2J2;A;rs759510111;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TERFENADINE;CYP2J2;A;rs759510111;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;AT;rs67376798;OTHER;DECREASED;CATALYTIC ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;GSK3B;A;rs334558;;INCREASED;TRANSCRIPTION;GSK3B;;;
;FCER2;GG;rs28364072;;DECREASED;EXPRESSION;FCER2;;;
GENTAMICIN;MT-RNR1;T;rs267606619;PD;DECREASED;ACTIVITY;MT-RNR1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;MIR27A;CC;rs895819;OTHER;INCREASED;EXPRESSION;MIR27A;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ADRB2;G;rs1042713;OTHER;DECREASED;ACTIVITY;ADRB2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROMOMYCIN;MT-RNR1;T;rs267606619;PD;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;T;rs553968231;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs1969376664;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;C;rs773494867;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CISPLATIN;UBE2I;CG;rs9597;METABOLISM/PK;INCREASED;EXPRESSION;SAE1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UBE2I;CG;rs9597;METABOLISM/PK;INCREASED;EXPRESSION;SAE1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs553968231;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs752695347;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs772413158;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs1969136524;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs142421637;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs373442191;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;T;rs752695347;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs142421637;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs1282926098;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;C;rs1969136524;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs773494867;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs1969376664;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs138264188;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;A;rs373442191;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;A;rs193922818;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;A;rs193922818;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCB1;AA;rs2032582;OTHER;DECREASED;EXPRESSION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;AA;rs1128503;OTHER;DECREASED;EXPRESSION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;AA;rs1045642;OTHER;DECREASED;EXPRESSION;ABCB1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs1969255598;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs1248477767;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs1282926098;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs750671397;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;G;rs4355801;;INCREASED;EXPRESSION;TNFRSF11B;;;
EFAVIRENZ;CYP2B6;A;rs141666881;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;PLG;G;rs783145;METABOLISM/PK;DECREASED;TRANSCRIPTION;PRSS55;;;CAUTION_DRUG_ACCUMULATION
;PLG;G;rs783145;METABOLISM/PK;INCREASED;TRANSCRIPTION;PLG;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs10871454;METABOLISM/PK;INCREASED;TRANSCRIPTION;VKORC1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;GCLC;CC;rs761142;OTHER;DECREASED;EXPRESSION;GCLC;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A4;A;rs4986909;;DECREASED;STEADY-STATE LEVEL;CYP3A4;;;
;;AA;rs446112;OTHER;INCREASED;EXPRESSION;AGPAT2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SQSTM1;C;rs10277;METABOLISM/PK;INCREASED;TRANSCRIPTION;SQSTM1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;SLC22A3;C;rs884742;METABOLISM/PK;INCREASED;TRANSCRIPTION;SLC22A3;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;MGMT;G;rs4751104;METABOLISM/PK;INCREASED;TRANSCRIPTION;MGMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;KDR;G;rs34231037;OTHER;DECREASED;STEADY-STATE LEVEL;KDR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;GSTT1;T;rs1007888;METABOLISM/PK;INCREASED;TRANSCRIPTION;GSTT1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;AG;rs10242455;METABOLISM/PK;INCREASED;TRANSCRIPTION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC11;C;rs11861379;METABOLISM/PK;INCREASED;TRANSCRIPTION;ABCC11;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NAT2;A;rs4646244;OTHER;DECREASED;TRANSCRIPTION;NAT2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;C;rs72549435;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2A6;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;T;rs9332239;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2C9;;;CAUTION_DRUG_ACCUMULATION
PAROMOMYCIN;MT-RNR1;G;rs267606617;PD;DECREASED;ACTIVITY;MT-RNR1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE ANALOGUES;TPMT;CT;rs1142345;OTHER;DECREASED;ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE ANALOGUES;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;SLC28A3;AA;rs11140490;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;PACSIN2;C;rs2413739;OTHER;INCREASED;ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PURINE ANALOGUES;PACSIN2;C;rs2413739;METABOLISM/PK;INCREASED;ACTIVITY;TPMT;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs1968919352;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;T;rs28399454;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
QUINIDINE;KCNH2;T;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR / LUMACAFTOR;CFTR;A;rs78655421;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NPPB;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESLICARBAZEPINE ACETATE;AADAC;G;rs144650170;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;G;rs368146607;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs371258350;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
ESLICARBAZEPINE ACETATE;AADAC;A;rs35084477;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs575853463;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs569661196;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs548783838;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs374825099;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs140989814;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs568367673;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs538336580;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs374527058;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;A;rs112563513;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
ESLICARBAZEPINE ACETATE;AADAC;A;rs1803155;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESLICARBAZEPINE ACETATE;AADAC;G;rs140197497;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;AADAC;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;A;rs193922832;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE;RYR1;A;rs118192168;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
DISOPYRAMIDE;KCNH2;T;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DISOPYRAMIDE;KCNH2;C;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINIDINE;KCNH2;C;rs104894021;EFFICACY;DECREASED;INHIBITION;KCNH2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CG;rs80034486;PD;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;rs193922843;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE;RYR1;T;rs193922803;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
ESLICARBAZEPINE ACETATE;AADAC;T;rs186388618;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;AADAC;;;CAUTION_DRUG_ACCUMULATION
ESLICARBAZEPINE ACETATE;AADAC;C;rs61733692;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;AADAC;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs536577604;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs558354142;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs538703919;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs55886062;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs372307932;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs527580106;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs201268750;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs570122671;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;CBR3;A;rs8133052;;DECREASED;EXPRESSION;CBR3;;;
;CBR3;A;rs1056892;;INCREASED;EXPRESSION;CBR3;;;
FLUOROURACIL;DPYD;A;rs528152707;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;VKORC1;T;rs9923231;;DECREASED;EXPRESSION;VKORC1;;;
;DPYD;CT + TT;rs56038477;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;SLC29A1;G;rs731780;OTHER;INCREASED;EXPRESSION;SLC29A1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLC29A1;A;rs70914;;INCREASED;EXPRESSION;SLC29A1;;;
;DPYD;CT + TT;rs1801160;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;DPYD;CC + CT;rs2297595;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;MIR6076;G;rs1463411;OTHER;DECREASED;EXPRESSION;P2RY12;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT2B17;C;rs6817882;OTHER;INCREASED;EXPRESSION;UGT2B17;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;CT;rs115232898;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;POR;AA;rs2868177;OTHER;DECREASED;ENZYME ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;POR;AA;rs2868177;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
;POR;AA;rs2868177;OTHER;DECREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;POR;AA;rs2868177;METABOLISM/PK;DECREASED;ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
;ABCB1;GG;rs1128503;;INCREASED;EXPRESSION;ABCB1;;;
ACETAMINOPHEN;CYP2E1;T;rs2515641;OTHER;INCREASED;EXPRESSION;CYP2E1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2E1;T;rs2515641;OTHER;DECREASED;EXPRESSION;CYP2E1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs376073289;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs369103276;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs367619008;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;POR;GG;rs2868177;OTHER;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;POR;GG;rs2868177;METABOLISM/PK;INCREASED;ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs758649719;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
HALOTHANE;CACNA1S;A;rs772226819;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISOFLURANE;CACNA1S;A;rs772226819;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;G;rs187713395;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs140039091;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CACNA1S;T;rs1800559;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CACNA1S;T;rs1800559;OTHER;INCREASED;ACTIVITY;CACNA1S;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL;CYP2D6;A;rs777560972;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;A;rs777560972;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED;EXPRESSION;NR3C1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL;CYP2D6;T;rs138417770;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;T;rs138417770;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;G;rs371793722;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;G;rs371793722;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;T;rs745746329;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;T;rs745746329;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;HSPA5;TT;rs430397;OTHER;INCREASED;EXPRESSION;HSPA5;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL;CYP2D6;T;rs750996195;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;T;rs750996195;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;POR;AG;rs2868177;EFFICACY;INCREASED;ENZYME ACTIVITY;CYP2B6;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE TRIPHOSPHATE;SLC28A3;CC;rs7867504;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;AT;rs3931660;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;TPMT;;;CAUTION_DRUG_ACCUMULATION
VITAMIN E;CYP4F2;T;rs2108622;METABOLISM/PK;INCREASED;STEADY-STATE LEVEL;;;;CAUTION_DRUG_ACCUMULATION
VITAMIN E;CYP4F2;T;rs2108622;METABOLISM/PK;INCREASED;STEADY-STATE LEVEL;;;;CAUTION_DRUG_ACCUMULATION
;HPR;G;rs2000999;OTHER;INCREASED;EXPRESSION;HP;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;G;rs35283911;OTHER;INCREASED;EXPRESSION;HP;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DCK;T;rs2306744;OTHER;INCREASED;EXPRESSION;DCK;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
XENOBIOTICS;AHR;A;rs2066853;METABOLISM/PK;INCREASED;EXPRESSION;CYP1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;AHR;G;rs75519181;METABOLISM/PK;DECREASED;EXPRESSION;CYP1A1;;;CAUTION_DRUG_ACCUMULATION
XENOBIOTICS;AHR;G;rs75519181;METABOLISM/PK;DECREASED;EXPRESSION;CYP1A1;;;CAUTION_DRUG_ACCUMULATION
VITAMIN E;CYP4F2;C;rs3093105;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;A;rs200458614;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs200238771;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs764288403;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
;NHLH1;T;rs11265375;OTHER;INCREASED;LUCIFERASE ACTIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VITAMIN E;CYP4F2;T;rs2108622;OTHER;DECREASED;ENZYME ACTIVITY;CYP4F2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;T;rs535039125;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs200458614;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs148009906;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;C;rs201500445;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs58871670;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs201500445;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs58871670;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs117872433;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs374099483;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs148009906;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
;SEMA6A;A;rs3806915;OTHER;INCREASED;LUCIFERASE ACTIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;A;rs117872433;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs200238771;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs764288403;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs374099483;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs535039125;METABOLISM/PK;DECREASED;CATALYTIC ACTIVITY;CYP2B6;;;CAUTION_DRUG_ACCUMULATION
ETHANOL;ADH1B;CT + TT;rs1229984;METABOLISM/PK;INCREASED;ENZYME ACTIVITY;ADH1B;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;GT;rs1801131;;INCREASED;CATALYTIC ACTIVITY;TYMS;;;
METHOTREXATE;SHMT1;AA;rs1979277;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;TYMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FASTKD3, MTRR;AG + GG;rs1801394;;INCREASED;CATALYTIC ACTIVITY;TYMS;;;
FLUOROURACIL;DPYD;G;rs755692084;METABOLISM/PK;DECREASED;ACTIVITY;DPYD;;;CAUTION_DRUG_ACCUMULATION
;CYP1A2;A;rs2069514;;DECREASED;ACTIVITY;CYP1A2;;;
;CYP1A2;A;rs762551;;INCREASED;ACTIVITY;CYP1A2;;;
;CYP3A4;A;rs35599367;OTHER;DECREASED;EXPRESSION;CYP3A4;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP1A2;del;rs35694136;;DECREASED;ACTIVITY;CYP1A2;;;
GLYBURIDE;KCNJ11;T;rs5219;METABOLISM/PK;DECREASED;ACTIVITY;KCNJ11;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CBR1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CATALYTIC ACTIVITY;CBR1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ATP2B1;CT + TT;rs12817819;;DECREASED;EXPRESSION;ATP2B1;;;
;IFNL3;C;rs4803217;OTHER;INCREASED;EXPRESSION;IFNL3;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CETP;GG;rs708272;OTHER;INCREASED;EXPRESSION;CETP;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
PALBOCICLIB;CDKN2A;C;rs759922342;EFFICACY;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DESMETHYLNAPROXEN;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;SULT1A1;T;rs765399160;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;G;rs4124874;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;T;rs887829;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXAZEPAM;UGT2B15;A;rs1902023;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;A;rs10929302;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;G;rs777924668;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;T;rs746398875;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;;CAUTION_DRUG_ACCUMULATION
ESTRADIOL;;GG;rs3802201;OTHER;INCREASED;EXPRESSION;MIR2052;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;CC;rs4476990;OTHER;INCREASED;EXPRESSION;MIR2052;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREGNENOLONE;SULT2B1;T;rs527454384;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;A;rs777140014;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;T;rs774212320;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;A;rs762765702;METABOLISM/PK;DECREASED;ENZYME ACTIVITY;SULT2B1;;;CAUTION_DRUG_ACCUMULATION
;CYP2C19;A;rs140278421;OTHER;DECREASED;EXPRESSION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C19;T;rs61311738;OTHER;DECREASED;EXPRESSION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C19;T;rs183701923;OTHER;DECREASED;EXPRESSION;CYP2C19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs761895497;OTHER;DECREASED;EXPRESSION;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs771237265;OTHER;DECREASED;EXPRESSION;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;T;rs762081829;OTHER;DECREASED;EXPRESSION;CYP2C9;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;TT;rs776746;OTHER;INCREASED;EXPRESSION;CYP3A5;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;HTR1B;C;rs130060;PD;INCREASED;CONCENTRATIONS;cAMP;;;CAUTION_DRUG_ACCUMULATION
;CYP2A6;AA + AG;rs8192720;;INCREASED;EXPRESSION;CYP2A6;;;
;CYP2A6;AG + GG;rs8192725;;INCREASED;EXPRESSION;CYP2A6;;;
;CYP2A6;AC + CC;rs28399433;;DECREASED;EXPRESSION;CYP2A6;;;
FLUOROURACIL;DPYD;TT;rs1801158;OTHER;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;GG;rs1801265;OTHER;INCREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CC;rs55886062;OTHER;DECREASED;ACTIVITY;DPYD;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXAZEPAM;UGT1A1;A;rs10929302;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
OXAZEPAM;UGT1A1;G;rs4124874;OTHER;;GLUCURONIDATION;;;;
OXAZEPAM;;G;rs1976391;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
OXAZEPAM;UGT1A1;T;rs887829;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
;;G;rs1976391;OTHER;DECREASED;CONCENTRATIONS;UGT1A1;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;PKNOX1;A;rs2839629;OTHER;INCREASED;EXPRESSION;PKNOX1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PKNOX1;A;rs2839629;OTHER;INCREASED;EXPRESSION;CBS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CBS;C;rs915854;OTHER;INCREASED;EXPRESSION;PKNOX1;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;rs186983396;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;T;rs186983396;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;CC;rs532545;OTHER;DECREASED;ACTIVITY;CDA;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;AA;rs602950;OTHER;DECREASED;ACTIVITY;CDA;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;AA;rs2072671;OTHER;DECREASED;ACTIVITY;CDA;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;YAP1;C;rs1820453;;DECREASED;TRANSCRIPTION;YAP1;;;
ELEXACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEZACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED;ACTIVITY;CFTR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;AA + AT;rs1801272;TOXICITY;DECREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SACITUZUMAB GOVITECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PITAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PITAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PRAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PRAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA5;T;rs615470;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CHRNA5;T;rs615470;OTHER;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;T;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;A;rs1799931;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED AUC24 IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED AUC24 IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
GEFITINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING OPTIMAL TROUGH LEVEL IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING OPTIMAL TROUGH LEVEL IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;UST;A;rs2500535;EFFICACY;DECREASED;NAN;EFFICACY;IMPROVEMENT OF DEPRESSION SYMPTOMS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;G;rs1851426;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
OSIMERTINIB;IL6;CG + GG;rs1800796;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*6/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;AA + AG;rs6313;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OXAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;NAN;PK;S-OXAZEPAM GLUCURONIDATION IN HUMAN LIVER MICROSOMES NAN  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
OXAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;NAN;PK;OXAZEPAM ORAL CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;PPARA;GG;rs4823613;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NITROUS OXIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD3;G;rs167771;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;DRD3;G;rs167771;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*1;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*5;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*9;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;UTERINE DISORDER;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEIOMYOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ENDOMETRIAL HYPERPLASIA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:POLYPS IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
CAPECITABINE;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY IN PEOPLE WITH  NAN;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;NAN;NAN;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY IN PEOPLE WITH  NAN;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;NAN;NAN;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY IN PEOPLE WITH  NAN;;CAUTION_DOSE_ADJUST
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IDO1;CC;rs9657182;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IDO1;CC;rs9657182;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;AA + AG;rs3129763;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
NITROUS OXIDE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
CIPROFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
LEVOFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
MOXIFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;TT;rs11188072;METABOLISM/PK;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;C;rs3735451;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;ABCB1;AA;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*10;CYP2D6*1;TOXICITY;NAN;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CYP2D6;*10;CYP2D6*10;TOXICITY;NAN;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;CYP2D6*2XN;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ASPARAGINASE;ATL2;T;rs59569490;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;MAXIMAL PLATELET AGGREGATION IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;A;rs4986893;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;A;rs4986893;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;RETN;GG;rs1862513;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*27;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
PRIMAQUINE;MAOA;CC + CT;rs1137070;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PRIMAQUINE;CYP2D6;*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;TT;rs11188072;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;TT;rs11188072;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC10;C;rs2125739;TOXICITY;INCREASED;NAN;SIDE EFFECT;KIDNEY TUBULAR DYSFUNCTION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATION/DOSAGE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATION/DOSAGE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PREGNANCY;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PREGNANCY;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DYSLIPIDAEMIA;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY IN PEOPLE WITH  OTHER:NEUROLOGICAL PROBLEMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY IN PEOPLE WITH  OTHER:NEUROLOGICAL PROBLEMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY IN PEOPLE WITH  OTHER:NEUROLOGICAL PROBLEMS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DYSLIPIDAEMIA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;A;rs2687116;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
CARBOPLATIN;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;A;rs4244285;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;A;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
NAN;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;NAN;OTHER;SPONTANEOUS HCV CLEARANCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC22A1;del;rs72552763;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;INFECTIOUS DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;;AA + AG;rs6856089;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;;AA + AG;rs6856089;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;METABOLISM/PK;DECREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
NAN;SOD1;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;rs36232792;OTHER;DECREASED;LIKELIHOOD;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERALL ADRS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
NAN;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;DISCONTINUATION;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER;OTHER:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3A;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3B;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3C;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMATOLOGICAL INDICES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3B;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;PLASMA LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;TT;rs12248560;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SUFENTANIL;ADRB1;GG;rs1801253;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ADRB1;GG;rs1801253;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*36;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*36;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  SIDE EFFECT:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC10;G;rs9349256;TOXICITY;INCREASED;NAN;SIDE EFFECT;KIDNEY TUBULAR DYSFUNCTION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MORTALITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MORTALITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;A;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:CHRONIC MYELOMONOCYTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
IMATINIB;NR1I2;TT;rs3814055;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:CHRONIC MYELOMONOCYTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;C;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;C;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;G;rs1801394;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*3;OTHER;INCREASED;NAN;OTHER;P2Y12 REACTION UNIT(PRU) VALUES IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;A;rs4646437;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*4;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*7;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*9;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*14;TOXICITY;INCREASED;RISK;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-C;*07:18;HLA-C*07:18;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;CC;rs4148738;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;THROMBOEMBOLISM IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ENDOMETRIAL HYPERPLASIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;A;rs2236225;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;T;rs2242480;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*2;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*2;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*12;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*12;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*24;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*24;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATION;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;CT + TT;rs3787728;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CT + TT;rs3787728;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DRB1;*04:04;HLA-DRB1*04:04;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;CG + GG;rs1005695;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CG + GG;rs1005695;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOEMBOLISM IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:GASTROESOPHAGEAL CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:GASTROESOPHAGEAL CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
RITUXIMAB;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CHOP;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
RITUXIMAB;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*6;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;NAN;NAN;EFFICACY;WORSE PROGNOSES IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION NAN  NAN;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*11;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*11;CYP2C9*11;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
GEMCITABINE;RRM1;C;rs1042927;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL PROBABILITY IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;RRM1;C;rs1042927;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL PROBABILITY IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC + TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TREMOR;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC + TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ASTHENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ASTHENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ASTHENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;C;rs1142345;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;RISK;DISEASE;MUCOSITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;ERAP1, ERAP2;G;rs1363907;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;ERAP1, ERAP2;G;rs1363907;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AMOXICILLIN;PTPN22;A;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;G;rs3786362;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TYMS;C;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;G;rs2790;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NME1, NME1-NME2;TT;rs2302254;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NME1, NME1-NME2;TT;rs2302254;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
RIVAROXABAN;SUSD3;TT;rs76292544;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
NAN;CYP3A5, ZSCAN25;CC;rs776746;NAN;NAN;NAN;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;G;rs4149081;TOXICITY;INCREASED;RISK;SIDE EFFECT;GI TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;FCER1G;AA;rs11587213;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;MS4A2;AG + GG;rs569108;TOXICITY;INCREASED;LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;CHANCE OF POSITIVE RESPONSE TO PACLITAXEL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;FECH;CC;rs536560;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;CC;rs536560;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NAN;FCER1G;AG + GG;rs11587213;TOXICITY;INCREASED;LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;C;rs2072671;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;CDA;C;rs2072671;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
NAN;CYP2A6;*4/*4;CYP2A6*4;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;AA;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;AA;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*6;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;AA;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;DISEASE;GASTRIC PH IN PEOPLE WITH  DISEASE:HELICOBACTER INFECTIONS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;NAN;DISEASE;GASTRIC PH IN PEOPLE WITH  DISEASE:HELICOBACTER INFECTIONS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;DISEASE;GASTRIC PH IN PEOPLE WITH  DISEASE:HELICOBACTER INFECTIONS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;OTHER;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;C;rs4149056;OTHER;DECREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG HYPERSENSITIVITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;CHRONIC KIDNEY FAILURE IN PEOPLE WITH  DISEASE:GLOMERULONEPHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;IGA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUCCINYLCHOLINE;RYR1;G;rs193922752;TOXICITY;INCREASED;RISK;SIDE EFFECT;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
VOLATILE ANESTHETICS;RYR1;G;rs193922752;TOXICITY;INCREASED;RISK;SIDE EFFECT;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;EGFR;GG;rs2227983;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;RRM1;A;rs12806698;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;RRM1;A;rs12806698;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;C;rs11030918;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;RRM1;C;rs11030918;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
VERAPAMIL;ADRB1;AA + AG;rs1801252;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
HEROIN;DRD2;G;rs12364283;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
REPAGLINIDE;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOPOIETIC TOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAEMATOPOIETIC TOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;A;rs4986893;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;G;rs4646437;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ASPARAGINASE;SOD2;GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;CYP1A2;AC + CC;rs762551;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:INCREASED COFFEE INTAKE;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;ERBB2;AG + GG;rs1136201;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
PACLITAXEL;FZD3;A;rs7001034;TOXICITY;DECREASED;RISK;SIDE EFFECT;SENSORY PERIPHERAL NEUROPATHY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;NAN;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;NAN;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_DOSE_ADJUST
SERTRALINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB1;*04:02;HLA-DRB1*04:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEPATOCELLULAR CARCINOMA IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*1;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*2;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*3;OTHER;INCREASED;RISK;DISEASE;HYPOGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*5/*5;CYP2D6*5;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;C;rs6956344;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:MOOD DISORDER;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEUROPATHIC PAIN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE CONTROL RATE AND LOWER OVERALL SURVIVAL RATE IN PEOPLE WITH  OTHER:METASTATIC BREAST CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;CLOPIDOGREL ACTIVE METABOLITE LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING TARGET CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING TARGET CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;POST-TREATMENT ADP-STIMULATED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP3A5;C;rs776746;TOXICITY;DECREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DPB1;*10:01;HLA-DPB1*10:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*10X2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*14;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*21;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*36;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;DISEASE;ASPIRIN-INDUCED ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*6/*6;CYP2D6*6;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*6/*6;CYP2D6*6;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*5;CYP2D6*4;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*5;CYP2D6*5;DOSAGE;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ARTHRITIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;GOUTY;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*14;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*21;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*36;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED BLOOD LEVELS IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED BLOOD LEVELS IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;C;rs2242480;METABOLISM/PK;NAN;NAN;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;OTHER;INCREASED;NAN;OTHER;CREATININE CLEARANCE IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;OTHER;INCREASED;NAN;OTHER;CREATININE CLEARANCE IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*21;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*36;METABOLISM/PK;INCREASED;NAN;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS NAN  NAN;;CAUTION_DOSE_ADJUST
TRANILAST;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:MYOCARDIAL ISCHEMIA;;CAUTION_SIDE_EFFECT
TRANILAST;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:MYOCARDIAL ISCHEMIA;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*21;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*36;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA NAN  NAN;;CAUTION_DOSE_ADJUST
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-DQA1;*01:03;HLA-DQA1*01:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-DQB1;*06:01;HLA-DQB1*06:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*20;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*20;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3 YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3 YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;T;rs548646;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  OTHER:HEART TRANSPLANTATION;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;TOXICITY;INCREASED;RISK;DISEASE;ACUTE CELLULAR REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
RHODAMINE 123;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;EFFLUX OF RHODAMINE FROM CD56+ NATURAL KILLER CELLS NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;NEUTROPENIA;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;NAN;NAN;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ASPIRIN;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
TICAGRELOR;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*68:01;HLA-A*68:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;PAIN IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;PAIN IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
TETANUS ANTITOXIN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*14:02;HLA-B*14:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLINDAMYCIN;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
CLINDAMYCIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;A;rs609148;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;*1/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*1/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;CYP3A4*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;CYP3A4*18;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:02;HLA-C*08:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-C;*12:03;HLA-C*12:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;DISEASE;ASPIRIN-INDUCED ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-C;*15:02;HLA-C*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*15:02;HLA-C*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2J2;AA + AC;rs890293;TOXICITY;INCREASED;RISK;DISEASE;NAUSEA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2J2;AA + AC;rs890293;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:VOMITING IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUPIRTINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:02;HLA-DRB1*01:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
HYDRALAZINE;HLA-DRB1;*04:01;HLA-DRB1*04:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LUPUS ERYTHEMATOSUS DUE TO HYDRALAZINE IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LDLR;G;rs2738466;EFFICACY;INCREASED;RISK;DISEASE;CORONARY DISEASE IN MEN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
FLUPIRTINE;HLA-DRB1;*16:01;HLA-DRB1*16:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
THALIDOMIDE;GSTT1;AA;rs4630;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
MINOCYCLINE;HLA-B;*35:02;HLA-B*35:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE IN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;METABOLISM/PK;DECREASED;NAN;PK;DOSE IN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE IN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;PROTHROMBIN TIME (PT) AT INDUCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;PROTHROMBIN TIME (PT) AT INDUCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:HYPERURICEMIA;;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2C8;*3;CYP2C8*1;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:HIGH RISK PATIENTS (ACUTE MYOCARIDAL INFARCTION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;EFFICACY;DIABETES E.G.);;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN MEN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN MEN  NAN;;CAUTION_SIDE_EFFECT
PACLITAXEL;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;;CYP1A2 LOW ACTIVITY;OTHER;INCREASED;NAN;OTHER;INTAKE IN WOMEN WITH  DISEASE:PREGNANCY;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;GNB3;CT + TT;rs5443;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;HMGCR;AA;rs3846662;OTHER;DECREASED;NAN;OTHER;HMGCRV_1 EXPRESSION AND AN INCREASE IN THE EXPRESSION OF THE FULL-LENGTH TRANSCRIPT NAN  NAN;;CAUTION_DOSE_ADJUST
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;NAN;NAN;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
RITONAVIR;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;NAN;NAN;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*5;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN CHILDREN WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;T/del + TT;rs35320474;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BRONCHOPULMONARY DYSPLASIA IN INFANTS WITH  OTHER:APNEA OF PREMATURITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;T/del + TT;rs35320474;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:PREMATURE BIRTH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
NAN;DHFR;del/del;rs70991108;OTHER;INCREASED;NAN;OTHER;SERUM AND RED BLOOD CELL FOLATE CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;DEPRESSION IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;EFFICACY;DECREASED;SEVERITY;EFFICACY;DEPRESSION IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY;DEPRESSION IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;ANXIETY DISORDERS IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY;ANXIETY DISORDERS IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*9;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*9;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*17;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*17;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*20;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*20;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*24;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*24;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*26;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*26;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*27;OTHER;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*27;METABOLISM/PK;DECREASED;NAN;PK;METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
INTERFERON BETA-1A;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*5;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*15;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*37;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;EGFR;A;rs2227983;EFFICACY;NAN;NAN;EFFICACY;CYTOTOXICITY NAN  NAN;;CAUTION_DOSE_ADJUST
ATAZANAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
INTERFERON BETA-1A;;G;rs4961252;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1B;;G;rs4961252;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-IFN-BETA ANTIBODIES IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGASPARGASE;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPARAGINASE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
ASPARAGINASE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
CYTARABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ETOPOSIDE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
ETOPOSIDE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
PREDNISONE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;CNS RELAPSE;;CAUTION_SIDE_EFFECT
VINCRISTINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:HEMATOLOGIC RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;G;rs9937;TOXICITY;DECREASED;RISK;DISEASE;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE;del/del;rs1799752;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;PD;DECREASED;LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;PD;DECREASED;LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;T;rs1381376;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DQB1;*02:02;HLA-DQB1*02:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR, MSH3;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ENOSF1, TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;LIKELIHOOD;OTHER;COVID-19 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
NAN;ACE;del;rs1799752;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;;A;rs1050450;OTHER;INCREASED;RISK;OTHER;IN-STENT RESTENOSIS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
NAN;ACE;del/del;rs1799752;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:COVID-19;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT EMERGENT MANIA IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANAKINRA;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ANAKINRA;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;;CAUTION_SIDE_EFFECT
CANAKINUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CANAKINUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;;CAUTION_SIDE_EFFECT
RILONACEPT;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
RILONACEPT;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;;CAUTION_SIDE_EFFECT
TOCILIZUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TOCILIZUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ADULT-ONSET STILL DISEASE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FLUCLOXACILLIN;HLA-B;*57:03;HLA-B*57:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3B + *3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3B + *3C;TPMT*3B;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3B + *3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
PREDNISONE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION IN PEOPLE WITH  OTHER:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION IN PEOPLE WITH  OTHER:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;ORAL CLEARANCE (CL) OF ATAZANAVIR IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;ORAL CLEARANCE (CL) OF ATAZANAVIR IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;EGFR;T;rs712829;TOXICITY;NAN;NAN;EFFICACY;CYTOTOXICITY NAN  NAN;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;TYMS;TTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:07;HLA-A*24:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LOW LEUKOCYTE COUNTS IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LOW LEUKOCYTE COUNTS IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LOW LEUKOCYTE COUNTS IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*1;TPMT*1;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT DURATION IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*1;TPMT*2;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT DURATION IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*1;TPMT*3A;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT DURATION IN PEOPLE WITH  DISEASE:RHEUMATIC DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*4;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*4;CYP2C19*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN C-REACTIVE PROTEIN (CRP) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN C-REACTIVE PROTEIN (CRP) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTM1;null/null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTM1;null/null;GSTM1 NULL;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:SUDDEN CARDIAC DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*7;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM OF TRAMADOL AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;DECREASED;NAN;EFFICACY;METABOLISM OF TRAMADOL AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*6;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*12:02;HLA-DRB1*12:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*12:02;HLA-DRB1*12:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;INTRAGASTRIC PH IN PEOPLE WITH  DISEASE:ULCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;INTRAGASTRIC PH IN PEOPLE WITH  DISEASE:ULCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DQA1;*03:02;HLA-DQA1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*22;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*11;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*11;CYP2D6*11;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;AA;rs1128503;DOSAGE;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;;CAUTION_DOSE_ADJUST
NAN;TMPRSS2;CC;rs383510;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*36;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs2032582;DOSAGE;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*17;METABOLISM/PK;INCREASED;NAN;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;G;rs2246709;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUVOXAMINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;FLUVOXAMINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;FLUVOXAMINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) NAN  NAN;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) NAN  NAN;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*4;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;;CAUTION_DOSE_ADJUST
LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;;CAUTION_DOSE_ADJUST
LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;INHIBITION OF METABOLISM IN PEOPLE WITH  DISEASE:BACK PAIN;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;T;rs2242480;OTHER;INCREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
DOCETAXEL;RPL13, SNORD68, SPG7;G;rs12960;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;RPL13, SNORD68, SPG7;G;rs12960;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;CHST3;A;rs1871450;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;CHST3;A;rs1871450;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;A;rs4646440;OTHER;INCREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
DOCETAXEL;NAT2;G;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;NAT2;G;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
DOCETAXEL;CYP4B1;T;rs4646487;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;CYP4B1;T;rs4646487;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*07:02;HLA-B*07:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;RESPIRATORY INSUFFICIENCY NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:02;HLA-C*07:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;RESPIRATORY INSUFFICIENCY NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;null/null;GSTM1 NULL;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;GGGAGCTGG/del + del/del;rs3045983;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;CC;rs589046;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;LEUKOCYTES AND NEUTROPHILS IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;DECREASED;NAN;SIDE EFFECT;LEUKOCYTES AND NEUTROPHILS IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;DECREASED;NAN;SIDE EFFECT;LEUKOCYTES AND NEUTROPHILS IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ALPRAZOLAM;CYP3A4;;CYP3A4 LOW ACTIVITY;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ALPRAZOLAM;CYP3A4;;CYP3A4 LOW ACTIVITY;EFFICACY;INCREASED;RISK;SIDE EFFECT;OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
DOCETAXEL;VEGFA;del/del;rs144854329;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN NAN  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531C;TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:ADENOCARCINOMA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*1/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOLIC PSYCHOSIS;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*1/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOLIC PSYCHOSIS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;DECREASED;RISK;DISEASE;ASPIRIN-INDUCED ASTHMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;DAOA;T;rs947267;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENOBARBITAL;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN CHILDREN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*2;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*2;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10X2;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*10X2;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*36;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*36;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;NAN;NAN;OTHER;HIGHER STABLE DOSE LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;NAN;NAN;OTHER;HIGHER STABLE DOSE LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;OPRM1;C;rs2075572;TOXICITY;DECREASED;RISK;OTHER;METHAMPHETAMINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;OMEPRAZOLE SULFONE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*21;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*33;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*34;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;A;rs2246709;OTHER;DECREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;CLOPI-H4 CONCENTRATIONS AFTER 300 OR 900 MG CLOPIDOGREL LOADING DOSE IN MEN WITH  DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
COMBINATIONS;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
COMBINATIONS;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ATENOLOL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRANDOLAPRIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:LEPROSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;CC;rs6265;TOXICITY;DECREASED;SEVERITY;OTHER;METHAMPHETAMINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;DELAYED GRAFT FUNCTION IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;DELAYED GRAFT FUNCTION IN PEOPLE WITH  NAN;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTICHOLINERGIC AGENTS;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;SERUM ANTICHOLINERGIC ACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN LIVER MICROSOMES;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN LIVER MICROSOMES;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
NAN;GSTT1;;GSTT1 NON-NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GSTT1;;GSTT1 NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;GSTM1;;GSTM1 NON-NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GSTM1;;GSTM1 NULL;OTHER;INCREASED;LIKELIHOOD;OTHER;ASTHMA IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;DAOA;A;rs2391191;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*4;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*5;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*22;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*4;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*5;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*22;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-DQB3;C;rs2859101;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;MTHFR;GG;rs3737967;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs3737967;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2C19;*1/*1;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;MTHFR;CC;rs2274976;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;CC;rs2274976;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
NAN;G6PD;T;rs1050828;NAN;INCREASED;NAN;OTHER;PROTECTION AGAINST SEVERE MALARIA NAN  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;JAUNDICE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;JAUNDICE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*36;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;JAUNDICE IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*37;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;GSTM1;null/null;GSTM1 NON-NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DEATH;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;GSTM1;null/null;GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OTHER:RECURRENCE IN WOMEN WITH  DISEASE:UTERINE CERVICAL NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;;CAUTION_DOSE_ADJUST
CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  OTHER:CHRONIC MIGRAINE;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;NAN;OTHER;USE IN PEOPLE WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
IRINOTECAN;DPYD;T;rs1042482;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*37;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;A;rs4646440;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CC;rs9923231;OTHER;INCREASED;LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*36;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERBILIRUBINEMIA IN WOMEN WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMEPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;CHRNB2;GG;rs2072661;NAN;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;PLIN1;CT + TT;rs894160;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PLIN1;CT + TT;rs894160;TOXICITY;DECREASED;NAN;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;;T;rs836554;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;*6;CYP2B6*6;TOXICITY;INCREASED;SEVERITY;DISEASE;PAIN IN MEN WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;LRP5;T;rs3736228;NAN;INCREASED;RISK;OTHER;OSTEOPOROTIC FRACTURE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DRUGS USED IN NICOTINE DEPENDENCE;COMT;AA;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;EFFICACY;DECREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;EFFICACY;DECREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  OTHER:FEMALE GENDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALGANCICLOVIR;ABCC4;AC;rs11568658;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NFATC1;CC;rs1017860;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;NFATC1;CC;rs1017860;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;AA;rs822442;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*3;CYP2C8*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*07:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;G;rs4680;TOXICITY;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;G;rs4680;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  SIDE EFFECT:EPILEPSY;;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
BOSENTAN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
BOSENTAN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;NAN;PK;BOSENTAN METABOLISM IN VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;NAN;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;TNF;GG;rs1800629;EFFICACY;INCREASED;NAN;EFFICACY;BONE MARROW DENSITY IN THE LUMBAR SPINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;TOXICITY;DECREASED;RISK;OTHER;RECURRENCE IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;TOXICITY;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*6;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*6;CYP2C9*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;T;rs11045879;OTHER;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;T;rs11045879;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*11;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*11;CYP2C9*11;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*5;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*5;CYP2C9*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;PAIN IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;PAIN IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOSENTAN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH LEVELS IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH LEVELS IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;DISEASE;INTERSTITIAL FIBROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;DISEASE;INTERSTITIAL FIBROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;C/D RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;TOXICITY;INCREASED;RISK;PK;ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;TOXICITY;INCREASED;RISK;PK;ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*6;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*7;EFFICACY;INCREASED;RISK;EFFICACY;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;BLOOD CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:COUGH NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:COUGH NAN  NAN;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;;CYP2D6 POOR AND ULTRARAPID METABOLIZErs;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
NAN;KCNE1;T;rs727957;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
AMOXICILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLAVULANATE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACEI-RELATED COUGH IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;RGS2;TC/del + del/del;rs34717272;OTHER;INCREASED;RISK;DISEASE;HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*14:05;HLA-DRB1*14:05;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;STOMATITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*30:01;HLA-A*30:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;DECREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:19;HLA-B*15:19;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*48:04;HLA-B*48:04;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
RALOXIFENE;UGT1A1;*28/*28;UGT1A1*1;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN WOMEN WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;UGT1A1;*28/*28;UGT1A1*28;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN WOMEN WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;EFFICACY;DECREASED;SEVERITY;DISEASE;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  SIDE EFFECT:ASPIRIN-INDUCED ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;SEVERITY;DISEASE;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  SIDE EFFECT:ASPIRIN-INDUCED ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*27:09;HLA-B*27:09;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED;RISK;OTHER;DISEASE RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*58:02;HLA-B*58:02;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;TT;rs3737224;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;HLA-C;*02:10;HLA-C*02:10;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;MIR27A;CT;rs895819;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;GG;rs4728709;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
BUPROPION;CYP2B6;TT;rs3211371;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  OTHER:FEMALE GENDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*3;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*4;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*5;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*5;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_SIDE_EFFECT
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_DOSE_ADJUST
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_SIDE_EFFECT
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*4;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_DOSE_ADJUST
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_SIDE_EFFECT
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*5;DOSAGE;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_DOSE_ADJUST
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*5;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BRAIN NEOPLASMS IN CHILDREN WITH  SIDE EFFECT:RUSSITIS;;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;TT;rs41273215;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD) IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD) IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED;RISK;OTHER;DISEASE RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;DOSAGE;NAN;NAN;OTHER;SIGNIFICANTLY HIGHER TRAMADOL CONSUMPTION IN CHINESE GASTRIC CANCER PATIENTS RECOVERING FROM GASTRECTOMY NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;DOSAGE;NAN;NAN;OTHER;SIGNIFICANTLY HIGHER TRAMADOL CONSUMPTION IN CHINESE GASTRIC CANCER PATIENTS RECOVERING FROM GASTRECTOMY NAN  NAN;;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;CC;rs822441;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;CARCINOMA;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;SQUAMOUS CELL IN PEOPLE WITH  DISEASE:LUNG TRANSPLANTATION;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE;CARCINOMA;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE;SQUAMOUS CELL IN PEOPLE WITH  DISEASE:LUNG TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;;CYP1A2 HIGH ACTIVITY;TOXICITY;INCREASED;RISK;DISEASE;ABORTION;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;;CYP1A2 HIGH ACTIVITY;TOXICITY;INCREASED;RISK;DISEASE;SPONTANEOUS IN WOMEN WITH  DISEASE:PREGNANCY;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;DECREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*60;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;VDR;A;rs731236;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIAC RHYTHM DISEASE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;A;rs10929302;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NFATC1;GG;rs8090560;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;NFATC1;GG;rs8090560;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA AND VOMITING IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA AND VOMITING IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
RISPERIDONE;LEP;A;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;DHFR;GG;rs34965641;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;DHFR;GG;rs34965641;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETRAVIRINE;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;ETRAVIRINE CLEARANCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVEL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;IN A GENE-DOSE-DEPENDENT MANNER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;TT;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMETREXED;GGH;A;rs11545078;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;GGH;A;rs11545078;TOXICITY;DECREASED;RISK;SIDE EFFECT;DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;GAT/del;rs72552763;OTHER;DECREASED;NAN;EFFICACY;TROUGH METFORMIN STEADY-STATE CONCENTRATION IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GAT/del;rs72552763;OTHER;DECREASED;NAN;EFFICACY;TYPE 2;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GAT/del;rs72552763;METABOLISM/PK;DECREASED;NAN;EFFICACY;TROUGH METFORMIN STEADY-STATE CONCENTRATION IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GAT/del;rs72552763;METABOLISM/PK;DECREASED;NAN;EFFICACY;TYPE 2;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:NEUROPATHIC PAIN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENAZEPAM;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
PHENAZEPAM;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
PHENAZEPAM;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
PHENAZEPAM;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;RISK;DISEASE;DEHYDRATION IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*2;CYP2D6*2;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP3A4;*22;CYP3A4*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP3A4;*22;CYP3A4*22;TOXICITY;DECREASED;NAN;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;;CAUTION_SIDE_EFFECT
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE;;CAUTION_SIDE_EFFECT
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEDATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  DISEASE:SKIN DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;ALCOHOL RESPONSE;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;CONSUMPTION;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;AND PREFERENCE NAN  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EXEMESTANE;;AA;rs934635;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;AA;rs12407843;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUDDEN CARDIAC DEATH NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;PEAR1;AA;rs77235035;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUDDEN CARDIAC DEATH NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;NAN;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;NAN;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUDDEN CARDIAC DEATH NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND AUC OF THIOL METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALL AND MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALL AND MINOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;G;rs10248420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs56293913;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs56293913;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:GASTROESOPHAGEAL CANCER;;CAUTION_SIDE_EFFECT
FLUTICASONE PROPIONATE;CD14, TMCO6;AA;rs2569190;EFFICACY;INCREASED;NAN;EFFICACY;PC20 IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*17;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*1;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*3;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*4;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;AA;rs3212986;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALBOCICLIB;ABCG2;CT;rs2231137;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*4;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
EXEMESTANE;;AA;rs934635;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF MUSCULOSKELETAL ADVERSE EVENTS (MSAES) IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DECREASED HEMOCRIT LEVELS IN PEOPLE WITH  DISEASE:MALARIA;;CAUTION_SIDE_EFFECT
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VIVAX;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DAOA;C;rs3916965;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;G;rs34993780;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;G;rs34993780;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C9;*2 + *3;CYP2C9 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:VASCULITIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C9;*2 + *3;CYP2C9 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:WEGENER GRANULOMATOSIS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;THE INTRINSIC METABOLIC ACTIVITY (V(MAX)/K(M)) IN CHILDREN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;THE MEAN MAXIMAL ELIMINATION RATES (V(MAX)) IN CHILDREN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PALBOCICLIB;SULT2A1;CC;rs182420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;;CAUTION_SIDE_EFFECT
PALBOCICLIB;SULT2A1;CC;rs182420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DISCONTINUATION IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;NAN;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
SULFANILAMIDE;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;NAN;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
CHLORAMPHENICOL;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;NAN;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
CODEINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;PAIN IN CHILDREN WITH  OTHER:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;PAIN IN CHILDREN WITH  OTHER:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;PAIN IN CHILDREN WITH  OTHER:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;UGT2B7;A;rs73823859;EFFICACY;INCREASED;NAN;EFFICACY;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
CISPLATIN;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
DOCETAXEL;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*8;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8;CYP2C9*8;METABOLISM/PK;DECREASED;NAN;PK;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN NAN  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*1;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;G;rs1056892;TOXICITY;INCREASED;RISK;DISEASE;HEART FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;G;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:STROKE;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;CC;rs10836235;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIAC DAMAGE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
EXEMESTANE;UGT2B17;;UGT2B17 DEFICIENCY;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FATIGUE IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;NAN;SIDE EFFECT;BLEEDING TIME IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 L ALLELE-rs25531C;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLEEDING TIME IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLEEDING TIME IN PEOPLE WITH  DISEASE:MOOD DISORDER;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
VALPROIC ACID;XBP1;G;rs2269577;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROPHYLACTIC TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;ACE;del;rs1799752;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PLAIN;ACE;del;rs1799752;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP1B1;GG;rs1056836;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*8;CYP2C9*1;DOSAGE;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8;CYP2C9*8;DOSAGE;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8;CYP2C9*8;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADR IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;INCREASED;NAN;OTHER;HYDROCHLOROTHIAZIDE INDUCED POTASSIUM EXCRETION IN MEN WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VENOUS THROMBOEMBOLISM NAN  NAN;;CAUTION_SIDE_EFFECT
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY RESPONSE IN WOMEN WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*14;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*2;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*3;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*8;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*9;OTHER;INCREASED;RISK;DISEASE;RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;T;rs130072;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;INCREASED;RISK;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;APOC3;G;rs5128;TOXICITY;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDE LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
METFORMIN;BDNF;C;rs6265;EFFICACY;INCREASED;LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*18;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
LUMIRACOXIB;HLA-DRB1;*15:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
LUMIRACOXIB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH ( R;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;S )-METHADONE PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;TROUGH ( R;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;S )-METHADONE PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*12;TPMT*1;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*12;TPMT*12;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*12;TPMT*1;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*12;TPMT*12;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278293;TOXICITY;DECREASED;RISK;SIDE EFFECT;BIOPSY-PROVEN ACUTE REJECTION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;ABCB1;AA;rs2032582;OTHER;INCREASED;NAN;OTHER;SENSITIVITY IN VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
LUMIRACOXIB;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;RISK;OTHER;OVERANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;INCREASED;RISK;OTHER;OVERANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROLONGED QTC NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROLONGED QTC NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;(S)-METHADONE PLASMA LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;(S)-METHADONE PLASMA LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*2XN;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*4;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*5;TOXICITY;INCREASED;NAN;SIDE EFFECT;SEDATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;A;rs1045642;OTHER;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;T;rs9461684;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;IL1B;A;rs1143627;TOXICITY;NAN;NAN;DISEASE;PEPTIC ULCER DISEASE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;EPHX1;G;rs2234922;TOXICITY;INCREASED;RISK;DISEASE;DISORDER OF FACIAL SKELETON IN PEOPLE WITH  OTHER:FIRST TRIMESTER PREGNANCY;;CAUTION_SIDE_EFFECT
PHENYTOIN;EPHX1;T;rs1051740;TOXICITY;INCREASED;RISK;DISEASE;DISORDER OF FACIAL SKELETON IN PEOPLE WITH  OTHER:FIRST TRIMESTER PREGNANCY;;CAUTION_SIDE_EFFECT
NEVIRAPINE;TCF19;T;rs2073724;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*10;CYP2D6*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*10;CYP2D6*10;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;NRG3;G;rs1649942;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;NRG3;G;rs1649942;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BEING OVERANTICOAGULATED NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;STEROL/BILE ACID METABOLITES IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;NAN;DISEASE;ANXIETY DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
PACLITAXEL;NAT2;AG + GG;rs1208;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;NAT2;AG + GG;rs1208;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*4;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*5;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
NEMONAPRIDE;ANKK1;A;rs1800497;TOXICITY;INCREASED;NAN;SIDE EFFECT;PROLACTIN CONCENTRATIONS IN WOMEN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;OTHER;INCREASED;NAN;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;NAN;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;NAN;PK;AREAS UNDER THE SERUM CONCENTRATION-TIME CURVE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;AA;rs3758149;METABOLISM/PK;DECREASED;NAN;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
RISPERIDONE;DRD2;C;rs1799978;TOXICITY;INCREASED;RISK;DISEASE;HYPERPROLACTINEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
RISPERIDONE;ANKK1;AA + AG;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HYPERPROLACTINEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH2;G;rs11706052;OTHER;INCREASED;NAN;OTHER;INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TREATMENT INTERRUPTION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2/*2 + *1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2/*2 + *1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B3;G;rs4149117;METABOLISM/PK;DECREASED;NAN;PK;DOSE-NORMALIZED  CMAX AND DOSE-NORMALIZED  AUC0TO12 H IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTS;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDINAVIR;UGT1A1;*6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
INDINAVIR;UGT1A1;*6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
INDINAVIR;UGT1A1;*6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ANASTROZOLE;ABCB1;AA;rs1045642;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;ARTHRALGIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;OTHER;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1 IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1 IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FEBRILE NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;;CAUTION_SIDE_EFFECT
FLECAINIDE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ETHANOL;ALDH2;GG;rs671;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
DIDANOSINE;XDH;AA;rs1429376;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;;CAUTION_SIDE_EFFECT
DIDANOSINE;XDH;AA;rs1429376;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SZRD1;T;rs6603859;OTHER;DECREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
DAUNORUBICIN;SZRD1;T;rs6603859;METABOLISM/PK;DECREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
DIDANOSINE;NT5C2;CC + CT;rs11598702;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;;CAUTION_SIDE_EFFECT
DIDANOSINE;NT5C2;CC + CT;rs11598702;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIDANOSINE;XDH;AA;rs1594160;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;;CAUTION_SIDE_EFFECT
DIDANOSINE;XDH;AA;rs1594160;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*6;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*6;CYP2C19*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;;GG;rs7929521;OTHER;INCREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
DAUNORUBICIN;;GG;rs7929521;METABOLISM/PK;INCREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*37;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
AZACITIDINE;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MYELODYSPLASTIC SYNDROMES;;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;MAN1B1;T;rs3750518;OTHER;INCREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
DAUNORUBICIN;MAN1B1;T;rs3750518;METABOLISM/PK;INCREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1XN;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*2XN;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*6;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*7;METABOLISM/PK;DECREASED;NAN;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIDANOSINE;NT5C2;CG + GG;rs11191561;TOXICITY;INCREASED;RISK;DISEASE;HYPERTENSION;;CAUTION_SIDE_EFFECT
DIDANOSINE;NT5C2;CG + GG;rs11191561;TOXICITY;INCREASED;RISK;DISEASE;PORTAL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;*01:02;HLA-DQA1*01:02;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;CYP2C19;A;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*22;CYP3A4*1;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*22;CYP3A4*22;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*14:02;HLA-C*14:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*14:02;HLA-C*14:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*56:02;HLA-B*56:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*56:02;HLA-B*56:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;AT + TT;rs1801272;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;(CA)16/(CA)16;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
NAN;NAT1;*11B/*4;NAT1*4;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*11B/*4;NAT1*11B;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3A;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*21;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*32;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*33;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*34;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*3A;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*3C;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*9;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*21;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*32;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*33;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*1/*3C;TPMT*34;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE CURVE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE CURVE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE CURVE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANASTROZOLE;CYP19A1;AA;rs727479;EFFICACY;INCREASED;NAN;OTHER;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*18/*18;CYP2B6*18;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ LEVELS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;NQO2;C;rs1143684;EFFICACY;NAN;NAN;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
DOXORUBICIN;NQO2;C;rs1143684;EFFICACY;NAN;NAN;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;CYP2C8*1;METABOLISM/PK;DECREASED;NAN;PK;M-III:PIOGLITAZONE AUC0-48 RATIO AND M-III:M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;CYP2C8*2;METABOLISM/PK;DECREASED;NAN;PK;M-III:PIOGLITAZONE AUC0-48 RATIO AND M-III:M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
DICLOFENAC;UGT2B7;T;rs7668258;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;RISK;OTHER;STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;EFFICACY;DECREASED;RISK;OTHER;REVASCULARIZATION OR DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER;STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER;REVASCULARIZATION OR DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C8;*1/*2;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*1/*2;CYP2C8*2;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP IN PEOPLE WITH  OTHER:DRUG-ELUTING STENTS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;NAN;NAN;SIDE EFFECT;NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP IN PEOPLE WITH  OTHER:DRUG-ELUTING STENTS;;CAUTION_DOSE_ADJUST
NAN;IRS1;C;rs1801123;OTHER;NAN;NAN;OTHER;LYMPH NODE INVOLVEMENT IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
ESTRADIOL;;A;rs1864729;OTHER;INCREASED;NAN;OTHER;PLASMA LEVEL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;MEDIAN SURVIVAL TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBIMAZOLE;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
METHIMAZOLE;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
PROPYLTHIOURACIL;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOMYOPATHIES IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOMYOPATHIES IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;NAN;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
DICLOFENAC;ABCC2;T;rs717620;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIARRHYTHMICS;;GG;rs10033464;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUCCESSFUL RHYTHM CONTROL IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLASS I AND III;;GG;rs10033464;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUCCESSFUL RHYTHM CONTROL IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;NAN;EFFICACY;BETTER CLINICAL RESPONSE IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
RIFAMPIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION NAN  NAN;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;NAN;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1XN;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*3;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*4;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*5;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*6;OTHER;DECREASED;NAN;OTHER;WAKEFULNESS ACTIVITY LEVEL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NAN;IGFBP3;T;rs2854744;OTHER;NAN;NAN;OTHER;TUMOR SIZE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;GSTM3;TC/TC + TC/TCCTC;rs36120609;OTHER;INCREASED;LIKELIHOOD;OTHER;METASTATIC NEOPLASM IN CHILDREN WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;OTHER;NAN;NAN;SIDE EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:HEPATITIS;;CAUTION_DOSE_ADJUST
RIBAVIRIN;ITPA;CC;rs1127354;OTHER;NAN;NAN;SIDE EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:HEPATITIS;;CAUTION_DOSE_ADJUST
TELAPREVIR;ITPA;CC;rs1127354;OTHER;NAN;NAN;SIDE EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:HEPATITIS;;CAUTION_DOSE_ADJUST
CARBOPLATIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
THIOTEPA;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
NAN;IFNL3;TT;rs8099917;NAN;INCREASED;NAN;OTHER;BASELINE VIRAL LOAD IN PEOPLE WITH  DISEASE:HEPATITIS;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;CYP2C8*3;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
HEPARIN;HLA-DRB3;*01:01;HLA-DRB3*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEPARIN-INDUCED THROMBOCYTOPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
SIMEPREVIR;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;RISK;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RISK;EFFICACY;NON-REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;RACEMIC;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;S-IBUPROFEN AND R-IBUPROFEN METABOLISM;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;RACEMIC;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;S-IBUPROFEN AND R-IBUPROFEN METABOLISM;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
LAMIVUDINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
LAMIVUDINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
STAVUDINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
STAVUDINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ZIDOVUDINE;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ZIDOVUDINE;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA 4BETA-OHC/CHOL RATIO IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;;CYP2D6 LOW ACTIVITY;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIROXICAM;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*4;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*9;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*10;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMIRACOXIB;HLA-DQA1;*01:02;HLA-DQA1*01:01;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
LUMIRACOXIB;HLA-DQA1;*01:02;HLA-DQA1*01:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*2;CYP2C9*1;OTHER;DECREASED;NAN;OTHER;INOS EXPRESSION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*2;CYP2C9*2;OTHER;DECREASED;NAN;OTHER;INOS EXPRESSION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A6;A;rs2070959;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*3;METABOLISM/PK;INCREASED;NAN;PK;R-IBUPROFEN METABOLISM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;EGFR;CC;rs2072454;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIORBITAL EDEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*9;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIROXICAM;CYP2C9;*1/*2;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PIROXICAM;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PIROXICAM;CYP2C9;*1/*2;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
GEFITINIB;CYP2D6;*10/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10;CYP2D6*114;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2D6;A;rs1065852;OTHER;NAN;NAN;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2D6;A;rs1065852;OTHER;NAN;NAN;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN MEN WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;NAN;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MYASTHENIA GRAVIS;;CAUTION_SIDE_EFFECT
NAN;CYP2D6;*2xN;CYP2D6*2XN;OTHER;INCREASED;RISK;DISEASE;SUICIDE IN PEOPLE WITH  OTHER:GENE DUPLICATION/MULTIDUPLICATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;CYP2C19;*2/*2;CYP2C19*1;OTHER;DECREASED;SEVERITY;DISEASE;DEPRESSION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2C19;*2/*2;CYP2C19*2;OTHER;DECREASED;SEVERITY;DISEASE;DEPRESSION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A9;C;rs11692021;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METOPROLOL;ADRB2;CG;rs1042714;TOXICITY;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDES IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
TAMOXIFEN;IGF1R;GG;rs2016347;EFFICACY;INCREASED;RISK;DISEASE;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2D6;*1xN;CYP2D6*1XN;OTHER;INCREASED;RISK;DISEASE;SUICIDE IN PEOPLE WITH  OTHER:GENE DUPLICATION/MULTIDUPLICATION;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*48:01;HLA-B*48:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;C;rs10509681;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SARCOMA;;CAUTION_SIDE_EFFECT
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SOFT TISSUE NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*2;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*4;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TTTTTTT/TTTTTTT;rs35060421;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*14:01;HLA-DRB1*14:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ZONISAMIDE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;NAN;NAN;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_DOSE_ADJUST
PHENOBARBITAL;HLA-B;*51:01;HLA-B*51:01;TOXICITY;NAN;NAN;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;OTHER;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;INCREASED;SEVERITY;OTHER;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;OTHER;PAIN IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;SEVERITY;OTHER;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
LAMIVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;NAN;NAN;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;NAN;NAN;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
STAVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;NAN;NAN;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;TIME TO ACHIEVE THERAPEUTIC WINDOW IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;TIME TO ACHIEVE THERAPEUTIC WINDOW IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AG + GG;rs3740065;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HYPERURICEMIA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB2;CC;rs1042714;TOXICITY;DECREASED;NAN;SIDE EFFECT;TOTAL CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;GG + GT;rs9516519;METABOLISM/PK;DECREASED;NAN;PK;PLASMA LEVEL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
THIOGUANINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;S-CIT SERUM CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;S-CIT SERUM CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;S-CIT SERUM CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;LOWER FINAL DAILY DOSE;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;LOWER FINAL DAILY DOSE;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;DOSAGE;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*3;CYP2C19*3;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
LISINOPRIL;MMP3;del/del;rs35068180;EFFICACY;DECREASED;RISK;SIDE EFFECT;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;NAN;NAN;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;NAN;NAN;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2 IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*1;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*2;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*3;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;TOXICITY;INCREASED;NAN;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:PAIN;;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:PAIN;;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2;CYP2C19*2;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2;CYP2C19*3;DOSAGE;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;SERUM CONCENTRATION IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;DECREASED;NAN;PK;DEMETHYLATION CLEARANCE OF DESMETHYLCITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LONG QT SYNDROME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;LONG QT SYNDROME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:CHRONIC KIDNEY FAILURE;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9;CYP2B6*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*9;CYP2B6*9;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT;rs56038477;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs56038477;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NAT2;*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;CYP2B6*1;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;CYP2B6*9;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:STROKE;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOCYTIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;CHRONIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE;B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;UGT2B15;*2/*2 + *1/*2;UGT2B15*1;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;UGT2B15;*2/*2 + *1/*2;UGT2B15*2;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;UGT2B15*1;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;UGT2B15*2;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR INHIBITORS;HLA-A;*03:01;HLA-A*03:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;NAN;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;SLCO1B3;A;rs3834935;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;A;rs3834935;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;GABRA1;GG;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;GABRA1;GG;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
VALPROIC ACID;GABRA1;GG;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*2;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*4;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN MEN WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CITALOPRAM;;A;rs1074145;OTHER;NAN;NAN;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;;A;rs1074145;OTHER;NAN;NAN;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:03;HLA-DQB1*06:03;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DRB1;*15:03;HLA-DRB1*15:03;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP1A2;AA;rs11636419;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIORBITAL EDEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION INHIBITION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;GABRA1;G;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;GABRA1;G;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
VALPROIC ACID;GABRA1;G;rs2279020;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*1;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*3;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*4;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*5;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*6;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*10;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*17;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*41;OTHER;NAN;NAN;OTHER;GREATER HEART RATE (HR) REDUCTION NAN  NAN;;CAUTION_DOSE_ADJUST
BUCILLAMINE;HLA-DRB1;*08:02;HLA-DRB1*08:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROTEINURIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
BUCILLAMINE;HLA-DQB1;*04:02;HLA-DQB1*04:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;PROTEINURIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*11;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;NANDISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;NANDISEASE;ACUTE CORONARY SYNDROME;PEOPLE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;OTHER;HIGH PLATELET REACTIVITY (HPR) NAN  NAN;;CAUTION_DOSE_ADJUST
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB5;*02:02;HLA-DRB5*02:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRASUGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRASUGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;JAUNDICE NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;JAUNDICE NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE);OTHER;NAN;NAN;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531C;OTHER;NAN;NAN;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;OTHER;NAN;NAN;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
AMOXICILLIN;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION NAN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATITIS IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*41;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
TICLOPIDINE;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;LEPR;GG;rs1805094;OTHER;INCREASED;NAN;OTHER;BONE MARROW DENSITY IN THE LUMBAR SPINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
TICLOPIDINE;HLA-DQB1;*06:04;HLA-DQB1*06:04;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;NAN;OTHER;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;NAN;OTHER;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICLOPIDINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;A;rs4680;OTHER;INCREASED;NAN;OTHER;METHYLATION AT SITES 1 AND 2 IN THE COMT PROMOTER IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*5B;CYP2E1*1A;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*5B;CYP2E1*5B;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;DECREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3C;TPMT*1;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;NAN;NAN;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
FLUTICASONE PROPIONATE;CD14, TMCO6;AA + AG;rs2569190;OTHER;DECREASED;NAN;EFFICACY;FEV1/FVC RATIO IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NON-NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ISONIAZID;GSTT1;;GSTT1 NULL;METABOLISM/PK;DECREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;GSTT1;;GSTT1 NULL;METABOLISM/PK;DECREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ISONIAZID;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;NAN;PK;SERUM HYDRAZINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;C;rs3735451;OTHER;INCREASED;SEVERITY;SIDE EFFECT;OPIOID WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*27;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*27;UGT1A1*27;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*13:01;HLA-B*07:02;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;NAN;NAN;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
NAN;TRPA1;CT + TT;rs920829;OTHER;INCREASED;LIKELIHOOD;DISEASE;PAIN IN PEOPLE WITH  DISEASE:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TRPA1;CT + TT;rs920829;OTHER;INCREASED;LIKELIHOOD;DISEASE;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ALDH2;A;rs671;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;;NAT2 DEFICIENCY;OTHER;NAN;NAN;DISEASE;INSULIN RESISTANCE NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
RITODRINE;CACNA1C;AA + AG;rs10774053;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN WITH  DISEASE:PREMATURE BIRTH;;LIKELIHOOD_THERAPEUTIC_FAILURE
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;rs1799752;EFFICACY;NAN;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION;;CAUTION_DOSE_ADJUST
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;rs1799752;EFFICACY;NAN;NAN;EFFICACY;END-SYSTOLIC AND END-DIASTOLIC VOLUME IN PEOPLE WITH  OTHER:CHRONIC HEART FAILURE;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOE;TT;rs429358;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOE;CC;rs7412;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN D-DIMER LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN D-DIMER LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
TIMOLOL;CYP2D6;;CYP2D6 POOR METABOLIZER;EFFICACY;INCREASED;NAN;PK;PLASMA TIMOLOL CONCENTRATION AND EXCERICE HEART RATE REDUCTION IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIMOLOL;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;NAN;PK;PLASMA TIMOLOL CONCENTRATION AND EXCERICE HEART RATE REDUCTION IN MEN  NAN;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZER;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
AMOXICILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
RABEPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZER;EFFICACY;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;AREG;A;rs1615111;OTHER;DECREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
CISPLATIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN IL-6 LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN IL-6 LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN CRP LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN CRP LEVELS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2/*2;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;*2/*2;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;DECREASED;NAN;SIDE EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*17;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CYP2E1;T;rs2031920;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;OTHER;INCREASED;LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:ATRIAL FLUTTER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:VENOUS THROMBOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:ATRIAL FLUTTER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER;DISEASE:VENOUS THROMBOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;TOLTERODINE EXPOSURE AND INCREASED ACTIVE METABOLITE (5-HM) CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;TOLTERODINE EXPOSURE AND INCREASED ACTIVE METABOLITE (5-HM) CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;TOLTERODINE EXPOSURE AND INCREASED ACTIVE METABOLITE (5-HM) CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
AMOXICILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ANASTROZOLE;CYP19A1;GG;rs1008805;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;ARTHRALGIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP3A5;*1/*1;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP3A5;*1/*1;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ATIC;AA;rs2177735;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;AA;rs2177735;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
LEVETIRACETAM;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs6759892;DOSAGE;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs6759892;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs2070959;DOSAGE;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs2070959;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MED12L, P2RY12;T/del;rs5853517;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
EXEMESTANE;;TT;rs16964189;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;INFLAMMATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;INSIG2;CC;rs11123469;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
FENOFIBRATE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
SERTRALINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TERBINAFINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;ABCB1;T;rs2032582;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;T;rs2032582;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
VALPROIC ACID;ABCB1;T;rs2032582;EFFICACY;NAN;NAN;EFFICACY;DRUG-RESISTANT PHENOTYPE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;*3;CYP4F2*1;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;*3;CYP4F2*3;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTRITIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTRITIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA METOPROLOL CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA METOPROLOL CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;UGT1A1*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;C;rs2285666;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 NAN  NAN;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA BLOCKING AGENTS""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""CALCIUM CHANNEL BLOCKERS""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIGOXIN""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";ACE;del;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;MORTALITY IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;NAN;SIDE EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;;CAUTION_DOSE_ADJUST
TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;NAN;SIDE EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;NAN;NAN;DISEASE;HEMOLYSIS IN  OTHER:G6PD DEFICIENT MICE;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;OTHER;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;OTHER;INCREASED;NAN;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION NAN  NAN;;CAUTION_DOSE_ADJUST
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;NAN;NAN;DISEASE;HEMOLYSIS IN  OTHER:G6PD DEFICIENT MICE;;CAUTION_DOSE_ADJUST
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;METABOLISM/PK;DECREASED;SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE IN  OTHER:HUMAN LIVER MICROSOMES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;;A;rs3764261;EFFICACY;DECREASED;NAN;EFFICACY;PROTECTION AGAINST MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;EFFICACY;DECREASED;NAN;SIDE EFFECT;TIME BELOW THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;EFFICACY;DECREASED;NAN;SIDE EFFECT;TIME BELOW THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;EFFICACY;DECREASED;NAN;SIDE EFFECT;TIME BELOW THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
OSIMERTINIB;CYP2A6;CC;rs28399433;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAZOPANIB;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMETREXED;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLIN G;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLIN V;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;GHSR;AG;rs2948694;OTHER;NAN;NAN;OTHER;WEIGHT NAN  NAN;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs495491;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*46/*46;CYP2A6*1;NAN;INCREASED;NAN;OTHER;CIGARETTES PER DAY NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*46/*46;CYP2A6*46;NAN;INCREASED;NAN;OTHER;CIGARETTES PER DAY NAN  NAN;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AA + AG;rs10457090;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;STEADY STATE CONCENTRATION PER DOSAGE IN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;STEADY STATE CONCENTRATION PER DOSAGE IN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01/*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ARTHRITIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01/*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;GOUTY;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;SCN2A;A;rs17183814;EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;SCN2A;A;rs17183814;EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;NAN;NAN;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4 NAN  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;rs45445694;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*6;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*18;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*18;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
DOCETAXEL;CYP2A6;*4/*4;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;CYP2A6;*4/*4;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR;CYP2A6;*4/*4;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR;CYP2A6;*4/*4;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;T;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;SLC6A3;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;rs3836790;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1;DOSAGE;NAN;NAN;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;NAN;NAN;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT NAN  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH IN  SIDE EFFECT:NEUROLOGICAL PATIENTS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH IN  SIDE EFFECT:NEUROLOGICAL PATIENTS;;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;DURATION OF INHIBITION OF PROSTANOIDS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;THE MAXIMAL ELIMINATION RATE (VMAX) IN  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;CYP2E1;*1/*5B;CYP2E1*1;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION RATE IN PEOPLE WITH  DISEASE:ALCOHOLIC LIVER DISEASES;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;CYP2E1;*1/*5B;CYP2E1*5B;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION RATE IN PEOPLE WITH  DISEASE:ALCOHOLIC LIVER DISEASES;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;NAN;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;NAN;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*4;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;CYP2A7;C;rs73032311;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*18;CYP2B6*18;METABOLISM/PK;DECREASED;NAN;PK;HYDROXYBUPROPION CONCENTRATIONS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;CUTANEOUS REACTIONS IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;CUTANEOUS REACTIONS IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*11A;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*11A;NAT1*11A;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;NAT1;*10/*4;NAT1*4;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*4;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
ISONIAZID;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;NAN;PK;CLERANCE OF PACLITAXEL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*6;CYP2B6*1;METABOLISM/PK;DECREASED;NAN;PK;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;NAN;PK;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;NAN;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION NAN  NAN;;CAUTION_DOSE_ADJUST
IRINOTECAN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED;RISK;DISEASE;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALTITREXED;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED;RISK;DISEASE;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;NAN;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION NAN  NAN;;CAUTION_DOSE_ADJUST
TEMSIROLIMUS;NR1I2;AG + GG;rs6785049;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
NAN;NAT1;*11B/*3;NAT1*3;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*11B/*3;NAT1*11B;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*10;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;NRP2;C;rs10932125;DOSAGE;INCREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
DAUNORUBICIN;NRP2;C;rs10932125;METABOLISM/PK;INCREASED;NAN;PK;IC50 NAN  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;del/del;rs5030655;OTHER;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF METOPROLOL NAN  NAN;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;NAN;NAN;NAN;EFFICACY;LACK OF REMISSION AND LACK OF RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION AFTER THE SECOND SWITCH IN TREATMENT IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;C;rs1105879;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION NAN  NAN;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ELEVATED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ISONIAZID;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRIDOXAL PHOSPHATE;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ATENOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/(E)-10- OH-AT RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/(E)-10- OH-AT RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE/(E)-10-OH-NT RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE/(E)-10-OH-NT RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*37;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED CLEARANCE) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
BENZENE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;TPH2;TT;rs4570625;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;TPH2;TT;rs4570625;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;EFFICACY;DECREASED;NAN;PK;PLASMA CONCENTRATION OF EFAVIRENZ IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION OF EFAVIRENZ IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ANTITHYROID PREPARATIONS;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
TEGAFUR;CYP2A6;*1;CYP2A6*1;OTHER;INCREASED;NAN;PK;PLASMA FLUOROURACIL IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
TEGAFUR;CYP2A6;*1;CYP2A6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA FLUOROURACIL IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE DRUG REACTIONS IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*2;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE DRUG REACTIONS IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE DRUG REACTIONS IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LIVER INJURY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*18;TOXICITY;INCREASED;RISK;SIDE EFFECT;LIVER INJURY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1;EFFICACY;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1;METABOLISM/PK;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*2;EFFICACY;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*2;METABOLISM/PK;INCREASED;NAN;PK;ATORVASTATIN LACTONIZATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;UGT1A3;*2;UGT1A3*1;EFFICACY;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2;UGT1A3*1;METABOLISM/PK;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;UGT1A3;*2;UGT1A3*2;EFFICACY;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2;UGT1A3*2;METABOLISM/PK;DECREASED;NAN;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;HOSPITAL STAY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;COMT;A;rs4680;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;NAN;EFFICACY;MEAN ABSOLUTE DIFFERENCE IN HBA1C IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1/*2xN;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*1/*2xN;CYP2D6*2XN;METABOLISM/PK;INCREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;RELATIVE BIOAVAILABILITY OF PRAVASTATIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;RELATIVE BIOAVAILABILITY OF PRAVASTATIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2C19;*17;CYP2C19*1;OTHER;NAN;RISK;DISEASE;PEPTIC ULCER DISEASE NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;CYP2C19;*17;CYP2C19*17;OTHER;NAN;RISK;DISEASE;PEPTIC ULCER DISEASE NAN  NAN;;CAUTION_DOSE_ADJUST
CAFFEINE;ADORA2A;TT;rs5751876;OTHER;INCREASED;NAN;SIDE EFFECT;ANXIETY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;SEVERITY;DISEASE;RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE ISCHEMIC EVENTS IN  OTHER:PATIENTS THAT HAD UNDERGONE CORONARY ANGIOGRAPHY OR HAD AN UNEVENTFUL PCI;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;NAN;SIDE EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE) NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;NAN;SIDE EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE) NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCC10;CC;rs2125739;EFFICACY;INCREASED;LIKELIHOOD;PK;LOWER NEVIRAPINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;ABCC10;CC;rs2125739;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;LOWER NEVIRAPINE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARBAMAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN) NAN  NAN;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;TOXICITY;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;METABOLISM/PK;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;METABOLISM/PK;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY SYNDROME IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;EFFICACY;NAN;NAN;EFFICACY;ENHANCED RESPONSE TO CLOPIDOGREL (AS MEASURED BY INHIBITION OF ADP-INDUCED PLATELET AGGREGATION) NAN  NAN;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;PHENYTOIN TOXICITY IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;PHENYTOIN TOXICITY IN  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NAT1;*10/*11B;NAT1*10;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*11B;NAT1*11B;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;5-HYDROXYOMEPRAZOLE;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;R-OMEPRAZOLE AND S-OMEPRAZOLE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NAN;NAT1;*11A/*4;NAT1*4;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
NAN;NAT1;*11A/*4;NAT1*11A;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION AND RS2066853 GENOTYPE AA OR GA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4 NAN  NAN;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1;TOXICITY;INCREASED;NAN;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*3A;TOXICITY;INCREASED;NAN;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*37;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*13;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;DOSAGE;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;DOSAGE;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;DOSAGE;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;OTHER;COMPLICATIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;INCREASED;RISK;DISEASE;BRADYCARDIA NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED;RISK;DISEASE;BRADYCARDIA NAN  NAN;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PCI;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE AFTER ADJUSTMENT FOR VKORC1*1173 NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*3/*5;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*3/*5;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HALOPERIDOL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCLE EFFECTS NAN  NAN;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2D6;*4/*5;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*4/*5;CYP2D6*5;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*13;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;CYP2C9*1;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;CYP2C9*14;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2B6;*5;CYP2B6*5;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;CMAX AND AUC OF VENLAFAXINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*2;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2/*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR VALUE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;CMAX AND AUC OF VENLAFAXINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;CMAX AND AUC OF VENLAFAXINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;CYP2C9*14;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*3;EFFICACY;NAN;NAN;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING A STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING A STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*10;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;OTHER;INTRAGASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;EFFICACY;TRAMADOL METABOLISM AND RESPONSE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS IN PEOPLE WITH  DISEASE:ULCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS IN PEOPLE WITH  DISEASE:ULCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*6/*7;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*6/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF REMITTERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*6;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*6;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*4;CYP2D6*3;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*4;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*4;CYP2D6*4;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*4;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOMIPRAMINE;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1;METABOLISM/PK;NAN;NAN;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3;METABOLISM/PK;NAN;NAN;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*4;METABOLISM/PK;NAN;NAN;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO NAN  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*1 + *1/*41;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*1 + *1/*41;CYP2D6*41;METABOLISM/PK;DECREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED DURING THE COURSE OF PREGNANCY IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*3;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIOS OF DESIPAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*2/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*2/*10;CYP2D6*2;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*2/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;DOSAGE;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*2;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;CYP2A6*1;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;CYP2A6*2;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;CYP2A6*9;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;CYP2A6*17;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;CYP2A6*20;METABOLISM/PK;NAN;NAN;PK;SHORTER CONTININ HALF-LIFE IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;CLEARANCE OF S(+) MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE LEVELS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOMIPRAMINE;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*36;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*36;CYP2D6*36;METABOLISM/PK;DECREASED;NAN;PK;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL OF MORPHINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;T;rs34946978;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;T;rs34946978;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;AUC;;CAUTION_DOSE_ADJUST
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;AUC;;CAUTION_DOSE_ADJUST
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;CYP2C8*1;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;CYP2C8*4;METABOLISM/PK;INCREASED;NAN;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
PYRIMIDINE ANALOGUES;MIR27A;CC + CT;rs895819;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;INCREASED;NAN;PK;PLASMA RATIO CITALOPRAM (CIT)/N-DESMETHYLCIT (DCIT) IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;LONGER ELIMINATION HALF-LIVES ) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;C;rs662;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
TENOXICAM;CYP2C9;*3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;AUC AND HALF-LIFE TIME (T1/2) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*3;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;AUC AND HALF-LIFE TIME (T1/2) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;AUC AND HALF-LIFE TIME (T1/2) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1;TOXICITY;DECREASED;NAN;SIDE EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*3;TOXICITY;DECREASED;NAN;SIDE EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;A;rs2046934;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
SULFONAMIDES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
LUMACAFTOR;CFTR;del/del;rs113993960;TOXICITY;INCREASED;NAN;EFFICACY;CHANGE IN SWEAT CHLORIDE IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ABORTION;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SPONTANEOUS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:LEPROSY;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*3;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;PLASMA LEVELS OF MORPHINE;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;PLASMA LEVELS OF MORPHINE;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;NAN;PK;M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*2;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*3;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*4;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*5;OTHER;INCREASED;NAN;OTHER;OROCECCAL TRANSIT TIME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NAN;CYP1B1;CC + CG;rs1056836;NAN;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;CAUTION_DOSE_ADJUST
NAN;CYP1B1;CC + CG;rs1056836;NAN;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
TETRABENAZINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;NAN;NAN;EFFICACY;LESS ROBUST TREATMENT RESPONSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;*3;CYP4F2*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;*3;CYP4F2*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 L ALLELE-rs25531T;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES NAN  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PTGS1;T;rs1330344;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;NAN;SIDE EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;NAN;SIDE EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AUC OF CITALOPRAM IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;PRESENTATION IN THE NON-REPONDER GROUP IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;NAN;EFFICACY;PRESENTATION IN THE NON-REPONDER GROUP IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENOBARBITAL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE DRUG REACTIONS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;PRU IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;PRU IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*07:02;HLA-B*07:02;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*07:02;HLA-B*08:01;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRICHLOROETHYLENE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CLINICAL EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*3A;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*3C;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;TPMT;*3A/*3C;TPMT*3A;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;TPMT;*3A/*3C;TPMT*3C;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
PREDNISONE;TPMT;*3A/*3C;TPMT*3A;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
PREDNISONE;TPMT;*3A/*3C;TPMT*3C;TOXICITY;NAN;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HEMATOLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTIONS;;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;CYP2C8;CC;rs11572076;TOXICITY;DECREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB3;*02:02;HLA-DRB3*02:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT2B7;G;rs7438135;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-C;*07:01;HLA-C*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;DECREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
PROPYLTHIOURACIL;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  DISEASE:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
PYRIMIDINE ANALOGUES;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOLASETRON;CYP2D6;*1/*1xN;CYP2D6*1;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:POSTOPERATIVE NAUSEA AND VOMITING;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLASETRON;CYP2D6;*1/*1xN;CYP2D6*1XN;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:POSTOPERATIVE NAUSEA AND VOMITING;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;NFATC2;AA;rs6123048;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;NFATC2;AA;rs6123048;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C8;*4;CYP2C8*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C8;*4;CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;CYP2C8;*4;CYP2C8*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;CYP2C8;*4;CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*4;CYP2C8*1;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*4;CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2C19;*1/*2;CYP2C19*1;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;*1/*2;CYP2C19*2;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
IFOSFAMIDE;ALDH1A1;AA;rs3764435;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IFOSFAMIDE;ALDH1A1;AA;rs3764435;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:SARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP2C19;*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTT1;null/null;GSTT1 NON-NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;GSTT1;null/null;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;ADAMTS1;CC;rs402007;EFFICACY;NAN;NAN;EFFICACY;THE MOST BENEFIT FROM STATIN TREATMENT IN REDUCING THE RISK OF MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*4;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*1/*1;CYP2A6*1;TOXICITY;DECREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*1;CYP2A6*12;TOXICITY;DECREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYROID PREPARATIONS;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;DISEASE;VIRUS DISEASES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE;VIRUS DISEASES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEFITINIB;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;DECREASED;RISK;EFFICACY;ALLOGRAFT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;RISK;EFFICACY;ALLOGRAFT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;SCN1A;C;rs3812718;EFFICACY;INCREASED;NAN;EFFICACY;TONIC BLOCK OF NA(V) 1.1 CHANNELS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN KIDNEY MICROSOMES;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;METABOLISM/PK;INCREASED;NAN;PK;FORMATION OF METABOLITES IN  OTHER:HUMAN KIDNEY MICROSOMES;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PEMETREXED;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;TYMS;del;rs11280056;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
NAN;SLCO1B1;C;rs4149056;OTHER;DECREASED;NAN;OTHER;ERYTHROMYCIN TRANSPORT NAN  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;HLA-B*13:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*03:01;HLA-A*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;THROMBOTIC DISEASE IN PEOPLE WITH  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;THROMBOTIC DISEASE IN PEOPLE WITH  NAN;;CAUTION_SIDE_EFFECT
BETA-LACTAM ANTIBACTERIALS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLINS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PROTON PUMP INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PROTON PUMP INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:HIGH ON-TREATMENT PLATELET REACTIVITY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:HIGH ON-TREATMENT PLATELET REACTIVITY;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
METOPROLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ZOLEDRONATE;;CC;rs1152003;TOXICITY;INCREASED;RISK;DISEASE;OSTEONECROSIS IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;T;rs17671591;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  OTHER:DRUG-DRUG PHARMACOKINETIC INTERACTION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP3A5;*3/*3;CYP3A5*1;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP3A5;*3/*3;CYP3A5*3;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CARBOPLATIN;LIG3;T;rs1052536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;LIG3;T;rs1052536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;T;rs10474433;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;PCSK9;T;rs11591147;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PENICILLINS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"PENICILLINS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""BETA-LACTAM ANTIBACTERIALS";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"PENICILLINS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""BETA-LACTAM ANTIBACTERIALS";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"PENICILLINS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""BETA-LACTAM ANTIBACTERIALS";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"PENICILLINS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
VALPROIC ACID;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;T;rs429358;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
ENALAPRIL;;TT;rs495828;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN WOMEN WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;;TT;rs495828;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;T;rs7412;EFFICACY;NAN;NAN;EFFICACY;LDL-C RESPONSE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
NAN;GSTT1;;GSTT1 NON-NULL;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
NAN;GSTT1;;GSTT1 NULL;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO DRUG IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"HYPONATREMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"HYPONATREMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"HYPONATREMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MACULOPAPULAR EXANTHEMA;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG HYPERSENSITIVITY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ERYTHEMA MULTIFORME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:DISCONTINUATION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE TO DRUG IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);C.1236G>A (HAPB3);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);C.1236G>A (HAPB3);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2A6;*4;CYP2A6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
OSIMERTINIB;ABCG2;TT;rs2622604;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
L-ASPARAGINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDL-C IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN LDL-C IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2B6;;CYP2B6 POOR METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2B6;;CYP2B6 POOR METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2B6;;CYP2B6 POOR METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP3A4;;CYP3A4 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP3A4;;CYP3A4 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP3A4;;CYP3A4 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-B;C;rs9266271;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;GG;rs3846662;EFFICACY;INCREASED;NAN;EFFICACY;LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IN BASAL STATE AND POSSIBLY IN RESPONSE TO ATORVASTATIN. IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREMOR;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREMOR;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:CROHN DISEASE;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:AUTOIMMUNE HEPATITIS;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
XELOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;ALOX5;T;rs1051713;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
ETOPOSIDE;;GG;rs6539870;OTHER;INCREASED;NAN;OTHER;SENSITIVITY TO ETOPOSIDE NAN  NAN;;CAUTION_DOSE_ADJUST
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;EFFICACY;DECREASED;NAN;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
"RECOMBINANT""";ITPA;CC;rs1127354;EFFICACY;DECREASED;NAN;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;DECREASED;NAN;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;STROKE NAN  NAN;;CAUTION_SIDE_EFFECT
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;EFFICACY;NAN;NAN;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
"RECOMBINANT""";ITPA;CC;rs1127354;EFFICACY;NAN;NAN;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
"""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;NAN;NAN;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
ASPARAGINASE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;NAN;PK;ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
DESIPRAMINE;MC1R;G;rs2228478;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;A;rs1045642;NAN;INCREASED;NAN;OTHER;LEVEL OF APOLIPOPROTEIN A1 NAN  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED;NAN;EFFICACY;DOSE REQUIREMENT NAN  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;DOSE REQUIREMENT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA;rs9934438;TOXICITY;DECREASED;NAN;EFFICACY;DOSE REQUIREMENT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;MC1R;A;rs2228479;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7;NAT2*4;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;LTA, TNF;A;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SERIOUS HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ASPARAGINASE;IL16;GG + GT;rs11556218;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOTIC DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC29A1;CT + TT;rs9394992;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;SPG7;A;rs2292954;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;SPG7;A;rs2292954;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CTH;CC;rs648743;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCC6;C;rs2238472;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;ABCC6;C;rs2238472;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;ATP7A;G;rs2227291;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;ATP7A;G;rs2227291;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC DISORDER IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CC;rs2108622;OTHER;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CC;rs2108622;METABOLISM/PK;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CT;rs2108622;OTHER;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CT;rs2108622;METABOLISM/PK;DECREASED;NAN;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENT IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;NAN;EFFICACY;DOSAGE REQUIREMENT IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CC;rs2108622;EFFICACY;DECREASED;NAN;EFFICACY;DOSAGE REQUIREMENT IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;CC;rs2108622;TOXICITY;DECREASED;NAN;EFFICACY;DOSAGE REQUIREMENT IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;AA + AG;rs4149015;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
NAN;CHRM3;AA + AG;rs2165870;NAN;INCREASED;RISK;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;A MILD INCREASE OF LIVER ENZYMES IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
SALBUTAMOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;ASTHMA EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;ASTHMA EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;del/del;rs3832043;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CISPLATIN;SLC16A5;T;rs4788863;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5G;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*30;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*34;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5G;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*5J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*30;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*34;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE REACTIONS IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC2;CC;rs3740066;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ENALAPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;CAUTION_SIDE_EFFECT
IMIDAPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;CAUTION_SIDE_EFFECT
LISINOPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;CT + TT;rs2231137;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;RISK;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;RISK;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SREBF1;AA + AG;rs11868035;OTHER;INCREASED;NAN;OTHER;TOTAL CHOLESTEROL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*3;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*4;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*5;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*6;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*7;DOSAGE;INCREASED;NAN;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTP1;G;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;BDKRB2;T;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
PLAIN;BDKRB2;T;rs1799722;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCG2;TT;rs2231142;DOSAGE;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
IRBESARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;NAN;EFFICACY;BLOOD PRESSURE RESPONSE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*5;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;NAN;EFFICACY;BISPECTRAL INDEX AND RAMSAY SEDATION SCORES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;NAN;EFFICACY;INDICATING A LONGER PERIOD FOR FALLING ASLEEP NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP2C8;G;rs1113129;TOXICITY;DECREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;TT;rs2231142;DOSAGE;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*6;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*5;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*14;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS IN PEOPLE WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GG;rs2231142;DOSAGE;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;GG;rs2231142;METABOLISM/PK;DECREASED;NAN;PK;AUC IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
SORAFENIB;TNF;GG;rs1800629;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RISK;DISEASE;PAIN IN PEOPLE WITH  OTHER:EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (ESWL);;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMOGLOBIN LEVELS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"RECOMBINANT""";ITPA;CC;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMOGLOBIN LEVELS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""RIBAVIRIN""";ITPA;CC;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEMOGLOBIN LEVELS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;rs1799971;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;OTHER;ASTHMA EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;DNAAF9, ITPA;C;rs6051702;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;DNAAF9, ITPA;C;rs6051702;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MIR6076;GG + GT;rs1463411;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZErs;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;LRMDA;C;rs10509373;EFFICACY;DECREASED;NAN;OTHER;RECURRENCE-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;G;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;G;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*6/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*7;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*6/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*7;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*7;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*14;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*16;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;AG + GG;rs3740065;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;NR3C1;A;rs61754806;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;VKORC1;T;rs7294;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;CT;rs1142345;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;TPMT;CT;rs1142345;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;*5;SLCO1B1*5;TOXICITY;DECREASED;RISK;SIDE EFFECT;CATARACT IN PEOPLE WITH  OTHER:CARDIO-METABOLIC CONDITIONS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;AA;rs9937;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;C;rs1799978;EFFICACY;DECREASED;NAN;EFFICACY;TIME UNTIL RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;C;rs1799978;EFFICACY;DECREASED;NAN;EFFICACY;TIME UNTIL RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*6J;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;GG + GT;rs9516519;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PSYCHOMOTOR AGITATION;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERKINESIS;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:IMPULSE CONTROL DISORDER IN CHILDREN WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALIPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
PALIPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WEIGHT GAIN IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;MAGNITUDE OF PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PYRAZINAMIDE;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16/*4;NAT2*4;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NAT2;*16/*4;NAT2*4;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;*16/*4;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NAT2;*16/*4;NAT2*16;METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;del;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO RESPOND IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;del;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO RESPOND IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP2A7P1, CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
SOFOSBUVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
PROTON PUMP INHIBITORS;CYP2C19;;CYP2C19 RAPID AND ULTRARAPID METABOLIZER GENOTYPES;TOXICITY;DECREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;TYMS;AG + GG;rs2853539;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:RHABDOMYOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACTINOMYCIN;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:RHABDOMYOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:RHABDOMYOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZErs;METABOLISM/PK;DECREASED;NAN;OTHER;GASTRIC PH IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;EFFICACY;INCREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;HOT FLASHES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;AKR1C3;G;rs1937840;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADIPOQ;CG + GG;rs266729;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
MYCOPHENOLIC ACID;IMPDH1;T;rs2278293;EFFICACY;DECREASED;LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;IMPDH1;T;rs2278293;EFFICACY;DECREASED;LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*4XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERHIDROSIS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URINARY RETENTION IN PEOPLE WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;DECREASED;RISK;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2D6;*2xN;CYP2D6*2XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2D6;*2xN;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2D6;*2xN;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
GEMCITABINE;DCK;TT;rs4694362;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;T;rs1801280;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1801280;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;AG + GG;rs4978536;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
OPIOIDS;BDNF-AS;CC + CT;rs11030096;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;NAT2;AA;rs1799930;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;NAT2;AA;rs1799930;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:HEMATOLOGIC DISORDER;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
COCAINE;SYT1;G;rs2251214;TOXICITY;INCREASED;RISK;SIDE EFFECT;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE HEPATITIS;;CAUTION_SIDE_EFFECT
VALGANCICLOVIR;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
TETRABENAZINE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER PHENOTYPE;EFFICACY;NAN;NAN;OTHER;LONGER TITRATION TO ACHIEVE OPTIMAL BENEFIT NAN  NAN;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP2C9;;CYP2C9 POOR METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
"""FOLIC ACID""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""VITAMIN B-COMPLEX";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;HTR3B;TT;rs3758987;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROESOPHAGEAL CANCER;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ENALAPRIL;PCGF3;A;rs1044147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*11;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;PAROXETINE PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
ANTICHOLINERGIC AGENTS;CYP2C19;;CYP2C19 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;SERUM ANTICHOLINERGIC ACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCG2;CC + CT;rs2231164;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRTAZAPINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;DECREASED;NAN;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID-7-O-GLUCURONIDE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF THE ACYL GLUCURONIDE OF MYCOPHENOLIC ACID IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;CT;rs2297595;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;DECREASED;NAN;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;DECREASED;NAN;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ATENOLOL;PAH;AA;rs2245360;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSULIN RESISTANCE IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*3;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*5;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*7;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD2;CC + CT;rs1125394;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;NAN;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs3025040;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD2;CT + TT;rs1079596;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;;CYP2B6 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEBRILE NEUTROPENIA IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;;TPMT INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;AG + GG;rs2847153;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;ABCC3;T;rs4148412;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;T;rs4148412;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A9;AA;rs7574296;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*28;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE METABOLIZER AND NORMAL METABOLIZER;DOSAGE;INCREASED;LIKELIHOOD;OTHER;DRUG DOSAGE ALTERED IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TRAMADOL;COMT;GG;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;GG;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
"""FOLIC ACID""";MTHFR;AG + GG;rs1801133;EFFICACY;NAN;NAN;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
"""VITAMIN B-COMPLEX";MTHFR;AG + GG;rs1801133;EFFICACY;NAN;NAN;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
"PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;NAN;NAN;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;ANTIDEPRESSANT SERUM LEVELS IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
SORAFENIB;SLC15A2;CC;rs2257212;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CCND1;AA;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;TIME-TO-TUMOR RECURRENCE IN  DISEASE:COLONIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CAPECITABINE;UMPS;CC + CT;rs2279199;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;UMPS;CC + CT;rs2279199;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;;TT;rs578427;METABOLISM/PK;INCREASED;NAN;PK;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;TYMS;CT + TT;rs2853741;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;;CYP2C19 RAPID AND ULTRARAPID METABOLIZER GENOTYPES;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;SLC22A7;AG + GG;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;;CYP2C19 NORMAL METABOLIZErs;OTHER;DECREASED;RISK;OTHER;MAJOR ADVERSE CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;T;rs1051266;TOXICITY;INCREASED;NAN;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABT-751;UGT1A4;AC;rs6755571;METABOLISM/PK;DECREASED;NAN;PK;PLASMA PREDOSE CONCENTRATION (CTROUGH) IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CAPECITABINE;UMPS;CC + CG;rs4678145;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ABT-751;UGT1A8;CC + CT;rs6431558;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION METABOLIC RATIOS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;MEAN AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC) OF DESIPRAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;DPYD;AA + AG;rs1760217;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;CC + CT;rs1142345;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;SERPINA3;AC + CC;rs17091162;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*2;METABOLISM/PK;DECREASED;NAN;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*17;METABOLISM/PK;DECREASED;NAN;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C19;;CYP2C19 POOR METABOLIZER AND INTERMEDIATE METABOLIZER GENOTYPES;TOXICITY;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A2;AA;rs12943590;METABOLISM/PK;INCREASED;NAN;PK;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TAMOXIFEN;NCOA1;CT;rs1804645;OTHER;INCREASED;SEVERITY;SIDE EFFECT;CHANGE IN LUMBAR BONE MINERAL DENSITY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;CARDIOVASCULAR DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;MYOCARDIAL INFARCTION OR STROKE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);;CAUTION_SIDE_EFFECT
CITALOPRAM;;A;rs352428;EFFICACY;NAN;NAN;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;;A;rs352428;EFFICACY;NAN;NAN;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);;CAUTION_SIDE_EFFECT
CITALOPRAM;;A;rs352428;EFFICACY;NAN;NAN;EFFICACY;POOR RESPONSE AT 6 WEEK OF TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;CARDIOVASCULAR DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;OTHER;MYOCARDIAL INFARCTION OR STROKE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);;CAUTION_SIDE_EFFECT
MIDAZOLAM;POR;CT;rs1057868;METABOLISM/PK;DECREASED;NAN;PK;MIDAZOLAM METABOLIC RATIOS BY 45% NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION (MOST OF THE PATIENTS);;CAUTION_SIDE_EFFECT
LENVATINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRY MOUTH;;CAUTION_SIDE_EFFECT
LENVATINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;G;rs578776;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL IN  OTHER:TOBACCO USERS;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*3;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*5;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*41;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED PLASMA LEVELS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_DOSE_ADJUST
TRAZODONE;CYP2D6;;CYP2D6 NORMAL METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;STOMATITIS IN PEOPLE WITH  DISEASE:GASTROESOPHAGEAL CANCER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER PHENOTYPE;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI);;CAUTION_SIDE_EFFECT
LENVATINIB;CYP3A4;C;rs2242480;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
LENVATINIB;CYP3A5;C;rs776746;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TT;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TT;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRK1;C;rs6473797;TOXICITY;DECREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;CSNK1E;T;rs1534891;TOXICITY;DECREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;AG;rs12119882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA5;G;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;GAL;A;rs694066;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRD1;A;rs2236861;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;SLC22A7;TT;rs2270860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;CRHBP;G;rs1500;OTHER;DECREASED;NAN;OTHER;RECURRENCE IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;FAAH;A;rs324420;OTHER;INCREASED;LIKELIHOOD;OTHER;DEPENDENCE IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CHRNA3;G;rs1051730;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*2;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*2XN;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*6;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*7;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*35;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;PEAK CORTISOL RESPONSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER PHENOTYPE;TOXICITY;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;CT + TT;rs699517;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEIOMYOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LIVER DISORDER;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:OVARIAN CYSTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEIOMYOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LIVER DISORDER;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:OVARIAN CYSTS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
HEROIN;HTR3B;C;rs3758987;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;;CYP2D6 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
OSIMERTINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2C;C;rs6318;EFFICACY;DECREASED;NAN;DISEASE;PAIN IN MEN WITH  DISEASE:NEUROPATHIC PAIN;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER PHENOTYPE;METABOLISM/PK;DECREASED;NAN;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN PAIN AUC IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER PHENOTYPE;EFFICACY;DECREASED;NAN;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;rs1051730;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;OTHER;INCREASED;NAN;OTHER;METABOLIC RATIO DEM/DOR IN PEOPLE WITH  DISEASE:ANXIETY DISORDERS;;CAUTION_DOSE_ADJUST
IRINOTECAN;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION IN WOMEN WITH  DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*2;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*3;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN AUC;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;METABOLISM/PK;INCREASED;NAN;PK;PLASMA HALF-LIFE AND STEADY-STATE PLASMA CONCENTRATIONS OF PAROXETINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*1/*1;CYP2D6*1XN;METABOLISM/PK;INCREASED;NAN;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO IN CHILDREN WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROESOPHAGEAL CANCER;;CAUTION_SIDE_EFFECT
ALKYLATING AGENTS;ESR1;A;rs2207396;TOXICITY;INCREASED;RISK;DISEASE;OLIGOSPERMIA IN PEOPLE WITH  OTHER:CHILDHOOD CANCER;;CAUTION_SIDE_EFFECT
CISPLATIN;ESR1;A;rs2207396;TOXICITY;INCREASED;RISK;DISEASE;OLIGOSPERMIA IN PEOPLE WITH  OTHER:CHILDHOOD CANCER;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;;CYP2D6 POOR METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZErs;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IF TOLERANT TO CITALOPRAM TREATMENT IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6 NORMAL METABOLIZErs;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6 NORMAL METABOLIZErs;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 NORMAL METABOLIZErs;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;PARKINSONIAN DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OSIMERTINIB;STAT3;GG;rs4796793;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAIL DISORDER IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;AA;rs1065852;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE AND REMISSION RATE IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
3;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERTENSION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;;CYP2C19 POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERTENSION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;GG + GT;rs4149014;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;;;POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;;;POOR METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;;T;rs6968865;DOSAGE;INCREASED;NAN;OTHER;COFFEE CONSUMPTION NAN  NAN;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE;GCLC;AA;rs761142;TOXICITY;DECREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;TOXICITY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;EFFICACY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;TOXICITY;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER GENOTYPE;METABOLISM/PK;INCREASED;NAN;PK;6-TG LEVELS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
NAN;CYP1A1;T;rs2472297;DOSAGE;INCREASED;NAN;OTHER;COFFEE CONSUMPTION NAN  NAN;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE;GCLC;A;rs761142;TOXICITY;DECREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APIXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
DABIGATRAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
EDOXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
RIVAROXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;;CYP2D6 NORMAL METABOLIZER AND ULTRARAPID METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LOW BACK PAIN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;;CYP2D6 NORMAL METABOLIZER AND ULTRARAPID METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:OSTEOARTHRITIS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;AG + GG;rs2273697;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;AG + GG;rs2273697;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:SARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG;rs35599367;OTHER;INCREASED;NAN;PK;CREATININE CLEARANCE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SOFT TISSUE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:SARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CC;rs662;EFFICACY;DECREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (PR) AT 1 MONTH AND AT 6 MONTHS AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) IN PEOPLE WITH  DISEASE:MYOCARDIAL ISCHEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER GENOTYPE;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ISONIAZID;ASTN2;C;rs117491755;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ALECTINIB;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTM1;;GSTM1 NON-NULL;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM1;;GSTM1 NULL;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*1/*4 + *4/*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
ETHANOL;CRHBP;TT;rs10055255;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEXUAL DYSFUNCTION IN MEN WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
OXALIPLATIN;HLA-DRB1;*12:01;HLA-DRB1*12:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*7;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*9;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*10;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFACLOR;HLA-DRB1;*14:54;HLA-DRB1*14:54;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*56:03;HLA-B*56:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*56:03;HLA-B*56:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;*1/*2;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;HEART RATE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;*1/*2;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;HEART RATE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHAMPHETAMINE;DAOA;C;rs778293;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANAPHYLAXIS NAN  NAN;;CAUTION_SIDE_EFFECT
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:ANGINA PECTORIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:ANGINA PECTORIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;GG;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;HYPOKALEMIA IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
RISPERIDONE;ADRB2;G;rs1042713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEXUAL ADVERSE EVENTS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
BECLOMETHASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BECLOMETHASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MOMETASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MOMETASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*1x2;CYP2A6*1;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*1/*1x2;CYP2A6*1X2;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;ABCB1;A;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;A;rs1128503;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
CAPECITABINE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:DRUG HYPERSENSITIVITY;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HYPERURICEMIA;;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN WOMEN WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN WOMEN WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
CODEINE;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;A;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS IN WOMEN WITH  DISEASE:PAIN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ELDERLY ADULT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CELSR2, PSRC1;T;rs602633;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;;CAUTION_DOSE_ADJUST
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
INDINAVIR;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
INDINAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;G;rs4149081;OTHER;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;G;rs4149081;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;EFFICACY;DECREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SCN1A;AA;rs10167228;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*5;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TROGLITAZONE;;C;rs10811661;EFFICACY;INCREASED;NAN;EFFICACY;BETA CELL FUNCTION IN PEOPLE WITH  OTHER:HIGH RISK FOR TYPE 2 DIABETES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;CC + CT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;OTHER;PLASMA LEVEL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*3;CYP2C19*1;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*3;CYP2C19*3;METABOLISM/PK;DECREASED;NAN;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;PICK1;T;rs713729;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
IMATINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
CAFFEINE;DRD2;GG;rs1110976;OTHER;DECREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
OPIOIDS;;AG + GG;rs4530637;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER;OTHER:OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;;C;rs1111875;METABOLISM/PK;DECREASED;NAN;PK;INSULIN SECRETION AT BASELINE IN PEOPLE WITH  OTHER:HIGH RISK OF TYPE 2 DIABETES;;CAUTION_DOSE_ADJUST
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*6;METABOLISM/PK;INCREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
OPIOIDS;TACR3;AG + GG;rs1384401;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;ABCC2;GG;rs2273697;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;T;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;PICK1;T;rs713729;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;RECURRENCE IN PEOPLE WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
OPIOIDS;DRD3;CC + CT;rs6280;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;;CC + CT;rs17137967;TOXICITY;INCREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*1;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*4;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*7;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*9;OTHER;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD3;AA + AG;rs324029;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;SEVERITY;DISEASE;BREAST TENDERNESS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:VAGINAL DRYNESS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZErs AND INTERMEDIATE METABOLIZErs;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;EXOC4;TT;rs718656;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs4646244;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs4646244;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;T;rs2072660;OTHER;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS;IFNL4;GG;rs11322783;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;rs3213239;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;rs3213239;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;GG;rs8099917;EFFICACY;NAN;NAN;EFFICACY;LACK OF TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;NAN;NAN;EFFICACY;LACK OF TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;GG;rs50872;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ABCG2;GG;rs1448784;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;HEPATITIS IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;A;rs2072661;OTHER;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*3;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP2C8;GG;rs10882526;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP2C8;GG;rs10882526;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;GG;rs660652;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;;T;rs1421292;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;ABO;GT + TT;rs495828;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;;CAUTION_DOSE_ADJUST
PLAIN;ABO;GT + TT;rs495828;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
GLICLAZIDE;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*1;EFFICACY;DECREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*2;EFFICACY;DECREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*17;EFFICACY;DECREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF804A;CC;rs7597593;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;NAN;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;AA;rs1051730;TOXICITY;INCREASED;SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;IL16;GT + TT;rs7170924;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
INDOMETHACIN;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN INFANTS WITH  OTHER:PATENT DUCTUS ARTERIOSUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDOMETHACIN;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN INFANTS WITH  OTHER:PATENT DUCTUS ARTERIOSUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA3;AA + AG;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER;NON-SMALL CELL LUNG CARCINOMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-B;*15:10;HLA-B*15:10;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;OTHER:STROKE;;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;A;rs1131882;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;A;rs1131882;EFFICACY;INCREASED;RISK;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;A;rs1131882;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;A;rs1131882;TOXICITY;INCREASED;RISK;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
OPIOIDS;CNR1;TT;rs2023239;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
NAN;NQO1;AA;rs1800566;OTHER;NAN;NAN;OTHER;SIGNIFICANTLY SHORTER SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*1;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*2;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*3;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
METFORMIN;SLC29A4;G;rs3889348;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
METFORMIN;SLC29A4;G;rs3889348;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;NQO1;A;rs1800566;TOXICITY;INCREASED;RISK;DISEASE;LEUKEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN WOMEN WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
OPIOIDS;CNR1;CC;rs6928499;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;CC + CG;rs58425034;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;DISEASE;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;NAN;DISEASE;DISEASE:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;CAUTION_SIDE_EFFECT
DOCETAXEL;CHST3;C;rs4148945;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;CHST3;C;rs4148945;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
"""FOLIC ACID""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""VITAMIN B-COMPLEX";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE;PAIN IN WOMEN WITH  DISEASE:MIGRAINE WITH AURA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
DOCETAXEL;SLC10A2;A;rs2301159;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;SLC10A2;A;rs2301159;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
AXITINIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CC + CT;rs1051266;EFFICACY;INCREASED;SEVERITY;DISEASE;RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;DBH;AA + AG;rs77905;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A;GG;rs2298383;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:HEMATOLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH ADP IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*2;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH ADP IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREMOR;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE RIGIDITY IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
NAN;CYP2B6;TT;rs3211371;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:RS1800497 GG GENOTYPES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2B6;CT;rs3211371;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:RS1800497 GG GENOTYPES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;PSYCHOMOTOR AGITATION;;CAUTION_SIDE_EFFECT
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;PSYCHOMOTOR AGITATION;;CAUTION_SIDE_EFFECT
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:INSOMNIA IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;G;rs4124874;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;CYP24A1;C;rs2762939;OTHER;DECREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;A;rs16969968;TOXICITY;INCREASED;SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE OUTCOME IN  OTHER:ORTHOPEDIC PATIENTS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE OUTCOME IN  OTHER:ORTHOPEDIC PATIENTS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE OUTCOME IN  OTHER:ORTHOPEDIC PATIENTS;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs739923;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs739923;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
CITALOPRAM;PAPLN;T;rs11628713;TOXICITY;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
SULFONAMIDES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFONAMIDES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;*1/*1xN;CYP2D6*1;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*1/*1xN;CYP2D6*1XN;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;TT;rs1867351;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIORBITAL EDEMA IN PEOPLE WITH  OTHER:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
VERAPAMIL;KCNIP1, KCNMB1;CT + TT;rs11739136;EFFICACY;NAN;NAN;EFFICACY;EARLIER ACHIEVEMENT OF BLOOD PRESSURE CONTROL IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
OPIOIDS;DRD3;AG + GG;rs9288993;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;CYP2C9;AC;rs1057910;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD3;AG + GG;rs2654754;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*53:01;HLA-B*53:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLIN G;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
APIXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
DABIGATRAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CAROTID STENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CAROTID STENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:CAROTID STENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;AMHR2;G;rs784892;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN SECRETORY CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*9;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*13;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY;SIDE EFFECT:UNSTABLE ANGINA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*2;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*4;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*17;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*8;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*8;CYP2C19*8;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;;CAUTION_SIDE_EFFECT
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;;CAUTION_SIDE_EFFECT
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;;CAUTION_SIDE_EFFECT
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;;CAUTION_SIDE_EFFECT
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;;CAUTION_SIDE_EFFECT
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;;CAUTION_SIDE_EFFECT
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THYROTOXICOSIS;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTHYROIDISM IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:UROLOGIC NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MELANOMA;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;RRM1;GG;rs9937;TOXICITY;NAN;RISK;DISEASE;HEMATOLOGIC DISORDER IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
GEMCITABINE;RRM1;GG;rs9937;TOXICITY;NAN;RISK;DISEASE;HEMATOLOGIC DISORDER IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;A;rs628031;TOXICITY;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;A;rs628031;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;A;rs628031;METABOLISM/PK;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;A;rs628031;METABOLISM/PK;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
OPIOIDS;GABRB3;AA;rs4906902;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*4;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*4;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*10;OTHER;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;NAN;PK;PLASMA NORTRIPTYLINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:EMERGENCIES IN CHILDREN WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;SLCO1B3;AA;rs7311358;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
SOFOSBUVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHANOL;DRD2;GG;rs1799732;TOXICITY;INCREASED;SEVERITY;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
SALBUTAMOL;THRB;A;rs892940;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (BDR) IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TACR1;AA;rs735668;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*1XN;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*2;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*3;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*4;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*5;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*6;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*7;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*9;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*35;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*41;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APIXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
DABIGATRAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
EDOXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
RIVAROXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1XN;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*3;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;DEATH;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:RECURRENCE IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;CC;rs510769;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
FIRST-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
FOURTH-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
OTHER CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
THIRD-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
"""METFORMIN""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICITY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*7;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*16;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
FIRST-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
FOURTH-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
OTHER CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
THIRD-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
FIRST-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
FOURTH-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
OTHER CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A13;CT;rs72552266;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*2;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*3;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CYSTITIS IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*3;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CYSTITIS IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CYSTITIS IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTT1;;GSTT1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BULLOUS PEMPHIGOID IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;CAUTION_SIDE_EFFECT
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:FEBRILE NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;TT;rs1870377;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28 + *6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28 + *6;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE;;CAUTION_SIDE_EFFECT
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE;;CAUTION_SIDE_EFFECT
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;GG;rs3768142;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*1;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3A;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*3C;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3A;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3A;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3C;TOXICITY;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*3C;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTT1;non-null;GSTT1 NON-NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEARING LOSS IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTT1;non-null;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEARING LOSS IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*5;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*6;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*7;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*16;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3A;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*3C;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*2;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*3;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG + GG;rs4646437;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY;HEART FAILURE;;CAUTION_SIDE_EFFECT
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:ANGINA PECTORIS IN PEOPLE WITH  OTHER:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
NAN;CYP4A11;AG + GG;rs1126742;METABOLISM/PK;DECREASED;NAN;PK;HDL-C CONCENTRATION IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*1X2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*2X2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*2XN;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*4;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*9;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*10;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*41;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*41X2;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
PEMETREXED;SLC19A1;TT;rs914232;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMETREXED;SLC19A1;TT;rs914232;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;DPYD;c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1;METABOLISM/PK;INCREASED;NAN;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*2;METABOLISM/PK;INCREASED;NAN;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*3;METABOLISM/PK;INCREASED;NAN;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PEMETREXED;SLC19A1;AA + AG;rs1051298;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMETREXED;SLC19A1;AA + AG;rs1051298;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEADACHE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE SPASM;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEADACHE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE SPASM;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEADACHE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCLE SPASM;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SOMNOLENCE;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
AMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
BACAMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DRD3;CC + CT;rs6280;TOXICITY;INCREASED;RISK;SIDE EFFECT;COGNITIVE DISORDER IN MEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;OTHER;DECREASED;RISK;DISEASE;LUNG NEOPLASMS IN MEN WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ACTN1;T;rs2268979;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;UPB1;GG;rs2070474;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMETREXED;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMETREXED;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STOMATITIS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;PAPPA;A;rs12235805;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;UPB1;GG;rs2070474;TOXICITY;DECREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;DECREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PEMETREXED;SLC19A1;GG + GT;rs3788189;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMETREXED;SLC19A1;GG + GT;rs3788189;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);C.1236G>A (HAPB3);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1679T>G (*13);TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;TOTAL CHOLESTEROL IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*6;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*1;UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
VINCRISTINE;NRG3;T;rs12253008;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*6;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*28;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;;TPMT INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;LRRTM3;G;rs10997459;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3A;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*3C;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
VINCRISTINE;ARHGAP5;G;rs8006511;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;;TPMT NORMAL METABOLIZER;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;TPMT;;TPMT NORMAL METABOLIZER;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;CC;rs28399433;TOXICITY;DECREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;METTL8;G;rs79802223;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DEATH;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL INFARCTION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;CT;rs4148325;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA IN INFANTS  NAN;;CAUTION_DOSE_ADJUST
NAN;UGT1A1;G;rs11888492;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA IN INFANTS  NAN;;CAUTION_DOSE_ADJUST
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;CORTISOL RESPONSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CERS6;T;rs13022792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;TLR4;C;rs10759932;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NFIB;G;rs10961381;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIARRHYTHMICS;;GT + TT;rs10033464;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLASS I AND III;;GT + TT;rs10033464;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MCM3AP;T;rs1815857;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;SPDYA;T;rs12474420;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;PDE4D;C;rs12658429;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;FBN2;T;rs12656510;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;VTI1A;T;rs17129858;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ZFAND3;C;rs200858088;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANAPHYLAXIS NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANAPHYLAXIS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1;TOXICITY;INCREASED;RISK;EFFICACY;PERIPHERAL VASCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;EFFICACY;PERIPHERAL VASCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;VIRUS DISEASES IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;CONSTIPATION IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASBURICASE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  OTHER:HYPERURICEMIA;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SIROLIMUS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDES IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ATRIAL FIBRILLATION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SURGERY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ATRIAL FIBRILLATION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SURGERY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ATRIAL FIBRILLATION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SURGERY;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ADALIMUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
AMIODARONE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
BICALUTAMIDE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
DOCETAXEL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ERLOTINIB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
EVEROLIMUS;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
GEFITINIB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
GEMCITABINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
LEUCOVORIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
OXALIPLATIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PACLITAXEL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
SITAGLIPTIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTERSTITIAL LUNG DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INTERSTITIAL LUNG DISEASES IN MEN  NAN;;CAUTION_SIDE_EFFECT
ANASTROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:ERYTHEMA MULTIFORME IN PEOPLE WITH  DISEASE:HYPERURICEMIA;;CAUTION_SIDE_EFFECT
PEMETREXED;DHFR;AA + AG;rs1650697;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PEMETREXED;DHFR;AA + AG;rs1650697;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*1;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*3;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*6;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*7;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C8;*1/*1;CYP2C8*1;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C8;*1/*1;CYP2C8*3;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIZZINESS;;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;GG;rs12042763;EFFICACY;DECREASED;RISK;DISEASE;PROSTATIC NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*15;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*15;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*15;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;G;rs56267346;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DBH;C;rs6479643;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
FLURBIPROFEN;UGT1A1;*1/*36;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLURBIPROFEN;UGT1A1;*1/*36;UGT1A1*36;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*36;UGT1A1*1;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*36;UGT1A1*36;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;CASP9;T;rs1052576;EFFICACY;INCREASED;SEVERITY;EFFICACY;LEUKOCYTOSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ATIC;CC;rs17514110;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;CC;rs17514110;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NFATC2;TT;rs3787186;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;NFATC2;TT;rs3787186;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CETUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ABCC1;AA;rs8058040;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;AA;rs8058040;EFFICACY;INCREASED;RISK;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;TPH2;GG;rs7305115;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;TPH2;GG;rs7305115;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;TPH2;GG;rs1386493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;TPH2;GG;rs1386493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN MEN WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;TT;rs2612091;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GI INTOLERANCE IN CHILDREN WITH  DISEASE:ORGAN TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GI INTOLERANCE IN CHILDREN WITH  DISEASE:ORGAN TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ERLOTINIB;USP36;CC;rs3744797;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;USP36;CC;rs3744797;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;HLA-B;*51:02;HLA-B*51:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STEVENS-JOHNSON SYNDROME;;CAUTION_SIDE_EFFECT
OSIMERTINIB;HLA-B;*51:02;HLA-B*51:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC EPIDERMAL NECROLYSIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CACNB2;CT;rs10764319;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CACNB2;CT;rs10764319;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CACNA2D2;AA;rs2236957;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CACNA2D2;AA;rs2236957;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;UGT2B10;AA;rs1841042;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;UGT2B10;AA;rs1841042;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2B;AA + CC;rs3813662;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ADRA2B;AA + CC;rs3813662;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;CES1;T;rs2307227;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;NUDT15;*1/*3;NUDT15*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;NUDT15;*1/*3;NUDT15*3;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;THSD7A;G;rs7807369;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;;C;rs1149515;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;;C;rs1149515;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ERAP2;TT;rs17524572;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  ""OTHER:ADENOCARCINOMA""";;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"""OTHER:NON-SMALL CELL LUNG CARCINOMA""";;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"""OTHER:CARCINOMA";;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"SQUAMOUS CELL""";;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;"""OTHER:NEUROENDOCRINE CARCINOMA""";;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"PNEUMONITIS IN PEOPLE WITH  ""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-SMALL CELL LUNG CARCINOMA""";;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEUROENDOCRINE CARCINOMA""";;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs1801158;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs1801158;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
MORPHINE;SLC22A1;del/del;rs72552763;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPOVENTILATION IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NON-NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;CASP9;C;rs4661636;EFFICACY;INCREASED;SEVERITY;EFFICACY;LEUKOCYTOSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;CASP8;G;rs6736233;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEPR;AG + GG;rs6657868;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;AG + GG;rs6657868;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CISPLATIN;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;A;rs4148323;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;A;rs4148323;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEPR, LEPROT;AA;rs1137101;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR, LEPROT;AA;rs1137101;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
DOLUTEGRAVIR;NR1I2;CT + TT;rs2472677;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;NR1I2;CT + TT;rs2472677;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;GG;rs1805096;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;GG;rs1805096;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;AC + CC;rs9436746;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;AC + CC;rs9436746;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;A;rs35350960;OTHER;INCREASED;LIKELIHOOD;OTHER;GILBERT SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;A;rs35350960;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:CRIGLER-NAJJAR SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;ASPH;T;rs4379440;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
TICAGRELOR;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;CETP;A;rs3764261;EFFICACY;INCREASED;NAN;OTHER;HDL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;CETP;A;rs3764261;METABOLISM/PK;INCREASED;NAN;OTHER;HDL CHOLESTEROL NAN  NAN;;CAUTION_DOSE_ADJUST
PYRIMIDINE ANALOGUES;MTHFR;AA + AC;rs1801133;NAN;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
METHOTREXATE;ITPA;A;rs1127354;TOXICITY;NAN;NAN;SIDE EFFECT;GASTROINTESTINAL TOXICITIES IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;CTLA4;A;rs231775;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;CTLA4;A;rs231775;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;CTLA4;A;rs231775;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;;T;rs4410790;OTHER;NAN;NAN;OTHER;HABITUAL CONSUMPTION NAN  NAN;;CAUTION_DOSE_ADJUST
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"WEIGHT LOSS IN PEOPLE WITH  ""OTHER:DIABETES MELLITUS";;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"TYPE 2""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"""OTHER:OBESITY""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ESR1;CC;rs2234693;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER IN MEN  NAN;;CAUTION_SIDE_EFFECT
NAN;ABCG8;CG;rs11887534;OTHER;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;ERCC5;GG;rs17655;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2C;T;rs3813929;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;FGD4;A;rs10771973;TOXICITY;INCREASED;RISK;SIDE EFFECT;SENSORY PERIPHERAL NEUROPATHY IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A1;T;rs2470893;OTHER;NAN;NAN;OTHER;HABITUAL CONSUMPTION NAN  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;SLC6A4;C;rs25531;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEMENTIA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;POR;TT;rs1057868;OTHER;INCREASED;NAN;PK;METABOLIC RATIO OF MIDAZOLAM NAN  NAN;;CAUTION_DOSE_ADJUST
MIDAZOLAM;POR;TT;rs1057868;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO OF MIDAZOLAM NAN  NAN;;CAUTION_DOSE_ADJUST
ENALAPRIL;PNPT1;G;rs13009649;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ITPA;A;rs1127354;EFFICACY;NAN;NAN;EFFICACY;RESPONSE TO METHOTREXATE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
NICOTINE;HTR3B;CT + TT;rs11606194;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;SLC6A12;A;rs499368;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
GEFITINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;GG;rs2189784;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;SLC6A12;G;rs557881;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;WIF1;GG + GT;rs10878232;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;AG;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;WNT5B;AG + GG;rs12819505;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;AXIN2;AA + AC;rs4541111;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;NAN;SIDE EFFECT;GI TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;CC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CXXC4;AA + AG;rs4413407;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;PNPT1;C;rs13015243;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
THIOGUANINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;GG;rs13181;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PNEUMONITIS IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PNEUMONITIS IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AMPHETAMINE;DRD2;AA;rs12364283;EFFICACY;DECREASED;NAN;OTHER;STOP REACTION TIME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG-RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG-RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATIONS DUE TO ADVERSE EVENTS AND GREATER SEVERITY OF SIDE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CD80;AA;rs34394661;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;UGT1A9;A;rs6714486;METABOLISM/PK;NAN;NAN;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;;TT;rs1633021;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;AXIN2;CC + CG;rs11868547;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs17868320;METABOLISM/PK;NAN;NAN;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY) IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;IL10;AA;rs1800871;METABOLISM/PK;INCREASED;LIKELIHOOD;PK;ACHIEVING TARGET CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHOTREXATE;ARID5B;CC + CT;rs4948496;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;CYP2B6;AA;rs3760657;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLLITROPIN BETA;FSHR;T;rs6166;EFFICACY;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;;CAUTION_DOSE_ADJUST
FOLLITROPIN BETA;FSHR;T;rs6166;METABOLISM/PK;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;;CAUTION_DOSE_ADJUST
THYROTROPIN ALFA;FSHR;T;rs6166;EFFICACY;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;;CAUTION_DOSE_ADJUST
THYROTROPIN ALFA;FSHR;T;rs6166;METABOLISM/PK;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;;CAUTION_DOSE_ADJUST
UROFOLLITROPIN;FSHR;T;rs6166;EFFICACY;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;;CAUTION_DOSE_ADJUST
UROFOLLITROPIN;FSHR;T;rs6166;METABOLISM/PK;NAN;NAN;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;AA + AG;rs4244285;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
NAN;UGT2B10;CC;rs11726322;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;CT + TT;rs12248560;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TYMP;AA + AG;rs11479;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMP;AA + AG;rs11479;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;NAN;PK;PLASMA MK-4 CONCENTRATION IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CG;rs75017182;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CG;rs75017182;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;PPARA;TT;rs135543;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN FASTING LDL-C NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;PPARA;CC + CT;rs9626730;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN FASTING IL-2 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;DECREASED;NAN;OTHER;WARFARIN SENSITIVITY INDEX (INR/CPSS) IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
NAN;VDR;CC;rs1544410;NAN;DECREASED;NAN;EFFICACY;BONE MINERAL DENSITY IN PEOPLE WITH  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;DEATH NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
FENOFIBRATE;PPARA;TT;rs135550;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN FASTING LDL-C NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED;NAN;EFFICACY;URINARY DPD/CR LEVELS IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EXEMESTANE;CYP19A1;TT;rs7176005;TOXICITY;NAN;NAN;SIDE EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
TACROLIMUS;PPARA;GG;rs4253728;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;SLC5A7;AG + GG;rs1013940;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;ADH1B;T;rs1229984;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERURICEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
VINCRISTINE;NKAIN3;A;rs10504361;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ATENOLOL;PROX1;C;rs340874;TOXICITY;INCREASED;NAN;SIDE EFFECT;GLUCOSE ELEVATION IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEPSIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEIZURES;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ABEMACICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PALBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
RIBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCC1;T;rs3784867;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;SIGNIFICANTLY HIGHER ON-TREATMENT PLATELET REACTIVITY WITH A MAINTENANCE DOSE OF 75 MG DAILY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABEMACICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
ABEMACICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PALBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
PALBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
RIBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
RIBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;GG;rs1065852;EFFICACY;DECREASED;NAN;EFFICACY;HEART RATE IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CONJUGATED ESTROGENS;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;OTHER;SPINE BONE MINERAL DENSITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEDROXYPROGESTERONE;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;OTHER;SPINE BONE MINERAL DENSITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;CACNB2;GG;rs2357928;EFFICACY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VERAPAMIL;CACNB2;GG;rs2357928;TOXICITY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE TO METFORMIN IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE TO METFORMIN IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAZODONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PROLONGED QTC INTERVAL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
INTERFERONS;BCL2;T;rs1800477;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;BCL2;T;rs1800477;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;NR1I2;GG;rs7643645;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:FATTY LIVER DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;CCND1;AA;rs9344;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;CCND1;AA;rs9344;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
VERAPAMIL;CACNB2;AT + TT;rs11014166;EFFICACY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VERAPAMIL;CACNB2;AT + TT;rs11014166;TOXICITY;INCREASED;RISK;EFFICACY;ADVERSE OUTCOME IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;;AA;rs2960436;EFFICACY;NAN;NAN;OTHER;BETTER SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;IGFBP3;TT;rs2854744;EFFICACY;NAN;NAN;OTHER;BETTER SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;C;rs1125394;TOXICITY;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;A;rs4149015;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs4646453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;CC;rs4633;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN WOMEN WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CONSTIPATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
NAN;VDR;AA + AG;rs2228570;NAN;DECREASED;NAN;EFFICACY;BONE MINERAL DENSITY NAN  NAN;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;CT;rs4633;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
CAPECITABINE;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;CC;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERECTILE DYSFUNCTION;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:INSOMNIA;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:SEDATION;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;NAN;NAN;OTHER;WARFARIN VARIABILITY NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;NAN;NAN;OTHER;WARFARIN VARIABILITY NAN  NAN;;CAUTION_DOSE_ADJUST
SUNITINIB;NR1I2;TT;rs3814055;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMPHETAMINE;OPRM1;TT;rs510769;OTHER;DECREASED;NAN;OTHER;STIMULATION AND EUPHORIA SCORES AFTER AMPHETAMINE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;CT;rs2231137;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;LRP5;T;rs3736228;NAN;DECREASED;NAN;OTHER;BONE MINERAL DENSITY NAN  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;NHLH1;CT + TT;rs11265375;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;NHLH1;CT + TT;rs11265375;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;A;rs4355801;NAN;DECREASED;NAN;OTHER;LUMBAR SPINE BONE MINERAL DENSITY NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;;A;rs4355801;NAN;INCREASED;RISK;DISEASE;OSTEOPOROSIS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;LRP5;T;rs3736228;NAN;INCREASED;RISK;DISEASE;OSTEOPOROSIS NAN  NAN;;CAUTION_SIDE_EFFECT
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;CAUTION_SIDE_EFFECT
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN;;CAUTION_SIDE_EFFECT
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUROPATHIC PAIN IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
NAN;UGT2B15;AA;rs3100;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE;OPRM1;CC;rs2281617;OTHER;INCREASED;NAN;OTHER;EUPHORIC AND ENERGETIC AFTER AMPHETAMINE (10 MG) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;HNF4A;CC;rs6130615;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;SEMA6A;A;rs3806915;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;SEMA6A;A;rs3806915;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
ASPIRIN;ABCB1;AA;rs1045642;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;OTHER;INCREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
WARFARIN;HNF4A;GG;rs1884613;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGB3;CC + CT;rs5918;EFFICACY;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGB3;CC + CT;rs5918;OTHER;DECREASED;RISK;DISEASE;THROMBOTIC DISEASE IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;HNF4A;TT;rs3212191;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ONDANSETRON;SLC6A4;AA;rs1042173;EFFICACY;INCREASED;NAN;EFFICACY;TREATMENT RESPONSE AMONG PATIENTS CARRYING THE SLC6A4 PROMOTER LENGTH POLYMORPHISM LONG/LONG GENOTYPE IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;G;rs61162043;OTHER;INCREASED;LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2A;GG;rs6313;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;G;rs2075572;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;;TT;rs1805054;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;NEDD4L;AA;rs4149601;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADRB1;GG;rs1801252;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;CT + TT;rs3813929;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
BLEOMYCIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
BLEOMYCIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
PREDNISONE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
PREDNISONE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
RITUXIMAB;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
RITUXIMAB;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
VINDESINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
VINDESINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:LUPUS ERYTHEMATOSUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;CC;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;;CAUTION_SIDE_EFFECT
METHADONE;OPRM1;G;rs1799971;OTHER;DECREASED;LIKELIHOOD;DISEASE;RECURRENCE IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2C9;C;rs1057910;NAN;DECREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2C9;C;rs1057910;NAN;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
SUFENTANIL;CYP3A4;TT;rs2242480;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPOVENTILATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
SUFENTANIL;CYP3A4;TT;rs2242480;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
NAN;ADRA2A;A;rs3750625;OTHER;INCREASED;LIKELIHOOD;DISEASE;DIABETES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADRA2A;A;rs3750625;OTHER;INCREASED;LIKELIHOOD;DISEASE;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADRA2A;G;rs11195418;OTHER;DECREASED;LIKELIHOOD;DISEASE;DIABETES;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ADRA2A;G;rs11195418;OTHER;DECREASED;LIKELIHOOD;DISEASE;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MURAGLITAZAR;REN;TT;rs2368564;TOXICITY;DECREASED;RISK;DISEASE;EDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED;SEVERITY;EFFICACY;PARASITEMIA IN PEOPLE WITH  DISEASE:MALARIA;;CAUTION_SIDE_EFFECT
PRIMAQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED;SEVERITY;EFFICACY;PARASITEMIA IN PEOPLE WITH  DISEASE:MALARIA;;CAUTION_SIDE_EFFECT
ASPIRIN;IL4;TT;rs2243250;OTHER;DECREASED;NAN;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;AC + CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO METHOTREXATE IN CHILDREN WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METFORMIN;AMHR2;G;rs784892;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;AMHR2;G;rs784892;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
DICLOFENAC;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
PROPIONIC ACID DERIVATIVES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
PYRAZOLONES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO FIRST THERAPEUTIC INR AND TIME TO FIRST INR>4 IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYCSP5;A;rs3099844;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYCSP5;A;rs3099844;OTHER;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:ACQUIRED IMMUNODEFICIENCY SYNDROME;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
DICLOFENAC;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PROPIONIC ACID DERIVATIVES;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PYRAZOLONES;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
ASPIRIN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
DICLOFENAC;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
DICLOFENAC;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
PROPIONIC ACID DERIVATIVES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
PROPIONIC ACID DERIVATIVES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
PYRAZOLONES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA;;CAUTION_SIDE_EFFECT
PYRAZOLONES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIHYPERTENSIVES;NOS3;G;rs1799983;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:PRE-ECLAMPSIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;NOS3;C;rs2070744;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:PRE-ECLAMPSIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
NAN;ADRA2A;A;rs1800038;OTHER;INCREASED;LIKELIHOOD;DISEASE;DIABETES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADRA2A;A;rs1800038;OTHER;INCREASED;LIKELIHOOD;DISEASE;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CISPLATIN;SLC22A1;CG + GG;rs683369;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;;G;rs4887074;TOXICITY;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CC;rs854552;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;PPARD;AG + GG;rs2038067;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs6977165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:LUPUS ERYTHEMATOSUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;PROPERTION OF THE FIRST 6 MONTHS' TREATMENT TIME SPENT WITHIN THE TARGET INR RANGE (PTIR) IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;G;rs17376848;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / TRAMADOL;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GSK3B;AA;rs334558;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:BIPOLAR DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / TRAMADOL;MIR23B;GG;rs1011784;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;MIR23B;GG;rs1011784;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NEUROPATHIC PAIN IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / TRAMADOL;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CYP1A2;AA + AG;rs2069514;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD3;AA + AG;rs2654754;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;DRD3;AG + GG;rs324029;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;FAAH;A;rs324420;TOXICITY;INCREASED;RISK;SIDE EFFECT;METHAMPHETAMINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;UGT1A6;AC + CC;rs1105879;EFFICACY;INCREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CONSTIPATION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;AA + AG;rs15524;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
REGORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;NR1I3;CC;rs11584174;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;G;rs8330;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;G;rs8330;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs28399499;TOXICITY;INCREASED;RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCB1;TT;rs10276036;TOXICITY;INCREASED;RISK;DISEASE;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;AA;rs7438284;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;TT;rs7439366;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED;RISK;SIDE EFFECT;NEPHROLITHIASIS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;AA;rs7662029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;UGT2B7;TT;rs7668258;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER IN MEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GRM3;TT;rs1468412;TOXICITY;INCREASED;RISK;SIDE EFFECT;MEMORY IMPAIRMENT IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;NON-RESPONSIVENESS IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
RISPERIDONE;BDNF;TT;rs6265;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;FCER2;G;rs28364072;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHMA-RELATED ER VISIT OR HOSPITALIZATION IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CXCL8;AA;rs4073;EFFICACY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;CXCL8;AA;rs4073;EFFICACY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;KDR;AA;rs1870377;TOXICITY;NAN;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
RADIOTHERAPY;KDR;AA;rs1870377;TOXICITY;NAN;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IL6;CC;rs1800795;TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IL6;CC;rs1800795;TOXICITY;DECREASED;RISK;DISEASE;DEPRESSION IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED;NAN;EFFICACY;MEAN PERCENTAGE REDUCTION OF TRIGLYCERIDES LEVEL IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANGRELOR;P2RY12;G;rs6787801;OTHER;NAN;NAN;OTHER;5% LOWER ADP-INDUCED PEAK PLATELET AGGREGATION IN-VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;APOC1, APOE;A;rs445925;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;;CAUTION_DOSE_ADJUST
SUNITINIB;FGFR2;AA;rs2981582;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE REACTIONS IN CHILDREN WITH  DISEASE:PNEUMONIA;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;CC + CT;rs307826;EFFICACY;DECREASED;NAN;DISEASE;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NR1I3;AA + AG;rs2307424;EFFICACY;DECREASED;NAN;DISEASE;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;FADS1, FEN1, MIR611, TMEM258;T;rs174541;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;;CAUTION_DOSE_ADJUST
NAN;;C;rs258494;METABOLISM/PK;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;;CAUTION_DOSE_ADJUST
NAN;LDLR;T;rs6511720;OTHER;NAN;NAN;PK;BASELINE LDL CHOLESTEROL IN PEOPLE WITH  DISEASE:VASCULAR DISEASES;;CAUTION_DOSE_ADJUST
NAN;PNMT;T;rs2934965;OTHER;DECREASED;RISK;OTHER;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  OTHER:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;PNMT;T;rs2934965;OTHER;DECREASED;RISK;OTHER;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVAMISOLE;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;GSTP1;GG;rs1695;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;DDRGK1, ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;PNMT;GG;rs2941523;OTHER;DECREASED;RISK;OTHER;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  OTHER:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;PNMT;GG;rs2941523;OTHER;DECREASED;RISK;OTHER;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED;RISK;OTHER;CHRONIC LUNG ALLOGRAFT DYSFUNCTION IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;CAUTION_SIDE_EFFECT
NAN;PNMT;AA + AG;rs876493;OTHER;DECREASED;RISK;OTHER;SICKLE CELL PAIN CRISIS IN WOMEN WITH  OTHER:ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;PNMT;AA + AG;rs876493;OTHER;DECREASED;RISK;OTHER;SICKLE CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED SYSTOLIC BLOOD PRESSURE IN MEN WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISOPROLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISOPROLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED SYSTOLIC BLOOD PRESSURE IN MEN WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;KIRREL2, NPHS1;T;rs3814995;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ADORA1;TT;rs16851030;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;FPGS;TT;rs1544105;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NR1I3;AA;rs4073054;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT4;AA + AC;rs307821;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALPRAZOLAM;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ALPRAZOLAM;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;INCREASED;RISK;OTHER;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP1A1;T;rs2472297;METABOLISM/PK;NAN;NAN;PK;25% HIGHER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED;RISK;OTHER;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ADGRV1;C;rs2366929;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS IN MEN  NAN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;MGAT4A;G;rs885036;EFFICACY;DECREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MGAT4A;G;rs885036;EFFICACY;DECREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;DECREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;FMO3;AA;rs1736557;EFFICACY;DECREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  EFFICACY:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;DECREASED;LIKELIHOOD;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LUNG TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;G;rs2644592;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PEAR1;G;rs2644592;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;PEAR1;C;rs11264580;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PEAR1;C;rs11264580;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
BUPROPION;APOE;CC + CT;rs429358;OTHER;INCREASED;LIKELIHOOD;DISEASE;RECURRENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;APOE;CC + CT;rs429358;OTHER;INCREASED;LIKELIHOOD;DISEASE;RECURRENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PEAR1;TT;rs57731889;EFFICACY;NAN;NAN;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PEAR1;TT;rs57731889;EFFICACY;NAN;NAN;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
ALENDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBANDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZOLEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;GSTM5;C;rs3754446;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;AT + TT;rs449647;EFFICACY;INCREASED;NAN;EFFICACY;LIPID-LOWERING EFFECT IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEZAFIBRATE;APOE;AT + TT;rs449647;EFFICACY;INCREASED;NAN;EFFICACY;LIPID-LOWERING EFFECT IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;SLC6A5;AA;rs2298826;TOXICITY;NAN;NAN;SIDE EFFECT;MOTOR SIDE EFFECTS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
OLANZAPINE;AHR;T;rs4410790;METABOLISM/PK;NAN;NAN;PK;29% LOWER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;T;rs3737224;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PEAR1;T;rs3737224;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;SEVERITY;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;del;rs5030655;METABOLISM/PK;NAN;NAN;PK;IMPAIRED METABOLIC ACTIVITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EPISTAXIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL HEMORRHAGE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEMATURIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOTIC DISEASE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;CASP3;C;rs2720376;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CASP3;C;rs2720376;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA IN MEN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA IN MEN  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs59502379;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;C;rs1265112;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CISPLATIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GLI1;CC;rs2228226;EFFICACY;DECREASED;NAN;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREMOR IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;NAN;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;ACKR1;CC;rs2814778;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;;A;rs2069521;TOXICITY;INCREASED;NAN;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;NAN;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;;A;rs2069521;TOXICITY;INCREASED;NAN;SIDE EFFECT;NAUSEA/VOMITING IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;NAN;SIDE EFFECT;NAUSEA/VOMITING IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;NAN;SIDE EFFECT;NAUSEA/VOMITING IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;EFFICACY;DECREASED;NAN;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CIGARETTE SMOKERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;METABOLISM/PK;DECREASED;NAN;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CIGARETTE SMOKERS;;CAUTION_DOSE_ADJUST
ETHANOL;OPRK1;CC + CT;rs6473797;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ALCOHOL ABUSE IN MEN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NQO1;A;rs1800566;EFFICACY;NAN;NAN;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
DOXORUBICIN;NQO1;A;rs1800566;EFFICACY;NAN;NAN;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
HEROIN;GRM3;T;rs274618;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
THIAZOLIDINEDIONES;AQP2;T;rs296766;TOXICITY;INCREASED;RISK;DISEASE;EDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
THIAZOLIDINEDIONES;AQP2;T;rs296766;TOXICITY;INCREASED;RISK;DISEASE;TYPE 2;;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA3;G;rs578776;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CHRNA3;G;rs578776;OTHER;DECREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ABCC5;G;rs939338;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCC5;G;rs939338;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;FASLG;T;rs763110;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;FASLG;T;rs763110;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;MSH2;C;rs4638843;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;MSH2;C;rs4638843;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;C;rs3087879;EFFICACY;INCREASED;SEVERITY;EFFICACY;PHARMACOLOGICAL RESISTANCE IN PEOPLE WITH  DISEASE:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
COCAINE;CHRNA5;G;rs684513;OTHER;INCREASED;LIKELIHOOD;DISEASE;COCAINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;AG + GG;rs2734583;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;AG + GG;rs2734583;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;AA + AG;rs9263726;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;AA + AG;rs9263726;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
FEXOFENADINE;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;NAN;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;SLC28A3;AA;rs17343066;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION (P<0.001) IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CLOZAPINE;TRAT1;C;rs116982346;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PANCYTOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2A6;AC + CC;rs8192726;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION (P=0.028) IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ADH1B;A;rs1789891;OTHER;INCREASED;NAN;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;DCTD;AA;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;UGT2B7;CC + CT;rs7439366;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PANCYTOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;TRAC;A;rs377360;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;G;rs746647;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NAN;FGFBP1;CC;rs2245964;OTHER;INCREASED;NAN;OTHER;BONE MINERAL DENSITY NAN  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;DISEASE:GASTROINTESTINAL HEMORRHAGE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
NAN;FGFBP1;TT;rs16892645;OTHER;INCREASED;NAN;OTHER;BONE MINERAL DENSITY NAN  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN LDL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;G;rs2824292;OTHER;INCREASED;RISK;DISEASE;VENTRICULAR FIBRILLATION IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
NEVIRAPINE;;G;rs6545803;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEVIRAPINE-INDUCED RASH IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NICOTINE;FMO1;C;rs10912675;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;POLR3G;T;rs2562519;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NICOTINE;FMO1;T;rs7877;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ASPARAGINASE;GRIA1;T;rs4958381;TOXICITY;INCREASED;RISK;NANDISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;PEOPLE;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP17A1;AG + GG;rs743572;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;DISEASE:GASTROINTESTINAL HEMORRHAGE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:OSTEOPOROSIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES2;CG + GG;rs11075646;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANALGESICS AND ANESTHETICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIBIOTICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIEPILEPTICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIFUNGALS FOR SYSTEMIC USE""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"NON-STEROIDS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIMYCOBACTERIALS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTITHYROID PREPARATIONS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED;LIKELIHOOD;OTHER;SHORT AND LONG-TERM WEIGHT LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOTANE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;NAN;NAN;PK;BEING A PREDICTOR OF MITOTANE PLASMA CONCENTRATIONS OF AT LEAST 14 ΜG/ML AFTER 3 MONTHS OF TREATMENT IN PEOPLE WITH  DISEASE:ADRENOCORTICAL CARCINOMA;;CAUTION_DOSE_ADJUST
BORTEZOMIB;CTLA4;GG;rs4553808;TOXICITY;NAN;NAN;SIDE EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_DOSE_ADJUST
MELPHALAN;CTLA4;GG;rs4553808;TOXICITY;NAN;NAN;SIDE EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_DOSE_ADJUST
PREDNISONE;CTLA4;GG;rs4553808;TOXICITY;NAN;NAN;SIDE EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PBMC-ASSOCIATED DRUG CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NAN;CRHR1;TT;rs1876828;METABOLISM/PK;DECREASED;NAN;PK;BASELINE CORTISOL LEVELS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;NAN;PK;INTRACELLULAR PBMC EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;INTRACELLULAR PBMC EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
VALPROIC ACID;SOD2;AG + GG;rs4880;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;AA;rs1045642;OTHER;INCREASED;LIKELIHOOD;OTHER;HELICOBACTER PYLORI INFECTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;OTHER;ADP-STIMULATED PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;AG + GG;rs10916825;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCB1;CC + CT;rs4148737;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;MINIMUM PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;DECREASED;RISK;EFFICACY;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;TT;rs887829;EFFICACY;DECREASED;RISK;DISEASE;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;AA + AG;rs12943590;METABOLISM/PK;INCREASED;NAN;PK;RENAL AND SECRETORY CLEARANCE OF METFORMIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE TO METFORMIN IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;ORAL CLEARANCE OF ATORVASTATIN IN PEOPLE WITH  DISEASE:OBESITY;;CAUTION_DOSE_ADJUST
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DEFERASIROX;CYP1A2;AA;rs762551;EFFICACY;DECREASED;RISK;EFFICACY;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;CYP1A1;CC;rs2606345;EFFICACY;DECREASED;RISK;EFFICACY;IRON OVERLOAD IN CHILDREN WITH  OTHER:BETA-THALASSEMIA AND RELATED DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;GRM3;C;rs274622;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;CC + CT;rs3842;METABOLISM/PK;INCREASED;NAN;PK;ACCUMULATION OF DRUG IN PBMCS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ETHANOL;CHRNA4;G;rs1044394;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;AG;rs1799963;TOXICITY;INCREASED;RISK;DISEASE;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;ENPP2;AA;rs2249015;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;DISEASE;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ADORA1;GG + GT;rs2228079;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG + GT;rs1801131;TOXICITY;DECREASED;RISK;SIDE EFFECT;SKIN DISORDER IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AG + GG;rs1801394;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PROPRANOLOL;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER PLASMA CONCENTRATION OF PROPRANOLOL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;T;rs6668296;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs6668296;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CT + TT;rs7412;OTHER;INCREASED;NAN;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
NAN;APOE;CT + TT;rs7412;OTHER;INCREASED;NAN;OTHER;OTHER:HYPERTENSION;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;C;rs115349832;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;C;rs115349832;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED;LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CC + CT;rs429358;OTHER;INCREASED;NAN;OTHER;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  OTHER:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
NAN;APOE;CC + CT;rs429358;OTHER;INCREASED;NAN;OTHER;OTHER:HYPERTENSION;;CAUTION_DOSE_ADJUST
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;APOE;C;rs429358;EFFICACY;INCREASED;RISK;OTHER;MORTALITY AFTER MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
SIMVASTATIN;APOE;C;rs429358;EFFICACY;INCREASED;RISK;OTHER;HOWEVER THIS CAN BE ELIMINATED NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
HALOPERIDOL;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ILOPERIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;SOD2;TT;rs5746136;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;ENPP2;A;rs7832704;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TOLCAPONE;;GG;rs4680;EFFICACY;INCREASED;NAN;EFFICACY;REACTION TIME IN  OTHER:ABSTINENT SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLASETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED;RISK;SIDE EFFECT;QTC PROLONGATION IN PEOPLE WITH  OTHER:SURGERY AS PART OF ANESTHETIC MANAGEMENT;;CAUTION_SIDE_EFFECT
GRANISETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED;RISK;SIDE EFFECT;QTC PROLONGATION IN PEOPLE WITH  OTHER:SURGERY AS PART OF ANESTHETIC MANAGEMENT;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;A;rs2032582;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;T;rs56276561;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs56276561;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOZAPINE;ELAVL2;A;rs73482673;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;MID-DOSE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;G;rs4149118;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
TOLCAPONE;COMT;AG;rs4680;EFFICACY;DECREASED;NAN;EFFICACY;REACTION TIME IN  OTHER:ABSTINENT SMOKERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
HEROIN;SOD2;AC + CC;rs2758339;TOXICITY;DECREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;G;rs11045585;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;A;rs7311358;METABOLISM/PK;INCREASED;NAN;PK;AUC IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_DOSE_ADJUST
IRINOTECAN;TOP1;GG;rs6072262;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOB;G;rs679899;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;GG;rs712829;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCG2;CC;rs2622604;OTHER;DECREASED;NAN;PK;MEAN AUC NAN  NAN;;CAUTION_DOSE_ADJUST
ERLOTINIB;ABCG2;CC;rs2622604;METABOLISM/PK;DECREASED;NAN;PK;MEAN AUC NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;APOB;G;rs1367117;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN PAIN IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN PAIN IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;;CAUTION_DOSE_ADJUST
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;NAN;NAN;SIDE EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;CYB5A;AA + AG;rs1790834;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS IN WOMEN WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;DISEASE;STROKE IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CETUXIMAB;KRAS;C;rs61764370;EFFICACY;NAN;NAN;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
PANITUMUMAB;KRAS;C;rs61764370;EFFICACY;NAN;NAN;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
EDOXABAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
BLEOMYCIN;BLMH;CC;rs1050565;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE HEARING IMPAIRMENT IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TH;AA + AG;rs10770141;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;DECREASED;SEVERITY;EFFICACY;COCAINE DEPENDENCE IN PEOPLE WITH  OTHER:COCAINE DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:SUBSTANCE-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AA;rs4680;TOXICITY;DECREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VEGFA;CC + CG;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VELPATASVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VOXILAPREVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TH;CT + TT;rs10770140;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;ABCB1;A;rs1128503;OTHER;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;A;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;A;rs1045642;OTHER;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;A;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;GG;rs1056892;TOXICITY;INCREASED;RISK;DISEASE;CARDIOMYOPATHIES IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;PRKCB;T;rs9922316;OTHER;INCREASED;NAN;OTHER;DEXMEDETOMIDINE ED50 VALUES FOR DRUG-INDUCED DORSAL HAND VEIN (DHV) CONSTRICTION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;CC;rs2229109;EFFICACY;INCREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ABCB1;CC;rs2229109;METABOLISM/PK;INCREASED;NAN;PK;INTRACELLULAR AND BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;RATE OF HIGH ON-TREATMENT PLATELET REACTIVITY (HTPR) AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;TOXICITY;INCREASED;RISK;SIDE EFFECT;CORONARY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;C;rs28399499;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING COMPLICATIONS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;A;rs686;EFFICACY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;A;rs686;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;A;rs686;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;INCREASED;NAN;EFFICACY;RATE OF HYPER-RESPONSE AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED;RISK;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
MITOTANE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;MITOTANE PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:ADRENOCORTICAL CARCINOMA;;CAUTION_DOSE_ADJUST
NICOTINE;DRD1;T;rs4532;EFFICACY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;T;rs4532;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;T;rs4532;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLC30A8;AG;rs16889462;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLC30A8;AG;rs16889462;EFFICACY;INCREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A7;AA;rs17863778;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A7;AA;rs17863778;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;UGT1A7;AA;rs17863778;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A7;AA;rs17863778;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;EDN1;TT;rs5370;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;G6PD, IKBKG;A;rs5030868;NAN;NAN;NAN;OTHER;PROTECTION FROM PLASMODIUM VIVAX MALARIA INFECTION NAN  NAN;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;EFFICACY;DECREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A3;CC;rs3806596;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A3;CC;rs3806596;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;UGT1A3;CC;rs3806596;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A3;CC;rs3806596;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EXANTHEMA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A7;GG;rs7586110;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A7;GG;rs7586110;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;UGT1A7;GG;rs7586110;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A7;GG;rs7586110;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ERCC2, KLC3;GG + GT;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;ERCC2, KLC3;GG + GT;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREPITANT;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A7;GG;rs17868323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A7;GG;rs17868323;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;UGT1A7;GG;rs17868323;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;UGT1A7;GG;rs17868323;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NAUSEA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:VOMITING IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAFENOQUINE;;A;rs62103056;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:MALARIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAFENOQUINE;;A;rs62103056;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;VIVAX;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;CC;rs719235;EFFICACY;INCREASED;RISK;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;CC;rs719235;TOXICITY;INCREASED;RISK;SIDE EFFECT;BONE MARROW TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TIMOLOL;ADRB1;AA;rs1801252;OTHER;INCREASED;NAN;OTHER;SYSTOLIC (SAP) AND DIASTOLIC (DAP) ARTERIAL PRESSURE RESPONSES TO TIMOLOL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;LRP2;G;rs2228171;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
DISULFIRAM;DBH;CT + TT;rs1611115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
FENTANYL;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
PROPOFOL;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
REMIFENTANIL;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOTENSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;NAN;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;RISK;DISEASE;DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;;CAUTION_SIDE_EFFECT
THIAZIDES;SLCO2A1;T;rs34550074;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPONATREMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
PLAIN;SLCO2A1;T;rs34550074;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPONATREMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;FMO3;A;rs1736557;EFFICACY;NAN;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;C;rs699664;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
WARFARIN;GGCX;G;rs11676382;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;COMT;A;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;COMT;A;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:FETAL ALCOHOL SYNDROME;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;G;rs11676382;EFFICACY;INCREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;NQO1;AA + AG;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;G6PD;T;rs1050828;NAN;INCREASED;NAN;OTHER;PROTECTION AGAINST SEVERE (P=0.006) AND MILD MALARIA (P=0.027) NAN  NAN;;CAUTION_DOSE_ADJUST
ANTITHYROID PREPARATIONS;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
METHIMAZOLE;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
PROPYLTHIOURACIL;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;AGRANULOCYTOSIS IN PEOPLE WITH  OTHER:GRAVES DISEASE;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC1;AA;rs11615;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;ERCC1;AA;rs11615;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;;CC + CT;rs4267385;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;;CAUTION_DOSE_ADJUST
PLAIN;;CC + CT;rs4267385;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;;CAUTION_DOSE_ADJUST
ACE INHIBITORS;;AA + AT;rs4459610;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;;CAUTION_DOSE_ADJUST
PLAIN;;AA + AT;rs4459610;OTHER;NAN;NAN;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH IN PEOPLE WITH  OTHER:HOMOZYGOUS GG GENOTYPE FOR RS4343;;CAUTION_DOSE_ADJUST
NAN;G6PD;T;rs1050828;NAN;INCREASED;NAN;OTHER;PROTECTION AGAINST DEVELOPING SEVERE MALARIA IN PEOPLE WITH  DISEASE:MALARIA;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;ALOPECIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;BDKRB2;AG;rs8016905;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;;CAUTION_DOSE_ADJUST
PLAIN;BDKRB2;AG;rs8016905;TOXICITY;NAN;NAN;DISEASE;COUGH NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;F5;C;rs6025;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;TRIM5;C;rs7950311;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;TRIM5;C;rs7950311;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;MTHFR;G;rs1801131;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;;G;rs6674079;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;MTHFR;G;rs1801133;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;;C;rs2549714;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;;C;rs2549714;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SERPINE1;A;rs2227631;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;;G;rs4910232;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;DECREASED;NAN;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ZNF100;C;rs3795247;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;MEAN INR DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PTGIR;AG + GG;rs1126510;OTHER;DECREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;NUMBER OF EXAMINATIONS ABOVE THE THERAPEUTIC RANGE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TBXA2R;GG;rs1131882;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGER3;A;rs7551789;OTHER;INCREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR>=2 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;PTGER2;GG;rs1353411;OTHER;INCREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGER2;G;rs2075797;OTHER;DECREASED;RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;NAN;OTHER;STABLE WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;VASP INDEX IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;NAN;SIDE EFFECT;DECLINE IN FEV 1 AFTER ASPIRIN PROVOCATION IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG + GG;rs4986893;EFFICACY;NAN;NAN;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY IN  OTHER:UNDERGOING SCHEDULED PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
ASPIRIN;NECAB1;G;rs74569896;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;NECAB1;G;rs74569896;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY IN  OTHER:UNDERGOING SCHEDULED PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;ATHEROTHROMBOTIC EVENTS DURING THE 6-YEAR FOLLOW UP IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;EFR3A;G;rs4736529;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;EFR3A;G;rs4736529;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A1;GG;rs2242046;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;CC + CT;rs1048977;OTHER;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU AND FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;CC + CT;rs1048977;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU AND FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;NAN;NAN;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC) NAN  NAN;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;NAN;NAN;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC) NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CMPK1;CC;rs1044457;OTHER;DECREASED;NAN;PK;FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
GEMCITABINE;CMPK1;CC;rs1044457;METABOLISM/PK;DECREASED;NAN;PK;FORMATION CLEARANCE OF DFDCTP IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
ASPIRIN;WDR24;G;rs11640115;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;WDR24;G;rs11640115;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;CC;rs4655226;OTHER;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;CC;rs4655226;METABOLISM/PK;INCREASED;NAN;PK;ELIMINATION CLEARANCE OF DFDU IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;BIOCHEMICAL RESPONSE;;CAUTION_DOSE_ADJUST
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;OPTIMAL CYTOREDUCTION;;CAUTION_DOSE_ADJUST
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_DOSE_ADJUST
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;BIOCHEMICAL RESPONSE;;CAUTION_DOSE_ADJUST
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;OPTIMAL CYTOREDUCTION;;CAUTION_DOSE_ADJUST
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;NAN;OTHER;AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_DOSE_ADJUST
VARENICLINE;ICAM5;T;rs901886;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SLEEP DISORDERS IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
VARENICLINE;ICAM5;T;rs901886;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SMOKING CESSATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;AG;rs2238476;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSORIASIS;;CAUTION_SIDE_EFFECT
MITOXANTRONE;ABCB1;AA;rs1128503;OTHER;INCREASED;NAN;OTHER;SENSITIVITY IN VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;FOLH1;A;rs61886492;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;FOLH1;A;rs61886492;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;NAT2;TT;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;STEVENS-JOHNSON SYNDROME/EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NAN;PPARA;AA + AG;rs135561;OTHER;DECREASED;RISK;OTHER;ALL-CAUSE MORTALITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS;;CAUTION_SIDE_EFFECT
CLOZAPINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE ACTIVITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;;AA;rs1495741;TOXICITY;DECREASED;NAN;SIDE EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH) IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
COMBINATIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
FLUTICASONE PROPIONATE;CYP3A4;AA + AG;rs35599367;EFFICACY;NAN;NAN;EFFICACY;IMPROVED ASTHMA CONTROL (AS MEASURED BY DECREASE IN AVERAGE ASTHMA CONTROL SCORE) IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
ALLOPURINOL;CCHCR1;A;rs9263745;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;AGTR1;C;rs5186;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PLAIN;AGTR1;C;rs5186;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH BLOOD CONCENTRATION NORMALIZED FOR THE DAILY DOSE (C) PER KILOGRAM BODY WEIGHT (D) (C/D;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;NG/ML/MG/KG/DAY) RATIO DURING THE FIRST MONTH AFTER TRANSPLANTATION NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE EFFECT;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;FOXP3;GT;rs3761548;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSORIASIS;;CAUTION_SIDE_EFFECT
NAN;CHAT;G;rs1880676;OTHER;INCREASED;RISK;DISEASE;SCHIZOPHRENIA NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
COMBINATIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
OXALIPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED;NAN;SIDE EFFECT;RENAL FUNCTION (LOWER CREATININE CLEARANCE) AT 3 MONTHS OF FOLLOW-UP IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AA;rs622342;METABOLISM/PK;DECREASED;NAN;PK;CL RENAL REFERENCE AND LOWER AND CL SEC REFERENCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ALLOPURINOL;PSORS1C2;T;rs9263733;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;DELAYED GRAFT FUNCTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;CT + TT;rs13120400;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:PSORIASIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1, PSORS1C2;A;rs9263726;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
EXEMESTANE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
COMBINATIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
VALPROIC ACID;POLG;C;rs2307441;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;ADH1C;CT;rs698;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;ADH1C;CT;rs698;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DRD2;G;rs6277;NAN;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;;CAUTION_DOSE_ADJUST
LOVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;;CAUTION_DOSE_ADJUST
LOVASTATIN;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;NAN;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;DRD2;G;rs1799732;NAN;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
VALPROIC ACID;POLG;A;rs3087374;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
EDOXABAN;SLCO1B1;GG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;TT;rs4961;OTHER;INCREASED;NAN;OTHER;HYDROCHLOROTHIAZIDE INDUCED CALCIUM RETENTION IN MEN WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
EDOXABAN;SLCO1B1;AA + AC;rs999278;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
LEVODOPA;DRD3;TT;rs6280;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
LEVODOPA;DRD2;GG;rs1799732;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  SIDE EFFECT:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
BUSULFAN;CTH;TT;rs1021737;TOXICITY;INCREASED;RISK;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE IN CHILDREN WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CTH;TT;rs1021737;TOXICITY;INCREASED;RISK;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE IN CHILDREN WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
FUROSEMIDE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SPIRONOLACTONE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EDOXABAN;SLCO1B1;CC + CT;rs4149057;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ACE;CG + GG;rs4341;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SPIRONOLACTONE;ACE;CG + GG;rs4341;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;NOS3;CC;rs2070744;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-INFLAMMATORY EFFECTS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;INCREASED;NAN;OTHER;WHOLE BLOOD NITRITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP1A2;A;rs2472304;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SPIRONOLACTONE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS IN PEOPLE WITH  DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;T;rs4646425;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCB1;AA;rs2032582;OTHER;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;ERCC1;AA;rs11615;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ERCC1;AA;rs11615;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ARRB2;C;rs4790694;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GT;rs2231142;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;T;rs2470890;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;SCARB1;GG;rs10846744;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;SCARB1;GG;rs10846744;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;;AA;rs1829346;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;;AA;rs1829346;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;AA;rs1128503;OTHER;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C19;AA;rs4244285;OTHER;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;GG;rs2306283;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;AG + GG;rs2027701;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;;AG + GG;rs2027701;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AA;rs1128503;OTHER;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGHER PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;SLC18A2;TT;rs363341;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;CC;rs1059698;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;;CC;rs1059698;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;GRIK3;CT;rs1334802;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;NAN;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
METHOTREXATE;SHMT1;AG + GG;rs1979277;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ABDOMINAL PAIN IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;A;rs762551;TOXICITY;INCREASED;RISK;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;AG + GG;rs9567733;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;CC;rs36080650;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;;CC;rs36080650;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATITIS IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;AA + AG;rs1124491;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;MEG3;CC;rs10132552;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;MEG3;CC;rs10132552;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;NAN;PK;SERUM R -WARFARIN CONCENTRATION NAN  NAN;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;NAN;NAN;SIDE EFFECT;DIMINISHED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DURING THE FIRST YEAR AFTER ENGRAFTMENT IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;AT + TT;rs17222723;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;SLC6A9;T;rs2486001;TOXICITY;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;SLC6A9;T;rs2486001;OTHER;INCREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;INCREASED;RISK;DISEASE;PROTEINURIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;rs1805123;OTHER;INCREASED;LIKELIHOOD;DISEASE;ATRIAL FIBRILLATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ARRB2;A;rs2036657;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN CHILDREN WITH  DISEASE:NON-HODGKIN LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED;RISK;EFFICACY;ASPIRIN-RESISTANT PHENOTYPE NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
NAN;CRHR1;AA;rs110402;OTHER;INCREASED;RISK;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;ARRB2;A;rs4790694;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;NAN;EFFICACY;MEDIAN WEEKLY WARFARIN DOSE REQUIREMENTS NAN  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN CHILDREN WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;MTHFR;GG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CARVEDILOL;ADRB2;C;rs1042714;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN RESTING BLOOD PRESSURE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CC + CT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CHILDREN WITH  OTHER:MUCOCUTANEOUS LYMPH NODE SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;NTRK2;G;rs1439050;TOXICITY;INCREASED;RISK;DISEASE;SUICIDE IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;;CT + TT;rs1478947;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;AA;rs4523;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN RESISTANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;ARRB2;T;rs1045280;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;GP1BA;CC;rs6065;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN RESISTANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;PMCH;G;rs7973796;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;TGFB1;AA + AG;rs1800469;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT CHRONIC URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;F7;AA;rs6046;EFFICACY;INCREASED;NAN;EFFICACY;SEN SITIVITY TO WARFARIN DURING INDUCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F7;AA;rs6046;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINORELBINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;KRTAP10-4, TSPEAR;A;rs201441480;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;KRTAP10-4, TSPEAR;A;rs201441480;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;DECREASED;NAN;OTHER;ERYTHROCYTE PLASMA MEMBRANE FLUIDITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;NAN;PK;S-WARFARIN CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;ECHS1;T;rs140410716;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ECHS1;T;rs140410716;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
EPIRUBICIN;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
LOVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
PITAVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;AGAP3;A;rs75750968;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;AGAP3;A;rs75750968;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
LOVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
PITAVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A2;CC;rs11854484;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;TLR4;AA + AG;rs1927911;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHMA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
TIMOLOL;;AA + AG;rs16947;TOXICITY;INCREASED;RISK;DISEASE;BRADYCARDIA IN PEOPLE WITH  DISEASE:OPEN-ANGLE GLAUCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
EPIRUBICIN;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A2;CC;rs1060896;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMATOLOGIC TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
LOVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
PITAVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;ZDHHC3;A;rs3749187;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ZDHHC3;A;rs3749187;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;CT + TT;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;VENLAFAXINE CONCENTRATION PER UNIT DOSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NAN;ADORA2A;AC + CC;rs5996696;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADORA2A;CT;rs71651683;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IFITM3;GG;rs12252;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;CC;rs762551;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE IN PEOPLE WITH  OTHER:COFFEE CONSUMPTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;CC;rs2470890;OTHER;DECREASED;RISK;DISEASE;PARKINSON DISEASE IN PEOPLE WITH  OTHER:COFFEE CONSUMPTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA;rs9934438;EFFICACY;INCREASED;NAN;EFFICACY;MEAN AUC (AREA UNDER CURVE) PROTHROMBIN TIME IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNJ11;TT;rs5219;NAN;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
NAN;KCNJ11;TT;rs5219;NAN;INCREASED;LIKELIHOOD;DISEASE;TYPE 2 NAN  NAN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED;SEVERITY;EFFICACY;HYPERCHOLESTEROLEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;SERPINE1;AA + AG;rs6092;TOXICITY;INCREASED;RISK;DISEASE;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;AA + AC;rs2072671;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;GG;rs2072661;EFFICACY;INCREASED;NAN;OTHER;ABSTINENCE IN  OTHER:SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB2;GG;rs2072661;TOXICITY;INCREASED;NAN;OTHER;ABSTINENCE IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;GG;rs2072661;OTHER;INCREASED;NAN;OTHER;ABSTINENCE IN  OTHER:SMOKERS;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS D VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS D VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;A;rs2069514;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED INSULIN LEVELS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:KIDNEY NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEUROENDOCRINE TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRM2;T;rs324650;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRM2;T;rs324650;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CETUXIMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VDR;C;rs1544410;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;del;rs35694136;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED INSULIN LEVELS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;VEGFA;GG;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CT + TT;rs662;OTHER;INCREASED;NAN;OTHER;SMALL-DENSE LDL LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
PROTON PUMP INHIBITORS;TRPM6;T;rs3750425;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOMAGNESEMIA PRIMARY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;FKBP5;CC + CT;rs1360780;EFFICACY;INCREASED;LIKELIHOOD;NANDISEASE;DEPRESSIVE DISORDER;PEOPLE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;T;rs193922803;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;T;rs193922803;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
CETUXIMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PROTON PUMP INHIBITORS;TRPM6;C;rs2274924;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOMAGNESEMIA PRIMARY NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC1;AA + AC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ERCC1;AA + AC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;rs2032582;OTHER;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;AUC SIMVASTATIN ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DESFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs2054675;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ASUNAPREVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
DACLATASVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs3786547;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CC + CT;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;C;rs1801159;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERABILITY IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;AA + AG;rs1872328;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS (COMPOSITE OF CARDIAC DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE EFFECT;MI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS) IN KOREAN PATIENTS AFTER PCI NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;XPC;GG + GT;rs2228001;TOXICITY;DECREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN PEOPLE WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;GG;rs9479757;TOXICITY;INCREASED;SEVERITY;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;BLUNTING OF ALCOHOL CRAVING IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;CC;rs1125338;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA-LACTAM ANTIBACTERIALS;;T;rs71542416;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLINS;;T;rs71542416;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG1;GG;rs425215;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;ABCA2;AA;rs2271862;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
XELOX;ABCA2;AA;rs2271862;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC5;CC;rs562;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;TACR1;AG + GG;rs6715729;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD2;CT + TT;rs4436578;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;AG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;CC + TT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;FPGS;CC + CT;rs10106;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALOPECIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
NAN;HIF1A;AG;rs11549467;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;GG;rs12596638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;GG;rs12596638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COUMARIN;CYP2A6;C;rs28399433;OTHER;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
COUMARIN;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;C;rs28399433;OTHER;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;NAN;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM NAN  NAN;;CAUTION_DOSE_ADJUST
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
NAN;PEMT;T;rs7946;NAN;INCREASED;RISK;DISEASE;FATTY LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIBIOTICS;LGALS3;AT + TT;rs11125;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CG + GG;rs12600192;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
NAN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;T;rs1650723;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CC;rs12600192;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CC;rs12600192;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;AG;rs2231135;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
NICOTINE;HINT1;CC;rs3852209;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN MEN WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;RISK;EFFICACY;METASTATIC NEOPLASM IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
NAN;VDR;CC;rs1544410;OTHER;DECREASED;LIKELIHOOD;OTHER;PRE-ECLAMPSIA IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC6A4;AA;rs3813034;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;A;rs3764435;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ALDH1A1;A;rs3764435;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;A;rs168351;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ALDH1A1;A;rs168351;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;INTOXICATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;INTOXICATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;TT;rs1799929;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;TT;rs1799929;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERALGESIA IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;DHFR;CC;rs1053129;TOXICITY;INCREASED;RISK;EFFICACY;METASTATIC NEOPLASM IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
TAMOXIFEN;HS6ST3;A;rs118042719;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;ABCB1;A;rs2229107;OTHER;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;A;rs2229107;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_DOSE_ADJUST
"""3";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
"4-METHYLENEDIOXYMETHAMPHETAMINE""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
"""COCAINE""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
"""ETHANOL""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
"""OPIOIDS""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"PRIMARY GRAFT FAILURE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"""EFFICACY:KIDNEY TUBULAR NECROSIS";;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"ACUTE"" IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION";;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"PRIMARY GRAFT FAILURE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"""EFFICACY:KIDNEY TUBULAR NECROSIS";;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;"ACUTE"" IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION";;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN WITH  ""OTHER:PAIN";;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE""";;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SCOLIOSIS""";;CAUTION_SIDE_EFFECT
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;BCHE;C;rs1799807;METABOLISM/PK;NAN;NAN;SIDE EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY NAN  NAN;;CAUTION_DOSE_ADJUST
SUCCINYLCHOLINE;BCHE;T;rs1803274;METABOLISM/PK;NAN;NAN;SIDE EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN WOMEN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C18;A;rs1042192;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HNMT;GG;rs2737385;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SEDATION IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HNMT;GG;rs2737385;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN WITH  ""OTHER:PAIN";;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE""";;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SCOLIOSIS""";;CAUTION_SIDE_EFFECT
CLOPIDOGREL;NOC3L;A;rs12572897;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;LPP;A;rs6790761;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;T;rs1799929;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1799929;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C8;A;rs1058932;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;A;rs578776;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;LPP;A;rs77693286;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
RIFAMPIN;RIPOR2;C;rs10946739;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROBLASTOMA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
NAN;EGFR;AA;rs763317;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;GAL;C;rs948854;OTHER;INCREASED;SEVERITY;DISEASE;ANXIETY DISORDERS IN WOMEN WITH  DISEASE:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;rs3869066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;rs3869066;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;EYS;G;rs1337512;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;A;rs393994;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;EYS;A;rs9342288;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
OTHER COMBINATIONS;EYS;A;rs9342288;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;SLC30A9;A;rs1047626;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;SLC30A9;A;rs1047626;OTHER;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;BDNF;C;rs962369;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;BDNF;C;rs962369;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;BDNF;C;rs962369;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;BDNF;C;rs962369;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;KCNMA1;G;rs2253201;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;KCNMA1;G;rs2253201;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;EYS;A;rs3857532;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
OTHER COMBINATIONS;EYS;A;rs3857532;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;TSC1;C;rs7862221;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;TSC1;C;rs7862221;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;G;rs320003;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ASPIRIN;THRA;G;rs11819745;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;THRA;G;rs11819745;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
RIFAMPIN;CUX2;G;rs7958375;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;CHIA;A;rs3818822;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;CHIA;A;rs3818822;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERBILIRUBINEMIA IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;;C;rs1074373;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;;C;rs1074373;OTHER;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;METABOLISM/PK;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;NAN;PK;PLASMA FREE PHENYTOIN CONCENTRATION IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
HEROIN;GRM3;A;rs1990040;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;ZBTB22;C;rs3130100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;ZBTB22;C;rs3130100;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SIROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;RHABDOMYOLYSIS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;rs3097671;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;rs3097671;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB2;C;rs3129294;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB2;C;rs3129294;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;G;rs1042151;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;G;rs1042151;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;rs1042136;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;rs1042136;OTHER;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
RIFAMPIN;RIPOR2;A;rs10946737;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PREDNISOLONE;GATA3;AA;rs3824662;PD;INCREASED;RISK;SIDE EFFECT;SEPSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;A;rs319952;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;AA;rs10485057;TOXICITY;INCREASED;RISK;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;DPP6;C;rs2533200;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;EPHX1;CT;rs1051740;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY GRADES 1-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;EPHX1;CT;rs1051740;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY GRADES 1-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;;G;rs192543598;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs7900002;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs2582405;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;NAT2;CT;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NAT2;CT;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs56722963;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MUTYH;CT;rs3219484;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;MUTYH;CT;rs3219484;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ALK;G;rs187926838;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;MED19, TMX2;A;rs576859;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;CC;rs7563206;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ENZYMES;A2M;TT;rs669;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGIC TRANSFORMATION IN PEOPLE WITH  DISEASE:STROKE;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;GT + TT;rs3821353;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENZYMES;F12;GG;rs1801020;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:STROKE;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;A;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;A;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;CG + GG;rs2372536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs6589386;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN MEN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;ADH1C;A;rs13125415;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;rs12995526;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CISPLATIN;RAD52;AG;rs11226;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;RAD52;AG;rs11226;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SLC39A8;A;rs13135092;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;LIG3;CC;rs1052536;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;LIG3;CC;rs1052536;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA GRADE 3-4 IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ABIRATERONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISOLONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDINAVIR;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  OTHER:HIV;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;AA;rs10760502;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FPGS;AA;rs10760502;TOXICITY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;AA;rs10760502;OTHER;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FPGS;TT;rs10106;EFFICACY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;TT;rs10106;OTHER;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs9679319;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs1402398;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;THSD7B;A;rs13382553;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;TT;rs868755;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ETHANOL;;A;rs2673136;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs13129401;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;TT;rs10280623;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ETHANOL;CADM2;A;rs62250713;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;ADH1B;T;rs75967634;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;;CAUTION_SIDE_EFFECT
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;;CAUTION_SIDE_EFFECT
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;;CAUTION_SIDE_EFFECT
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;;CAUTION_SIDE_EFFECT
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;;CAUTION_SIDE_EFFECT
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;;CAUTION_SIDE_EFFECT
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;;CAUTION_SIDE_EFFECT
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;;CAUTION_SIDE_EFFECT
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER;;CAUTION_SIDE_EFFECT
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ASTROCYTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;HEROIN DEPENDENCE IN MEN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;T;rs56113850;OTHER;DECREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;PDE4B;A;rs6421482;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs61767420;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;GCKR;T;rs1260326;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;T;rs494904;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;AA + AT;rs503464;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SPATA9;A;rs72783407;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;BIRC5;GG;rs9904341;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEIN KINASE INHIBITORS;STAT6;TT;rs324011;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
OPIOIDS;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;C1QTNF6;C;rs114557570;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;AA + AT;rs637137;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN WOMEN WITH  OTHER:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;CC;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;GG;rs13207351;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;GG;rs35864111;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGASPARGASE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGASPARGASE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED;NAN;EFFICACY;MINIMAL RESIDUAL DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;AA;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;;C;rs62293499;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP4F2;CT;rs2108622;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP4F2;CT;rs2108622;OTHER;INCREASED;NAN;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT + TT;rs4294451;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;COL26A1;T;rs17135437;TOXICITY;INCREASED;NAN;SIDE EFFECT;HEARING AND VISION-RELATED SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CITALOPRAM;;A;rs16965962;TOXICITY;INCREASED;NAN;SIDE EFFECT;GENERAL SIDE-EFFECT BURDEN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1, PSORS1C2;A;rs9263726;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;ACE;CC + CT;rs4292;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;NAN;NAN;EFFICACY;STRONGER AGGREAGTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;T;rs4982753;TOXICITY;DECREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;T;rs4982753;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT + TT;rs4294451;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;T;rs2074192;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED;RISK;EFFICACY;CLOPIDOGREL RESISTANCE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;NAN;EFFICACY;OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED;NAN;EFFICACY;NET DECREASE IN AA-INDUCED PLATELET AGGREGATION AFTER ASPIRIN TREATMENT IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;AC;rs1127354;METABOLISM/PK;INCREASED;NAN;PK;6-MMPN LEVELS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
NAN;FGFR2;G;rs1219648;TOXICITY;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN  DISEASE:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
NAN;FGFR2;G;rs1219648;OTHER;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN  DISEASE:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
ANASTROZOLE;;T;rs6735923;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;CT + TT;rs1799853;TOXICITY;INCREASED;RISK;DISEASE;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  OTHER:TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;A;rs7319981;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;A;rs7319981;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
NAN;AGT;AG;rs699;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;;C;rs1877193;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs2786783;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER;PAIN IN CHILDREN WITH  OTHER:DENTAL CARIES;;CAUTION_SIDE_EFFECT
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER;OTHER:TOOTH DISORDER;;CAUTION_SIDE_EFFECT
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER;OTHER:TOOTHACHE;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;G;rs7662029;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;C;rs7439366;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;NAN;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CEFACLOR;LIMD1;C;rs62242178;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CEFACLOR;LIMD1;G;rs62242177;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLCO1B1;CC;rs4149056;OTHER;INCREASED;NAN;PK;MEAN PLASMA AUC NAN  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;MEAN PLASMA AUC NAN  NAN;;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;AG + GG;rs1048101;EFFICACY;DECREASED;RISK;EFFICACY;KIDNEY DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;XRCC5;AG;rs1051685;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;ERCC1;AC + CC;rs735482;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GCG;C;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
OLANZAPINE;GCG;C;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
CLOZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
OLANZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AA + AG;rs1799971;DOSAGE;INCREASED;NAN;OTHER;SMOKING IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;NAN;OTHER;SMOKING IN CHILDREN  NAN;;CAUTION_DOSE_ADJUST
TOLCAPONE;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;ALCOHOL ABUSE IN PEOPLE WITH  OTHER:ALCOHOL-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
NICOTINE;UGT2B10;AG + GG;rs112561475;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION OF NICOTINE NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;NAN;PK;NICOTINE GLUCURONIDATION NAN  NAN;;CAUTION_DOSE_ADJUST
CLOZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
OLANZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;KIDNEY DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;HTR1A;A;rs878567;TOXICITY;NAN;NAN;DISEASE;PSYCHOTIC DISORDER IN PEOPLE WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;HTR1A;A;rs878567;OTHER;NAN;NAN;DISEASE;PSYCHOTIC DISORDER IN PEOPLE WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;AA;rs4291;EFFICACY;DECREASED;SEVERITY;DISEASE;KIDNEY FAILURE IN PEOPLE WITH  DISEASE:ALZHEIMER DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;;T;rs4471527;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;;T;rs4471527;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;LEPR;G;rs1137101;OTHER;INCREASED;LIKELIHOOD;DISEASE;OBESITY IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;A;rs2232228;TOXICITY;DECREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;A;rs2232228;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;;T;rs77542827;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;;T;rs77542827;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
STAVUDINE;SAMHD1;A;rs8124728;TOXICITY;DECREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE (HEART-RATE LOWERING) IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;TGFB1;AG + GG;rs1800469;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  OTHER:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SARCOMA;;CAUTION_SIDE_EFFECT
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;NIPAL2;A;rs199755581;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;NIPAL2;A;rs199755581;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
AMLODIPINE;ACE;AA + AT;rs4291;OTHER;DECREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
CHLORTHALIDONE;ACE;AA + AT;rs4291;OTHER;DECREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
LISINOPRIL;ACE;AA + AT;rs4291;OTHER;DECREASED;NAN;SIDE EFFECT;FASTING GLUCOSE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;TGFBR2;GG;rs3087465;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;CT;rs307826;EFFICACY;NAN;NAN;EFFICACY;REDUCED PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_DOSE_ADJUST
SUNITINIB;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE REDUCTIONS DUE TO TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
RITODRINE;PDE4B;AA;rs17128809;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;AC;rs307821;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;;CAUTION_SIDE_EFFECT
SALBUTAMOL;;C;rs9552679;EFFICACY;DECREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;COL22A1;T;rs6988229;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs17495520;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;DDX12P;C;rs77491650;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;DDX12P;C;rs77491650;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs1663332;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;G;rs1663330;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;A;rs17701271;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs518350;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;G;rs10511905;EFFICACY;DECREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SALBUTAMOL;CLOCK;A;rs1522113;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;A;rs1423515;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs1419555;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;C;rs6002674;EFFICACY;DECREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ACE2;A;rs2106809;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 IN MEN WITH  OTHER:COVID-19;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPIRIN;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:DISEASE PROGRESSION IN PEOPLE WITH  OTHER:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;T;rs1634776;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
SALBUTAMOL;;A;rs11252394;EFFICACY;INCREASED;NAN;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) IN  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;SLCO1B1;CT + TT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;GABRA2;G;rs11503014;TOXICITY;INCREASED;SEVERITY;OTHER;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;C;rs2236256;TOXICITY;DECREASED;SEVERITY;OTHER;COCAINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;AGT;A;rs699;OTHER;DECREASED;SEVERITY;OTHER;COVID-19 IN PEOPLE WITH  OTHER:COVID-19;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANGRELOR;P2RY12;TT;rs9859552;OTHER;NAN;NAN;OTHER;20% AND 17% LESS INHIBITION OF PLATELET AGGREGATION WITH CRANGRELOR (0.05 AND 0.25 MICROM) IN-VITRO NAN  NAN;;CAUTION_DOSE_ADJUST
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;TANC1;C;rs10497203;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;GLCCI1;GG;rs37973;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POOR RESPONSE IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCG2;A;rs7699188;EFFICACY;INCREASED;NAN;EFFICACY;TUMOR RESPONSE RATE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCG2;A;rs7699188;EFFICACY;INCREASED;NAN;EFFICACY;TUMOR RESPONSE RATE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;ABCG2;A;rs7699188;EFFICACY;INCREASED;NAN;EFFICACY;TUMOR RESPONSE RATE IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;DECREASED;NAN;SIDE EFFECT;INTERVAL OF THERAPY TO LEUKOPENIA ONSET IN PEOPLE WITH  DISEASE:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;AG + GG;rs3087243;TOXICITY;DECREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;GG;rs10782001;TOXICITY;INCREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;AG;rs11209026;TOXICITY;INCREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;INCREASED;SEVERITY;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;METABOLISM/PK;INCREASED;RISK;PK;PROLONGED HIGH CONCENTRATIONS IN CHILDREN WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COLISTIMETHATE;SLC15A2;T;rs2257212;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPARAGINASE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISOLONE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;FOLIC ACID DEFICIENCY ANEMIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPARAGINASE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISOLONE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CT;rs28371685;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CETUXIMAB;CCND1;G;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;F7;GT + TT;rs510335;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;IL10;AA;rs1800871;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR1B;AC + CC;rs11568817;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE COGNITIVE EFFECTS IN PEOPLE WITH  DISEASE:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
CETUXIMAB;CCND1;AA;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXSUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
MILNACIPRAN;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXSUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEXSUAL DYSFUNCTION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;NAN;SIDE EFFECT;NON-HDL CHOLESTEROL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;NAN;SIDE EFFECT;NON-HDL CHOLESTEROL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
"""RITONAVIR""";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;NAN;SIDE EFFECT;NON-HDL CHOLESTEROL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE COGNITIVE EFFECTS IN PEOPLE WITH  DISEASE:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
TACROLIMUS;IL10;TT;rs1800872;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;G;rs17234657;NAN;INCREASED;RISK;DISEASE;CROHN DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED;RISK;DISEASE;DYSKINESIAS IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED;RISK;DISEASE;HALLUCINATIONS IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;T;rs2200733;NAN;INCREASED;RISK;DISEASE;ATRIAL FIBRILLATION NAN  NAN;;CAUTION_SIDE_EFFECT
ESTRADIOL;NFE2L2;T;rs6721961;TOXICITY;INCREASED;RISK;DISEASE;VENOUS THROMBOEMBOLISM NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;HLA-DRA;A;rs3135388;NAN;INCREASED;RISK;DISEASE;MULTIPLE SCLEROSIS NAN  NAN;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
NAN;NOD2;G;rs17221417;NAN;INCREASED;RISK;DISEASE;CROHN DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;NAN;EFFICACY;ONE YEAR PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;NAN;EFFICACY;ONE YEAR PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FLU-LIKE SYMPTOMS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1;CT;rs71647871;PD;INCREASED;LIKELIHOOD;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TCF7L2;T;rs12255372;NAN;INCREASED;RISK;DISEASE;DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
NAN;TCF7L2;T;rs12255372;NAN;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;IL6;AG + GG;rs1800797;OTHER;INCREASED;SEVERITY;OTHER;PAIN IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;TCF7L2;C;rs12243326;NAN;INCREASED;RISK;DISEASE;DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
NAN;TCF7L2;C;rs12243326;NAN;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;TCF7L2;T;rs4506565;NAN;INCREASED;RISK;DISEASE;DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
NAN;TCF7L2;T;rs4506565;NAN;INCREASED;RISK;DISEASE;TYPE 2 NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;NAN;OTHER;PLATELET REACTIVITY NAN  NAN;;CAUTION_DOSE_ADJUST
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED;NAN;EFFICACY;NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN DURING PAINFUL PROCEDURE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;RABGAP1L;G;rs61826952;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL MEAN NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;CC;rs1058172;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE IN PEOPLE WITH  OTHER:DEATH;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2B6;CC;rs4803419;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVERDOSE IN PEOPLE WITH  OTHER:DEATH;;CAUTION_SIDE_EFFECT
NAN;ACE2;CC;rs4240157;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:COVID-19;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
NAN;ACE2;C;rs4240157;OTHER;INCREASED;LIKELIHOOD;OTHER;COVID-19 IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;CONCENTRATION-TO-ADJUSTED DOSE RATIO IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PANCREATITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ5;AA + AG;rs10849757;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
ZOLEDRONATE;FDPS;TT;rs2297480;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ3;TT;rs11548336;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
IMATINIB;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ2;CG + GG;rs4693075;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CLMN;A;rs8014194;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN TOTAL CHOLESTEROL NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;CLMN;A;rs8014194;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN TOTAL CHOLESTEROL NAN  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CLMN;A;rs8014194;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN TOTAL CHOLESTEROL NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;AG;rs12721655;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYP2B6;AG;rs12721655;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NINTEDANIB;DSP;TT;rs2076295;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:PULMONARY FIBROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs8192709;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO PROGRESSION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYP2B6;CT;rs8192709;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO PROGRESSION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;GG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;MTHFR;GG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C19;CC;rs12248560;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;CAUTION_DOSE_ADJUST
CAPECITABINE;MTHFR;TT;rs1801131;TOXICITY;DECREASED;NAN;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F7;GG;rs510317;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;CT;rs1135216;TOXICITY;DECREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HEADACHE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HEADACHE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;HEADACHE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;AA;rs651630;TOXICITY;DECREASED;RISK;SIDE EFFECT;PSORIASIS IN PEOPLE WITH  DISEASE:PSORIASIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TANC1;A;rs264588;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
RADIOTHERAPY;TANC1;G;rs264631;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
BUSULFAN;CYP2C9;CT + TT;rs1799853;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO IN CHILDREN WITH  DISEASE:HEMOPOIETIC STEM CELL TRANSPLANT;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;SLC22A16;C;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;C;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TANC1;T;rs7582141;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;T;rs6432512;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;T;rs264663;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCB1;CC;rs2032582;EFFICACY;NAN;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
IRINOTECAN;ABCB1;CC;rs2032582;EFFICACY;NAN;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
LEUCOVORIN;ABCB1;CC;rs2032582;EFFICACY;NAN;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
RADIOTHERAPY;TANC1;G;rs264651;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;T;rs8192709;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2B6;T;rs8192709;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEMATOLOGIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SECUKINUMAB;ERAP2;GG;rs2248374;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:PSORIASIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;SLC22A16;G;rs12210538;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;SLC22A16;G;rs12210538;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SLC22A16;G;rs723685;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;G;rs723685;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;SLC22A16;G;rs6907567;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;G;rs6907567;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DOSE DELAY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;LTC4S;C;rs730012;TOXICITY;INCREASED;RISK;SIDE EFFECT;URTICARIA NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:HYPERLIPOPROTEINEMIA TYPE II;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:HYPERLIPOPROTEINEMIA TYPE II;;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AVELUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DURVALUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
IPILIMUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NIVOLUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs2884737;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NELFINAVIR;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NELFINAVIR;ABCB1;AA;rs1045642;OTHER;INCREASED;NAN;EFFICACY;RISE IN CD4-CELL COUNT IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;FAVORABLE VIROLOGIC RESPONSES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATEZOLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
AVELUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DURVALUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
IPILIMUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NIVOLUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCC2;A;rs17222723;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;A;rs17222723;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROMYELITIS OPTICA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEUROMYELITIS OPTICA;;CAUTION_SIDE_EFFECT
NAN;ATP8B3;G;rs10421558;TOXICITY;DECREASED;LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;AA;rs1045642;OTHER;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;T;rs1799929;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;T;rs1799929;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;T;rs1799929;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs1799930;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;GG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;APOC3;T;rs2854117;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NAN;AGTR1;CC;rs5186;OTHER;INCREASED;RISK;DISEASE;ISCHEMIA IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
IMATINIB;ARID5B;TT;rs10821936;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ARID5B;TT;rs10821936;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BCR-ABL1 POSITIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;T;rs1041983;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;T;rs1041983;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;T;rs1041983;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;C;rs1801280;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;C;rs1801280;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;C;rs1801280;METABOLISM/PK;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
FEXOFENADINE;ABCB1;AA;rs1045642;DOSAGE;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FEXOFENADINE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CMIN VALUES IN  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs4803419;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CMIN VALUES IN  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
IMATINIB;ATIC;G;rs2372536;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CHRONIC MYELOGENOUS LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ATIC;G;rs2372536;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BCR-ABL1 POSITIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED;RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED;RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEXOFENADINE;ABCB1;AA;rs2032582;DOSAGE;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FEXOFENADINE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RITODRINE;KCNMB2;GG;rs7625907;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CMIN VALUES IN  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCC1;T;rs45511401;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC1;T;rs45511401;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;A;rs8187710;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
CAPECITABINE;SMAD7;CC;rs4939827;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;SMAD7;CC;rs4939827;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR;SMAD7;CC;rs4939827;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
NAN;ATP8B3;A;rs10403288;TOXICITY;DECREASED;LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  OTHER:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;A;rs1128503;EFFICACY;DECREASED;RISK;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;T;rs2074192;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYBA;A;rs4673;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;A;rs1045642;EFFICACY;DECREASED;RISK;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;RAC2;T;rs13058338;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;C;rs2032582;EFFICACY;INCREASED;RISK;SIDE EFFECT;MYALGIA IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_SIDE_EFFECT
NAN;ABO;T;rs8176746;NAN;INCREASED;NAN;OTHER;ACE ACTIVITY IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION-TO-ADJUSTED DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
ATORVASTATIN;PON1;AA + AG;rs705379;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
SIMVASTATIN;PON1;AA + AG;rs705379;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
ATORVASTATIN;PON1;CC + CT;rs662;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
SIMVASTATIN;PON1;CC + CT;rs662;EFFICACY;NAN;NAN;EFFICACY;CHANGE IN HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
ATORVASTATIN;PON1;GG;rs705379;OTHER;DECREASED;NAN;OTHER;OXIDATIVE STRESS IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
CLOZAPINE;TACR1;C;rs58933792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRY MOUTH NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;CONCENTRATION/DOSE RATIO IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
FLUCONAZOLE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
FLUCONAZOLE;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;NAN;PK;DOSE OF TACROLIMUS IN CHILDREN WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;NAN;PK;TIME TO REACH STABLE DOSE IN CHILDREN WITH  DISEASE:TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TAMOXIFEN;SLCO1A2;AG + GG;rs10841795;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DIZZINESS IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ERBB4;C;rs3942465;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRY MOUTH NAN  NAN;;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"PLAIN""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""BETA BLOCKING AGENTS""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""DIGOXIN""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""DIURETICS""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""SPIRONOLACTONE""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
L-ASPARAGINE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CUSHING SYNDROME IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CUSHING SYNDROME IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CUSHING SYNDROME IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"PLAIN""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""BETA BLOCKING AGENTS""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""DIGOXIN""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""DIURETICS""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
"""SPIRONOLACTONE""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
LOPINAVIR;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
RITONAVIR;;G;rs2853826;TOXICITY;INCREASED;NAN;SIDE EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP2C19;CT + TT;rs12248560;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACE INHIBITORS";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANGIOTENSIN II ANTAGONISTS""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA BLOCKING AGENTS""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIGOXIN""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SPIRONOLACTONE""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER;EMERGENCIES IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
L-ASPARAGINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A4;GG + GT;rs2011425;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;AUTONOMIC NERVOUS SYSTEM DISORDER IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRY MOUTH IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;T;rs17327624;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;T;rs17327624;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATED METABOLITES OF OLANZAPINE NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;FRACTURES;;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;BONE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AG;rs1045642;TOXICITY;INCREASED;SEVERITY;DISEASE;GINGIVAL HYPERPLASIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE REJECTION IN CHILDREN WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;T;rs2235040;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;T;rs2235040;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NOD2;CC;rs2066844;OTHER;INCREASED;NAN;OTHER;HOSPITAL STAY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;EFFICACY;INCREASED;RISK;OTHER;ACUTE REJECTION IN  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED;RISK;OTHER;ACUTE REJECTION IN  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs2359612;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;NAN;NAN;PK;SIGNIFICANTLY LARGER MEAN AUC OF OSELTAMIVIR;;CAUTION_DOSE_ADJUST
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;NAN;NAN;PK;LOWER CMAX OF OSELTAMIVIR CARBOXYLATE;;CAUTION_DOSE_ADJUST
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;NAN;NAN;PK;AND A SMALLER OSELTAMIVIR CARBOXYLATE-TO-OSELTAMIVIR AUC RATIO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  OTHER:ULCERATIVE COLITIS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:CROHN DISEASE;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;PBMC CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CABAZITAXEL;CYP2C8;T;rs11572093;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASTHENIA IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
CABAZITAXEL;CYP2C8;T;rs11572093;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;A;rs4244285;TOXICITY;INCREASED;NAN;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;NAN;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;rs8050894;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SLEEP INITIATION AND MAINTENANCE DISORDERS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AC + CC;rs2884737;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;rs5443;EFFICACY;NAN;NAN;EFFICACY;IMPROVEMENTS IN NEUROVEGETATIVE SYMPTOMS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
NAN;SLC19A1;C;rs1051266;OTHER;INCREASED;LIKELIHOOD;OTHER;DOWN SYNDROME IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;NAN;PK;DUODENAL ABSORPTION OF DIGOXIN AFTER DIRECT DELIVERY TO THE SURFACE OF THE DUODENUM BY ENDOSCOPE NAN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  OTHER:PSYCHIATRIC DISORDERS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;A;rs1045642;EFFICACY;NAN;NAN;EFFICACY;POSITIVE RELATIONSHIP BETWEEN OLANZAPINE PLASMA LEVELS AND POSITIVE SYMPTOM REDUCTION COMPARED TO SUBJECTS WITH THE GG GENOTYPE NAN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS IN PEOPLE WITH  OTHER:PSYCHIATRIC DISORDERS;;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;A;rs6275;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;A;rs6275;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;GG;rs9024;TOXICITY;INCREASED;RISK;DISEASE;CARDIOMYOPATHIES IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;G;rs6279;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;G;rs6279;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
CEPHALEXIN;;T;rs34545984;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;T;rs1124493;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;T;rs1124493;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;A;rs2734841;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;A;rs2734841;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;;A;rs115346678;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;A;rs2236225;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;PPARA;AA;rs4253728;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CODEINE;WBP2NL;G;rs9620007;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
CODEINE;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A2;CC;rs316009;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A2;CC;rs316009;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A2;CC;rs316019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A2;CC;rs316019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;CAUTION_SIDE_EFFECT
SIMVASTATIN;PPARA;GG;rs4823613;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ANKK1;GG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SUICIDAL IDEATION;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DELIBERATE SELF-HARM IN CHILDREN WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMIODARONE;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIBIOTICS;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;;CAUTION_SIDE_EFFECT
DIURETICS;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;;CAUTION_SIDE_EFFECT
QUINIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;;CAUTION_SIDE_EFFECT
SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE;TORSADES DE POINTES NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;ANKK1;GG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;G;rs2734842;OTHER;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;G;rs2734842;METABOLISM/PK;INCREASED;NAN;OTHER;PROLACTIN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
PYRIMIDINE ANALOGUES;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GG;rs2231142;EFFICACY;DECREASED;NAN;EFFICACY;PERCENTAGE CHANGE IN LDL-CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;AA;rs4244285;OTHER;INCREASED;NAN;PK;LOG METABOLIC RATIO OF AMITRIPTYLINE/NORTRIPTYLINE NAN  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;LOG METABOLIC RATIO OF AMITRIPTYLINE/NORTRIPTYLINE NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;OR STROKE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS OF ROSUVASTATIN IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;OR STROKE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF ROSUVASTATIN IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;CARDIOVASCULAR DEATH;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;OR STROKE IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"ANEMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"ANEMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"ANEMIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
NAN;SERPINE1;T;rs7242;OTHER;INCREASED;LIKELIHOOD;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SERPINE1;G;rs2227684;OTHER;INCREASED;LIKELIHOOD;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CLINICAL RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;A;rs60369023;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;A;rs60369023;METABOLISM/PK;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;IL1B;GG;rs16944;EFFICACY;INCREASED;LIKELIHOOD;PK;RESISTANCE IN PEOPLE WITH  DISEASE:OSTEITIS DEFORMANS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLODRONATE;VDR;C;rs1544410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:OSTEITIS DEFORMANS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER ANTI-COAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CLODRONATE;VDR;A;rs731236;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:OSTEITIS DEFORMANS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;INDUCTION FAILURE IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;INDUCTION FAILURE IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDLC IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDLC IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LDLC IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;HTR2A;T;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;HTR2A;T;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ANEMIA IN PEOPLE WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
BUPRENORPHINE / NALOXONE;OPRM1;AG + GG;rs648893;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DEPRESSION IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A;T;rs2267076;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A;T;rs2236624;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A;T;rs2298383;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER;INCREASED;NAN;PK;BLOOD PRESSURE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHOTREXATE;ADORA2A;T;rs3761422;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"THROMBOCYTOPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"NEUTROPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"NEUTROPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"NEUTROPENIA IN PEOPLE WITH  ""OTHER:CARCINOMA";;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:ADENOSQUAMOUS CARCINOMA""";;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;"""OTHER:NEOPLASM OF ESOPHAGUS""";;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;NELL1;C;rs12279250;METABOLISM/PK;INCREASED;NAN;SIDE EFFECT;PLASMA TRIGLYCERIDES IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
BUPRENORPHINE / NALOXONE;OPRD1;TT;rs678849;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANXIETY DISORDERS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DAOA;A;rs2391191;EFFICACY;DECREASED;NAN;EFFICACY;BRIEF PSYCHIATRIC RATING SCALE SCORES IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE / NALOXONE;OPRD1;A;rs569356;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CRAVING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2C;C;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;RISK;OTHER;TACROLIMUS NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RISK;OTHER;SUBCLINICAL ALLOGRAFT NEPHROPATHY IN  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;RISK;OTHER;SUBCLINICAL ALLOGRAFT NEPHROPATHY IN  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYBA;AA + AG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DNA DAMAGE IN PEOPLE WITH  DISEASE:HYPERCHOLESTEROLEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;CT;rs3211371;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN PEOPLE WITH  OTHER:FEMALE GENDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD3;CC;rs6280;EFFICACY;NAN;NAN;EFFICACY;GREATER POSITIVE SYMPTOM IMPROVEMENT AND POSITIVE SYMPTOM REMISSION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:CROHN DISEASE;;CAUTION_SIDE_EFFECT
OLANZAPINE;RGS4;CT;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;TUBB1;G;rs151352;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;TUBB1;G;rs151352;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;RGS4;TT;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;RGS4;CC;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSITIVE RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERPHENAZINE;RGS4;CC;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;POSITIVE RESPONSE IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;CYP2C8;C;rs1341164;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;CYP2C8;C;rs1341164;EFFICACY;INCREASED;NAN;EFFICACY;OTHER:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;LEP;GG;rs4731426;TOXICITY;INCREASED;RISK;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HEROIN;GRM3;T;rs13242038;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE;G;rs4343;METABOLISM/PK;INCREASED;NAN;OTHER;ACE ACTIVITY IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;HTR1A;GG;rs6295;EFFICACY;DECREASED;NAN;EFFICACY;TREATMENT RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;CC + CT;rs9282564;TOXICITY;DECREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
TAXANES;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1A;CC;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:PANIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;HTR1A;CC;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:PANIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KCNJ6;TT;rs2070995;EFFICACY;INCREASED;NAN;EFFICACY;FREQUENCY OF RESCUE ANALGESIC ADMINISTRATION IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;G;rs8050894;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;EFFICACY;NAN;NAN;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED RISK OF OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;CT;rs28399499;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP3A5;CC + CT;rs776746;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;T;rs3849942;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DTNBP1;C;rs3213207;TOXICITY;INCREASED;RISK;SIDE EFFECT;PSYCHOTIC DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;T;rs2814707;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;PICK1;T;rs2076369;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;RELAPSE OF PSYCHOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CT + TT;rs12721646;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;A;rs928655;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OVERALL GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;C;rs774359;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;T;rs983332;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs868856;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE BASE ON DISEASE ACTIVITY SCORE IN 44 JOINTS IMPROVEMENT AT 6 MONTHS OF TREATMENT IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;LESS PATIENT-ASSESSED DIFFICULTY WITH PHYSICAL TASKS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;AND FEWER SWOLLEN JOINTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIANDROGENS;AKR1C3;CC;rs12529;EFFICACY;INCREASED;RISK;EFFICACY;PROSTATE CANCER-SPECIFIC MORTALITY IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;NAN;OTHER;MAINTENANCE DOSE OF WARFARIN NAN  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;ERCC1;AG;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ERCC1;AG;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;TP53;GG;rs1042522;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;TT;rs11572080;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;GG;rs2238476;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;T;rs6028945;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;C;rs6071980;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;T;rs6138150;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AA;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CLCN6, MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854548;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854555;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs7046653;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED;RISK;OTHER;SUBSTANCE WITHDRAWAL SYNDROME IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AG;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE OF INR (TTR) NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;;CT;rs11185648;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
DOCETAXEL;RXRA;AG;rs11185647;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;rs11185647;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;rs2234753;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;GT;rs6413517;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;GG;rs62576288;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;DRD2;GG;rs1799732;NAN;INCREASED;LIKELIHOOD;DISEASE;SCHIZOPHRENIA NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;SCN1A;CT;rs2298771;OTHER;INCREASED;LIKELIHOOD;DISEASE;EPILEPSY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;;G;rs9345389;TOXICITY;NAN;NAN;SIDE EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE. NAN  NAN;;CAUTION_DOSE_ADJUST
DOCETAXEL;HNF4A;TT;rs6130615;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;GG;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;;A;rs76103438;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP3A4;GG;rs35599367;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;AG;rs6314;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;HNF4A;CT;rs2273618;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;HNF4A;CT;rs3746574;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs9934438;DOSAGE;NAN;NAN;OTHER;A MORE RAPID ATTAINMENT OF TARGET INR AND HIGHER FREQUENCY OF DOSE ADJUSTMENTS NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;EFFICACY;NAN;NAN;OTHER;A MORE RAPID ATTAINMENT OF TARGET INR AND HIGHER FREQUENCY OF DOSE ADJUSTMENTS NAN  NAN;;CAUTION_DOSE_ADJUST
DOCETAXEL;NR1I2;TT;rs3732360;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;NRXN1;C;rs985919;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA BLOCKING AGENTS";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"SELECTIVE""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPERIDINE;SERINC5;C;rs185462714;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;AA;rs3957357;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;NR1I2;AA;rs3732359;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;rs17408276;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;;T;rs139945292;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
NICOTINE;COMT;AA;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLIN G;;A;rs115200108;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
PENICILLIN V;;A;rs115200108;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;COMT;AG;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RELAPSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
DOCETAXEL;NR1I2;CC + TT;rs3814058;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NRXN1;C;rs1882296;OTHER;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;NR1I3;TT;rs10538494;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CODEINE;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPERIDINE;FIP1L1;G;rs113100019;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AG;rs75114882;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;NRXN1;C;rs10865246;OTHER;INCREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;CC;rs2501873;TOXICITY;DECREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;CT;rs1799793;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC1;AC;rs3212986;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ERCC1;AC;rs3212986;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;XRCC1;CC;rs25487;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;XRCC1;CC;rs25487;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
MEPERIDINE;;A;rs11049274;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;rs1536475;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;XPC;G;rs2228001;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;GG;rs2502815;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AA;rs9725457;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2, KLC3;G;rs13181;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;ACSS2;T;rs6088638;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG;rs17376848;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs1058164;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;G;rs11615;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CC;rs429358;OTHER;INCREASED;SEVERITY;OTHER;COVID-19 NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs1985842;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;T;rs1801280;OTHER;INCREASED;SEVERITY;DISEASE;INSULIN RESISTANCE NAN  NAN;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs1135840;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs28371713;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;A;rs1208;OTHER;INCREASED;SEVERITY;DISEASE;INSULIN RESISTANCE NAN  NAN;;CAUTION_SIDE_EFFECT
AMOXICILLIN;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
GEFITINIB;ABCG2;GT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs112568578;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MIR23A, MIR24-2, MIR27A;C;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MIR23A, MIR24-2, MIR27A;C;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;NAN;NAN;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
AMOXICILLIN;PTPN22;A;rs2476601;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SLEEP APNEA SYNDROMES IN MEN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;PTGS2;G;rs20417;NAN;INCREASED;RISK;DISEASE;STROKE NAN  NAN;;CAUTION_SIDE_EFFECT
ATENOLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;NAN;OTHER;CARDIAC REHOSPITALIZATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;RARG;AG;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ASPIRIN;TMEM196;T;rs9886152;TOXICITY;DECREASED;RISK;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;HIF1A;AG;rs11549467;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CLOCK;AA + AG;rs1801260;OTHER;INCREASED;LIKELIHOOD;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE RESPONSE RATE IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
RITUXIMAB;FCGR3A;AA;rs396991;NAN;DECREASED;NAN;OTHER;LEVELS OF IGG IN PEOPLE WITH  OTHER:NON-HODGKIN'S LYMPHOMA AND STEM CELL TRANSPLANTATION;;CAUTION_DOSE_ADJUST
COCAINE;CNR1;C;rs806368;OTHER;DECREASED;RISK;DISEASE;COCAINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN BONE MINERAL DENSITY IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN BONE MINERAL DENSITY IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;VDR;CC;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
DEXAMETHASONE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
METHOTREXATE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY;RELAPSE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
INTERFERONS;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;CXCL8;AA;rs4073;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERONS;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR) TO INTERFERON MONOTHERAPY IN HCV GENOTYPE 1 PATIENTS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;;G;rs4888024;TOXICITY;NAN;NAN;SIDE EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG;rs1128503;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AC + CT;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC1;AA;rs3784862;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE IN MEN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;A;rs945665113;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN  OTHER:PCI-SCHEDULED PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLC22A5;C;rs2631367;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;PRIMARY CLINICAL ENDPOINT OF DEATH DUE TO CARDIOVASCULAR CAUSES;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;NON-FATAL MI OR STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;PRIMARY CLINICAL ENDPOINT OF DEATH DUE TO CARDIOVASCULAR CAUSES;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NON-FATAL MI OR STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLC22A5;C;rs2631370;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;PTGS2;CG + GG;rs20417;NAN;DECREASED;RISK;DISEASE;STROKE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;G;rs376695472;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRB2;GG;rs1042713;EFFICACY;DECREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYS;G;rs2959023;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;IL4R;C;rs1805015;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;CG + GG;rs20417;OTHER;INCREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;PTGS2;CG + GG;rs20417;OTHER;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYS;G;rs2669429;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CLCN6, MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;SLC22A5;C;rs2631372;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;IL4R;G;rs1801275;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;BDNF;TT;rs16917234;TOXICITY;DECREASED;AGE AT ONSET;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;T;rs267606619;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC4;CC + CT;rs1751034;METABOLISM/PK;INCREASED;NAN;PK;INTRACELLULAR TENOFOVIR DIPHOSPHATE (TFV-DP) CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN;;CAUTION_SIDE_EFFECT
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;;CAUTION_SIDE_EFFECT
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:INFLUENZA;;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN;;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DIARRHEA IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:INFLUENZA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;DTNBP1;T;rs35514893;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP1B1;CC + CG;rs1056836;OTHER;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
THIOTEPA;GSTP1;T;rs1138272;OTHER;INCREASED;NAN;PK;NON-INDUCIBLE THIOTEPA CLEARANCE AND DECREASED TEPA CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;TT;rs1751034;OTHER;INCREASED;NAN;PK;TENOFOVIR RENAL CLEARANCE;;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;TT;rs1751034;OTHER;INCREASED;NAN;PK;AND LOWER AUC NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;A;rs2786783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;G6PD;T;rs72554664;OTHER;INCREASED;LIKELIHOOD;OTHER;DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;G6PD;T;rs72554664;OTHER;INCREASED;LIKELIHOOD;OTHER;TYPE 2 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;;T;rs12442183;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;KL;G;rs450789;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A;IRF6;G;rs2205986;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;CAUTION_SIDE_EFFECT
INTERFERON BETA-1B;IRF6;G;rs2205986;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;NR1I2;C;rs3814058;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;A;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;BONE MARROW DISORDER IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;WNT5B;CC;rs2010851;EFFICACY;DECREASED;NAN;OTHER;TIME TO TUMOR RECURRENCE (TTR) IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ME3;A;rs2125362;EFFICACY;INCREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;GG;rs508448;TOXICITY;DECREASED;AGE AT ONSET;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NR1I2;G;rs6785049;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;LHX2;A;rs7851998;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;C;rs2811178;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;LHFPL3;G;rs61585310;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;IL10;CC;rs1800896;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;BONE MARROW DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;BDNF;TT;rs6265;TOXICITY;DECREASED;AGE AT ONSET;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;T;rs12208357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;TRDN;T;rs4897302;EFFICACY;INCREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;rs55781567;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;AA;rs4654327;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GIPR;AA + AT;rs10423928;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs503464;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;G;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;rs55853698;TOXICITY;INCREASED;NAN;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
AMANTADINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_DOSE_ADJUST
AMANTADINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
AMANTADINE;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
ANTICHOLINERGICS;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_DOSE_ADJUST
ANTICHOLINERGICS;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
ANTICHOLINERGICS;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
DOPAMINE AGONISTS;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_DOSE_ADJUST
DOPAMINE AGONISTS;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
DOPAMINE AGONISTS;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
LEVODOPA;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_DOSE_ADJUST
LEVODOPA;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
LEVODOPA;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
SELEGILINE;SLC22A1;C;rs622342;DOSAGE;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_DOSE_ADJUST
SELEGILINE;SLC22A1;C;rs622342;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
SELEGILINE;SLC22A1;C;rs622342;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
MELPHALAN;POLR1G;A;rs967591;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND TIME-TO-TREAT FAILURE IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MELPHALAN;POLR1G;A;rs967591;TOXICITY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL AND TIME-TO-TREAT FAILURE IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ACOT7;G;rs11121611;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:COGNITIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SCAP;CC + CT;rs12487736;EFFICACY;DECREASED;SEVERITY;EFFICACY;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:METABOLIC SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;APOBEC3B;A;rs5995653;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CDA;CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
MONTELUKAST;ABCC1;CT;rs119774;EFFICACY;INCREASED;NAN;EFFICACY;CHANGES IN FEV1 IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIAMCINOLONE;HCG22;T;rs2523864;TOXICITY;INCREASED;NAN;SIDE EFFECT;OCULAR HYPERTENSION IN PEOPLE WITH  DISEASE:RETINAL DISEASES;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CREB1, METTL21A;GG;rs7569963;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;CAUTION_SIDE_EFFECT
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;A;rs184278615;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;;T;rs4675690;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT-EMERGENT SUICIDALITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CITALOPRAM;CREB1, METTL21A;A;rs7569963;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT-EMERGENT SUICIDALITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;T;rs201469165;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
"""RITONAVIR""";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
TRIAMCINOLONE;HCG22;G;rs3873352;TOXICITY;INCREASED;NAN;SIDE EFFECT;OCULAR HYPERTENSION IN PEOPLE WITH  DISEASE:RETINAL DISEASES;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:FATIGUE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;C;rs1071748;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CHLORTHALIDONE;NPPA;G;rs5065;EFFICACY;DECREASED;NAN;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SOD2;G;rs4880;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;C;rs2740574;TOXICITY;DECREASED;RISK;SIDE EFFECT;PRIMARY OVARIAN FAILURE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;CC;rs714368;TOXICITY;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;SLC22A16;CC;rs714368;METABOLISM/PK;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;AGRANULOCYTOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
PHENYTOIN;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;RISK;SIDE EFFECT;ORAL MUCOSITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;ORAL MUCOSITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGIC CYSTITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;HEMORRHAGIC CYSTITIS IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;G;rs973541788;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;TOXICITY;DECREASED;RISK;SIDE EFFECT;VENOOCCLUSIVE DISEASE OF THE LIVER IN PEOPLE WITH  OTHER:HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;VENOOCCLUSIVE DISEASE OF THE LIVER IN PEOPLE WITH  OTHER:HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs28371725;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SLEEP DISORDERS IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;MTHFR;A;rs1801133;OTHER;NAN;NAN;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;rs1801133;OTHER;NAN;NAN;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:RECIPIENTS OF HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CARBOPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:GALLBLADDER NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:GALLBLADDER NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:GALLBLADDER NEOPLASMS;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs2004511;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;rs8133052;EFFICACY;DECREASED;NAN;EFFICACY;TUMOR RESPONSE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY;DECREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;G;rs8133052;METABOLISM/PK;DECREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;A;rs1056892;DOSAGE;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
DOXORUBICIN;CBR3;A;rs1056892;METABOLISM/PK;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
ANTIHYPERTENSIVES;ATP2B1;AA + AG;rs1401982;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;A;rs28371702;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS IN WOMEN WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
HEROIN;GRM3;A;rs724226;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:ATRIAL FLUTTER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:VENOUS THROMBOSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
CORTICOSTEROIDS;CRHR1;AA;rs242941;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT CHANGE IN FEV IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CLCN6, MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;FKBP5;AA + AG;rs4713916;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;GLUCOCORTICOID RESPONSIVENESS IN PEOPLE WITH  DISEASE:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;CRHR1;AA;rs242941;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
FLUTICASONE PROPIONATE;CRHR1;AA;rs242941;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;G;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:LOW BACK PAIN;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;CRHR1;TT;rs1876828;EFFICACY;INCREASED;NAN;EFFICACY;PERCENT CHANGE IN FEV IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;;C;rs1155463;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;CRHR1;TT;rs1876828;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
FLUTICASONE PROPIONATE;CRHR1;TT;rs1876828;EFFICACY;NAN;NAN;PK;DELAYED CORTISOL RESPONSE TO STRESS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROTHIAZIDE;;A;rs61824877;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CHLOROTHIAZIDE;;A;rs61824877;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;;A;rs61824877;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;;A;rs61824877;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;NAUSEA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CHLOROTHIAZIDE;HMGCS2;G;rs9943291;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
METHOTREXATE;CLCN6, MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHADONE;DAO;TT;rs55944529;EFFICACY;INCREASED;SEVERITY;EFFICACY;SUBSTANCE WITHDRAWAL SYNDROME IN PEOPLE WITH  OTHER:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;KCNIP1, KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;RISK;DISEASE;HYPERTENSION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AT;rs2032582;TOXICITY;INCREASED;RISK;DISEASE;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
DABIGATRAN;ABCB1;CC + CT;rs4148738;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:STROKE;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL23R;TT;rs10489629;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
INFLIXIMAB;SLCO1C1;GG;rs3794271;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR FUNCTION (LVEF) IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;A;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC1;CT + TT;rs3743527;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCB1;AC + CC;rs12720066;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;C;rs3743078;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB4;G;rs3813567;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC1;AG + GG;rs17501331;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;NAN;NAN;EFFICACY;SIGNIFICANTLY GREATER IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION (LVEF) IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CEREBRAL PALSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEARING LOSS IN CHILDREN WITH  OTHER:NEONATAL HYPERBILIRUBINEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;NT5C2;CT;rs10883841;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
INFLIXIMAB;ADAM17;TT;rs10929587;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:CROHN DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;MED12L, P2RY12;AG;rs10935838;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;AGO2;AA + AC;rs4961280;OTHER;DECREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_DOSE_ADJUST
STAVUDINE;TNF;C;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROPATHY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MED12L, P2RY12;AG;rs2046934;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;MED12L, P2RY12;AC;rs6809699;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;rs684513;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;C;rs267606618;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs637137;OTHER;DECREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL1A;A;rs1800587;OTHER;INCREASED;SEVERITY;DISEASE;PAIN IN PEOPLE WITH  DISEASE:ANEMIA;;CAUTION_SIDE_EFFECT
NAN;IL1A;A;rs1800587;OTHER;INCREASED;SEVERITY;DISEASE;SICKLE CELL;;CAUTION_SIDE_EFFECT
FLUTICASONE / SALMETEROL;CRHR1;CC;rs242941;EFFICACY;INCREASED;NAN;EFFICACY;MEAN CHANGE IN FEV IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;COMT;G;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;;CAUTION_SIDE_EFFECT
PROPRANOLOL;COMT;G;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;CYP27B1, METTL1;GT + TT;rs10877012;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS B VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPRANOLOL;COMT;G;rs4818;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;;CAUTION_SIDE_EFFECT
PROPRANOLOL;COMT;G;rs4818;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;APOBEC3B;T;rs6001366;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS B VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;KCNN1;C;rs2278992;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;VDR;AA;rs7975232;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS B VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ANKRD30B;A;rs12959468;EFFICACY;DECREASED;SEVERITY;DISEASE;ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CRP;CT + TT;rs1205;EFFICACY;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;CRP;CT + TT;rs1205;OTHER;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CRP;CT + TT;rs1205;METABOLISM/PK;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
PROPRANOLOL;COMT;G;rs6269;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;;CAUTION_SIDE_EFFECT
PROPRANOLOL;COMT;G;rs6269;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:ANEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;GRM3;T;rs2189814;OTHER;INCREASED;RISK;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;;CC + CT;rs2808630;EFFICACY;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;;CC + CT;rs2808630;OTHER;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;;CC + CT;rs2808630;METABOLISM/PK;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;AT + TT;rs204076;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;EFFICACY;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;OTHER;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;METABOLISM/PK;DECREASED;NAN;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING AND GREATER INCREASE IN LVEF (LEFT VENTRICULAR EJECTION FRACTION) IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;COMT;C;rs4633;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN WOMEN WITH  EFFICACY:PAIN;;CAUTION_SIDE_EFFECT
PROPRANOLOL;COMT;C;rs4633;EFFICACY;INCREASED;SEVERITY;EFFICACY;DISEASE:TEMPOROMANDIBULAR JOINT DISORDER;;CAUTION_SIDE_EFFECT
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROMYCIN;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:BACTERIAL INFECTIONS;;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:INFLUENZA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;KCNIP1, KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;NAN;OTHER;BLOOD PRESSURE IN MEN  NAN;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN CHILDREN WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;AC;rs118192162;TOXICITY;NAN;NAN;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_DOSE_ADJUST
ISOFLURANE;RYR1;AC;rs118192162;TOXICITY;NAN;NAN;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;NR1I2;GG;rs7643645;METABOLISM/PK;DECREASED;NAN;PK;9-HYDROXY-RISPERIDONE LEVELS IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;GG;rs2306283;OTHER;DECREASED;NAN;PK;REPAGLINIDE PLASMA CONCENTRATION (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;GG;rs2306283;METABOLISM/PK;DECREASED;NAN;PK;REPAGLINIDE PLASMA CONCENTRATION (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HALOTHANE;RYR1;CT;rs118192161;TOXICITY;NAN;NAN;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_DOSE_ADJUST
RISPERIDONE;NR1I2;GG;rs7643645;METABOLISM/PK;DECREASED;NAN;PK;ACTIVE MOIETY LEVELS IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN CHILDREN WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;CYP2D6;AA + AG;rs1065852;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;DECREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR INHIBITORS;PIK3CA;C;rs6443624;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR INHIBITORS;PIK3CA;T;rs2677760;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MISOPROSTOL;SLCO1B1;GG;rs4149087;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER IN WOMEN WITH  DISEASE:POST-PARTUM HEMORRHAGE;;CAUTION_SIDE_EFFECT
MISOPROSTOL;ABCC4;AA;rs11568658;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FEVER IN WOMEN WITH  DISEASE:POST-PARTUM HEMORRHAGE;;CAUTION_SIDE_EFFECT
MISOPROSTOL;ABCC4;AA;rs11568658;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:THERAPEUTIC ABORTION;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;A;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PEAR1;A;rs12041331;EFFICACY;DECREASED;NAN;EFFICACY;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;ALOX15;C;rs3892408;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
NON-STEROIDS;ALOX15;C;rs3892408;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
METHADONE;CCL11;A;rs1129844;TOXICITY;INCREASED;NAN;SIDE EFFECT;INSOMNIA IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;PIK3CA;C;rs2699905;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;EXANTHEMA IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;;GG;rs2433320;EFFICACY;DECREASED;NAN;EFFICACY;HAMD SCORES IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;MTHFR;G;rs1801133;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;MTHFR;G;rs1801133;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ASPARAGINASE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISOLONE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;PTGS1;C;rs5789;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-STEROIDS;PTGS1;C;rs5789;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA;;CAUTION_SIDE_EFFECT
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;T;rs121434568;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION NEGATIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGASPARGASE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;PTGS1;A;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
NON-STEROIDS;PTGS1;A;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ASPIRIN-INDUCED ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;NAN;DISEASE;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;NAN;DISEASE;BCR-ABL1 POSITIVE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GABRG3;A;rs2061051;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
GEMCITABINE;;CT + TT;rs642990;TOXICITY;DECREASED;RISK;DISEASE;NEUTROPENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;LONGER MEDIAN PROGRESSION-FREE SURVIVAL TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;A;rs1042858;DOSAGE;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
CARBOPLATIN;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;;AG + GG;rs17661089;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;rs246240;TOXICITY;DECREASED;RISK;SIDE EFFECT;ONSET OF TOXICITY IN PEOPLE WITH  DISEASE:PSORIASIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;EPB41;AA;rs6702335;EFFICACY;INCREASED;NAN;EFFICACY;ABSTINENCE IN MEN WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;EPB41;AA;rs6702335;EFFICACY;INCREASED;NAN;EFFICACY;ABSTINENCE IN MEN WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;G;rs62328061;TOXICITY;DECREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL17F;CC;rs763780;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL17A;AA;rs2275913;OTHER;INCREASED;LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;KCNIP4;A;rs145489027;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;KCNIP4;A;rs145489027;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;ATIC;C;rs12995526;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;A;rs910080;TOXICITY;INCREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:BILIARY TRACT NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE;DISEASE:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;KCNIP4;C;rs1495509;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;KCNIP4;C;rs1495509;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
XELOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;ALG10;AA + AG;rs1705772;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
RITONAVIR;APOC3;C;rs2854116;OTHER;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PEMETREXED;GGH;CT + TT;rs16930092;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;UGT1A4;GG;rs3732218;METABOLISM/PK;INCREASED;NAN;PK;GLUCURONIDATION IN  OTHER:HUMAN LIVER MICROSOMES;;CAUTION_DOSE_ADJUST
HALOPERIDOL;CYP2D6;CT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL WITHDRAWAL DELIRIUM;;CAUTION_SIDE_EFFECT
FOLFIRI;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
XELOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS;KCNIP4;A;rs7675300;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;KCNIP4;A;rs7675300;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;VEGFA;CC;rs2010963;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING IN WOMEN  OTHER:SMOKERS WHO ARE PREGNANT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;TRAF3IP2;C;rs76228616;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;TRAF3IP2;C;rs76228616;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
GEMCITABINE;ALOX5AP;AG + GG;rs4769060;METABOLISM/PK;DECREASED;NAN;PK;CMAX AND A LOWER MEAN AUC NAN  NAN;;CAUTION_DOSE_ADJUST
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
SUFENTANIL;OPRM1;AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
IPILIMUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
NIVOLUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;NAN;SIDE EFFECT;DEATH IN CHILDREN WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;NAN;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;NAN;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
FOLFIRI;BRAF;T;rs113488022;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;BRAF;T;rs113488022;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
XELOX;BRAF;T;rs113488022;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;CLCN6, MTHFR;AG + GG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
OPIOIDS;TH;G;rs2070762;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2E1, DUX1;AT;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;CYP2E1, DUX1;AT;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO TUMOR RECURRENCE IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO TUMOR RECURRENCE IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO TUMOR RECURRENCE IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DBH;G;rs1611131;TOXICITY;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HSPG2;C;rs2445142;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
FOLFIRI;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
XELOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;HSPG2;T;rs878949;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;RIMS1;CC + CT;rs502046;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;RIMS1;CC + CT;rs502046;TOXICITY;DECREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;TAS2R16;C;rs846664;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;G;rs1139130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;C1orf167, CLCN6, MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;SCN1A;CC;rs3812718;OTHER;DECREASED;NAN;OTHER;TIME TO TUMOR RECURRENCE (TTR) IN  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIEPILEPTICS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIEPILEPTICS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME IN THERAPEUTIC RANGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;rs2472677;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;NAN;EFFICACY;VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DACTINOMYCIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;CG + GG;rs2010963;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
CISPLATIN;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DACTINOMYCIN;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;AA + AG;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCULAR DISEASES;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:RHABDOMYOLYSIS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;COCAINE DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DISEASE:HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;COCAINE DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DISEASE:HEROIN DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CETUXIMAB;KRAS;A;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;KRAS;A;rs112445441;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;T;rs1799853;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NAN;MTR;GG;rs1805087;OTHER;INCREASED;LIKELIHOOD;DISEASE;RHEUMATOID ARTHRITIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METHOTREXATE-INDUCED NODULOSIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
"""ACETAMINOPHEN""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
"""ACETAMINOPHEN""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
"""ANTIEPILEPTICS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
"""ANTIEPILEPTICS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
"NON-STEROIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
"NON-STEROIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
"""OPIOIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
"""OPIOIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:METASTATIC NEOPLASM;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;AUC0-12 IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RISK;EFFICACY;DISCONTINUATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
FLUOROURACIL;SCN1A;TT;rs3812718;OTHER;DECREASED;NAN;OTHER;TIME TO TUMOR RECURRENCE (TTR) IN  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_DOSE_ADJUST
ATAZANAVIR;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;rs4363657;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;TOXICITY;DECREASED;RISK;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;TOXICITY;INCREASED;RISK;DISEASE;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CT + TT;rs4803419;TOXICITY;INCREASED;RISK;SIDE EFFECT;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs1801160;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ALLOPURINOL;PSORS1C1;AG + GG;rs3131003;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;DISEASE;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;DISEASE;DISEASE:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;CT + TT;rs1997794;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CYP2A6;GG;rs8192733;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CYP2A6;GG;rs8192733;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIEPILEPTICS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIEPILEPTICS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;CC;rs1022563;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RISPERIDONE;LEP;GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;;CAUTION_SIDE_EFFECT
RISPERIDONE;LEP;GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
PERINDOPRIL;AGTR1;TT;rs5182;EFFICACY;DECREASED;RISK;EFFICACY;CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;GG;rs602950;EFFICACY;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;GG;rs602950;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;GG;rs602950;METABOLISM/PK;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_DOSE_ADJUST
CYTARABINE;CDA;GG;rs602950;METABOLISM/PK;INCREASED;NAN;EFFICACY;MYELOID;;CAUTION_DOSE_ADJUST
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  DISEASE:ALCOHOLIC PSYCHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:ALCOHOL-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;TT;rs532545;METABOLISM/PK;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_DOSE_ADJUST
CYTARABINE;CDA;TT;rs532545;METABOLISM/PK;INCREASED;NAN;EFFICACY;MYELOID;;CAUTION_DOSE_ADJUST
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;RBMS3;A;rs17024608;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;OSTEONECROSIS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;NEDD4L;AG;rs4149601;OTHER;INCREASED;RISK;DISEASE;CARDIOVASCULAR DISEASE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AC;rs55886062;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;INSIG2;C;rs17587100;OTHER;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CTLA4;A;rs3087243;OTHER;DECREASED;RISK;DISEASE;RHEUMATOID ARTHRITIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs115232898;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:LIVER CIRRHOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC4;G;rs1059751;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;KIDNEY DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
EPIRUBICIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;CC;rs2072671;EFFICACY;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;CC;rs2072671;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;CC;rs2072671;METABOLISM/PK;INCREASED;NAN;EFFICACY;CYTOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_DOSE_ADJUST
CYTARABINE;CDA;CC;rs2072671;METABOLISM/PK;INCREASED;NAN;EFFICACY;MYELOID;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;NOTCH4;AA + AG;rs367398;TOXICITY;DECREASED;RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NQO1;AA;rs1800566;OTHER;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;NAN;NAN;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
EPIRUBICIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;NAN;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:CHEMOREFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;RISK;EFFICACY;IMMUNOLOGICAL FAILURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER;SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;GT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SLEEP DISORDERS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;CACNA1C;AA;rs1051375;EFFICACY;DECREASED;RISK;OTHER;PRIMARY OUTCOME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;MEDIAN SURVIVAL TIME (MST) IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA LEVEL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2A6;AC + CC;rs28399433;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
VERAPAMIL;CACNA1C;GG;rs1051375;EFFICACY;INCREASED;RISK;EFFICACY;PRIMARY OUTCOME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
EPIRUBICIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG IN USERS WITH A STARTING DOSE OF MORE THAN 20 MG NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;;AG;rs12118636;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;;AG;rs12118636;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;;AG;rs12118636;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN WOMEN WITH  DISEASE:FEMALE REPRODUCTIVE SYSTEM NEOPLASM;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;NAN;NAN;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;TT;rs116855232;TOXICITY;NAN;NAN;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;ABCB1;AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;MEDIAN SURVIAL TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  EFFICACY:NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NRAS;CT;rs1065634;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;NRAS;CT;rs1065634;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NRAS;CT;rs1065634;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  EFFICACY:NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ACTG1;A;rs1135989;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;T;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME IN INFANTS  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ATP7B;AA;rs1801249;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;ATP7B;AA;rs1801249;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;CAPG;T;rs3770102;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;COL1A1;AA + AC;rs1800012;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCB1;A;rs4728709;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;AKR1C3;GG;rs1937840;OTHER;DECREASED;NAN;OTHER;ABSOLUTE LEUCOCYTE AND NEUTROPHIL COUNTS ON DAY 15 IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;AA;rs2279343;TOXICITY;INCREASED;SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME IN INFANTS  NAN;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2C9;CC;rs1799853;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DYSPEPSIA IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOPROFEN;CYP2C9;CC;rs1799853;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;OTHER;TIME TO THERAPEUTIC INR IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
REMIFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN WOMEN WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;GSR;CC;rs3594;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;GSR;CC;rs3594;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;T;rs4251417;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;VEGFA;TT;rs6900017;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;VEGFA;TT;rs6900017;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALOXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;NAN;EFFICACY;CORTISOL RESPONSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SLC6A4;C;rs25531;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS;VDR;AG + GG;rs2228570;TOXICITY;DECREASED;RISK;SIDE EFFECT;CRYOGLOBULINEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;VDR;AG + GG;rs2228570;TOXICITY;DECREASED;RISK;SIDE EFFECT;CRYOGLOBULINEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
EGFR INHIBITORS;PIK3CA;C;rs2677760;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CETUXIMAB;EGFR;AA + AG;rs2227983;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EGFR INHIBITORS;PIK3CA;T;rs2459693;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;GG;rs2372536;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;A;rs2066713;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;EXACERBATIONS IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;IL1B;AA + AG;rs4849127;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;IL1B;AA + AG;rs4849127;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;CYP2D6;GG;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;GG;rs1801265;METABOLISM/PK;INCREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  OTHER:WITHOUT THE RS115232898 A>G VARIANT (DPYD Y186C);;CAUTION_DOSE_ADJUST
EGFR INHIBITORS;PIK3CA;C;rs6443624;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;IL1B;AG;rs16944;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;IL1B;AG;rs16944;TOXICITY;INCREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GINGIVAL OVERGROWTH IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TRANSPLANTATION;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;PIK3CA;T;rs2677760;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY;UNCONTROLLED ASTHMA IN CHILDREN WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;IL1B;AA;rs1143634;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;IL1B;AA;rs1143634;TOXICITY;DECREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;TOXICITY;DECREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;TOXICITY;DECREASED;NAN;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADGRL3;CG + GG;rs2345039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;NAN;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;CAUTION_DOSE_ADJUST
CARBOPLATIN;ATP7B;TT;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;ATP7B;TT;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;T;rs4379368;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NAN;FMO3;AG + GG;rs2266780;OTHER;DECREASED;SEVERITY;DISEASE;TOBACCO USE DISORDER IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;C;rs710446;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPIRIN;LPA;CT;rs3798220;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
BOCEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;T;rs3814637;TOXICITY;NAN;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs72728438;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;ABCC11;GG + GT;rs7194667;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;PIK3CA;C;rs2699905;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs115632870;METABOLISM/PK;DECREASED;NAN;PK;DPD ACTIVITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;del;rs56392308;TOXICITY;DECREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A3;AG;rs6350;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;C;rs8176719;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;G;rs9574;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;T;rs2289252;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOSIS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;NAN;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;NR1I2;CC;rs3814057;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;BRADYCARDIA;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;NR1I2;CC;rs3814057;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPOTENSIVE DISORDER IN CHILDREN WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
NAN;MAOA;TT;rs1137070;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MAOB;CC;rs1799836;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOBACCO USE DISORDER IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;;C;rs9936750;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;NAN;SIDE EFFECT;INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;NAN;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;NAN;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;GG;rs4124874;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MYELOSUPPRESSION NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;GG;rs4444903;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE PATHOLOGIC RESPONSE IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HAVCR2;AA + AC;rs10515746;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HAVCR2;AC + CC;rs1036199;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;;T;rs12459996;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;OR10AE3P, PSMB3P;A;rs10876844;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;BDNF;TT;rs6265;OTHER;INCREASED;RISK;OTHER;ADDICTION NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;T;rs6265;OTHER;INCREASED;RISK;OTHER;ADDICTION NAN  NAN;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;T;rs540825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;T;rs540825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;T;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
AFATINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;;GG;rs2207418;OTHER;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:HEART FAILURE;;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;RESPIRATORY INSUFFICIENCY IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs9332197;EFFICACY;NAN;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;NAN;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C18;AG + GG;rs2901783;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F5;G;rs6018;TOXICITY;NAN;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;PROS1;AA;rs8178607;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRM3;GG;rs2165870;TOXICITY;INCREASED;RISK;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;CDA;AA;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;G;rs1801265;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;NAN;SIDE EFFECT;MICRONUCLEATED BINUCLEATED CELLS NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG;rs1801274;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SCN5A;GT + TT;rs7626962;OTHER;INCREASED;LIKELIHOOD;DISEASE;CARDIAC RHYTHM DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;VEGFA;GG;rs879825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;VEGFA;GG;rs879825;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
EXEMESTANE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;AG + GG;rs1801394;METABOLISM/PK;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
CARBOPLATIN;SCN10A;TT;rs9825762;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;SCN10A;TT;rs9825762;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;VEGFA;CC;rs9369421;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;VEGFA;CC;rs9369421;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;ESR1;TT;rs4870061;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN MEN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
EXEMESTANE;ESR1;TT;rs9322335;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;NQO1;AA;rs1800566;OTHER;DECREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
ETOPOSIDE;NQO1;AA;rs1800566;OTHER;DECREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
CISPLATIN;SLC22A2;AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
LETROZOLE;ESR2;CC;rs10140457;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;ESR1;AA;rs2813543;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
BISPHOSPHONATES;;C;rs2736308;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;;C;rs2736308;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  OTHER:OSTEOPOROSIS;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;PTGS1;TT;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NON-STEROIDS;PTGS1;TT;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;TNF;A;rs1800629;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;TNF;A;rs1800629;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;CC;rs2305948;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;CC;rs2305948;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;COMT;AG + GG;rs4680;OTHER;DECREASED;NAN;OTHER;LENGTH OF HOSPITAL STAY IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;;CAUTION_DOSE_ADJUST
CARBOPLATIN;PRRC2A;G;rs11229;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;PRRC2A;G;rs11229;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;PRRC2A;T;rs10885;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;PRRC2A;T;rs10885;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
METHADONE;COMT;AG + GG;rs4680;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  OTHER:NEONATAL ABSTINENCE SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;AG + GG;rs4680;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  OTHER:NEONATAL ABSTINENCE SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;FLT1;TT;rs664393;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;FLT1;TT;rs664393;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;MSH5;T;rs3115672;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;MSH5;T;rs3115672;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEC100;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;ATP2B1;T;rs17381194;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;DOCK8;A;rs10491684;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;DOCK8;A;rs10491684;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;;C;rs4693570;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;CAUTION_SIDE_EFFECT
NAN;EPO;A;rs1617640;OTHER;INCREASED;NAN;OTHER;ENDOGENOUS LEVELS OF EPO IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;DMPK;G;rs672348;TOXICITY;INCREASED;RISK;DISEASE;MYALGIA IN PEOPLE WITH  DISEASE:HYPERLIPIDEMIAS;;CAUTION_SIDE_EFFECT
ASPIRIN;EYA1;T;rs12678747;TOXICITY;INCREASED;RISK;SIDE EFFECT;PEPTIC ULCER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CYP2C8;A;rs1058932;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CYP2C8;A;rs1058932;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;CYP2C8;A;rs11572078;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CYP2C8;A;rs11572078;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZITHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CHLORPROMAZINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CILOSTAZOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CIPROFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CITALOPRAM;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CLARITHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
DOFETILIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
DONEPEZIL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
DRONEDARONE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
FLECAINIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
FLUCONAZOLE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
HALOPERIDOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
LEVOFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
METHADONE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
MOXIFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
ONDANSETRON;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
OXALIPLATIN;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
PAPAVERINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
PENTAMIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
PROCAINAMIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
PROPOFOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
QUINIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;C6orf15;A;rs2233980;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;C6orf15;A;rs2233980;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;CDSN;T;rs3130985;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDSN;T;rs3130985;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ETOPOSIDE;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN  EFFICACY:BRONCHIOLOALVEOLAR CARCINOMA AND ADENOCARCINOMA PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;TREATMENT IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ2;A;rs6535454;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN INTOLERANCE;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ2;A;rs6535454;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY NAN  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN INTOLERANCE;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;HLA-C;C;rs1049709;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;HLA-C;C;rs1049709;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:BRONCHIOLOALVEOLAR CARCINOMA AND ADENOCARCINOMA PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;HCP5;G;rs3130907;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;HCP5;G;rs3130907;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CTNNB1;AA;rs4135385;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;SERPINC1;C;rs5877;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SERPINC1;C;rs5877;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIAC RHYTHM DISEASE;;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SIDE EFFECT:CARDIOTOXICITY IN PEOPLE WITH  ""OTHER:LEUKEMIA";;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOCYTIC;;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CHRONIC;;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"B-CELL""";;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WALDENSTROM MACROGLOBULINEMIA""";;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:MANTLE CELL LYMPHOMA""";;CAUTION_SIDE_EFFECT
TAMOXIFEN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;SCN5A;GG;rs7626962;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUDDEN INFANT DEATH NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;CTNNB1;AA;rs4533622;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;;C;rs886423;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;;C;rs886423;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;;T;rs886424;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;;T;rs886424;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ATAT1;C;rs9262132;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;ATAT1;C;rs9262132;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABO;GG;rs495828;METABOLISM/PK;INCREASED;NAN;OTHER;ACE ACTIVITY IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
CARBOPLATIN;PPP1R18;T;rs9262143;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;PPP1R18;T;rs9262143;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
NAN;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;NAN;OTHER;LENGTH OF HOSPITAL STAY IN INFANTS WITH  DISEASE:NEONATAL ABSTINENCE SYNDROME;;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;;CC;rs4604006;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIAC RHYTHM DISEASE;;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SIDE EFFECT:CARDIOTOXICITY IN PEOPLE WITH  ""OTHER:LEUKEMIA";;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOCYTIC;;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CHRONIC;;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"B-CELL""";;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WALDENSTROM MACROGLOBULINEMIA""";;CAUTION_SIDE_EFFECT
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:MANTLE CELL LYMPHOMA""";;CAUTION_SIDE_EFFECT
CARBOPLATIN;MUCL3;A;rs3094086;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;MUCL3;A;rs3094086;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
OLANZAPINE;GIPR;AA;rs10423928;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA INSULIN LEVELS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
SORAFENIB;;CC;rs4604006;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;;A;rs28714259;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CTLA4;A;rs231775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GINGIVAL OVERGROWTH IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;POSTOPERATIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
NAN;ABCC4;AA + AC;rs2274407;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PHYSICAL AND LIFE WELL-BEING QUALITY OF LIFE (QOL) SCALES IN  OTHER:PEOPLE WITH EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  OTHER:EGFR MUTATION POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;INCREASED;RISK;EFFICACY;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RISK;EFFICACY;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;EFFICACY;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PAZOPANIB;HFE;TT;rs2858996;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;;GG;rs2207418;OTHER;INCREASED;RISK;DISEASE;HEART FAILURE NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;TROUGH CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
GLATIRAMER ACETATE;;A;rs75041078;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;CAUTION_SIDE_EFFECT
GLATIRAMER ACETATE;;A;rs1056854;TOXICITY;INCREASED;RISK;DISEASE;CORONARY ARTERY DISEASE IN PEOPLE WITH  DISEASE:MULTIPLE SCLEROSIS;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE;METHAMPHETAMINE DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:PSYCHOTIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;CT + TT;rs2229109;EFFICACY;INCREASED;RISK;EFFICACY;RENAL TRANSPLANT FAILURE IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3;CC;rs4803217;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPOVENTILATION IN PEOPLE WITH  DISEASE:PAIN;;CAUTION_SIDE_EFFECT
FENTANYL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;NAN;PK;TROUGH LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;NAN;PK;TROUGH LEVELS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
AFATINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CT + TT;rs2031920;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEPRESSION;;CAUTION_SIDE_EFFECT
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:GASTRITIS;;CAUTION_SIDE_EFFECT
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HYPERSENSITIVITY IN PEOPLE WITH  OTHER:ACUTE RESPIRATORY DISEASES;;CAUTION_SIDE_EFFECT
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:SUSPECTED INFLUENZA A/H1N1 INFECTION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;AA + AT;rs9895420;TOXICITY;INCREASED;NAN;SIDE EFFECT;PLASMA LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;AA + AT;rs9895420;METABOLISM/PK;INCREASED;NAN;SIDE EFFECT;PLASMA LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
COCAINE;OPRD1;T;rs678849;TOXICITY;DECREASED;RISK;OTHER;COCAINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERIVASTATIN;RYR2;AA;rs2819742;TOXICITY;DECREASED;RISK;DISEASE;RHABDOMYOLYSIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCC2;A;rs2273697;EFFICACY;INCREASED;NAN;EFFICACY;PROBABILITY OF ANTIEPILEPTIC DRUG RESPONSE IN CHILDREN WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;INCREASED;RISK;EFFICACY;RELAPSE IN THE CENTRAL NERVOUS SYSTEM IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;CYP1A2;T;rs35694136;OTHER;INCREASED;LIKELIHOOD;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYMOCYTE GLOBULIN;FCGR3A;AC + CC;rs396991;OTHER;INCREASED;NAN;OTHER;SENSITIVE TO ANTILYMPHOCYTE SERUM IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;ARHGAP28;T;rs9958628;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;;CAUTION_SIDE_EFFECT
IFOSFAMIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;;CAUTION_SIDE_EFFECT
THEOPHYLLINE;CYP1A2;T/del + TT;rs35694136;EFFICACY;INCREASED;SEVERITY;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;CAUTION_SIDE_EFFECT
THEOPHYLLINE;CYP1A2;T;rs35694136;EFFICACY;DECREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;T;rs35694136;METABOLISM/PK;DECREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;CAUTION_DOSE_ADJUST
NAN;CYP1A2;C;rs762551;OTHER;INCREASED;LIKELIHOOD;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;ATP7B;CC;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;CC;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;T;rs921451;NAN;NAN;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_DOSE_ADJUST
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;C;rs3735273;NAN;NAN;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_DOSE_ADJUST
SEVOFLURANE;KCNK2;CC + CG;rs6686529;EFFICACY;INCREASED;NAN;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;T;rs1451371;NAN;NAN;SEVERITY;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_DOSE_ADJUST
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEASE INHIBITORS;APOC3;CC + CT;rs2854116;EFFICACY;DECREASED;SEVERITY;SIDE EFFECT;HYPERTRIGLYCERIDEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNB1, ZBTB4;C;rs2302764;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
PROTEASE INHIBITORS;APOC3;CT + TT;rs2854117;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERTRIGLYCERIDEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNB2;A;rs2072661;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGASPARGASE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
THIOGUANINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VARENICLINE;CHRNB2;T;rs4292956;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
VARENICLINE;CHRNB2;C;rs2072660;TOXICITY;INCREASED;SEVERITY;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;;CAUTION_SIDE_EFFECT
IFOSFAMIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE EFFECT;DEATH IN CHILDREN WITH  OTHER:CENTRAL NERVOUS SYSTEM CANCER;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;DDRGK1, ITPA;A;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA;rs324420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;RESPIRATORY INSUFFICIENCY IN CHILDREN WITH  DISEASE:KYPHOSIS;;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA;rs324420;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCOLIOSIS;;CAUTION_SIDE_EFFECT
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;FAAH;TT;rs11576941;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN WITH  DISEASE:KYPHOSIS;;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;TT;rs11576941;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCOLIOSIS;;CAUTION_SIDE_EFFECT
PROTEASE INHIBITORS;APOC3;CG + GG;rs5128;TOXICITY;DECREASED;NAN;SIDE EFFECT;HYPERTRIGLYCERIDEMIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;rs11045585;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
APIXABAN;ABCB1;CT + TT;rs4148738;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCC2;G;rs12762549;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;rs3213207;NAN;DECREASED;RISK;DISEASE;BIPOLAR DISORDER NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CT;rs5918;OTHER;INCREASED;NAN;OTHER;SENSITIVITY TO ASPIRIN NAN  NAN;;CAUTION_DOSE_ADJUST
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;C/del + del/del;rs3215400;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;INCREASED;LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;PSYCHOTIC DISORDER IN MEN WITH  DISEASE:SUBSTANCE-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;;GG + GT;rs9346455;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;rs3213207;NAN;DECREASED;SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;;CAUTION_SIDE_EFFECT
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
NAN;DTNBP1;C;rs2619539;NAN;DECREASED;SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;CT + TT;rs532545;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;A;rs2236855;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;THROMBOEMBOLISM NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;NRXN1;C;rs2193225;OTHER;NAN;NAN;OTHER;SMOKING QUANTITY IN  OTHER:SMOKERS;;CAUTION_DOSE_ADJUST
HEROIN;OPRD1;C;rs2298897;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;NRXN1;C;rs2193225;OTHER;NAN;NAN;OTHER;SMOKING QUANTITY;;CAUTION_DOSE_ADJUST
NICOTINE;NRXN1;C;rs2193225;OTHER;NAN;NAN;OTHER;HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE IN  OTHER:SMOKERS;;CAUTION_DOSE_ADJUST
NICOTINE;NRXN1;A;rs6721498;OTHER;NAN;NAN;OTHER;SMOKING QUANTITY;;CAUTION_DOSE_ADJUST
NICOTINE;NRXN1;A;rs6721498;OTHER;NAN;NAN;OTHER;HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE IN  OTHER:SMOKERS;;CAUTION_DOSE_ADJUST
SUNITINIB;ABCB1;AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;;CAUTION_SIDE_EFFECT
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE;;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;rs2619538;NAN;DECREASED;SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;FUT2;A;rs492602;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;FTO;A;rs9937709;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM;RICTOR;GG;rs6878291;TOXICITY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;NR3C1;G;rs852977;EFFICACY;INCREASED;NAN;PK;ANTIDEPRESSANT RESPONSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERIVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;DISEASE;RHABDOMYOLYSIS NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR3B;AA;rs1176744;TOXICITY;INCREASED;RISK;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
ETHANOL;;A;rs1783835;TOXICITY;DECREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;A;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN MEN WITH  OTHER:CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SQUAMOUS CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;SLC4A8;C;rs12296477;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;NAN;NAN;OTHER;SHORTER BLEEDING TIME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NAN;NR3C1;G;rs10482633;NAN;INCREASED;NAN;EFFICACY;ANTIDEPRESSANT RESPONSE NAN  NAN;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;HTR2A;C;rs9316233;EFFICACY;INCREASED;NAN;EFFICACY;ANTIDEPRESSANT RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ARID4A;T;rs61974485;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs8008020;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;AG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;TNRC6A;A;rs72768626;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
GLIMEPIRIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;HYPOGLYCEMIA IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIMEPIRIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;TYPE 2;;CAUTION_SIDE_EFFECT
GLIPIZIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;HYPOGLYCEMIA IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLIPIZIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;TYPE 2;;CAUTION_SIDE_EFFECT
GLYBURIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;HYPOGLYCEMIA IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
GLYBURIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER;TYPE 2;;CAUTION_SIDE_EFFECT
KETOROLAC;;CC;rs2562456;EFFICACY;NAN;NAN;EFFICACY;SLOWER ANALGESIC ONSET IN EUROPEAN AMERICANS UNDERGOING ORAL SURGERY NAN  NAN;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING NAN  NAN;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ABCC1;CC + CG;rs2074087;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
FLUVASTATIN;SREBF1;CC;rs60282872;EFFICACY;INCREASED;NAN;EFFICACY;APOLIPOPROTEIN A1 AND C3 IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;SLC19A1;G;rs1051298;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;SLC19A1;G;rs1051298;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TP53;CG;rs1042522;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  OTHER:UTERINE CERVICAL NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TP53;CG;rs1042522;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  OTHER:UTERINE CERVICAL NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;NAN;OTHER;BASELINE PROINSULIN LEVELS AFTER ADJUSTING FOR INSULIN LEVELS IN PEOPLE WITH  OTHER:SUSPECTED INCREASED RISK OF DIABETES;;CAUTION_DOSE_ADJUST
NAN;SLC30A8;C;rs13266634;METABOLISM/PK;INCREASED;NAN;OTHER;BASELINE PROINSULIN LEVELS AFTER ADJUSTING FOR INSULIN LEVELS IN PEOPLE WITH  OTHER:SUSPECTED INCREASED RISK OF DIABETES;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN PEOPLE WITH  OTHER:PAIN;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE;;CAUTION_DOSE_ADJUST
ANTIINFLAMMATORY AGENTS;AGT;GG;rs943580;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-STEROIDS;AGT;GG;rs943580;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS;MMP1, MMP10;AG + GG;rs2071230;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NON-STEROIDS;MMP1, MMP10;AG + GG;rs2071230;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
LEVONORGESTREL;ADAMTS10;CG;rs7255721;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS;MMP1, MMP10;CT + TT;rs7945189;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-STEROIDS;MMP1, MMP10;CT + TT;rs7945189;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEART PALPITATIONS IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS;PTGS1;TT;rs12353214;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NON-STEROIDS;PTGS1;TT;rs12353214;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;KL;CG + GG;rs211247;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NON-STEROIDS;KL;CG + GG;rs211247;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;CRP;CT + TT;rs1205;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NON-STEROIDS;CRP;CT + TT;rs1205;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;AG;rs1044396;OTHER;INCREASED;LIKELIHOOD;OTHER;SMOKING INITIATION IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-STEROIDS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;GG;rs1044396;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER IN MEN  NAN;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;AGT;GG;rs699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-STEROIDS;AGT;GG;rs699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;CC;rs1044397;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOBACCO USE DISORDER IN MEN  NAN;;CAUTION_SIDE_EFFECT
COXIBS;PTGS2;CG + GG;rs20417;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
COXIBS;PTGS2;AG + GG;rs4648276;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
SEVOFLURANE;FASTKD3, MTRR;CC + CT;rs3733784;EFFICACY;INCREASED;NAN;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ADK;TT;rs10824095;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;A;rs1872328;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  DISEASE:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;SLC29A1;CG + GG;rs747199;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;IMPDH2;AG + GG;rs11706052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN CHILDREN WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HEROIN;;A;rs9478495;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;;G;rs9424490;NAN;INCREASED;RISK;OTHER;CURRENT SMOKING NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;USH2A;C;rs12126638;NAN;INCREASED;RISK;OTHER;CURRENT SMOKING NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;AK4;C;rs1109374;NAN;INCREASED;RISK;OTHER;CURRENT SMOKING NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
NAN;ITGB1;AA;rs1187075;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;rs562859;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL PAIN;;CAUTION_SIDE_EFFECT
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ARTHRITIS;;CAUTION_SIDE_EFFECT
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:DISCONTINUATION IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM;STMN1;AA;rs182455;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINORELBINE;STMN1;AA;rs182455;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR;DPYD;TT;rs1801159;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ITGB1;GG;rs2230395;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;rs3778150;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;GGH;G;rs3780126;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;GGH;G;rs3780126;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TPH2;TT;rs1843809;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;AGGRESSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;TPH2;TT;rs1843809;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DEPRESSION IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;RISK;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
HEROIN;;C;rs9384169;TOXICITY;INCREASED;RISK;OTHER;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;NAN;SIDE EFFECT;QT INTERVAL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;;CAUTION_SIDE_EFFECT
BENZODIAZEPINE DERIVATIVES;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;;CAUTION_SIDE_EFFECT
BENZODIAZEPINE DERIVATIVES;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;;CAUTION_SIDE_EFFECT
SYMPATHOMIMETICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;CARDIAC ARREST;;CAUTION_SIDE_EFFECT
SYMPATHOMIMETICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER;OTHER:RESPIRATORY INSUFFICIENCY NAN  OTHER:OVERDOSE;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;GGH;CT;rs11545077;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;GGH;CT;rs11545077;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;NAN;SIDE EFFECT;SHORTENED QT INTERVAL NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;COLLAGEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;AND EPINEPHRINE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;COLLAGEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;NAN;EFFICACY;AND EPINEPHRINE IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;NAN;NAN;EFFICACY;HIGHER FENTANYL DOSE REQUIREMENT TO ACHIEVE ADEQUATE PAIN RELIEF IN CHINESE WOMEN UNDERGOING GYNECOLOGIC SURGERY NAN  NAN;;CAUTION_DOSE_ADJUST
CANNABINOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MIR27A;CT;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;GG;rs7993418;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;NFE2L2;GG + GT;rs6721961;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;NAN;NAN;EFFICACY;HIGHER RESPONSIVENESS TO OPIOIDS AND REQUIRED LESS ANALGESIC DRUGS IN LABORING WOMEN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;NAN;NAN;EFFICACY;HIGHER RESPONSIVENESS TO OPIOIDS AND REQUIRED LESS ANALGESIC DRUGS IN LABORING WOMEN IN WOMEN  NAN;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;HTR2A;CC + CT;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;NAN;NAN;EFFICACY;LESS PAIN CONTROL IN JAPANESE PATIENTS UNDERGOING PAINFUL OROFACIAL COSMETIC SURGERY NAN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;FMO3;GG;rs2266780;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED SERUM OLANZAPINE N-OXIDE CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF METOPROLOL AND GREATER REDUCTIONS IN HEART RATE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED;NAN;PK;DIASTOLIC BLOOD PRESSURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED;NAN;PK;AND MEAN ARTERIAL PRESSURE IN PMS THAN IN NON-PMS. NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;T;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF METOPROLOL AND GREATER REDUCTIONS IN HEART RATE;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;T;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;DIASTOLIC BLOOD PRESSURE;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;T;rs3892097;METABOLISM/PK;INCREASED;NAN;PK;AND MEAN ARTERIAL PRESSURE IN PMS THAN IN NON-PMS. NAN  NAN;;CAUTION_DOSE_ADJUST
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CCN4;AA + AC;rs10956697;EFFICACY;DECREASED;RISK;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CCN4;AA + AC;rs10956697;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;INCREASED;RISK;EFFICACY;THE LACK OF ASPIRIN EFFECT IN MEN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;FMO1;AA + AC;rs12720462;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PSYCHOMOTOR AGITATION IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TAXANES;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;HEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM;ABCB1;CC;rs2032582;TOXICITY;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;ABCB1;CC;rs2032582;TOXICITY;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;FMO1;CT + TT;rs7877;METABOLISM/PK;INCREASED;NAN;PK;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;NAN;EFFICACY;RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;NAN;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;NAN;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TORASEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;NAN;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABINOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IMATINIB;ABCG2;TT;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;NAT2;C;rs4271002;TOXICITY;INCREASED;RISK;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"NAUSEA IN PEOPLE WITH  ""OTHER:PAIN""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:PAIN";;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"POSTOPERATIVE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED;RISK;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
BUMETANIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
FUROSEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TORASEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;CCN4;GG + GT;rs2929973;EFFICACY;DECREASED;RISK;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;TT;rs6311;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED;RISK;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;MYOCD;AA + AG;rs1714984;EFFICACY;NAN;NAN;EFFICACY;INCREASED RISK OF BEING NONRESPONDERS NAN  NAN;;CAUTION_DOSE_ADJUST
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED;RISK;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
BUMETANIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
FUROSEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TORASEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;A;rs1065852;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;DECREASED;RISK;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;CETP;AG;rs708272;EFFICACY;DECREASED;SEVERITY;EFFICACY;CORONARY ARTERY DISEASE IN MEN WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;NAN;EFFICACY;BENEFIT IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;NAN;NAN;EFFICACY;ASPIRIN-DEPRESSED THROMBIN GENERATION AND PROLONGED BLEEDING TIME AFTER ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_DOSE_ADJUST
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;NAN;EFFICACY;INHIBITION OF FXIII ACTIVATION BY ASPIRIN IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;ADRB1;CC + CG;rs1801253;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;C;rs1127354;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;DECREASED;SEVERITY;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;NAN;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;CETP;GG;rs708272;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN LUMINAL DIAMETER IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;;CAUTION_DOSE_ADJUST
DIURETICS;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;;CAUTION_DOSE_ADJUST
SOTALOL;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;;CT + TT;rs6977820;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;NAN;NAN;SIDE EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs17880887;DOSAGE;NAN;NAN;EFFICACY;LOWER LEVELS OF TRANSTHYRETIN PRECUROR NAN  NAN;;CAUTION_DOSE_ADJUST
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;NAN;NAN;SIDE EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;HNMT;G;rs1050891;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACETYLSALICYLIC ACID-INTOLERANT CHRONIC URTICARIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;NAN;NAN;SIDE EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;LTC4S;AC + CC;rs730012;TOXICITY;INCREASED;RISK;SIDE EFFECT;SENSITIVITY TO ASPIRIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;SMYD3;T;rs2485914;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEPATOTOXICTY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;COMPLETE REMISSION IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;;CAUTION_DOSE_ADJUST
LEVONORGESTREL;TP53;CG;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;GP6;AG;rs1613662;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IFOSFAMIDE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3-YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;3-YEAR EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IFOSFAMIDE;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;NAN;NAN;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) NAN  NAN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP4F2;CT + TT;rs2108622;DOSAGE;NAN;NAN;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;NAN;NAN;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) NAN  NAN;;CAUTION_DOSE_ADJUST
ASPIRIN;ITGB3;CT;rs5918;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD LOSS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  OTHER:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;C;rs2305948;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;C;rs2305948;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
CAPECITABINE;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;GSTP1;GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ITGB3;CC + CT;rs5918;OTHER;NAN;NAN;OTHER;SHORTER BLEEDING TIME IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;OTHER;INCREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;CXCR4;AA + AG;rs2228014;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;OTHER;DECREASED;RISK;OTHER;DEATH IN PEOPLE WITH  OTHER:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEC100;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZOLEDRONATE;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT4;GG;rs6877011;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;ABCB5;CT;rs17143212;TOXICITY;INCREASED;NAN;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
DOCETAXEL;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEC100;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZOLEDRONATE;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
OPIOIDS;CNIH3;A;rs10799590;TOXICITY;DECREASED;RISK;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;CT + TT;rs3025039;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED;SEVERITY;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CYP3A4;AA + AG;rs4646437;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;C;rs2032582;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"PLAIN""";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;NFE2L2;T;rs6721961;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB2;CC;rs1042714;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;IMPROVED LEFT VENTRICULAR EJECTION FRACTION IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;FOXP3;GT + TT;rs3761548;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;RAVER2;A;rs72675408;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;ATAXIA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIPLOPIA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIZZINESS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DYSARTHRIA IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;ATAXIA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIPLOPIA;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DIZZINESS;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:DYSARTHRIA IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CAPECITABINE;PPARD;T;rs2016520;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;PPARD;T;rs2016520;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CT + TT;rs8192719;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NAN;SULT1A1, SULT1A2;CC + CT;rs1801030;OTHER;INCREASED;LIKELIHOOD;DISEASE;HOT FLASHES IN PEOPLE WITH  OTHER:MENOPAUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;MCOLN1;A;rs116181528;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OVERDOSE NAN  NAN;;CAUTION_SIDE_EFFECT
CERIVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;AKT1;CC;rs2494732;OTHER;INCREASED;LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER IN PEOPLE WITH  DISEASE:MARIJUANA ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;;CAUTION_DOSE_ADJUST
BEVACIZUMAB;KCNAB1;G;rs6770663;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CEP68;AA;rs7572857;TOXICITY;INCREASED;NAN;SIDE EFFECT;DECLINE OF FORCED EXPIRATORY VOLUME IN 1S (FEV(1)) BY ASPIRIN PROVOCATION IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
OPIOIDS;MCOLN1;T;rs114077267;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OVERDOSE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;MDM2;GT + TT;rs2279744;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ASPIRIN;ITGB3;CT;rs5918;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION BY ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SLC2A9;AG;rs62293298;OTHER;DECREASED;LIKELIHOOD;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
ASPIRIN;TLR3;CT + TT;rs3775291;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-EXACERBATED RESPIRATORY DISEASE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
OPIOIDS;MCOLN1;G;rs115208233;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OVERDOSE NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;NAN;SIDE EFFECT;CRAVING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;DRD2;GG;rs1800497;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;CRAVING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IL6;CC;rs1800795;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IL6;CC;rs1800795;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IL6;CC;rs1800795;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCG2;GT + TT;rs2231142;OTHER;INCREASED;LIKELIHOOD;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;AG;rs72558189;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AG;rs72558189;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELBIVUDINE;TK2;CC + CT;rs3826160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION IN PEOPLE WITH  OTHER:HEPATITIS B;;CAUTION_SIDE_EFFECT
TELBIVUDINE;TK2;CC + CT;rs3826160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CHRONIC;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;SLC22A12;CT;rs3825017;OTHER;INCREASED;LIKELIHOOD;OTHER;HYPERURICEMIA IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;T;rs2440390;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
PRAVASTATIN;ADAMTS1;GG;rs428785;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;FATAL CORONARY DISEASE OR NONFATAL MYOCARDIAL INFARCTION IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2C;G;rs6318;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN WOMEN WITH  DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;NEURAL TUBE DEFECTS IN WOMEN  OTHER:WHO ARE PREGNANT;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs2497538;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN WOMEN WITH  DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;G;rs1414334;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN WOMEN WITH  DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PIOGLITAZONE;LPL;CG + GG;rs328;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE RATE AFTER 10 WEEKS OF PIOGLITAZONE TREATMENT IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;LPL;CG + GG;rs328;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;EPHA5;CT + TT;rs7349683;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;SCN1A;T;rs3812718;OTHER;INCREASED;RISK;DISEASE;SEIZURES;;CAUTION_SIDE_EFFECT
NAN;SCN1A;T;rs3812718;OTHER;INCREASED;RISK;DISEASE;FEBRILE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;AA + AG;rs4148323;OTHER;INCREASED;SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;AA + AG;rs4148323;OTHER;INCREASED;SEVERITY;OTHER;OTHER:HYPERBILIRUBINEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG + GG;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;RISK;SIDE EFFECT;QTC PROLONGATION NAN  NAN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;;A;rs1051730;OTHER;INCREASED;SEVERITY;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
NAN;CYP2R1;A;rs12794714;OTHER;INCREASED;LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;SOCIAL AND CLINICAL NEEDS IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;A;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NAN;CYP2R1;A;rs10741657;OTHER;DECREASED;LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;NAT2;T;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE AT 4 WEEKS AFTER THE INITIATION OF TREATMENT IN PEOPLE WITH  DISEASE:PANIC DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;E2F7;CC;rs310786;TOXICITY;INCREASED;NAN;SIDE EFFECT;LUMBAR BONE LOSS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ALENDRONATE;DKK1;AA;rs2241529;EFFICACY;DECREASED;NAN;EFFICACY;BONE DENSITY IN WOMEN WITH  DISEASE:METABOLIC BONE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALENDRONATE;DKK1;AA;rs2241529;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CES1;G;rs8192950;EFFICACY;DECREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CES1;G;rs8192950;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;GG;rs1799732;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECTS NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;CC;rs2305948;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs4918758;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;CC;rs3025039;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;NAN;PK;AREA UNDER THE CURVE FROM BASELINE TO THE LAST MEASURED CONCENTRATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EXEMESTANE;ESR1;CC;rs9322336;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULOSKELETAL TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;rs9332096;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS NAN  NAN;;CAUTION_DOSE_ADJUST
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;NAN;OTHER;PEAK PLASMA CONCENTRATION OF INCREASED PROLACTIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;C;rs6877011;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT4;C;rs6877011;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SYNCOPE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;AA;rs2232228;TOXICITY;INCREASED;RISK;DISEASE;CARDIOMYOPATHIES IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ORTHOSTATIC HYPOTENSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HNF4A;GG;rs2071197;EFFICACY;INCREASED;NAN;PK;CONCENTRATION-TO-DOSE RATIOS IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;MTHFR;GG;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;MTHFR;GG;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;DISEASE:MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA;rs1128503;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;TNF;AA + AG;rs1800629;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;TNF;AA + AG;rs1800629;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;IL10;TT;rs1800872;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IL10;TT;rs1800872;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AT;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;TRANSIENT ISCHEMIC ATTACK;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CEREBROVASCULAR DISORDERS;;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;G;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER;SMOKING IN PEOPLE WITH  OTHER:SCHIZOPHRENIA WHO ARE SMOKERS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER;SMOKING IN PEOPLE WITH  OTHER:SMOKING;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE;SCHIZOPHRENIA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;N6AMT1;GG;rs2254638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NON-HODGKIN LYMPHOMA;;CAUTION_SIDE_EFFECT
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED;SEVERITY;OTHER;CRAVING IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;NAN;PK;ERYTHROMYCIN METABOLISM IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
PAZOPANIB;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GENTAMICIN;MT-RNR1;G;rs267606617;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN INFANTS  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;LEP;A;rs2167270;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;LEP;A;rs2167270;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;GT;rs73189762;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
ETHANOL;HTR3B;C;rs1176744;OTHER;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;NAN;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A, SPECC1L;G;rs5760410;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CALCIUM CHANNEL BLOCKERS;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NITRENDIPINE;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;KDR;CC;rs7667298;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANGINA PECTORIS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;RISK;DISEASE;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;RISK;DISEASE;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RISK;DISEASE;GRAFT VS HOST DISEASE IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RISK;DISEASE;BCR-ABL1 POSITIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED;SEVERITY;OTHER;CRAVING IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;LYMPHOCYTIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;CHRONIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;LYMPHOCYTIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;CHRONIC;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS NAN  NAN;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;RISK;EFFICACY;RELAPSE IN PEOPLE WITH  OTHER:ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA.;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;KDR;TT;rs2305948;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGINA PECTORIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;KDR;TT;rs2305948;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;BCR-ABL1 POSITIVE;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ORAL MUCOSITIS IN PEOPLE WITH  OTHER:HEMATOPOIETIC-CELL-TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;FKBP5;CC + CT;rs1360780;NAN;INCREASED;RISK;OTHER;POST-TRAUMATIC STRESS DISORDER (PTSD) IN PEOPLE WITH  OTHER:HISTORY OF CHILD ABUSE;;CAUTION_SIDE_EFFECT
NAN;FKBP5;AA + AC;rs3800373;OTHER;INCREASED;RISK;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY IN PEOPLE WITH  OTHER:HISTORY OF CHILD ABUSE;;CAUTION_SIDE_EFFECT
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TBX21;A;rs17244587;NAN;INCREASED;RISK;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;PSMB4;T;rs2296840;OTHER;INCREASED;RISK;DISEASE;MAJOR DEPRESSIVE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;A;rs34059508;DOSAGE;INCREASED;NAN;PK;BIOAVAILABILITY NAN  NAN;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;NAN;PK;BIOAVAILABILITY NAN  NAN;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;C;rs12208357;DOSAGE;INCREASED;NAN;PK;BIOAVAILABILITY (AUC;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;C;rs12208357;DOSAGE;INCREASED;NAN;PK;CL & AUC/CL RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;C;rs12208357;METABOLISM/PK;INCREASED;NAN;PK;BIOAVAILABILITY (AUC;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;C;rs12208357;METABOLISM/PK;INCREASED;NAN;PK;CL & AUC/CL RATIO) NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;rs680244;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  OTHER:PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
METHOTREXATE;PTPN22;AA;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
NAN;CHRNA3;G;rs1051730;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;TNFAIP3;A;rs6920220;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:ARTHRITIS;;CAUTION_SIDE_EFFECT
NAN;CHRNA3, CHRNA5;G;rs578776;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;A;rs16969968;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN WOMEN WITH  DISEASE:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;rs569207;NAN;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENOBARBITAL;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENOBARBITAL;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
VALPROIC ACID;CYP1A1;A;rs2606345;EFFICACY;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
VALPROIC ACID;CYP1A1;A;rs2606345;METABOLISM/PK;INCREASED;RISK;DISEASE;SEIZURES IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
NAN;SLCO1B3;C;rs2417940;OTHER;INCREASED;SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA;;CAUTION_SIDE_EFFECT
NAN;SLCO1B3;C;rs2417940;OTHER;INCREASED;SEVERITY;OTHER;OTHER:HYPERBILIRUBINEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
SERTRALINE;;G;rs13432159;TOXICITY;INCREASED;NAN;SIDE EFFECT;GENERAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;NAN;EFFICACY;RELAPSE FREE TIME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;KIF6;AG + GG;rs20455;OTHER;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;GATM;AA + AG;rs9806699;TOXICITY;DECREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;DECREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;C;rs7270101;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;NAN;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES;;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES;;CAUTION_SIDE_EFFECT
IRINOTECAN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;NEUROTOXICITY SYNDROMES;;CAUTION_SIDE_EFFECT
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;NAN;OTHER;CORONARY FLOW RESERVE IN MEN  NAN;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;;G;rs116561224;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;rs3815459;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
FENOFIBRATE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
SERTRALINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TERBINAFINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TICLOPIDINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;CC;rs17288723;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNH2;CT + TT;rs3807375;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;GRIK4;C;rs1954787;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;KCNH2;GT + TT;rs1805123;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;NR1I2;C;rs2276707;DOSAGE;DECREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;NR1I2;C;rs2276707;METABOLISM/PK;DECREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT + TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;GSTP1;G;rs1695;TOXICITY;DECREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;GSTP1;G;rs1695;METABOLISM/PK;DECREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;;T;rs149104283;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799931;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;KCNH2;G;rs1805123;OTHER;DECREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
ASPARAGINASE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISOLONE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;rs3807375;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
OXALIPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;KCNQ1;G;rs757092;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;KCNH2;T;rs3815459;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;NAN;OTHER;ADENOSINE-STIMULATED MYOCARDIAL FLOW IN MEN  NAN;;CAUTION_DOSE_ADJUST
NAN;VEGFA;CG + GG;rs2010963;OTHER;INCREASED;RISK;OTHER;PREMATURE BIRTH IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
NAN;KCNH2;GG;rs1805123;OTHER;DECREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;KCNQ1;G;rs757092;OTHER;INCREASED;NAN;OTHER;QT INTERVAL NAN  NAN;;CAUTION_DOSE_ADJUST
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;SEVERITY;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;INFECTIOUS DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NR1I2;T;rs2276707;DOSAGE;INCREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;NR1I2;T;rs2276707;METABOLISM/PK;INCREASED;NAN;PK;BIOAVAILABILITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
RIFAMPIN;NR1I2;TT;rs3814055;OTHER;INCREASED;NAN;PK;ERYTHROMYCIN BREATH TEST NAN  NAN;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977549;EFFICACY;DECREASED;RISK;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;CC + TT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + TT;rs2740574;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NR1I2;C;rs3814055;DOSAGE;DECREASED;NAN;PK;BIOAVAILABILTY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;NR1I2;C;rs3814055;METABOLISM/PK;DECREASED;NAN;PK;BIOAVAILABILTY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
ASPIRIN;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED;RISK;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;G;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;COMT;AA + AG;rs4680;DOSAGE;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PREGNANCY;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:PREGNANCY;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GRIK4;GG;rs12800734;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KIF6;AG + GG;rs20455;OTHER;INCREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;NAN;PK;PLASMA AUC NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;AG;rs4149015;OTHER;INCREASED;NAN;PK;AUC0-12 IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;NAN;PK;AUC0-12 IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977551;EFFICACY;DECREASED;RISK;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977551;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TP53;GG;rs1042522;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3, CHRNA5;GG;rs578776;TOXICITY;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;AA;rs1044396;TOXICITY;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;CC;rs2229959;TOXICITY;INCREASED;LIKELIHOOD;OTHER;SMOKING CESSATION IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;T;rs13306278;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;TLR4;AG + GG;rs4986790;EFFICACY;DECREASED;RISK;EFFICACY;CARDIOVASCULAR EVENTS IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;G;rs267606617;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;VDR;TT;rs1544410;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;VDR;TT;rs1544410;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;IGFBP3;CC;rs2854746;EFFICACY;NAN;NAN;OTHER;BETTER SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO ACHIEVE STABLE DOSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DYING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;RISK;EFFICACY;DYING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;EFFICACY;DYING IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;INCREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA + AG;rs10929302;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:PERITONEUM CANCER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:UTERINE NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;G;rs1044396;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;LRP2;T;rs2075252;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;C/del + CC;rs3215400;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;POR;GG;rs2286823;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;POR;TT;rs1057868;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLCO1B3;GG;rs4149117;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  EFFICACY:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME ABOVE THERAPEUTIC RANGE NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1P1;AC + CC;rs3785161;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET ACTIVITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;G;rs2372536;NAN;NAN;SEVERITY;DISEASE;RHEUMATOID ARTHRITIS NAN  NAN;;CAUTION_DOSE_ADJUST
LEUCOVORIN;FASTKD3, MTRR;GG;rs1801394;TOXICITY;INCREASED;SEVERITY;DISEASE;STOMATITIS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;FASTKD3, MTRR;GG;rs1801394;TOXICITY;INCREASED;SEVERITY;DISEASE;STOMATITIS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANY GRADE 3 ADVERSE EVENT IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANY GRADE 3 ADVERSE EVENT IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PAZOPANIB;CXCL8;TT;rs1126647;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;G;rs2236196;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;CT;rs111564371;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;CT;rs111564371;EFFICACY;DECREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;AA + AG;rs1051730;TOXICITY;DECREASED;NAN;SIDE EFFECT;LUNG FUNCTION IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LEDIPASVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HSPA1A;T;rs1043620;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
LEDIPASVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HSPA1A;G;rs506770;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;F13A1;AA;rs5985;EFFICACY;DECREASED;NAN;EFFICACY;FIBRIN CLOT FORMATION TIME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;F13A1;AA;rs5985;EFFICACY;DECREASED;NAN;EFFICACY;FIBRIN CLOT FORMATION TIME IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;TP53;G;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TP53;G;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HSPA1L;G;rs2227956;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;HYPERSENSITIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;rs6787801;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;NAN;SIDE EFFECT;HYPERTENSION IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;MLN;A;rs2894342;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;NAN;PK;EXPOSURE IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN MEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN MEN WITH  NAN;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;CC;rs2298383;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_SIDE_EFFECT
CAFFEINE;;CC;rs4822492;TOXICITY;INCREASED;NAN;SIDE EFFECT;ANXIETY IN PEOPLE WITH  OTHER:NO DISEASE;;CAUTION_SIDE_EFFECT
NAN;MT-RNR1;G;rs267606617;OTHER;INCREASED;LIKELIHOOD;OTHER;HEARING LOSS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MT-RNR1;G;rs267606617;OTHER;INCREASED;LIKELIHOOD;OTHER;SENSORINEURAL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;;T;rs3130690;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;CC;rs5751876;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BEING SENSITIVE TO CAFFEINE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;CC;rs5751876;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSOMNIA NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:METHAMPHETAMINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:METHAMPHETAMINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:HEROIN DEPENDENCE;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:METHAMPHETAMINE DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;MICA;C;rs2848716;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ASPIRIN""";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;TT;rs5751876;DOSAGE;DECREASED;NAN;OTHER;HABITUAL CONSUMPTION NAN  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;BAG6, PRRC2A;C;rs750332;TOXICITY;INCREASED;RISK;DISEASE;STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ASPIRIN""";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRNA5;T;rs588765;EFFICACY;NAN;NAN;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;NAN;OTHER;WARFARIN DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;INCREASED;NAN;EFFICACY;PERCENTAGE CHANGE IN HDL-C LEVELS IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;SOST;CC;rs1234612;EFFICACY;INCREASED;NAN;EFFICACY;BONE DENSITY IN WOMEN WITH  DISEASE:METABOLIC BONE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;SOST;CC;rs1234612;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COLITIS IN CHILDREN WITH  OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;COLITIS IN CHILDREN WITH  OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_DOSE_ADJUST
ALENDRONATE;SOST;GG;rs865429;EFFICACY;DECREASED;NAN;EFFICACY;BONE DENSITY IN WOMEN WITH  DISEASE:METABOLIC BONE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALENDRONATE;SOST;GG;rs865429;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMOLYTIC ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MED12L, P2RY12;T;rs6801273;EFFICACY;DECREASED;NAN;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MED12L;G;rs6798347;EFFICACY;DECREASED;NAN;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;ABCB1;GG;rs1128503;OTHER;DECREASED;LIKELIHOOD;OTHER;ADVERSE EVENTS IN CHILDREN WITH  OTHER:TONSILLECTOMY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE EFFECT;TYPE 2 IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;ETV6;GG;rs2724635;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;ETV6;GG;rs2724635;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TAPBP;CC + CG;rs2071888;TOXICITY;INCREASED;NAN;SIDE EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;AG + GG;rs3740065;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;RISK;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;COMPOSITE OUTCOME OF NON-FATAL MI;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALL CAUSE DEATH AND STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;C;rs12795437;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
VALPROIC ACID;LEPR;AA + AG;rs1137101;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CFHR4;G;rs78239784;TOXICITY;INCREASED;RISK;DISEASE;MACULOPAPULAR EXANTHEMA NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs11600347;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ANKK1;AG + GG;rs1800497;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs658903;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;G;rs6787801;EFFICACY;DECREASED;NAN;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CABAZITAXEL;CYP3A5;T;rs776746;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs675388;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;GG;rs1695;EFFICACY;DECREASED;RISK;EFFICACY;CHEMORESISTANCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;A;rs1128503;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;DRD2;AA + AC;rs2283265;OTHER;DECREASED;NAN;OTHER;HEART RATE NAN  NAN;;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA4;A;rs2236196;OTHER;INCREASED;LIKELIHOOD;OTHER;NICOTINE DEPENDENCE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;rs1042640;TOXICITY;DECREASED;RISK;DISEASE;LIVER FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;rs1042640;TOXICITY;DECREASED;RISK;DISEASE;ACUTE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;NAN;SIDE EFFECT;BLEEDING EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;rs8330;TOXICITY;DECREASED;RISK;DISEASE;LIVER FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;rs8330;TOXICITY;DECREASED;RISK;DISEASE;ACUTE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN  EFFICACY:NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;KCNJ1;AG;rs59172778;TOXICITY;INCREASED;NAN;SIDE EFFECT;SERUM POTASSIUM IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ETHANOL;CACNA1C;TT;rs1034936;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALCOHOL ABUSE IN PEOPLE WITH  OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
WARFARIN;EPHA7;A;rs114504854;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;UGT1A;CT + TT;rs10929303;TOXICITY;DECREASED;RISK;DISEASE;LIVER FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CT + TT;rs10929303;TOXICITY;DECREASED;RISK;DISEASE;ACUTE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;XPNPEP2;T;rs2050011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;XPNPEP2;T;rs2050011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NICOTINE;ADGRL3;AG;rs2271339;TOXICITY;INCREASED;RISK;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
NICOTINE;ADGRL3;AT;rs1456862;TOXICITY;INCREASED;RISK;OTHER;TOBACCO USE DISORDER IN PEOPLE WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;MAP2K4;CT;rs2159140;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN PEOPLE WITH  OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A9;T;rs17868320;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL (OS) TIME IN  EFFICACY:ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOVENTILATION IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) (MORE THAN ONE YEAR) WHEN RECEIVING A LOADING DOSE OF 300 MG IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC10;CT;rs2125739;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ARNT;CG + GG;rs2228099;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
RIFAMPIN;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
NAN;DEPTOR;AA + AG;rs4871827;OTHER;INCREASED;NAN;OTHER;HDL CHOLESTEROL IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
NAN;DEPTOR;AA + AG;rs4871827;OTHER;INCREASED;NAN;OTHER;TYPE 2;;CAUTION_DOSE_ADJUST
CISPLATIN;SYNE3;CC;rs8020368;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;BRAIN ISCHEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;OTHER:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;OTHER:PERIPHERAL VASCULAR DISEASES IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;DIABETIC RETINOPATHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;OTHER:CHRONIC KIDNEY FAILURE IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;STK39;GG + GT;rs6749447;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN AMBULATORY BLOOD PRESSURE IN MEN WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
NAN;AHR;AA + AG;rs2066853;OTHER;INCREASED;RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS IN PEOPLE WITH  OTHER:A NAT1 RAPID ACETYLATOR GENOTYPE AND HIGH MEAT CONSUMPTION;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR6;CC + CT;rs9659997;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;;CAUTION_SIDE_EFFECT
CISPLATIN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;;AG + GG;rs7186128;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;;AG + GG;rs7186128;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TYMS;A;rs3786362;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
NAN;TNF;C;rs1800630;EFFICACY;INCREASED;SEVERITY;EFFICACY;LEUKOCYTOSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CISPLATIN;;TT;rs2166219;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;;TT;rs2166219;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2A;CC;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;;CAUTION_SIDE_EFFECT
CISPLATIN;;CC;rs4655567;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;;CC;rs4655567;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CISPLATIN;;TT;rs2018683;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;;TT;rs2018683;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;BDNF;CT + TT;rs6265;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;NAN;PK;DISTRIBUTION VOLUME IN PEOPLE WITH  DISEASE:LYMPHOMA;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;NAN;PK;DISTRIBUTION VOLUME IN PEOPLE WITH  DISEASE:LYMPHOMA;;CAUTION_DOSE_ADJUST
CISPLATIN;;TT;rs2018683;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;;TT;rs2018683;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
NAN;OPRM1;G;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;SYNE3;CC;rs8020368;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
CISPLATIN;;CC;rs4655567;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;;CC;rs4655567;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT RELAPSE IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;AA;rs7317112;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;UGT1A1;AG;rs1976391;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;;GG;rs2275913;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;ABCB1;AA;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;DBH;TT;rs1611114;TOXICITY;DECREASED;RISK;SIDE EFFECT;MEMORY IMPAIRMENT IN PEOPLE WITH  OTHER:HEROIN DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DILTIAZEM;PLCD3;T;rs12946454;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;MTHFR;GG;rs1801131;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;ITPA;AC;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA NAN  NAN;;CAUTION_SIDE_EFFECT
"""BETA BLOCKING AGENTS""";;C;rs11191548;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""THIAZIDES";;C;rs11191548;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"PLAIN""";;C;rs11191548;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;SEVERITY;SIDE EFFECT;WITHDRAWAL IN WOMEN  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;MINIMUM PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;CC + CT;rs9282564;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOVENTILATION IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCC1;GG;rs246240;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ABCC1;GG;rs246240;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;NAN;OTHER;BLOOD PRESSURE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_DOSE_ADJUST
LENALIDOMIDE;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ABCC4;CT;rs16950650;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;ABCC4;CT;rs16950650;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:SMALL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;NAN;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION IN  OTHER:PATIENTS UNDERGOING CORONARY STENTING;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;NAN;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION IN  OTHER:PATIENTS UNDERGOING CORONARY STENTING;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMIVUDINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLC29A3;CT + TT;rs780668;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED;RISK;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;C;rs7270101;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ALBUMINURIA;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
GEMCITABINE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN WOMEN  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;METABOLISM/PK;DECREASED;NAN;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUSCULAR DISEASES;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:RHABDOMYOLYSIS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CFLAR;A;rs1594;TOXICITY;NAN;NAN;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_DOSE_ADJUST
OXYCODONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OXYCODONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES2;CG + GG;rs11075646;EFFICACY;INCREASED;NAN;EFFICACY;TIME TO PROGRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE OF DISEASE IN WOMEN  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;DECREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;AGT;GG;rs5050;TOXICITY;INCREASED;RISK;DISEASE;PEPTIC ULCER HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;A;rs6785049;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
BUPROPION;SACM1L;C;rs2251954;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;GATM;AA;rs9806699;TOXICITY;DECREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;G;rs2742421;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;CYP3A4;AG;rs28371759;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;AG;rs28371759;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SACM1L;G;rs2742423;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;NAN;NAN;SIDE EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;METABOLISM/PK;DECREASED;NAN;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;T;rs1969624;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;NR1I3;GG;rs2307424;TOXICITY;NAN;NAN;SIDE EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY NAN  NAN;;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;C;rs2245705;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SACM1L;G;rs2742435;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED;NAN;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;SACM1L;A;rs2742390;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;LIKELIHOOD;OTHER;EARLY RELAPSE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;DHFR;GG;rs442767;TOXICITY;INCREASED;RISK;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
BUPROPION;SACM1L;T;rs2742417;TOXICITY;DECREASED;NAN;SIDE EFFECT;SEXUAL SIDE-EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEMSIROLIMUS;NR1I2;T;rs3814055;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AA;rs1933437;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AA;rs1933437;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;CT + TT;rs71647871;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HAND-FOOT SYNDROME;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;CT + TT;rs71647871;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
GEMCITABINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED;NAN;EFFICACY;LDL-C REDUCTION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRD1;A;rs4654327;EFFICACY;INCREASED;NAN;EFFICACY;NALTREXONE-INDUCED BLUNTING OF ALCOHOL STIMULATION AND ALCOHOL CRAVING IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A;AG + GG;rs11563250;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES;;CAUTION_SIDE_EFFECT
ATORVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:MYALGIA IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
SIMVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES;;CAUTION_SIDE_EFFECT
SIMVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:MYALGIA IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SPARC;GG;rs2347128;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MET;AG + GG;rs40239;OTHER;INCREASED;NAN;OTHER;OVERALL SURVIVAL IN MEN  DISEASE:STOMACH NEOPLASMS;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:CROHN DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SPARC;TT;rs17718347;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MET;AG + GG;rs40239;OTHER;INCREASED;NAN;OTHER;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:STOMACH NEOPLASMS;;CAUTION_DOSE_ADJUST
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"COMBINATIONS""";ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  OTHER:HIV AND TUBERCULOSIS CO-INFECTION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;OTHER;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE (AUC) DURING THE FIRST 24 WEEKS OF ANTIRETROVIRAL THERAPY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE (AUC) DURING THE FIRST 24 WEEKS OF ANTIRETROVIRAL THERAPY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP3A4;C;rs2740574;OTHER;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISCONTINUATION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;NAN;PK;PLASMA EFAVIRENZ EXPOSURE IN PEOPLE WITH  PK:HIV;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;MME;CT + TT;rs989692;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;MME;CT + TT;rs989692;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;LILRB5;TT;rs12975366;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;LILRB5;TT;rs12975366;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER IN MEN WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CABAZITAXEL;CYP3A5;CT;rs776746;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
FLUOXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
SERTRALINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:DEPRESSION;;CAUTION_SIDE_EFFECT
CABAZITAXEL;TUBB1;AC;rs463312;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:TRANSITIONAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;SIDE EFFECT;ISCHAEMIC EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4986893;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;NAN;OTHER;PLASMA LEVEL IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NAN;SLC2A9;T;rs16890979;METABOLISM/PK;DECREASED;NAN;PK;SERUM URIC ACID IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;IKZF3;CC;rs9908694;EFFICACY;INCREASED;NAN;DISEASE;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:NEUROBLASTOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DRD4;CC + CT;rs1800955;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG PSYCHOSIS IN PEOPLE WITH  OTHER:METHAMPHETAMINE DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;GC;TT;rs4588;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;GC;TT;rs4588;EFFICACY;DECREASED;NAN;EFFICACY;DISEASE:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_FAILURE
CETUXIMAB;GC;TT;rs4588;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;GC;TT;rs4588;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE:METASTATIC NEOPLASM;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;TAPBP;AG + GG;rs1059288;TOXICITY;INCREASED;NAN;SIDE EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"PLAIN""";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
GEFITINIB;IKBKB;CC;rs2272733;TOXICITY;DECREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
DESFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ENFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
HALOTHANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
ISOFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SEVOFLURANE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE;MALIGNANT HYPERTHERMIA NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;T;rs12208357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;A;rs34130495;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;P2RY12;G;rs2046934;OTHER;INCREASED;RISK;DISEASE;PERIPHERAL VASCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
GEFITINIB;RELA;CC;rs11227247;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;C;rs55918055;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;KCNQ5;C;rs9351963;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;A;rs34059508;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
NAN;P2RY12;G;rs2046934;OTHER;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION NAN  NAN;;CAUTION_DOSE_ADJUST
GEFITINIB;IKBKE;AG + GG;rs2151222;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;T;rs28371725;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;NAN;NAN;EFFICACY;IMPROVED RESPONSE IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_DOSE_ADJUST
GABAPENTIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEUROPATHIC PAIN;;CAUTION_SIDE_EFFECT
PREGABALIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEUROPATHIC PAIN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;CXCR2;TT;rs2230054;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CXCR2;TT;rs2230054;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;DECREASED;RISK;EFFICACY;RECURRENCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLCO1B1;AG + GG;rs4149086;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG REACTION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;TT;rs5443;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:HEART FAILURE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;RISK;DISEASE;LUNG NEOPLASMS IN PEOPLE WITH  OTHER:WHO HAVE EVER BEEN SMOKERS;;CAUTION_SIDE_EFFECT
CITALOPRAM;GRIK2;CC;rs2518224;TOXICITY;INCREASED;RISK;SIDE EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;G;rs7586110;TOXICITY;INCREASED;RISK;DISEASE;ANEMIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;HYKK;C;rs8034191;OTHER;INCREASED;RISK;DISEASE;LUNG NEOPLASMS IN PEOPLE WITH  OTHER:WHO HAVE EVER BEEN SMOKERS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
TACROLIMUS;TCF7L2;CC + CT;rs290487;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;POLR2A;CC;rs2228130;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
VALPROIC ACID;CYP2C9;AC;rs1057910;OTHER;INCREASED;NAN;PK;MEAN PLASMA DRUG CONCENTRATIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;NAN;PK;MEAN PLASMA DRUG CONCENTRATIONS IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
CITALOPRAM;GRIA3;G;rs4825476;TOXICITY;INCREASED;RISK;SIDE EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A5;AA + AG;rs274558;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A5;AA + AG;rs274558;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;CC + CG;rs4818;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL VASCULAR DISEASES IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;DISEASE;LUNG NEOPLASMS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;NAN;OTHER;NUMBER OF CIGARETTES SMOKED PER DAY IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CENTRAL NERVOUS SYSTEM TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PHENYTOIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MENINGEAL TUBERCULOSIS;;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;CT;rs2235040;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;CT;rs2235040;TOXICITY;DECREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) IN PEOPLE WITH  DISEASE:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
IMATINIB;EGFR;CT + TT;rs10258429;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
IMATINIB;EGFR;CT + TT;rs10258429;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AG;rs165599;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TARDIVE DYSKINESIA IN MEN WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CG + GG;rs683369;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CG + GG;rs683369;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:EYE DISEASES IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
DACLATASVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ERGOT ALKALOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ERGOT ALKALOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SUMATRIPTAN""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SUMATRIPTAN""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TBXA2R;AA;rs4523;EFFICACY;INCREASED;RISK;OTHER;HIGH ON-ASPIRIN RESIDUAL PLATELET REACTIVITY IN PEOPLE WITH  OTHER:OFF-PUMP CORONARY ARTERY BYPASS GRAFTING;;CAUTION_SIDE_EFFECT
"""ANALGESICS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANALGESICS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;CT;rs1799978;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSULIN RESISTANCE IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;;CAUTION_SIDE_EFFECT
RISPERIDONE;DRD2;CT;rs1799978;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs2032582;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
"""ANALGESICS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"NON-STEROIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ERGOT ALKALOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ERGOT ALKALOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""OPIOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SUMATRIPTAN""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SUMATRIPTAN""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANALGESICS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;COMT;AA;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;TARDIVE DYSKINESIA IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  OTHER:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANALGESICS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN CHILDREN WITH  DISEASE:ATYPICAL BEHAVIOR;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:MENTAL DISORDERS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CAPN10;CT;rs5030952;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C18;G;rs2901783;DOSAGE;NAN;NAN;OTHER;OUTCOME TIME TO STABLE DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANALGESICS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIINFLAMMATORY AGENTS";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"NON-STEROIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ERGOT ALKALOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""OPIOIDS""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;HEADACHE DISORDERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""SUMATRIPTAN""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE WITHDRAWAL SYNDROME NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOTOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG;rs9479757;OTHER;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEASE INHIBITORS;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;GAL;CC;rs948854;OTHER;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;ABCB1;GG;rs1045642;OTHER;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRD1;A;rs2236861;OTHER;DECREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;NOS3;GG;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;CETP;A;rs708272;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN MEN WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
PROTEASE INHIBITORS;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
DACLATASVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;PDE4D;TT;rs702553;EFFICACY;DECREASED;NAN;EFFICACY;BASELINE MEAN ARTERIAL BLOOD PRESSURE IN PEOPLE WITH  DISEASE:NEPHROSCLEROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;KCNE1;C;rs1805127;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;KCNE1;TT;rs4817668;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;OTHER;HIGH PLATELET REACTIVITY IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE UNDERGOING STENT IMPLANTATION;;CAUTION_SIDE_EFFECT
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs588765;EFFICACY;NAN;NAN;EFFICACY;INCREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY) NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;CHRNA3;A;rs1051730;EFFICACY;NAN;NAN;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP NAN  NAN;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCYTOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;A;rs1051730;EFFICACY;NAN;NAN;EFFICACY;INCREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY) NAN  NAN;;CAUTION_DOSE_ADJUST
CITALOPRAM;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PAROXETINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
SERTRALINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
VENLAFAXINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EFFECTS IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CC;rs1801159;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CISPLATIN;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
NAN;FOXO3;TT;rs4946936;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;FOXO3;GG;rs17069665;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN CHILDREN WITH  OTHER:RHABDOMYOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ARNT;T/del + del/del;rs3215133;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHANOL;GHSR;AG;rs2232165;OTHER;NAN;NAN;OTHER;HEAVY CONSUMPTION NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;NEFM;G;rs1379357;EFFICACY;NAN;NAN;EFFICACY;RESPONSE TIME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
CISPLATIN;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;NEFM;G;rs1457266;EFFICACY;NAN;NAN;EFFICACY;RESPONSE TIME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
NAN;ARNT;AA + AG;rs12410394;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;IL23R;A;rs7518660;TOXICITY;INCREASED;RISK;DISEASE;ADENOMA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CELECOXIB;ALOX12;A;rs11078659;TOXICITY;INCREASED;RISK;DISEASE;ADENOMA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;CYP1A2;CT + TT;rs2470890;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;;CT + TT;rs11072508;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;PTGES;C;rs2302821;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR TOXICITY AND SYMPTOMS IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;CSK;CG + GG;rs4886410;OTHER;DECREASED;LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;PTGER4;T;rs4133101;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITIES IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;CYSTITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;CYSTITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
THIOTEPA;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;CYSTITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE OF BREAST CANCER IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCC2;AA;rs3740065;METABOLISM/PK;INCREASED;RISK;EFFICACY;RECURRENCE OF BREAST CANCER IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INSOMNIA NAN  NAN;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FARGLITAZAR;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
FARGLITAZAR;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
INSULINS AND ANALOGUES;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
INSULINS AND ANALOGUES;SCNN1B;A;rs34241435;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;SCNN1G;CC;rs5723;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
FARGLITAZAR;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
FARGLITAZAR;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
GLYBURIDE;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;OEDEMA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_DOSE_ADJUST
GLYBURIDE;SCNN1B;A;rs889299;TOXICITY;NAN;NAN;SIDE EFFECT;TYPE 2;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;SCNN1G;TT;rs5729;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;IKBKE;CC;rs12142086;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;C;rs680244;OTHER;DECREASED;LIKELIHOOD;OTHER;ABSTINENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ORAL ULCER IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;DECREASED;NAN;EFFICACY;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;INCREASED;NAN;PK;AREA UNDER THE VISUAL ANALOG SCALE-TIME CURVE DURING THE INDUCED STATE NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
NALOXONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;DECREASED;NAN;PK;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATIONS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA5;A;rs16969968;OTHER;DECREASED;LIKELIHOOD;OTHER;ABSTINENCE IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED LIVER ENZYMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
BISOPROLOL;CYP3A5;TT;rs776746;EFFICACY;INCREASED;SEVERITY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE;;CAUTION_SIDE_EFFECT
BISOPROLOL;CYP3A5;TT;rs776746;EFFICACY;INCREASED;SEVERITY;EFFICACY;EFFICACY:ELEVATED DIASTOLIC BLOOD PRESSURE IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NALOXONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ERYTHEMA IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
PAZOPANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;WNK1;GG;rs1159744;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:LUPUS NEPHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SLC22A3;TT;rs2504938;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NALOXONE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OXYCODONE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;GT;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:LUPUS NEPHRITIS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;UMPS;CC + CG;rs1801019;TOXICITY;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
FLUOROURACIL;UMPS;CC + CG;rs1801019;METABOLISM/PK;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
LEUCOVORIN;UMPS;CC + CG;rs1801019;TOXICITY;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
LEUCOVORIN;UMPS;CC + CG;rs1801019;METABOLISM/PK;NAN;NAN;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
FLUOROURACIL;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;UMPS;CC;rs1801019;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_SIDE_EFFECT
LEUCOVORIN;UMPS;CC;rs1801019;METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;CAUTION_DOSE_ADJUST
BUPRENORPHINE;COMT;AG + GG;rs4680;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;COMT;AG + GG;rs4680;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;SLC22A3;AA;rs512077;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:GASTROESOPHAGEAL CANCER;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:GASTROESOPHAGEAL CANCER;;CAUTION_SIDE_EFFECT
GLUCARPIDASE;ABCC4;AG + GG;rs7317112;TOXICITY;INCREASED;RISK;OTHER;NEPHROTOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADRB2;AA + AG;rs2400707;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:LUPUS NEPHRITIS;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;GG;rs16969968;OTHER;INCREASED;NAN;OTHER;FUNCTIONAL MRI REACTIVITY TO SMOKING IMAGES IN WOMEN WITH  OTHER:NICOTINE DEPENDENCE;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;WNK1;CC;rs1159744;OTHER;INCREASED;NAN;SIDE EFFECT;URINARY POTASSIUM EXCRETION IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;CAUTION_DOSE_ADJUST
HEROIN;DRD2;A;rs1076560;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_SIDE_EFFECT
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;"POSTOPERATIVE IN PEOPLE WITH  ""OTHER:SURGERY""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;"""OTHER:FRACTURES";;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY;"BONE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;WNK1;CC + CT;rs2107614;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;RAD52, WNK1;CC;rs2277869;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A2;T;rs34399035;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN UPTAKE IN HEK-293 CELLS AND REDUCTION IN PROTEIN EXPRESSION LEVELS NAN  NAN;;CAUTION_DOSE_ADJUST
OXALIPLATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HAND-FOOT SYNDROME IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:HEPATOCELLULAR CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;T;rs16871327;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;EPHA7;C;rs78132896;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
FENOFIBRATE;FABP1;CC + CT;rs2241883;TOXICITY;INCREASED;RISK;DISEASE;HYPERTRIGLYCERIDEMIA IN PEOPLE WITH  DISEASE:HYPERTRIGLYCERIDEMIA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;SNAP25;TT;rs1051312;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;TAB2;CT + TT;rs577001;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFIT1;TT;rs304478;EFFICACY;INCREASED;NAN;EFFICACY;SVR (SUSTAINED VIROLOGICAL RESPONSE) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFIT1;TT;rs304478;EFFICACY;INCREASED;NAN;EFFICACY;SVR (SUSTAINED VIROLOGICAL RESPONSE) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;OASL;T;rs12819210;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;OASL;T;rs12819210;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ABCB1;AG;rs1045642;EFFICACY;INCREASED;NAN;EFFICACY;RECURRENCE-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;TT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;SLC6A3;TT;rs6347;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE (RR) IN PEOPLE WITH  DISEASE:ADENOCARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;NFKBIA;AA + AT;rs2233407;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
GEFITINIB;NR1H2;CT + TT;rs2695121;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CG + GG;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;;G;rs115112393;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;GG;rs6318;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;GG;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:COCAINE DEPENDENCE;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;A;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;CC;rs7131056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;INSIG2;C;rs17047764;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GNB3;TT;rs5443;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;MC4R;AA;rs489693;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
TIANEPTINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;OTHER;SUICIDAL IDEATION IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;A;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;BDNF, BDNF-AS;CC;rs6265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;ADRA2A;G;rs1800544;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;GG;rs2069514;METABOLISM/PK;INCREASED;NAN;PK;RATIO OF 1;;CAUTION_DOSE_ADJUST
THEOPHYLLINE;CYP1A2;GG;rs2069514;METABOLISM/PK;INCREASED;NAN;PK;3 DMU/THEOPHYLLINE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIA;AG + GG;rs2233409;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;NFKBIA;AG + GG;rs8904;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;CLOPIDOGREL RESISTANCE IN  OTHER:PATIENTS WHO UNDERWENT SUCCESSFUL PERCUTANEOUS CORONARY INTERVENTION;;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIB;CC;rs2053071;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HALLUCINATIONS IN PEOPLE WITH  OTHER:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIA;AG + GG;rs2233406;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGB3;C;rs5918;EFFICACY;NAN;NAN;EFFICACY;LESS DECREASE IN THE PLATELET REACTIVITY AFTER 600 MG OF CLOPIDOGREL IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ITGB3;CT;rs5918;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET EFFECT TO A 300 MG CLOPIDOGREL LOADING-DOSE UP TO 24 H FOLLOWING INTERVENTION IN  OTHER:PATIENTS UNDERGOING CORONARY STENT IMPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
PERINDOPRIL;AGTR1;TT;rs275651;EFFICACY;DECREASED;RISK;EFFICACY;CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;KCNH2;AA;rs3807372;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) NAN  NAN;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;AA + AG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;ADDICTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;IKBKB;AA;rs9694958;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FEVER IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
GEFITINIB;IKBKE;CC + CT;rs3748022;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ASPIRIN;FSIP1;G;rs7179742;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS1;G;rs10306114;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO ASPIRIN IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;AA;rs4430924;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ASPIRIN;CEP68;AA + AG;rs7572857;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN-INTOLERANT ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;A;rs2032582;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;ABCB1;A;rs2032582;EFFICACY;INCREASED;RISK;DISEASE;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;G;rs10945919;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS IN PEOPLE WITH  OTHER:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:BIPOLAR DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PERSONALITY DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTHER:OBSESSIVE-COMPULSIVE DISORDER;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CETUXIMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANITUMUMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;NAN;DISEASE;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1;CT;rs71647871;METABOLISM/PK;INCREASED;NAN;PK;LEVELS OF CLOPIDOGREL ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED;NAN;EFFICACY;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED;NAN;EFFICACY;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;NAN;PK;CMAX OF THE ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;PK;CMAX OF THE ACTIVE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;MTHFR;AA;rs1801133;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VEMURAFENIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:MELANOMA;;CAUTION_SIDE_EFFECT
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARCINOMA;;CAUTION_SIDE_EFFECT
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;CAUTION_SIDE_EFFECT
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""SIDE EFFECT:HYPERBILIRUBINEMIA""";;CAUTION_SIDE_EFFECT
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""SIDE EFFECT:NAUSEA"" IN PEOPLE WITH  OTHER:MELANOMA";;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
FLUOXETINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
SERTRALINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;NAN;NAN;PK;RISK OF BEING UNDERDOSED IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;NAN;NAN;PK;RISK OF BEING UNDERDOSED IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
OPIOIDS;SLC18A2;A;rs363332;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;SLC18A2;G;rs363334;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;SLC18A2;C;rs363338;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;NAN;NAN;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;;CAUTION_DOSE_ADJUST
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO CLOPIDOGREL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;RISK;DISEASE;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;NON-RESPONSE TO CLOPIDOGREL IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
WARFARIN;VEGFA;CC;rs35410204;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA8;G;rs209709;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA8;G;rs209709;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:CHOLANGITIS;;CAUTION_SIDE_EFFECT
GLUCOCORTICOIDS;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;NAN;SIDE EFFECT;BONE DENSITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;IMPDH2;AG;rs11706052;TOXICITY;DECREASED;RISK;DISEASE;LYMPHOPENIA IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;DECREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;NAN;NAN;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION IN PEOPLE WITH  DISEASE:CEREBROVASCULAR DISORDERS;;CAUTION_DOSE_ADJUST
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE;;CAUTION_SIDE_EFFECT
WARFARIN;VEGFA;AA;rs866236;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCG1;AA;rs492338;TOXICITY;INCREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCB1;AG;rs1128503;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA6;AA;rs301927;TOXICITY;DECREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE;LUNG NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;OTHER;LYMPH NODE METASTASIS IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET RESPONSIVENESS TO CLOPIDOGREL IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
IMIPRAMINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
MAPROTILINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
OPIPRAMOL;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CALCIUM;VDR;G;rs731236;EFFICACY;INCREASED;RISK;DISEASE;FRACTURES;;CAUTION_SIDE_EFFECT
CALCIUM;VDR;G;rs731236;EFFICACY;INCREASED;RISK;DISEASE;BONE NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;SULT1A1;T;rs1042028;OTHER;DECREASED;LIKELIHOOD;DISEASE;UROLOGIC NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET RESPONSIVENESS TO CLOPIDOGREL IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"PLATELET REACTIVITY IN PEOPLE WITH  ""DISEASE:CORONARY ARTERY DISEASE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"""DISEASE:DIABETES MELLITUS";;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"TYPE 2""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"PLATELET REACTIVITY IN PEOPLE WITH  ""DISEASE:CORONARY ARTERY DISEASE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"""DISEASE:DIABETES MELLITUS";;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;NAN;EFFICACY;"TYPE 2""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VAC14;T;rs875858;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN MEN WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A4;CT + TT;rs2242480;EFFICACY;NAN;NAN;EFFICACY;REDUCED GP IIB/IIIA ACTIVATION AND LOWER PLATELET ACTIVATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT FACTOR XA INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
DIRECT THROMBIN INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AG + GG;rs6269;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;LIKELIHOOD_THERAPEUTIC_FAILURE
OSIMERTINIB;EGFR;T;rs121434569;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;EGFR;T;rs121434569;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AG + GG;rs4680;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;TT;rs1229984;METABOLISM/PK;INCREASED;NAN;PK;VMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;NAN;NAN;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;CG + GG;rs4818;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;NAN;EFFICACY;AVERAGE DAILY DOSE DURING THE FIRST PERIOD OF STABILITY IN PEOPLE WITH  DISEASE:VENOUS THROMBOEMBOLISM;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;CC + CT;rs4633;OTHER;INCREASED;LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION IN CHILDREN WITH  OTHER:ADENOTONSILLECTOMY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NAT2;A;rs1799931;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;UGT1A;TT;rs6744284;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;UGT1A;TT;rs6744284;EFFICACY;INCREASED;NAN;EFFICACY;SIDE EFFECT:HYPERBILIRUBINEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT FACTOR XA INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
DIRECT THROMBIN INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
BORTEZOMIB;PKNOX1;A;rs2839629;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;UGT1A;T;rs6744284;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERBILIRUBINEMIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;A;rs699947;TOXICITY;INCREASED;NAN;SIDE EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED RISK OF DEVELOPING GRADE 3 HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;FTO;G;rs9940629;OTHER;NAN;NAN;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;C;rs833061;TOXICITY;INCREASED;NAN;SIDE EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED RISK OF DEVELOPING GRADE 3 HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;PAIN;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY;POSTOPERATIVE IN CHILDREN WITH  OTHER:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;NAN;SIDE EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED RISK OF DEVELOPING GRADE 3 HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ABCB1;G;rs10267099;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;DECREASED;NAN;OTHER;PLATELET FUNCTION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
ATENOLOL;ABCB1;G;rs3213619;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;DCAF4;CC;rs7160796;EFFICACY;INCREASED;NAN;EFFICACY;CHANGE IN FORCED EXPIRATORY VOLUME IN 1 S (FEV1) IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NOS3;CC + CT;rs2070744;TOXICITY;INCREASED;RISK;SIDE EFFECT;GRADE 3 HYPERTENSION NAN  NAN;;CAUTION_SIDE_EFFECT
ATENOLOL;PRKCB;GT + TT;rs11649514;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;CAUTION_SIDE_EFFECT
ATENOLOL;PRKCB;GT + TT;rs11649514;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;FTO;AA;rs12595985;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TREATMENT MODIFICATION IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;OTHER;DECREASED;NAN;OTHER;PLATELET FUNCTION IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_DOSE_ADJUST
ATENOLOL;GALNT2;T;rs2144297;OTHER;NAN;NAN;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
ATENOLOL;GALNT2;C;rs2144300;OTHER;NAN;NAN;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
ETHANOL;ANKK1, DRD2;A;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;NAN;PK;IN VIVO METABOLISM OF (S)-WARFARIN BUT NOT (R)-WARFARIN NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;NAN;PK;IN VIVO METABOLISM OF (S)-WARFARIN BUT NOT (R)-WARFARIN NAN  NAN;;CAUTION_DOSE_ADJUST
ATENOLOL;PLA2G4A;C;rs10157410;OTHER;INCREASED;RISK;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET AGGREGATION VALUES IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;PTGS2;G;rs4648287;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERCHOLESTEROLEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NOS2;CC;rs11080344;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;NOS2;CC;rs11080344;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ENALAPRIL;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;COUGH IN PEOPLE WITH  OTHER:HYPERTENSION;;CAUTION_SIDE_EFFECT
ISONIAZID;BACH1;GG;rs2070401;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;BACH1;GG;rs2070401;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET AGGREGATION VALUES IN PEOPLE WITH  EFFICACY:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CC;rs12248560;EFFICACY;NAN;NAN;EFFICACY;GREATER PLATELET INHIBITION 2 H AFTER A 600-MG DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;G;rs1495741;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;C;rs1057910;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION 7H AFTER A CLOPIDOGREL 600-MG LOADING DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
ANASTROZOLE;ESR1;A;rs9340799;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;;CAUTION_SIDE_EFFECT
LETROZOLE;ESR1;A;rs9340799;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;ESR1;C;rs2234693;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;;CAUTION_SIDE_EFFECT
LETROZOLE;ESR1;C;rs2234693;OTHER;INCREASED;RISK;DISEASE;MUSCULOSKELETAL PAIN IN WOMEN  OTHER:WITH EARLY BREAST CANCER;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP3A4;CC;rs2740574;OTHER;INCREASED;LIKELIHOOD;OTHER;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION IN PEOPLE WITH  OTHER:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP3A4;CC;rs2740574;OTHER;INCREASED;LIKELIHOOD;OTHER;OTHER:HYPERLIPIDEMIAS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA + AG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER;ADDICTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;C;rs75017182;DOSAGE;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;C;rs75017182;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;C;rs75017182;DOSAGE;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;PAX4;AA + AG;rs114202595;EFFICACY;DECREASED;NAN;EFFICACY;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;PAX4;AA + AG;rs114202595;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP3A4;CT;rs2740574;OTHER;INCREASED;RISK;DISEASE;ENDOMETRIAL NEOPLASMS NAN  NAN;;CAUTION_SIDE_EFFECT
VINCRISTINE;COCH;CG + GG;rs1045644;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TEGAFUR;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP3A4;CT;rs2740574;OTHER;INCREASED;RISK;DISEASE;ENDOMETRIAL NEOPLASMS IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;;C;rs7963521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;DIFFERENCE IN FASTING PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;VDR;G;rs3782905;OTHER;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRL1;C;rs6090043;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH-ON CLOPIDOGREL PLATELET REACTIVITY IN  OTHER:PATIENTS UNDERGOING ELECTIVE CORONARY STENT PLACEMENT;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;A;rs6785930;EFFICACY;INCREASED;RISK;SIDE EFFECT;NEUROLOGICAL EVENTS IN PEOPLE WITH  DISEASE:PERIPHERAL VASCULAR DISEASES;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs165599;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs165599;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VDR;G;rs2239185;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;VDR;T;rs1540339;NAN;INCREASED;RISK;DISEASE;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET EFFECT IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCITRIOL;VDR;A;rs2228570;EFFICACY;INCREASED;RISK;DISEASE;FRACTURES;;CAUTION_SIDE_EFFECT
CALCITRIOL;VDR;A;rs2228570;EFFICACY;INCREASED;RISK;DISEASE;BONE NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;DECREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
PERINDOPRIL;BDKRB1;AA;rs12050217;EFFICACY;DECREASED;RISK;EFFICACY;CARDIAC EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AQP1;CC;rs1049305;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
ATENOLOL;GRK4;TT;rs1801058;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ATENOLOL;GRK4;TT;rs1801058;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
ATENOLOL;GRK4;TT;rs1801058;OTHER;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VERAPAMIL;GRK4;TT;rs1801058;EFFICACY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VERAPAMIL;GRK4;TT;rs1801058;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
VERAPAMIL;GRK4;TT;rs1801058;OTHER;INCREASED;RISK;SIDE EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES IN PEOPLE WITH  OTHER:HYPERTENSION AND CORONORY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED;RISK;SIDE EFFECT;BIOPSY-PROVEN ACUTE REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANT;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;HLA-DOB;CT + TT;rs2071554;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;AA + AG;rs2900420;EFFICACY;DECREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
OPIOIDS;DRD2;AG + GG;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  OTHER:PAIN;;CAUTION_SIDE_EFFECT
OPIOIDS;DRD2;AG + GG;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
CISPLATIN;;AG + GG;rs3746444;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;G;rs20417;OTHER;DECREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AQP1;AG;rs28362731;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:MESOTHELIOMA;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ISONIAZID;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
PYRAZINAMIDE;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
RIFAMPIN;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;G;rs20417;OTHER;INCREASED;RISK;DISEASE;CORONARY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFIRI;ABCC1;AA + AG;rs17501011;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRL1;G;rs6090041;TOXICITY;INCREASED;RISK;DISEASE;OPIOID-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;ANTIPLATELET EFFECT IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CUX1;G;rs365836;EFFICACY;NAN;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
NAN;SULT1A1;CC + CT;rs1042028;NAN;INCREASED;RISK;DISEASE;PROSTATIC NEOPLASMS NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;SULT1A1;CT + TT;rs1042028;OTHER;INCREASED;RISK;DISEASE;BREAST NEOPLASMS IN WOMEN WITH  DISEASE:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SULT1A1;CT + TT;rs1042028;OTHER;DECREASED;LIKELIHOOD;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  OTHER:AT LEAST THREE PREGNANCIES AND PREMENOPAUSAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:HEART VALVE REPLACEMENT;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CUX1;A;rs201522;EFFICACY;NAN;LIKELIHOOD;EFFICACY;NON-RESPONSE IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;CAUTION_SIDE_EFFECT
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PAIN;;CAUTION_SIDE_EFFECT
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUROPATHIC PAIN IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED;RISK;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;NAN;DISEASE;DRUG TOXICITY IN CHILDREN WITH  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFIRI;CES1;CC;rs9921399;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROAMPHETAMINE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER;SOCIAL WITHDRAWAL IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER;SOCIAL WITHDRAWAL IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GRIN1;GG;rs1126442;TOXICITY;INCREASED;RISK;DISEASE;PSYCHOTIC DISORDER IN MEN WITH  DISEASE:METHAMPHETAMINE DEPENDENCE;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A10, UGT1A8;AA;rs1113193;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED;RISK;DISEASE;OTOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIALOADENITIS IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIALOADENITIS IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;CT + TT;rs588765;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN  OTHER:SMOKERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED;SEVERITY;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED;SEVERITY;DISEASE;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ATENOLOL;DPYS;AG + GG;rs2669429;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MYELODYSPLASTIC SYNDROMES;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;IFNL3, IFNL4;CC;rs12979860;OTHER;INCREASED;NAN;OTHER;SPONTANEOUS HCV CLEARANCE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_DOSE_ADJUST
RISPERIDONE;LEP;G;rs7799039;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;NAN;SIDE EFFECT;BLOOD COAGULATION DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;EIF4E2, TIGD1;CC;rs1656402;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;EIF4E2, TIGD1;CC;rs1656402;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IODINE (131I) COMPOUNDS;ATM;AG;rs11212570;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;ATM;AG;rs11212570;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;FATIGUE IN PEOPLE WITH  OTHER:THYROID TUMOR;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;;CT + TT;rs2056527;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN  OTHER:SMOKERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;;CT + TT;rs2056527;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SMOKING CESSATION IN  OTHER:SMOKERS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PIRFENIDONE;TOLLIP;CC + CT;rs5743890;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:PULMONARY FIBROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED;NAN;EFFICACY;TIME TO THERAPEUTIC INR NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;BCR-ABL1 POSITIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XBP1;GG;rs2269577;TOXICITY;INCREASED;RISK;DISEASE;NAUSEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CC;rs683369;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:CHRONIC MYELOGENOUS LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CC;rs683369;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;BCR-ABL1 POSITIVE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN;DSCAM;TT;rs9981861;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;DSCAM;TT;rs9981861;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HEADACHE IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;ATG10;TT;rs1864183;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;ATG10;TT;rs1864183;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:THYROID TUMOR;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;A;rs186364861;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AMISULPRIDE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
PALIPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
AMISULPRIDE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
HALOPERIDOL;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ZIPRASIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;SIDE EFFECT:WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;NAN;DISEASE;PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:ANGINA PECTORIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;NAN;DISEASE;DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
REGADENOSON;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED;SEVERITY;SIDE EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SOMNOLENCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER;SUBSTANCE-RELATED DISORDERS IN PEOPLE WITH  OTHER:METHAMPHETAMINE DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER;OTHER:ALCOHOL ABUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER;OTHER:EATING DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;CT;rs1799793;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:VENOUS THROMBOEMBOLISM;;CAUTION_SIDE_EFFECT
NICOTINE;DBH;CC;rs1541333;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;END OF TREATMENT ABSTINENCE IN  OTHER:SMOKERS WITH LOW DEPENDENCY;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGADENOSON;AMPD1;AA + AG;rs17602729;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CNR1;T;rs806378;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;CNR1;C;rs1049353;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;T;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPARAGINASE;NFATC2;T;rs6021191;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPARAGINASE;HLA-DRB1;T;rs17885382;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERSENSITIVITY IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;CYSTIC FIBROSIS PULMONARY EXACERBATION IN PEOPLE WITH  DISEASE:CYSTIC FIBROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
VANCOMYCIN;;A;rs2789047;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;;CAUTION_SIDE_EFFECT
LISINOPRIL;MMP3;AA;rs35068180;EFFICACY;INCREASED;RISK;SIDE EFFECT;STROKE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CARBOPLATIN;SERPINA5;C;rs6113;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;SERPINA5;C;rs6113;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;NAN;NAN;EFFICACY;SUBOPTIMAL REPERFUSION (POST-PCI TIMI FLOW <3) IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_DOSE_ADJUST
CARBOPLATIN;SERPINA5;T;rs6118;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;SERPINA5;T;rs6118;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;XYLT2;G;rs6504649;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;XYLT2;G;rs6504649;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;SERPINA5;G;rs6119;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;SERPINA5;G;rs6119;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CARBOPLATIN;ETS2;A;rs73450548;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;ETS2;A;rs73450548;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-VEGF INJECTIONS IN PEOPLE WITH  DISEASE:CHOROIDAL NEOVASCULARIZATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGAPTANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-VEGF INJECTIONS IN PEOPLE WITH  DISEASE:CHOROIDAL NEOVASCULARIZATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;NAN;EFFICACY;ANTI-VEGF INJECTIONS IN PEOPLE WITH  DISEASE:CHOROIDAL NEOVASCULARIZATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;NAN;OTHER;PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;DISEASE;RECURRENCE IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:SARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
PALIPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE EFFECT;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED;SEVERITY;DISEASE;ALCOHOL ABUSE IN PEOPLE WITH  DISEASE:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
NAN;ERCC1;AC;rs3212986;OTHER;DECREASED;NAN;OTHER;DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;GABRA2;GG;rs279847;TOXICITY;DECREASED;NAN;SIDE EFFECT;HEART RATE IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ESR1;AG + GG;rs9340799;TOXICITY;INCREASED;RISK;SIDE EFFECT;VENOUS THROMBOEMBOLISM IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"PLAIN""";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA + AG;rs3766246;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CLOZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;FAAH;CT + TT;rs4141964;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
NAN;ABCB11;GG;rs2287622;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEPATOCELLULAR INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPOVENTILATION IN WOMEN WITH  DISEASE:PREGNANCY;;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECTS IN WOMEN WITH  DISEASE:PREGNANCY;;CAUTION_SIDE_EFFECT
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DISEASE:SUBSTANCE-RELATED DISORDERS NAN  NAN;;CAUTION_SIDE_EFFECT
OPIOIDS;GNB3;CT + TT;rs5443;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INCREASED PULSE RATE IN PEOPLE WITH  SIDE EFFECT:WITHDRAWAL FROM OPIOID ADDICTION;;CAUTION_SIDE_EFFECT
OPIOIDS;GNB3;CT + TT;rs5443;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;INCREASED PULSE RATE IN PEOPLE WITH  SIDE EFFECT:WITHDRAWAL FROM OPIOID ADDICTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
HALOPERIDOL;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;GT + TT;rs2295632;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AC + CC;rs762551;OTHER;DECREASED;RISK;DISEASE;BREAST NEOPLASMS IN PEOPLE WITH  OTHER:BRCA1 MUTATIONS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;FAAH;AA + AC;rs324420;TOXICITY;INCREASED;RISK;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;VDR;AA + AG;rs2228570;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;VDR;AA + AG;rs2228570;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB11;GG;rs2287622;TOXICITY;INCREASED;RISK;DISEASE;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
SIMEPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AA;rs3003593;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NASOPHARYNGEAL NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;EHMT2;G;rs652888;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;TNF;AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TNF;AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;CONSTIPATION IN WOMEN WITH  DISEASE:PREGNANCY;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;HLA-G;G;rs1063320;OTHER;DECREASED;LIKELIHOOD;DISEASE;ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;DISEASE;DRY MOUTH IN WOMEN WITH  DISEASE:PREGNANCY;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;EFFICACY;INCREASED;NAN;EFFICACY;SEDATION IN WOMEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BETA-THALASSEMIA AND RELATED DISEASES;;CAUTION_SIDE_EFFECT
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:BETA-THALASSEMIA AND RELATED DISEASES;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;;del;rs111618861;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-B;C;rs1071816;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;ATM;AA + AG;rs11212570;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;ATM;AA + AG;rs11212570;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
EFAVIRENZ;IL10;TT;rs1800896;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG HYPERSENSITIVITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
ETHANOL;ANKK1, DRD2;A;rs1800497;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;NFKB1;AT;rs230493;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;NFKB1;AT;rs230493;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER;OPIOID-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;DRD2;A;rs1800497;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;TGFB1;TT;rs2241716;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TGFB1;TT;rs2241716;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;TGFB1;GG;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TGFB1;GG;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PAIN IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;FOXF2;del;rs199564443;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;AGRANULOCYTOSIS NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1P1;T;rs7187684;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPARAGINASE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
HYDROCORTISONE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1P1;G;rs11861118;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM;XRCC1;TT;rs25487;EFFICACY;NAN;NAN;OTHER;WORSE OVERALL SURVIVAL OUTCOME IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
PLATINUM;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RESPONSE IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CES1;G;rs2244613;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PLATINUM;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;GG;rs2069514;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
ETHANOL;CYP1A2;GG;rs2069514;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PSYCHOTIC DISORDER;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED;RISK;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ASPARAGINASE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCORTISONE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CES1;G;rs2244614;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;AG;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN MEN WITH  OTHER:ALCOHOL ABUSE;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;AG;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS;ATM;TT;rs620815;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;ATM;TT;rs620815;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:THYROID TUMOR;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
RIBAVIRIN;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS NAN  NAN;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC2;A;rs17222723;TOXICITY;DECREASED;RISK;SIDE EFFECT;RENAL PROXIMAL TUBULOPATHY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC2;A;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;RENAL PROXIMAL TUBULOPATHY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs1801160;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPARAGINASE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
HYDROCORTISONE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PREDNISONE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CC + CT;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CC + CT;rs28399499;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCORTISONE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;TT;rs2248359;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;GG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN WOMEN WITH  DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;GG;rs4646536;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DDC;C;rs2060761;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;AA + AG;rs10946737;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:TUBERCULOSIS;;CAUTION_SIDE_EFFECT
NICOTINE;DDC;A;rs12718541;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER IN  OTHER:SMOKERS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;CYP2C19;CT + TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2C19;CT + TT;rs11188072;METABOLISM/PK;DECREASED;NAN;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS IN PEOPLE WITH  DISEASE:DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CXCL5;GG;rs352046;OTHER;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME IN WOMEN WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;G;rs602950;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;A;rs6690069;TOXICITY;INCREASED;RISK;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;SIDE EFFECT;KIDNEY TUBULAR DYSFUNCTION IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER;SOCIAL WITHDRAWAL IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;SUBCLINICAL INTRA-STENT THROMBUS IN  OTHER:PATIENTS UNDERGOING DRUG-ELUTING STENT (DES) IMPLANTATION;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;G;rs3217164;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;A;rs10916825;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;CT + TT;rs11854484;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DIZZINESS IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED;NAN;EFFICACY;SERUM OSTEOCALCIN IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;INCREASED;RISK;EFFICACY;INADEQUATE INHIBITION OF PLATELET ACTIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:URINARY BLADDER NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
TICAGRELOR;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSPNEA IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;NAN;NAN;EFFICACY;A 22% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT AFTER ADJUSTMENT FOR CLINICAL AND GENETIC COVARIATES IN HISPANIC-AMERICANS NAN  NAN;;CAUTION_DOSE_ADJUST
AMOXICILLIN;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CLAVULANATE;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:DRUG TOXICITY;;CAUTION_SIDE_EFFECT
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"TOXIC LIVER DISEASE IN PEOPLE WITH  ""DISEASE:BURKITT LYMPHOMA""";;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:LYMPHOMA";;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"T-CELL""";;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOCETAXEL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EPIRUBICIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
GOSERELIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;AMENORRHEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
WARFARIN;NQO1;A;rs1800566;DOSAGE;NAN;NAN;EFFICACY;A 34% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT WHILE HOLDING CLINICAL AND GENETIC PREDICTORS CONSTANT IN HISPANIC-AMERICANS NAN  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CETUXIMAB;RASSF1;CC;rs2236947;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;RGS2;C;rs4606;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;RGS2;C;rs4606;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:PARKINSONIAN DISORDER IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;WBP2NL;AA;rs5758550;EFFICACY;INCREASED;SEVERITY;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;NFATC1;CC;rs2280055;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID;NFATC1;CC;rs2280055;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
PREDNISONE;NFATC1;CC;rs2280055;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CARBOPLATIN;;AA + AC;rs2498804;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;;AA + AC;rs2498804;EFFICACY;DECREASED;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE EFFECT;BODY WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE EFFECT;BODY WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE EFFECT;BODY WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELAPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCC2;T;rs12826;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;NAN;PK;PLASMA EXPOSURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_DOSE_ADJUST
NICOTINE;GRIN3A;C;rs10121600;OTHER;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;NAN;EFFICACY;MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY IN CHILDREN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR1B;CC;rs6296;TOXICITY;INCREASED;RISK;SIDE EFFECT;AGITATION IN CHILDREN WITH  DISEASE:ANXIETY DISORDERS;;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR1B;CC;rs6296;TOXICITY;INCREASED;RISK;SIDE EFFECT;DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
PRAVASTATIN;ABCA1;TT;rs2230806;EFFICACY;INCREASED;NAN;EFFICACY;HDL-CHOLESTEROL IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:STROKE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ABCG2;GG;rs2231142;EFFICACY;INCREASED;SEVERITY;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"NON-STEROIDS""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""CELECOXIB""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""IBUPROFEN""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""NAPROXEN""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""PIROXICAM""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NICOTINE;GRIN3A;G;rs11788456;OTHER;NAN;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;FATIGUE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"NON-STEROIDS""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""CELECOXIB""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
"""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE EFFECT;ACUTE GASTROINTESTINAL BLEEDING NAN  NAN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;SLEEP DISORDERS IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE;CORONARY DISEASE IN PEOPLE WITH  OTHER:PRIOR VASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"DRUG TOXICITY IN PEOPLE WITH  ""DISEASE:BURKITT LYMPHOMA""";;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:LYMPHOMA";;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"T-CELL""";;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"PLAIN""";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY;EFFICACY:DEATH IN PEOPLE WITH  OTHER:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;NAN;OTHER;HEART RATE NAN  NAN;;CAUTION_DOSE_ADJUST
CARBOPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CISPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;NAN;OTHER;HEART RATE NAN  NAN;;CAUTION_DOSE_ADJUST
CARBOPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CARBOPLATIN;AKT1;C;rs3803304;EFFICACY;NAN;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
CISPLATIN;AKT1;C;rs3803304;EFFICACY;NAN;RISK;EFFICACY;DISEASE PROGRESSION IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_DOSE_ADJUST
COCAINE;BCHE;TT;rs1803274;OTHER;NAN;NAN;DISEASE;COCAINE DEPENDENCE IN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;MEAN PEAK CONCENTRATION IN PLASMA AND AREA UNDER THE PLASMA CONCENTRATION IN MEN  NAN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;EGFR;AA;rs11506105;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL RATE IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED;NAN;EFFICACY;SURVIVAL RATE IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET REACTIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;STAT4;T;rs7574865;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY IN PEOPLE WITH  DISEASE:DRUG-INDUCED LIVER INJURY;;CAUTION_SIDE_EFFECT
CISPLATIN;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RISK;EFFICACY;LYMPH NODE METASTASES IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RISK;EFFICACY;LYMPH NODE METASTASES IN PEOPLE WITH  DISEASE:NEOPLASM OF ESOPHAGUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
HEROIN;ALDH2;AA + AG;rs671;OTHER;INCREASED;NAN;DISEASE;HEROIN DEPENDENCE NAN  NAN;;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE EFFECT;"POSTOPERATIVE NAUSEA AND VOMITING IN WOMEN WITH  ""OTHER:PAIN";;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE EFFECT;"POSTOPERATIVE""";;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE EFFECT;"""OTHER:CAESARIAN SECTION""";;CAUTION_DOSE_ADJUST
"""METFORMIN""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""SULFONAMIDES";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TREATMENT FAILURE IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"UREA DERIVATIVES""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STROKE IN PEOPLE WITH  OTHER:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GRIN3A;T;rs17189632;OTHER;NAN;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1A2;T;rs4149000;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;POOR-RESPONSE TO CLOPIDOGREL IN  OTHER:PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI);;CAUTION_SIDE_EFFECT
TRAMADOL;SLC22A1;del;rs35167514;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;FASTKD3, MTRR;AA + AG;rs2307116;EFFICACY;INCREASED;NAN;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED;RISK;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
TRAMADOL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;T;rs12208357;METABOLISM/PK;NAN;NAN;PK;HIGHER PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
METHADONE;KCNJ6;TT;rs2070995;TOXICITY;DECREASED;RISK;SIDE EFFECT;WITHDRAWAL EFFECTS IN PEOPLE WITH  DISEASE:HEROIN DEPENDENCE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1A2;CC;rs3764043;METABOLISM/PK;DECREASED;NAN;PK;IMATINIB CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
IMATINIB;SLCO1A2;CC;rs4148978;METABOLISM/PK;INCREASED;NAN;PK;IMATINIB CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
VINCRISTINE;ABCC2;T;rs3740066;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1A2;CC;rs4148977;METABOLISM/PK;INCREASED;NAN;PK;IMATINIB CLEARANCE NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AC;rs55886062;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;NR1I2;CC;rs3814055;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;FASTKD3, MTRR;AG + GG;rs1801394;EFFICACY;INCREASED;NAN;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC;rs28399499;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACE INHIBITORS";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"PLAIN""";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ACE INHIBITORS";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"PLAIN""";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANGIOEDEMA NAN  NAN;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;NAN;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CC;rs3812718;OTHER;INCREASED;NAN;OTHER;CORTICAL SILENT PERIOD DURATION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
METHOTREXATE;MIR1206;GG;rs2114358;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED;NAN;EFFICACY;SLOWER RESPONSE TIME IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
FOLIC ACID;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENT IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENT IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUSCULAR DISEASES NAN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;PIK3R5;T;rs444904;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs17868323;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYTARABINE;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;AA;rs2273697;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CYTARABINE;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CC + CT;rs4148396;TOXICITY;INCREASED;NAN;SIDE EFFECT;TIME TO DISCONTINUATION OR DOSE REDUCTION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CC;rs4148396;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ALOPECIA IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CYTARABINE;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;;CAUTION_SIDE_EFFECT
IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;MYELOID;;CAUTION_SIDE_EFFECT
IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY;ACUTE;;CAUTION_SIDE_EFFECT
FOLIC ACID;TLR4;G;rs4986790;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;TLR4;G;rs4986790;TOXICITY;INCREASED;RISK;SIDE EFFECT;ADVERSE DRUG EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS NAN  NAN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX NAN  NAN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;EFFICACY:SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;;G;rs10792367;EFFICACY;DECREASED;NAN;EFFICACY;BLOOD PRESSURE (BP) REDUCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs17868323;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
NAN;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;NAN;OTHER;SERUM TOTAL CHOLESTEROL NAN  NAN;;CAUTION_DOSE_ADJUST
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"CARDIOTOXICITY IN CHILDREN WITH  ""OTHER:NEOPLASMS""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WILMS TUMOR""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SARCOMA";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"EWING'S""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:HODGKIN DISEASE""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-HODGKIN LYMPHOMA""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:OSTEOSARCOMA""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEUROBLASTOMA""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;T;rs3743075;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOBACCO USE DISORDER IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB4;G;rs7178270;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOBACCO USE DISORDER IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB4;A;rs1948;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;TOBACCO USE DISORDER IN MEN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG COA REDUCTASE INHIBITORS;;T;rs1719247;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;;T;rs1719247;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;;CAUTION_SIDE_EFFECT
HMG COA REDUCTASE INHIBITORS;;C;rs1346268;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;;C;rs1346268;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IMATINIB;UGT2A1;CC;rs11249454;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;A;rs11155012;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A1;AA;rs3825876;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;AUC IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;PROLONGED QTC INTERVAL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
PITAVASTATIN;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;NAN;PK;PITAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
SORAFENIB;EGFR;C;rs2330951;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;NAN;PK;AUC (P=0.002) AND CMAX (P=0.003) IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;MUSCULAR DISEASES NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
EVEROLIMUS;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EVEROLIMUS;ABCB1;A;rs2032582;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;LYMPHOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;;C;rs2647087;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;;C;rs2647087;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
EVEROLIMUS;RPTOR;T;rs9906827;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;RPTOR;T;rs9906827;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;XPC;G;rs2228001;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EVEROLIMUS;ABCB1;A;rs1045642;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;C;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;C;rs116855232;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL ISCHEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZACITIDINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MYELODYSPLASTIC SYNDROMES;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION (PCI);;CAUTION_SIDE_EFFECT
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:MYOCARDIAL ISCHEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:STROKE IN PEOPLE WITH  OTHER:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;GG;rs628031;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
IBUPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
IBUPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LOXOPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
LOXOPROFEN;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
SALICYLAMIDE;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SALICYLAMIDE;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
IMATINIB;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;CC;rs1994862;OTHER;DECREASED;RISK;SIDE EFFECT;AROUSAL DYSFUNCTION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;RPTOR;CT + TT;rs9906827;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CHST1;AA + AG;rs9787901;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
IMATINIB;CYP2F1;AA;rs305968;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
IBUPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
IBUPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
LOXOPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
LOXOPROFEN;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
SALICYLAMIDE;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXIC EPIDERMAL NECROLYSIS;;CAUTION_SIDE_EFFECT
SALICYLAMIDE;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:STEVENS-JOHNSON SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SORAFENIB;PRKCE;G;rs11125039;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;IL10;C;rs1800896;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
NON-STEROIDS;IL10;C;rs1800896;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS;CTLA4;G;rs231775;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NON-STEROIDS;CTLA4;G;rs231775;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADH7;CT + TT;rs971074;OTHER;INCREASED;SEVERITY;OTHER;PAIN IN PEOPLE WITH  OTHER:ANEMIA;;CAUTION_SIDE_EFFECT
NAN;ADH7;CT + TT;rs971074;OTHER;INCREASED;SEVERITY;OTHER;SICKLE CELL;;CAUTION_SIDE_EFFECT
SORAFENIB;ADAMTS18;A;rs1346563;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;SLC31A1;GG + GT;rs10981694;TOXICITY;INCREASED;SEVERITY;DISEASE;OTOTOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ABCC9;AA;rs11046209;EFFICACY;INCREASED;SEVERITY;EFFICACY;SEDATION IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:GLIOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:BRAIN NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;FTO;A;rs79206939;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;FTO;A;rs79206939;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCC4;AC;rs2274407;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;ABCC4;AC;rs2274407;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC4;AC;rs2274407;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY IN  OTHER:PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION (PCI);;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EVEROLIMUS;FGFR4;A;rs351855;TOXICITY;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;FGFR4;A;rs351855;OTHER;DECREASED;LIKELIHOOD;OTHER;DISCONTINUATION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  ""OTHER:MEDULLOBLASTOMA""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:GLIOMA""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:BRAIN NEOPLASMS""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:LYMPHOMA";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"B-CELL""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:LEUKEMIA""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SARCOMA";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"EWING'S""";;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-HODGKIN LYMPHOMA""";;CAUTION_SIDE_EFFECT
AZATHIOPRINE;;T;rs2834826;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;;T;rs2834826;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
IMATINIB;SLC19A1;AG + GG;rs12659;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;FTO;C;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;FTO;C;rs16952570;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:IRRITABLE BOWEL SYNDROME;;CAUTION_SIDE_EFFECT
AZACITIDINE;XRCC1;CC;rs25487;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:MYELODYSPLASTIC SYNDROMES;;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;NQO1;GG;rs10517;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;PIK3R1;G;rs10515074;OTHER;DECREASED;LIKELIHOOD;SIDE EFFECT;HYPERGLYCEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DESLORATADINE;HRH1;CC;rs901865;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:URTICARIA;;CAUTION_SIDE_EFFECT
IMATINIB;ABCC2;GG;rs2273697;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;NAN;SIDE EFFECT;IQ IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB4;AA + AG;rs1202283;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:GASTROINTESTINAL STROMAL TUMORS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
EVEROLIMUS;PIK3R1;G;rs10515074;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SJOGREN'S SYNDROME;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;CT + TT;rs1105525;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;NECTIN4;AA;rs11265549;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PRURITUS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:AUTOIMMUNE DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SJOGREN'S SYNDROME;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A4;AA;rs2246709;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;A;rs11545078;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
NAN;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;NAN;OTHER;SERUM LDL NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:NEPHROTOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
PRAVASTATIN;HMGCR;AT;rs17244841;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;TT;rs12654264;EFFICACY;DECREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A4;TT;rs3735451;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;RBFOX1;G;rs6500843;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED;RISK;DISEASE;COLONIC NEOPLASMS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;ANEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC1;A;rs17287570;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;EPAS1;C;rs1868089;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;;CAUTION_SIDE_EFFECT
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2A6;A;rs143731390;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;T;rs2622604;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLIC ACID;MTHFD1;AA;rs2236225;OTHER;DECREASED;LIKELIHOOD;OTHER;DIABETES;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC ACID;MTHFD1;AA;rs2236225;OTHER;DECREASED;LIKELIHOOD;OTHER;GESTATIONAL IN WOMEN WITH  OTHER:PREGNANCY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;GG;rs442767;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;CT + TT;rs11692021;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
APIXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B3;G;rs7977213;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TT;rs408626;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NEUTROPENIA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B3;T;rs10841661;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;AA;rs1650697;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE;DIARRHEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:NAUSEA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE;DISEASE:VOMITING IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:NAUSEA;;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE;DISEASE:VOMITING IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
MEPHENYTOIN;CYP2C19;C;rs41291556;METABOLISM/PK;NAN;NAN;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE NAN  NAN;;CAUTION_DOSE_ADJUST
TOLBUTAMIDE;CYP2C19;C;rs41291556;METABOLISM/PK;NAN;NAN;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE NAN  NAN;;CAUTION_DOSE_ADJUST
PLATINUM;CD74;A;rs2748249;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ASPIRIN;TBXAS1;AA;rs6962291;OTHER;DECREASED;RISK;SIDE EFFECT;INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;CD74;C;rs1560661;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;GRADE III/IV LIVER TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;GRADE III/IV LIVER TOXICITY IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;MYELOID;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;RISK;SIDE EFFECT;ACUTE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;INDEPENDENT OF CYP2C9*2 AND CYP2C9*3. NAN  NAN;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;DOSAGE;NAN;NAN;EFFICACY;INDEPENDENT OF CYP2C9*2 AND CYP2C9*3. NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;ALDH1A2;A;rs12915901;OTHER;INCREASED;LIKELIHOOD;OTHER;OSTEOARTHRITIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;;G;rs10030044;EFFICACY;INCREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
TAMOXIFEN;;G;rs10030044;EFFICACY;INCREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MUCOSITIS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;SLC2A1;CG + GG;rs841844;TOXICITY;INCREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;TT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;TT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY;INSUFFICIENT ANTIPLATELET RESPONSE TO CLOPIDOGREL IN  OTHER:PATIENTS UNDERGOING ELECTIVE CORONARY STENT IMPLANTATION;;CAUTION_SIDE_EFFECT
DASATINIB;ABL1;CT;rs121913459;OTHER;DECREASED;NAN;PK;AUC 0-4 HOURS IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_DOSE_ADJUST
DASATINIB;ABL1;CT;rs121913459;METABOLISM/PK;DECREASED;NAN;PK;AUC 0-4 HOURS IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;DECREASED;SEVERITY;DISEASE;HEPATITIS C VIRUS INFECTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;DECREASED;SEVERITY;DISEASE;HEPATITIS C VIRUS INFECTION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;AGT;T;rs5051;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN WOMEN WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;AGTR1;A;rs5186;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN WOMEN WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ESR2;CC;rs4986938;OTHER;INCREASED;NAN;SIDE EFFECT;TRIGLYCERIDES IN POSTMENOPAUSAL WOMAN NAN  NAN;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;LEUKOPENIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;SIDE EFFECT:NEUTROPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;AA;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;ESR1;GG;rs9340799;OTHER;DECREASED;NAN;SIDE EFFECT;IN TOTAL CHOLESTEROL IN POSTMENOPAUSAL WOMAN AND INCREASE IN TRIGLYCERIDES AND DECREASE IN HIGH DENSITY LIPOPROTEIN IN PREMENOPAUSAL WOMEN NAN  NAN;;CAUTION_DOSE_ADJUST
TALINOLOL;ABCC2;A;rs2273697;OTHER;INCREASED;NAN;PK;RESIDUAL CLEARANCE OF INTRAVENOUS TALINOLOL AND LOWER BIOAVAILABLILTY OF ORALLY ADMINISTERED TALINOLOL NAN  NAN;;CAUTION_DOSE_ADJUST
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;rs8133052;METABOLISM/PK;INCREASED;NAN;PK;DOXORUBICINOL AUC IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_DOSE_ADJUST
ONDANSETRON;ABCB1;AA;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING NAN  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;METABOLIC SYNDROME IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYANOCOBALAMIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC ACID;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEAD AND NECK NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARTESUNATE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
PRIMAQUINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
PYRIMETHAMINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
SULFADOXINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RALOXIFENE;ZNF423;A;rs8060157;EFFICACY;DECREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ZNF423;A;rs8060157;EFFICACY;DECREASED;RISK;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + AG;rs1045642;EFFICACY;NAN;NAN;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROLOGICAL ADR IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;RISK;SIDE EFFECT;NEUROLOGICAL ADR IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ARTESUNATE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
PRIMAQUINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
PYRIMETHAMINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
SULFADOXINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE EFFECT;MODERATE ANEMIA IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFB;T;rs12366035;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;NAN;EFFICACY;5 YEAR SURVIVAL IN PEOPLE WITH  DISEASE:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;NAN;EFFICACY;MYELOID;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;NAN;EFFICACY;ACUTE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:LEUKEMIA;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE;MYELOID;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE;ACUTE;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RISK;DISEASE;INFECTIOUS DISEASE IN PEOPLE WITH  DISEASE:HEART TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;GG;rs2046934;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ACUTE CORONARY SYNDROME NAN  NAN;;CAUTION_SIDE_EFFECT
VINCRISTINE;MIR6076;CC + CG;rs35650931;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;WWOX;A;rs9927200;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2C19;AA;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;DISEASE;CARDIOTOXICITY IN CHILDREN WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;MIR4481;G;rs7896283;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;CC;rs2297595;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC;rs2297595;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;INCREASED;RISK;OTHER;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ACP1;TT;rs11553746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SORAFENIB;MAP2K6;C;rs11651488;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED;RISK;OTHER;TOXIC LIVER DISEASE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;CDH13;C;rs17682789;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:NEPHROTIC SYNDROME;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE IN PEOPLE WITH  DISEASE:MENTAL DISORDERS;;CAUTION_DOSE_ADJUST
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
LIOTHYRONINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
LITHIUM;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NEFAZODONE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
ILOPERIDONE;CYP2D6;GG;rs1065852;OTHER;INCREASED;NAN;SIDE EFFECT;QTC INTERVAL IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
GEMCITABINE;SLC28A1;A;rs12148896;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RISK;SIDE EFFECT;MYELOSUPPRESSION IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIOTHYRONINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEFAZODONE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1B;A;rs130058;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;A;rs471760;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:PANCREATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABIDIOL;ABCC5;AA + AG;rs3749442;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEDATION IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;AG;rs1872328;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
LIOTHYRONINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
LITHIUM;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
NEFAZODONE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
PAROXETINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
VENLAFAXINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE EFFECT;SUICIDAL IDEATION IN PEOPLE WITH  DISEASE:DEPRESSION;;CAUTION_SIDE_EFFECT
MELPHALAN;SLC7A5;AA + AG;rs4240803;TOXICITY;DECREASED;RISK;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;MC4R;CC + CT;rs17782313;OTHER;INCREASED;RISK;DISEASE;WEIGHT GAIN NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM;SLC2A1;T;rs3738514;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:LUNG NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"CARDIOTOXICITY IN CHILDREN WITH  ""OTHER:NEOPLASMS""";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:WILMS TUMOR""";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:SARCOMA";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"EWING'S""";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:HODGKIN DISEASE""";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NON-HODGKIN LYMPHOMA""";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:OSTEOSARCOMA""";;CAUTION_SIDE_EFFECT
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:NEUROBLASTOMA""";;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;EGFR;A;rs917881;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:HODGKIN DISEASE;;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:RHABDOMYOSARCOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:MEDULLOBLASTOMA;;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;OTHER:GLIOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;RISK;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ERCC2, KLC3;GT;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ERCC2, KLC3;GT;rs13181;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;SLC2A1;CC;rs4658;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADD1;GT + TT;rs4961;OTHER;INCREASED;NAN;OTHER;AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
BLEOMYCIN;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:STROKE;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;RAD52, WNK1;CC;rs2277869;OTHER;INCREASED;NAN;OTHER;AMBULATORY BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_DOSE_ADJUST
FENTANYL;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;C;rs13422094;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
FENTANYL;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;G;rs12211463;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FENTANYL;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;A;rs7757130;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
FENTANYL;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;G;rs2473967;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
THIAZIDES;ADD1;GG;rs4961;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;ADD1;GG;rs4961;EFFICACY;DECREASED;RISK;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SOMNOLENCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE EFFECT;STATIN-RELATED MYOPATHY NAN  NAN;;CAUTION_SIDE_EFFECT
FENTANYL;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS;SH2B1;T;rs192613545;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;SH2B1;T;rs192613545;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;OSMR;T;rs1239344;TOXICITY;INCREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;;CAUTION_SIDE_EFFECT
BLEOMYCIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;PAIN IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;PAIN IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;PAIN IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;CDK1;G;rs10711;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONITIS NAN  NAN;;CAUTION_SIDE_EFFECT
BLEOMYCIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;CT;rs1799853;METABOLISM/PK;NAN;NAN;PK;HIGHER PLASMA CONCENTRATIONS OF CELECOXIB IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;REN;GG;rs11240688;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN SBP IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;YEATS4;C;rs7297610;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;RBFOX3;C;rs62063838;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;RBFOX3;C;rs62063838;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;PRKCE;G;rs940052;TOXICITY;DECREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;MBOAT1;T;rs10946364;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;MBOAT1;T;rs10946364;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;PRKCE;T;rs11125035;TOXICITY;DECREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROFECOXIB;PTGS1;T;rs3842787;EFFICACY;NAN;NAN;EFFICACY;REDUCTION IN COX-1 INHIBITION AND DEPRESSION OF THE URINARY THROMBOXANE METABOLITE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
BLEOMYCIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;FEBRILE NEUTROPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;FEBRILE NEUTROPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;FEBRILE NEUTROPENIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;RIGI;C;rs11795343;TOXICITY;INCREASED;RISK;SIDE EFFECT;PNEUMONITIS NAN  NAN;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;SIDE EFFECT;OTOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;RBFOX3;G;rs56044629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;RBFOX3;G;rs56044629;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;WNK1;TT;rs880054;EFFICACY;DECREASED;NAN;EFFICACY;REDUCTION IN SBP IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;;C;rs7259857;TOXICITY;DECREASED;RISK;SIDE EFFECT;ESOPHAGITIS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;PTGS1;T;rs3842787;EFFICACY;NAN;NAN;EFFICACY;REDUCTION IN COX-1 INHIBITION IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;FRACTURES;;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE;BONE NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;T;rs4961;EFFICACY;DECREASED;NAN;EFFICACY;ABSOLUTE MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS;GABRG2;G;rs77370934;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;GABRG2;G;rs77370934;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;rs1800012;NAN;DECREASED;NAN;OTHER;BONE MINERAL DENSITY (BMD) NAN  NAN;;CAUTION_DOSE_ADJUST
VINCRISTINE;BAHD1;AA + AC;rs3803357;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;RBFOX3;G;rs56209714;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;RBFOX3;G;rs56209714;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
METHYLPREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFECTIOUS DISEASE IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ANASTROZOLE;ZNF613;C;rs8113308;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
LETROZOLE;ZNF613;C;rs8113308;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;ZNF613;C;rs8113308;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PIRFENIDONE;CYP1A2;AA;rs762551;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:PULMONARY FIBROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;OTOS;CC + CT;rs2291767;TOXICITY;DECREASED;RISK;SIDE EFFECT;OTOTOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS;RBFOX3;G;rs2061538;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;RBFOX3;G;rs2061538;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISCONTINUATION NAN  NAN;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIMINISHED ABILITY TO CONCENTRATE IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA;;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;RISK;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;RISK;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CXCL8;TT;rs1126647;OTHER;INCREASED;LIKELIHOOD;SIDE EFFECT;HYPERTENSION IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;PNPLA3;GG;rs738409;TOXICITY;INCREASED;RISK;OTHER;ALCOHOL ABUSE IN MEN  NAN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;EPAS1;T;rs9973653;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;WT1;CC + CT;rs16754;OTHER;INCREASED;LIKELIHOOD;DISEASE;EVENT-FREE SURVIVAL IN CHILDREN WITH  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;A;rs1127354;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CANNABINOIDS;FAAH;AA;rs324420;TOXICITY;DECREASED;RISK;DISEASE;SUBSTANCE-RELATED DISORDERS NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;;C;rs315498;TOXICITY;DECREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;A;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
VINCRISTINE;MRPL47;CT + TT;rs10513762;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
VINCRISTINE;SYNE2;A;rs2781377;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SORAFENIB;EPAS1;A;rs4035887;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ELEVATED SYSTOLIC BLOOD PRESSURE IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;NAN;EFFICACY;ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:JUVENILE RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;CC;rs408626;EFFICACY;DECREASED;NAN;OTHER;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;CC;rs408626;EFFICACY;DECREASED;NAN;OTHER;OTHER:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ELEVATED TRANSAMINASES IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DEATH IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXICITY-RELATED TREATMENT FAILURE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:HEPATOCELLULAR CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2D6;CC;rs28360521;TOXICITY;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;CYP2D6;CC;rs28360521;OTHER;INCREASED;RISK;SIDE EFFECT;GASTROINTESTINAL HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
DESFLURANE;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;CAUTION_SIDE_EFFECT
DESFLURANE;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
PROPOFOL;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;CAUTION_SIDE_EFFECT
PROPOFOL;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  OTHER:SURGERY;;CAUTION_SIDE_EFFECT
LOSARTAN;CAMK1D;AG + GG;rs10752271;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;PSORIATIC;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TT;rs408626;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LOSARTAN;CAMK1D;AG + GG;rs10737062;EFFICACY;DECREASED;SEVERITY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;T;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;GT;rs442767;TOXICITY;INCREASED;RISK;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;C;rs1057910;EFFICACY;DECREASED;RISK;DISEASE;ADENOMA IN PEOPLE WITH  DISEASE:ADENOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTIONS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
BLEOMYCIN;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;ALOPECIA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT INTERRUPTION IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EMERGING VIRAL DRUG RESISTANCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEUCOVORIN;CSPG4;AG;rs1127648;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;;G;rs10958704;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SHMT1;AG;rs1979277;TOXICITY;DECREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AG;rs1801394;TOXICITY;INCREASED;NAN;SIDE EFFECT;SPEED OF PLATELET RECOVERY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
SORAFENIB;EPAS1;G;rs7557402;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;RED BLOOD CELL TRANSFUSIONS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GRAFT VS HOST DISEASE IN PEOPLE WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;CAUTION_SIDE_EFFECT
APIXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EMERGING VIRAL DRUG RESISTANCE IN PEOPLE WITH  DISEASE:HIV INFECTIOUS DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;VEGFA;AA;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;AA;rs1570360;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN;OR4D6;CC;rs1453542;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
GEMCITABINE;OR4D6;CC;rs1453542;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
SORAFENIB;MAP2K6;G;rs12948059;TOXICITY;INCREASED;RISK;SIDE EFFECT;DERMATOLOGIC TOXICITY IN PEOPLE WITH  OTHER:RENAL CELL CARCINOMA;;CAUTION_SIDE_EFFECT
CARBOPLATIN;DDX53;T;rs5925720;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DDX53;T;rs5925720;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;THROMBOCYTOPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA;rs2236225;OTHER;INCREASED;NAN;PK;RED BLOOD CELL FOLATE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
METHOTREXATE;FASTKD3, MTRR;AA;rs1801394;OTHER;INCREASED;NAN;PK;RED BLOOD CELL FOLATE IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_DOSE_ADJUST
IRINOTECAN;SEMA3C;T;rs11979430;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;A;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS NAN  NAN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SEMA3C;C;rs7779029;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;NAN;NAN;EFFICACY;PROTECTION FROM DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;NAN;NAN;EFFICACY;PROTECTION FROM DRUG RESISTANCE IN MEN WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED;RISK;DISEASE;TARDIVE DYSKINESIA IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
IRINOTECAN;;G;rs1661167;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;NAN;NAN;EFFICACY;PROTECTION FROM DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
AMISULPRIDE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CISPLATIN;CYP2E1;TT;rs6413432;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2E1;TT;rs6413432;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;FCER2;G;rs28364072;OTHER;NAN;NAN;OTHER;SEVERE EXACERBATIONS WITH ASTHMA IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;NOS3;TT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IL12A;A;rs568408;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;;CAUTION_SIDE_EFFECT
IRINOTECAN;PLCB1;C;rs2745761;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NOS3;CC;rs2070744;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
AMISULPRIDE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
QUETIAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;NAN;EFFICACY;DISEASE FREE SURVIVAL IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;PDZRN3;C;rs11128347;TOXICITY;INCREASED;SEVERITY;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;TT;rs4554144;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;TT;rs4554144;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-DRB1;A;rs201929247;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
OLANZAPINE;PPARG;CG;rs1801282;OTHER;INCREASED;NAN;DISEASE;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;CC;rs11940316;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs11940316;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;BCL2L11;AA;rs2241843;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;AA;rs7438135;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;AA;rs7438135;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;UGT2B7;GG;rs7662029;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;GG;rs7662029;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;ANEMIA IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;PIN1;CC + CG;rs2233678;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;PIN1;CC + CG;rs2233678;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;UGT2B7;CC;rs7668258;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs7668258;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;TT;rs2231142;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;AG;rs17602729;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CNS ADVERSE EVENTS IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;A;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN MEN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs7439366;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs7439366;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;A;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN MEN WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;GG;rs4292394;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;GG;rs4292394;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
ETHAMBUTOL;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE EFFECT;MACULOPAPULAR EXANTHEMA IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CYP2E1;CG;rs2070676;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE EMESIS IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2E1;CG;rs2070676;TOXICITY;INCREASED;RISK;SIDE EFFECT;SEVERE EMESIS IN WOMEN WITH  DISEASE:OVARIAN NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED;RISK;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:MUCOSITIS IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_SIDE_EFFECT
THIAZIDES;GNB3;CC;rs5443;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;GNB3;CC;rs5443;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;;CAUTION_SIDE_EFFECT
AMLODIPINE;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;DISEASE;HEART FAILURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;GG;rs1695;TOXICITY;DECREASED;RISK;SIDE EFFECT;HAEMATOLOGICAL TOXICITY IN PEOPLE WITH  DISEASE:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;COL1A1;AA;rs1800012;NAN;DECREASED;NAN;OTHER;BONE MINERAL DENSITY AT FEMORAL NECK AND LUMBAR SPINE NAN  NAN;;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;GG;rs6600879;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;GG;rs6600879;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;rs1800012;NAN;DECREASED;NAN;OTHER;BMD VALUES AT THE LUMBAR SPINE AND FEMORAL NECK NAN  NAN;;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;AA;rs6600880;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;AA;rs6600880;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE EFFECT;THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
THIAZIDES;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;;CAUTION_SIDE_EFFECT
THIAZIDES;ACE;GG;rs4341;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;;CAUTION_SIDE_EFFECT
PLAIN;ACE;GG;rs4341;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;NAN;NAN;PK;A NEARLY TRIPLED INCREASED PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN NAN  NAN;;CAUTION_DOSE_ADJUST
RIFAMPIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;NAN;NAN;PK;A NEARLY TRIPLED INCREASED PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN NAN  NAN;;CAUTION_DOSE_ADJUST
CAPECITABINE;MIR27A;C;rs895819;TOXICITY;NAN;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
FLUOROURACIL;MIR27A;C;rs895819;TOXICITY;NAN;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
ATORVASTATIN;FDPS;TT;rs2297480;TOXICITY;INCREASED;NAN;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;SUBJECTIVE FEELINGS OF INTOXICATION;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;STIMULATION;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;SEDATION;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;NAN;OTHER;AND HAPPINESS NAN  NAN;;CAUTION_DOSE_ADJUST
NAN;ABCC2;C;rs3740066;METABOLISM/PK;NAN;NAN;OTHER;ALLELIC IMBALENCE NAN  NAN;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTM4;CC;rs560018;EFFICACY;INCREASED;NAN;EFFICACY;IC-50 NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTM4;CC;rs560018;TOXICITY;INCREASED;NAN;EFFICACY;IC-50 NAN  NAN;;CAUTION_SIDE_EFFECT
ATORVASTATIN;FDPS;AA;rs11264359;TOXICITY;INCREASED;NAN;SIDE EFFECT;BONE DENSITY IN PEOPLE WITH  DISEASE:CORONARY DISEASE;;CAUTION_SIDE_EFFECT
IRINOTECAN;C8orf34;C;rs1517114;TOXICITY;INCREASED;SEVERITY;DISEASE;DIARRHEA IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
DICLOXACILLIN;ABCB1;GG;rs1045642;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
DICLOXACILLIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
PROBENECID;ABCB1;GG;rs1045642;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
PROBENECID;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OBESITY IN PEOPLE WITH  DISEASE:SCHIZOAFFECTIVE DISORDER;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;OTHER;NAN;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;CC;rs2032582;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
DICLOXACILLIN;ABCB1;CC;rs2032582;OTHER;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
DICLOXACILLIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;NAN;PK;CLEARANCE OF DICLOXACILLIN NAN  NAN;;CAUTION_DOSE_ADJUST
ETHAMBUTOL;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRAZINAMIDE;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:TUBERCULOSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;NAN;OTHER;CHOLESTEROL SYNTHESIS RATE NAN  NAN;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;MDM2;CC;rs1690924;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;GRIN2B;AA + AG;rs1806201;OTHER;INCREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;DECREASED;NAN;EFFICACY;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;GG;rs1042714;EFFICACY;INCREASED;NAN;OTHER;STATUS ASTHMATICUS IN CHILDREN WITH  DISEASE:ASTHMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CCND1;AA;rs9344;TOXICITY;DECREASED;SEVERITY;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCB1;A;rs1045642;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE;LEUKOPENIA IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SOD2;AA;rs4880;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;NAN;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
DOCETAXEL;ERCC2;TT;rs13181;TOXICITY;INCREASED;RISK;SIDE EFFECT;NEUTROPENIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERLIPIDEMIAS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
DOCETAXEL;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;RATES OF TARGET LESION REVASCULARIZATION AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;rs2683511;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN SECRETORY CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3, CHRNA5;A;rs16969968;TOXICITY;INCREASED;RISK;DISEASE;TOBACCO USE DISORDER NAN  NAN;;CAUTION_SIDE_EFFECT
METFORMIN;;G;rs10747673;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;;G;rs10747673;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;TO BE CLASSIFIED AS CLOPIDOGREL POOR RESPONDERS IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;;G;rs10747673;METABOLISM/PK;DECREASED;NAN;PK;METFORMIN SECRETORY CLEARANCE IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ATP10A;AA + AG;rs12913988;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE EFFECT;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;EFFICACY;CLOPIDOGREL POOR RESPONSE IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN PEOPLE WITH  DISEASE:CARDIOVASCULAR DISEASE;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;ABCB1;GG + GT;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;A;rs2032582;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN WOMEN WITH  DISEASE:SCHIZOPHRENIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;NAN;PK;PLASMA DRUG LEVELS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_DOSE_ADJUST
SEVOFLURANE;KCNK3;CT + TT;rs1275988;OTHER;INCREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
LEUCOVORIN;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
LEUCOVORIN;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE;MYELOSUPPRESSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
DOCETAXEL;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE EFFECT;INFUSION RELATED REACTION IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METFORMIN;SP1;G;rs784888;EFFICACY;DECREASED;SEVERITY;DISEASE;HYPERGLYCEMIA IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SP1;G;rs784888;EFFICACY;DECREASED;SEVERITY;DISEASE;TYPE 2;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;MTR;AA + AG;rs1805087;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;GABRA2;CC + CT;rs279858;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
LEUCOVORIN;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STAYING IN REMISSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STAYING IN REMISSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;STAYING IN REMISSION IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:LEUKOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE EFFECT;SIDE EFFECT:VOMITING IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;CG + GG;rs1113129;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
METFORMIN;PPARA;T;rs149711321;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PPARA;T;rs149711321;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;COL1A1;AA;rs1800012;NAN;INCREASED;RISK;DISEASE;FRACTURES;;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA;rs1800012;NAN;INCREASED;RISK;DISEASE;BONE NAN  NAN;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;CYP2C8;CT + TT;rs1934951;TOXICITY;INCREASED;RISK;SIDE EFFECT;ANEMIA IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;VEGFA;AA;rs699947;EFFICACY;DECREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;rs2683511;EFFICACY;DECREASED;NAN;EFFICACY;POST-HBA1C LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;rs2683511;EFFICACY;DECREASED;NAN;EFFICACY;TYPE 2;;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;FASTKD3, MTRR;AG + GG;rs1801394;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
BUPROPION;DRD1;A;rs2168631;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD1;A;rs2168631;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;HMGCR;TT;rs17238540;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION OF LDL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NR3C1;C;rs9324918;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  DISEASE:ANEMIA;;CAUTION_DOSE_ADJUST
NAN;NR3C1;C;rs9324918;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;DISEASE;DEATH IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
SEVOFLURANE;FASTKD3, MTRR;AA + AG;rs2307116;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
PACLITAXEL;ERCC1;AA + AC;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;C;rs1978153;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;C;rs1978153;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
NAN;P2RY12;G;rs2046934;NAN;INCREASED;RISK;SIDE EFFECT;CORONARY ARTERY DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE EFFECT;BLEEDING IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;CAUTION_SIDE_EFFECT
BUPROPION;DRD1;T;rs11749035;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD1;T;rs11749035;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;NAN;EFFICACY;ADP-INDUCED PLATELET AGGREGATION IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;CXCL8;T;rs1126647;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;CXCL8;T;rs1126647;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NR3C1;G;rs2963155;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  DISEASE:ANEMIA;;CAUTION_DOSE_ADJUST
NAN;NR3C1;G;rs2963155;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL;;CAUTION_DOSE_ADJUST
MORPHINE;ABCC3;G;rs733392;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs733392;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs6600893;EFFICACY;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs6600893;METABOLISM/PK;INCREASED;SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS IN PEOPLE WITH  DISEASE:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;MYD88;G;rs6853;TOXICITY;DECREASED;RISK;SIDE EFFECT;COGNITIVE DISORDER IN PEOPLE WITH  DISEASE:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;REMISSION IN PEOPLE WITH  DISEASE:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;DRD1;G;rs11746641;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD1;G;rs11746641;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS IN PEOPLE WITH  DISEASE:TOBACCO USE DISORDER;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NR3C1;T;rs33389;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL PAIN CRISIS IN PEOPLE WITH  DISEASE:ANEMIA;;CAUTION_DOSE_ADJUST
NAN;NR3C1;T;rs33389;OTHER;INCREASED;NAN;DISEASE;SICKLE CELL;;CAUTION_DOSE_ADJUST
SPIRONOLACTONE;ACE;AA + AG;rs4343;EFFICACY;NAN;NAN;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION;;CAUTION_DOSE_ADJUST
SPIRONOLACTONE;ACE;AA + AG;rs4343;EFFICACY;NAN;NAN;EFFICACY;END-SYSTOLIC AND END-DIASTOLIC VOLUME IN PEOPLE WITH  OTHER:CHRONIC HEART FAILURE;;CAUTION_DOSE_ADJUST
SIMVASTATIN;HMGCR;AA;rs17244841;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION OF LDL CHOLESTEROL NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ERCC1;CC;rs3212986;TOXICITY;INCREASED;RISK;SIDE EFFECT;MUCOSITIS IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
SEVOFLURANE;CYP2E1;CC + CG;rs3813867;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;CYP2E1, DUX1;CT + TT;rs2031920;OTHER;DECREASED;NAN;OTHER;MEAN ARTERIAL PRESSURE IN PEOPLE WITH  OTHER:OTORHINOLARYNGOLOGY SURGERY;;CAUTION_DOSE_ADJUST
ANTIHYPERTENSIVES;NOS3;CC;rs2070744;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
DIURETICS;NOS3;CC;rs2070744;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANT HYPERTENSION IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;LARGE B-CELL;;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;DIFFUSE;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;PTGS2;CG + GG;rs20417;EFFICACY;INCREASED;NAN;EFFICACY;PAIN RELIEF NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIFLOMOTECAN;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;NAN;PK;PLASMA CONCENTRATIONS OF DIFLOMOTECAN NAN  NAN;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AA;rs2032582;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:ULCERATIVE COLITIS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;CAUTION_SIDE_EFFECT
ROFECOXIB;PTGS2;CC;rs20417;EFFICACY;INCREASED;NAN;EFFICACY;PAIN RELIEF NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;G;rs2884129;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;;C;rs13210472;TOXICITY;INCREASED;RISK;OTHER;NEOPLASMS IN WOMEN  NAN;;CAUTION_SIDE_EFFECT
FENTANYL;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;T;rs7104613;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
PAZOPANIB;CXCL8;A;rs4073;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;CXCL8;A;rs4073;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:RENAL CELL CARCINOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE EFFECT;NAUSEA IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
FENTANYL;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
MORPHINE;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OPIOIDS;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
OXYCODONE;;T;rs10413396;EFFICACY;NAN;NAN;EFFICACY;OPIOIDS RESPONSE IN PEOPLE WITH  DISEASE:NEOPLASMS;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;NAN;EFFICACY;PHARMACODYNAMIC RESPONSE IN HEALTHY INDIVIDUALS  NAN;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;CCND1;AA;rs9344;EFFICACY;DECREASED;NAN;EFFICACY;EVENT FREE SURVIVAL IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PTGS1;AA + AG;rs10306114;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:CEREBRAL INFARCTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;CC;rs2032582;EFFICACY;INCREASED;RISK;EFFICACY;RESISTANCE IN PEOPLE WITH  DISEASE:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;CAUTION_SIDE_EFFECT
TACROLIMUS;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;NAN;SIDE EFFECT;WEIGHT GAIN IN PEOPLE WITH  DISEASE:TRANSPLANTATION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;NAN;PK;PLASMA EXPOSURE TO THE ACTIVE METABOLITE OF CLOPIDOGREL IN HEALTHY INDIVIDUALS  NAN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;NAN;EFFICACY;ACENOCOUMAROL DOSE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;T;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;STENT THROMBOSIS IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs886493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs886493;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
BLEOMYCIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
CISPLATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
ETOPOSIDE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE EFFECT;VOMITING IN MEN WITH  DISEASE:TESTICULAR NEOPLASMS;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;T;rs7216383;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;HYPOVENTILATION IN CHILDREN WITH  DISEASE:SLEEP APNEA SYNDROMES;;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;T;rs7216383;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;DISEASE:TONSILLECTOMY;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs10516440;TOXICITY;DECREASED;RISK;OTHER;ALCOHOL ABUSE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;A;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS IN PEOPLE WITH  DISEASE:FRACTURES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;A;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BONE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES NAN  NAN;;CAUTION_DOSE_ADJUST
TRAMADOL;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS IN PEOPLE WITH  DISEASE:FRACTURES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;BONE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE EFFECT;ANEMIA IN PEOPLE WITH  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE EFFECT;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:MYOCARDIAL INFARCTION;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;A;rs17222723;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUROTOXICITY SYNDROMES IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
RISPERIDONE;UGT1A1;CT;rs887829;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
FLUOXETINE;CRHR1;CC;rs242941;EFFICACY;INCREASED;NAN;EFFICACY;RESPONSE IN PEOPLE WITH  OTHER:MAJOR DEPRESSION AND HIGH ANXIETY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;UGT1A1;AG;rs10929302;TOXICITY;INCREASED;RISK;SIDE EFFECT;HYPERPROLACTINEMIA IN CHILDREN WITH  DISEASE:AUTISM SPECTRUM DISORDER;;CAUTION_SIDE_EFFECT
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;CT + TT;rs1138272;EFFICACY;DECREASED;NAN;EFFICACY;EVENT-FREE SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTP1;CT + TT;rs1138272;EFFICACY;DECREASED;NAN;EFFICACY;EFFICACY:OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:OSTEOSARCOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;TT;rs4845625;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VITAMIN K ANTAGONISTS;CYP4F2;TT;rs2108622;EFFICACY;INCREASED;RISK;EFFICACY;STROKE IN PEOPLE WITH  DISEASE:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;GG;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE EFFECT;WEIGHT GAIN IN CHILDREN WITH  DISEASE:AUTISM;;CAUTION_SIDE_EFFECT
WARFARIN;CRP;CT + TT;rs1205;TOXICITY;INCREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;TCF7L2;A;rs4132670;TOXICITY;INCREASED;RISK;SIDE EFFECT;DIABETES IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs7917983;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
CERIVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs4506565;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN PEOPLE WITH  OTHER:STROKE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;NAN;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE NAN  NAN;;CAUTION_DOSE_ADJUST
LENALIDOMIDE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;NAN;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC1;CC;rs25487;OTHER;NAN;NAN;OTHER;LATER ONSET OF SENSORY NEUROPATHY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_DOSE_ADJUST
LEUCOVORIN;XRCC1;CC;rs25487;OTHER;NAN;NAN;OTHER;LATER ONSET OF SENSORY NEUROPATHY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_DOSE_ADJUST
OXALIPLATIN;XRCC1;CC;rs25487;OTHER;NAN;NAN;OTHER;LATER ONSET OF SENSORY NEUROPATHY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_DOSE_ADJUST
DOCETAXEL;CHST3;A;rs4148950;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
THALIDOMIDE;CHST3;A;rs4148950;TOXICITY;INCREASED;RISK;SIDE EFFECT;TOXICITY IN PEOPLE WITH  DISEASE:PROSTATIC NEOPLASMS;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;VOMITING IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
SARILUMAB;IL6R;CC;rs4537545;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSLIPIDAEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;MEAN SPINAL BONE MINERAL DENSITY CHANGES IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETIDRONIC ACID;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;MEAN SPINAL BONE MINERAL DENSITY CHANGES IN PEOPLE WITH  DISEASE:OSTEOPOROSIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETIDRONIC ACID;VDR;TT;rs1544410;EFFICACY;INCREASED;NAN;EFFICACY;POSTMENOPAUSAL;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;AA;rs2228145;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSLIPIDAEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SOD2;AA + AG;rs4880;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISPHOSPHONATES;CYP2C8;TT;rs1934951;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS OF THE JAW IN PEOPLE WITH  DISEASE:MULTIPLE MYELOMA;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:PHYSIOLOGICAL SEXUAL DISORDER IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
NAN;IFNL3, IFNL4;CC;rs12979860;OTHER;INCREASED;LIKELIHOOD;DISEASE;JAUNDICE IN WOMEN  DISEASE:HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NAUSEA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE;DRUG TOXICITY IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
TRAMADOL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CRBN;CC;rs1705814;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;;CAUTION_DOSE_ADJUST
LENALIDOMIDE;CRBN;CC;rs1705814;DOSAGE;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DISCONTINUATION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;CAUTION_DOSE_ADJUST
LENALIDOMIDE;CRBN;CC;rs1705814;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DOSE REDUCTION;;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CRBN;CC;rs1705814;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DISCONTINUATION IN PEOPLE WITH  OTHER:MANTLE CELL LYMPHOMA;;CAUTION_SIDE_EFFECT
BUPRENORPHINE;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:OPIOID-RELATED DISORDERS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOROURACIL;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEUCOVORIN;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NR1I2;T;rs2472677;OTHER;DECREASED;NAN;PK;CYP3A4 ACITVITY NAN  NAN;;CAUTION_DOSE_ADJUST
RIFAMPIN;NR1I2;T;rs2472677;METABOLISM/PK;DECREASED;NAN;PK;CYP3A4 ACITVITY NAN  NAN;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
OXCARBAZEPINE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
PHENYTOIN;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
TOPIRAMATE;SCN2A;A;rs2304016;EFFICACY;NAN;NAN;EFFICACY;DRUG RESISTANCE IN PEOPLE WITH  DISEASE:EPILEPSY;;CAUTION_DOSE_ADJUST
CAPECITABINE;PTGS2;AA;rs5275;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;PTGS2;AA;rs5275;EFFICACY;INCREASED;NAN;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CETP;A;rs708272;NAN;NAN;NAN;OTHER;VARIANCE IN LDL;;CAUTION_DOSE_ADJUST
NAN;CETP;A;rs708272;NAN;NAN;NAN;OTHER;HDL AND LDL/HDL NAN  NAN;;CAUTION_DOSE_ADJUST
HMG-COA_REDUCTASE_INHIBITORS;CETP;A;rs708272;EFFICACY;DECREASED;RISK;EFFICACY;CARDIOVASCULAR EVENTS IN PEOPLE WITH  DISEASE:CORONARY ARTERY DISEASE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;ADD1;GT + TT;rs4961;EFFICACY;DECREASED;LIKELIHOOD;DISEASE;MYOCARDIAL INFARCTION IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;NAN;NAN;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT NAN  NAN;;CAUTION_DOSE_ADJUST
ETHANOL;DRD2;A;rs1076560;OTHER;INCREASED;RISK;DISEASE;ALCOHOL ABUSE NAN  NAN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;NAN;EFFICACY;PLATELET ACTIVATION RESPONSE TO ADP IN PEOPLE WITH  DISEASE:ACUTE CORONARY SYNDROME;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
LEUCOVORIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
OXALIPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE;NEUTROPENIA IN PEOPLE WITH  DISEASE:COLONIC NEOPLASMS;;CAUTION_SIDE_EFFECT
BROMPERIDOL;DRD2;GG;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEMONAPRIDE;DRD2;GG;rs1799732;EFFICACY;INCREASED;NAN;EFFICACY;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS IN PEOPLE WITH  DISEASE:SCHIZOPHRENIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIAZIDES;SLC12A3;CC;rs13306673;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;SLC12A3;CC;rs13306673;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;DECREASED;LIKELIHOOD;SIDE EFFECT;GASTROINTESTINAL TOXICITY IN CHILDREN WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;NAN;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;DISEASE;LEUKOPENIA IN PEOPLE WITH  DISEASE:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ALOPECIA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:HYPERSENSITIVITY IN CHILDREN WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERLIPIDEMIAS;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OBESITY;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUSCULAR DISEASES IN PEOPLE WITH  DISEASE:DIABETES MELLITUS;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERLIPIDEMIAS;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DISEASE:OBESITY;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE IN CHILDREN WITH  OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIAZIDES;ADRB3;AA;rs4994;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;ADRB3;AA;rs4994;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION FREE SURVIVAL IN WOMEN WITH  DISEASE:BREAST NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DIARRHEA IN PEOPLE WITH  OTHER:STOMACH NEOPLASMS;;CAUTION_SIDE_EFFECT
ASPARAGINASE;CPA2;T;rs199695765;TOXICITY;INCREASED;RISK;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;NAN;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-DRB1;T;rs701829;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;POR;CT + TT;rs1057868;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
WARFARIN;THBD;CC + CT;rs1042580;TOXICITY;DECREASED;RISK;SIDE EFFECT;HEMORRHAGE NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;CES1;AC + CC;rs3815583;TOXICITY;INCREASED;RISK;SIDE EFFECT;APPETITE SUPPRESSION IN CHILDREN WITH  DISEASE:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;BDKRB2;C;rs8012552;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
PLAIN;BDKRB2;C;rs8012552;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;BCL2L11;CC;rs724710;TOXICITY;INCREASED;RISK;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;MME;A;rs2016848;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
PLAIN;MME;A;rs2016848;TOXICITY;INCREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;CAUTION_SIDE_EFFECT
IRINOTECAN;PIN1;CC + CG;rs2233678;EFFICACY;INCREASED;NAN;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  DISEASE:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;NAN;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PEOPLE WITH  DISEASE:CHRONIC HEPATITIS C VIRUS INFECTION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;ADD1;GT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN ARTERIAL PRESSURE IN PEOPLE WITH  DISEASE:ESSENTIAL HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OVER-ANTICOAGULATION NAN  NAN;;CAUTION_SIDE_EFFECT
ASPIRIN;ACE;AT + TT;rs4291;TOXICITY;INCREASED;RISK;SIDE EFFECT;ASPIRIN INTOLERANCE IN PEOPLE WITH  DISEASE:ASTHMA;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;CYP2C8;A;rs11572103;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;NAN;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;CYP2C8;T;rs11572076;TOXICITY;INCREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS;PTGER3;C;rs11209716;TOXICITY;DECREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLAIN;PTGER3;C;rs11209716;TOXICITY;DECREASED;RISK;DISEASE;COUGH IN PEOPLE WITH  DISEASE:HYPERTENSION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;HUS1;T;rs1056663;TOXICITY;DECREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-DRB1;A;rs17211071;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG HYPERSENSITIVITY NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED;RISK;DISEASE;DIABETES MELLITUS IN PEOPLE WITH  DISEASE:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;HUS1;A;rs2037483;TOXICITY;DECREASED;RISK;SIDE EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADD1;GT + TT;rs4961;OTHER;INCREASED;LIKELIHOOD;DISEASE;HYPERTENSION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCB1;C;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;EXANTHEMA IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SLCO1B1;A;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
NAN;ARG1;TT;rs2781666;OTHER;INCREASED;SEVERITY;OTHER;ASTHMA NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;TT;rs2740574;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;ABCC1;CT;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEFT VENTRICULAR DYSFUNCTION IN PEOPLE WITH  OTHER:BREAST NEOPLASMS;;CAUTION_SIDE_EFFECT
LEVODOPA;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DYSKINESIA;;CAUTION_SIDE_EFFECT
LEVODOPA;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED IN PEOPLE WITH  OTHER:PARKINSON DISEASE;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"TOXIC LIVER DISEASE IN PEOPLE WITH  ""DISEASE:BURKITT LYMPHOMA""";;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:LYMPHOMA";;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"T-CELL""";;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE EFFECT;"""DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA""";;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);C.1236G>A (HAPB3);EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;RECURRENCE FREE SURVIVAL IN PEOPLE WITH  OTHER:RECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DOXORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
DAUNORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;CARDIOTOXICITY IN CHILDREN WITH  OTHER:NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CEFAZOLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CEFDINIR;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CEFTRIAXONE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CEFUROXIME;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
CEPHALEXIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG-INDUCED LIVER INJURY NAN  NAN;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;WNT7B;A;rs73175102;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;WNT7B;A;rs73175102;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;POGK;A;rs115587273;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;POGK;A;rs115587273;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;FAM240C;A;rs78233573;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;FAM240C;A;rs78233573;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ZNF37A;A;rs376867011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OSTEONECROSIS IN CHILDREN WITH  OTHER:LEUKEMIA;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ZNF37A;A;rs376867011;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:LYMPHOMA;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EMERGENCIES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PAIN IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EMERGENCIES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCODONE;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PAIN IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EMERGENCIES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;EFFICACY:PAIN IN PEOPLE WITH  OTHER:PAIN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*2;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*3;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;NEUTROPENIA IN CHILDREN WITH  OTHER:LIVER TRANSPLANTATION;;CAUTION_DOSE_ADJUST
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:CYTOMEGALOVIRUS INFECTION;;CAUTION_DOSE_ADJUST
VALPROIC ACID;ACOT1;T;rs758109;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
TACROLIMUS;SLCO1B1;AA + AG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;MOCOS;GT;rs73430958;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
VALPROIC ACID;GABPA;CC;rs59288687;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;NQO1;GG;rs10517;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;PPARA;G;rs881740;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TOXIC LIVER DISEASE IN PEOPLE WITH  OTHER:EPILEPSY;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ANEMIA IN PEOPLE WITH  OTHER:RHEUMATOID ARTHRITIS;;CAUTION_SIDE_EFFECT
APIXABAN;APOE;C;rs7412;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INTRACRANIAL HEMORRHAGES IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
APIXABAN;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;INTRACRANIAL HEMORRHAGES IN PEOPLE WITH  OTHER:ATRIAL FIBRILLATION;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs8099917;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs8099917;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs12980275;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PNEUMONITIS IN PEOPLE WITH  OTHER:LUNG NEOPLASMS;;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:TOBACCO USE DISORDER;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;TT;rs9282564;EFFICACY;DECREASED;RISK;EFFICACY;DEATH IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCC2;GG;rs2273697;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;NEPHROTOXICITY IN PEOPLE WITH  OTHER:KIDNEY TRANSPLANTATION;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;RRM1;AG + GG;rs1735053;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;GT + TT;rs9465102;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"NEPHROTOXICITY IN PEOPLE WITH  ""OTHER:CARCINOMA";;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"SQUAMOUS CELL""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:CARCINOMA""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;"""OTHER:ADENOCARCINOMA""";;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT MODIFICATION NAN  NAN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;;CYP2D6 ULTRARAPID METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;TREATMENT MODIFICATION NAN  NAN;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;EFFICACY:RECURRENCE FREE SURVIVAL IN CHILDREN WITH  OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY;OTHER:LEUKEMIA;;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL IN PEOPLE WITH  OTHER:NON-SMALL CELL LUNG CARCINOMA;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS NAN  NAN;;CAUTION_SIDE_EFFECT
FOLFOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
XELOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
XELOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;LIKELIHOOD_THERAPEUTIC_SUCCESS
XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:MYELOSUPPRESSION IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;HAND-FOOT SYNDROME;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;;CAUTION_SIDE_EFFECT
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:DRUG TOXICITY IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
FOLFOX;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
XELOX;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;MUCOSITIS IN PEOPLE WITH  OTHER:COLORECTAL NEOPLASMS;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;PANCREATITIS IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;ABCG2;T;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;DRUG TOXICITY;;CAUTION_SIDE_EFFECT
HMG-COA_REDUCTASE_INHIBITORS;ABCG2;T;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:TOXIC LIVER DISEASE NAN  NAN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1XN;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*2;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE EFFECT;DRUG TOXICITY IN PEOPLE WITH  DISEASE:MAJOR DEPRESSIVE DISORDER;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*3B;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;LEUKOPENIA IN PEOPLE WITH  OTHER:INFLAMMATORY BOWEL DISEASES;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*1;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*1XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*4XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*5;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*9;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*29;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*35;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*41;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;ADVERSE EVENTS IN CHILDREN  NAN;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;URINARY RETENTION;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ABDOMINAL PAIN;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WHEEZING;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;URINARY RETENTION;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ABDOMINAL PAIN;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WHEEZING;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;URINARY RETENTION;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:CONSTIPATION;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:NAUSEA;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:VOMITING;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ABDOMINAL PAIN;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:EXANTHEMA;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:WHEEZING;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;SIDE EFFECT:ADVERSE EVENTS IN PEOPLE WITH  OTHER:NEOPLASMS;;CAUTION_SIDE_EFFECT
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE EFFECT;OTHER:PAIN;;CAUTION_SIDE_EFFECT
